Structural studies on the sialidase from Aspergillus fumigatus, and, Fragment based drug discovery against the trans-sialidase from Trypanosoma cruzi by Telford, Judith Christina
STRUCTURAL STUDIES ON THE SIALIDASE FROM
ASPERGILLUS FUMIGATUS
AND
FRAGMENT BASED DRUG DISCOVERY AGAINST THE
TRANS-SIALIDASE FROM TRYPANOSOMA CRUZI
Judith Christina Telford
A Thesis Submitted for the Degree of PhD
at the
University of St Andrews
2014




Please use this identifier to cite or link to this item:
http://hdl.handle.net/10023/8086
This item is protected by original copyright
	  	  	  	  	  	  
Structural	  studies	  on	  the	  sialidase	  
from	  Aspergillus	  fumigatus	  	  
And	  
	  Fragment	  based	  drug	  discovery	  
against	  the	  trans-­‐sialidase	  from	  
Trypanosoma	  cruzi	  
	  
Judith	  Christina	  Telford	  	  	   Biomedical	  Sciences	  Research	  complex	  University	  of	  St	  Andrews	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  Submitted	  for	  the	  degree	  of	  Doctor	  of	  Philosophy	  in	  Biology	  	  	  August	  2013	  	  	  
	  	  	  	  
	   i	  
Declaration	  
1.	  Candidate’s	  declarations:	  
 
I, Judith Christina Telford hereby certify that this thesis, which is approximately 40, 000 words 
in length, has been written by me, that it is the record of work carried out by me and that it has 
not been submitted in any previous application for a higher degree. 
 
I was admitted as a research student in September 2009 and as a candidate for the degree of 
Ph.D in September 2010; the higher study for which this is a record was carried out in the 
University of St Andrews between 2009 and 2013. 
 
I, Judith Christina Telford, received assistance in the writing of this thesis in respect of 
language, grammar, spelling or syntax, which was provided by Dr Jane Potter 
 
 
Date     Signature of candidate  
 
2.	  Supervisor’s	  declaration:	  	  
I hereby certify that the candidate has fulfilled the conditions of the Resolution and 
Regulations appropriate for the degree of Ph.D in the University of St Andrews and that the 
candidate is qualified to submit this thesis in application for that degree. 
 
 




3.	  Permission	  for	  electronic	  publication:  
 
In submitting this thesis to the University of St Andrews I understand that I am giving 
permission for it to be made available for use in accordance with the regulations of the 
University Library for the time being in force, subject to any copyright vested in the work not 
being affected thereby. I also understand that the title and the abstract will be published, and 
that a copy of the work may be made and supplied to any bona fide library or research worker, 
that my thesis will be electronically accessible for personal or research use unless exempt by 
award of an embargo as requested below, and that the library has the right to migrate my thesis 
into new electronic forms as required to ensure continued access to the thesis. I have obtained 
any third-party copyright permissions that may be required in order to allow such access and 
migration, or have requested the appropriate embargo below. 
The following is an agreed request by candidate and supervisor regarding the electronic 
publication of this thesis: 
 
Access to printed copy and electronic publication of thesis through the University of St 
Andrews. 
 
Date   Signature of candidate   Signature of supervisor  























	   iii	  
Acknowledgments	  	  	  
I	  cannot	  emphasize	  enough	  how	  thankful	  I	  am	  to	  Professor	  Garry	  Taylor	  and	  the	  Taylor	  group	  for	  their	  help	  and	  support	  over	  the	  last	  4	  years.	  I	  have	  been	  blessed	  to	   have	   found	   such	   an	   encouraging	   and	   inspirational	   supervisor.	   The	  wealth	   of	  intellect	  and	  kindness	  in	  the	  Taylor	  group	  is	  the	  perfect	  platform	  for	  learning	  as	  well	   as	   being	   a	   fantastic	   environment	   for	   anyone.	   They	   are	  more	   than	   friends,	  they	  are	   family.	   I	  would	   like	  to	  thank	  Professor	  Garry	  Taylor	  and	  Dr	  Jane	  Potter	  for	  their	  patience	  and	  time	  that	  they	  have	  so	  selflessly	  invested	  in	  me.	  I	  would	  like	  to	  thank	  Jane	  for	  sharing	  her	  broad	  technical	  and	  language	  knowledge	  as	  well	  as	  her	  kindness	   in	   the	   face	  of	  my	  shortcomings.	  Garry’s	  open	  door	  and	  trust	   in	  me	  has	   allowed	   me	   to	   explore	   my	   projects	   independently	   without	   fearing	   the	  occasional	  mistake.	  	  Former	  Taylor	  group	  member	  Dr	  Gougang	  Xu	  stewarded	  me	   through	  my	   first	  6	  months.	   He	  was	   an	   excellent	   role	  model	   for	   an	   early	   PhD	   student;	   he	   is	   bright,	  ambitious	  and	  disciplined.	  Another	  role	  model	  and	  former	  Taylor	  group	  member,	  Dr	  Rupert	  Russell,	  was	  my	   internal	  adviser	  until	  his	   too	  soon	  passing	   in	  2012.	   I	  wish	  I	  could	  thank	  him	  personally	   for	  his	  enjoyment	   in	  my	  successes	  and	  astute	  observations.	  He	  is	  missed.	  	  	  I	  would	  like	  to	  thank	  all	  of	  my	  collaborators	  for	  their	  hard	  work,	  team	  work	  and	  sharing	  of	  chemicals,	  knowledge	  and	  time.	  I	  would	  like	  to	  thank	  Juliana	  Yeung	  and	  Margo	  Moore	  for	  introducing	  me	  to	  AfS	  and	  their	  excitement	  in	  my	  results.	  I	  am	  so	  grateful	   for	   numerous	   chemical	   products	   provided	   by	   Milton	   Kiefel,	   Jefferson	  Chan	  and	  Andrew	  Bennet.	  Without	   their	  generosity	  and	  hard	  work	  much	  of	   this	  thesis	  would	  not	  be	  possible.	  	  	  I	  would	   like	   to	   thank	  Dr	   Jennifer	  Wilson	   and	  Dr	  Ulrich	   Schwarz-­‐Linek	   for	   their	  teaching	   and	   help	   with	   NMR.	   Upon	   starting	   my	   PhD	   NMR	   stood	   for	   Not	   My	  Responsibility	  and	  they	  patiently	  helped	  me	  learn	  Nuclear	  Magnetic	  Resonance.	  St	  Andrews	   has	   an	   outstanding	   academic	   in-­‐house	   X-­‐ray	   crystallography	   set	   up	  which	  would	  not	  run	  without	  the	  continuous	  maintenance	  and	  protection	  (mainly	  from	  the	  students)	  by	  Dr	  Magnus	  Alphey.	  Magnus	  and	  Dr	  Philip	  Kerry	  have	  helped	  me	  with	  the	  equipment	  and	  trickier	  data	  processing	  and	  I	  am	  very	  grateful.	  	  	  I	  am	  grateful	  also	  for	  the	  fun	  I	  have	  had	  in	  the	  past	  4	  years.	  I	  am	  aware	  that	  very	  few	  PhD	  students	  are	   lucky	  enough	   to	   say	   that	   they	  had	  a	   fun	  4	  years	  however	  thanks	   to	   Dr	   Alison	   Lilley,	   Christopher	   David	   Owen,	   Erin	   McCammick,	   Fraser	  Duthie	  and	  may	  others,	   I	   can	  say	   that	   I	  have!	   I	  must	   thank	  Dr	  Terry	  Smith	  also,	  mainly	  for	  his	  humor	  but	  also	  for	  his	  academic	  help.	  	  My	  close	  friends	  Emma	  Branigan,	  Riho	  Seljamäe-­‐Green	  and	  Christopher	  Musgrave	  have	  provided	  fun,	  entertainment	  and	  perspective	   in	  the	  most	  challenging	  times	  in	  this	  PhD.	  I	  am	  ever	  indebted	  to	  my	  family	  and	  my	  partner	  Christianne	  Fahey	  for	  their	  support	  and	  belief	  when	  I	  had	  run	  out.	  To	  Christianne	  and	  my	  parents	  Mary	  Finlayson	   and	  David	   Telford	   I	   am	   so	   grateful	   for	   their	   provisions	   and	   love	   that	  they	  give	  so	  generously.	  You	  make	  me	  want	  to	  be	  a	  better	  person.	  	  
	   iv	  




	  	  	  	  	  	  
	   v	  
Abstract	  
Sialic	   acids	   are	   a	   family	   of	   9	   carbon	  acidic	   sugars	   that	   are	  often	  part	   of	   glycans	  that	  decorate	  glycoproteins	  and	  glycolipids.	  N-­‐acetylneuraminic	  acid,	  or	  Neu5Ac,	  is	  the	  predominant	  sialic	  acid	  in	  Homo	  sapiens	  and	  is	  most	  commonly	  found	  on	  the	  terminus	  of	  glycan	  chains	  where	  it	  functions	  as	  a	  signaling	  molecule	  or	  providing	  a	  negatively-­‐charged	  mask	  to	  cells.	  Neu5Ac	  is	  less	  commonly	  found	  in	  microbes.	  A	  number	  of	  pathogens,	  including	  the	  fungus	  Aspergillus	  fumigatus	  and	  the	  parasite	  
Trypanosoma	   cruzi,	   present	   Neu5Ac	   on	   their	   surface	   which	   aids	   evasion	   of	   the	  host	  immune	  system.	  	  	  
A.	  fumigatus	  has	  no	  known	  sialic	  acid	  synthesis	  genes	  however	  a	  single	  sialidase,	  
AfS,	   has	   been	   identified.	   This	   sialidase	   is	   relatively	   poor	   at	   cleaving	   Neu5Ac	   in	  comparison	   with	   other	   members	   of	   the	   sialidase	   family.	   Here	   we	   present	   the	  structure	  of	  AfS	  to	  1.8Å,	  the	  first	  fungal	  sialidase	  structure	  published.	  The	  overall	  topology	   of	   AfS	   shares	   the	   6-­‐bladed	   β-­‐propeller	   fold	   common	   to	   all	   known	  sialidases	  and	  has	  an	  rmsd	  of	  only	  1.44	  Å	  over	  309	  Cαs	  with	  the	  bacterial	  sialidase	  from	  Micromonospora	   viridifaciens.	   The	   active	   site	   of	   AfS	   also	   contains	   all	   the	  residues	   necessary	   for	   efficient	   hydrolysis	   of	   sialic	   acids.	   Despite	   repeated	  attempts,	   it	  was	   not	   possible	   to	   crystallize	  AfS	   in	   complex	  with	   Neu5Ac.	   Closer	  inspection	   of	   the	   AfS	   active	   site	   revealed	   that	   the	   pocket	   that	   usually	  accommodates	  the	  N-­‐acetyl	  moiety	  of	  Neu5Ac	  contained	  more	  polar	  residues	  and	  was	   shallower	   than	   that	   of	   other	   sialidases.	   	   The	   apo	   structure	   suggested	   that	  substitution	  of	  the	  N-­‐acetyl	  group	  on	  C5	  of	  Neu5Ac	  with	  a	  smaller	  group	  may	  be	  accommodated	   better	   in	   the	   active	   site	   of	   AfS.	   2-­‐Keto-­‐3-­‐deoxy-­‐D-­‐galacto-­‐nonulosonic	  acid	  (KDN),	  which	  has	  a	  hydroxyl	  group	  at	  this	  position,	  is	  capable	  of	  binding	  in	  the	  active	  site	  and	  is	  the	  preferred	  substrate	  of	  AfS.	  The	  structure	  of	  AfS	  in	   complex	   with	   KDN	   was	   determined	   to	   1.45	   Å	   and	   is	   the	   first	   KDN	   specific	  sialidase	  structure	  determined.	  Crystal	  complexes	  with	  either	  a	  di-­‐fluoro-­‐KDN	  or	  KDN2en	   allowed	   atomic	   snapshots	   to	   be	   obtained	   of	   the	   catalytic	   cycle	   from	  Michaelis	   complex,	   through	   transition	   state	   to	   covalent	   intermediate.	   	   Several	  KDN	  binding	  sites	  on	  the	  surface	  of	  the	  enzyme	  were	  discovered	  suggesting	  that	  the	  enzyme	  may	  be	  specific	  for	  polyKDN,	  which	  intriguingly	  has	  been	  found	  in	  the	  human	  lung.	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Mutations	  were	  made	  to	  AfS	  	  to	  enlarge	  the	  cavity	  around	  C5	  to	  see	  if	  the	  enzyme	  could	   accommodate	   Neu5Ac-­‐related	   substrates.	   Identification	   and	   mutation	   of	  arginine	  171	  in	  the	  active	  site	  to	  leucine	  increased	  the	  depth	  and	  hydrophobicity	  of	  the	  cavity	  and	  improved	  the	  ability	  of	  AfS	  to	  utilize	  Neu5Ac,	  albeit	  poorly.	  The	  structure	  AfSR171L	  in	  complex	  with	  Neu5Ac2en	  was	  solved	  to	  1.8	  Å.	  	  
Trypanosoma	  cruzi	  is	   the	  etiological	  agent	  of	  Chagas	  disease.	  The	   trans	  sialidase	  from	  T.	  cruzi,	  TcTs,	  is	  a	  verified	  virulence	  factor.	  Here	  we	  detail	  a	  fragment-­‐based	  search	   for	   novel	   inhibitors	   of	   TcTs	   using	   a	   fluorogenic	   assay,	   STD-­‐NMR	   and	  WaterLOGSY-­‐NMR,	   in	  silico	  screening	  and	  X-­‐ray	  crystallography.	  There	  was	  poor	  agreement	  between	   the	   techniques	  used	  and	  only	   fragment	  hits	   validated	  by	  X-­‐ray	   crystallography	   were	   pursued.	   All	   protein-­‐ligand	   complexes	   shared	   two	  common	  interactions.	  The	  verified	  compounds	  interacted	  with	  the	  arginine	  triad	  via	   a	   carboxylic	   acid,	   as	   is	   the	   case	   with	   the	   sialic	   acid	   substrate.	   Secondly,	   all	  compounds	  possessed	  an	  amine	  that	  was	  within	  hydrogen	  bonding	  distance	  of	  the	  
TcTs	  catalytic	  aspartic	  acid.	  	  One	  of	   these	   compounds,	   3-­‐piperidinic	   acid,	  was	   capable	  of	   binding	   in	   the	  TcTs	  active	   site	   in	   both	   of	   its	   anomeric	   forms.	   Interestingly,	   each	   anomer	   binds	   in	   2	  similar	   but	   distinct	   positions	   in	   the	   active	   site.	   In	   one	   of	   these	   conformations	  Tyr119	  moves	  into	  the	  active	  site	  and	  hydrogen	  bonds	  with	  the	  fragment’s	  amine.	  In	  an	  attempt	  to	  combine	  the	  interaction	  seen	  in	  both	  the	  R	  and	  S	  anomers	  of	  3-­‐piperidinic	   acid,	   (R)-­‐2-­‐piperazine	   carboxylic	   acid	  was	   soaked	   into	  TcTs	   crystals.	  This	  compound	  made	  additional	  interactions	  with	  the	  protein	  and	  demonstrated	  a	  4-­‐fold	  improvement	  in	  the	  IC50.	  	  	  A	  known	  sialidase	  inhibitor,	  Siastatin	  B,	  based	  on	  a	  3-­‐piperidinic	  acid	  frame	  was	  also	  investigated	  and	  we	  present	  a	  TcTs-­‐siastatin	  B	  complex	  structure	  to	  2.1	  Å,	  the	  first	  structure	  of	  Siastatin	  B	  in	  complex	  with	  a	  glycoside	  hydrolase.	  	  	  	  There	  is	  much	  work	  to	  be	  done	  to	  these	  preliminary	  inhibitors	  however	  here	  we	  have	   identified	   3	   druggable	   sites	   within	   the	   TcTs	   active	   site.	   The	   research	  presented	  herein	  provides	  a	  platform	  for	  future	  drug	  design	  studies	  on	  TcTs.	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1.1	  Sialic	  acid	  	  The	   term	   sialic	   acid,	   also	   known	   as	   neuraminic	   acid,	   encompasses	   a	   family	   of	  more	   than	   50	   9-­‐carbon	   acidic	   sugars	   obtained	   from	   substitutions	   to	   common	  frames	  2-­‐keto-­‐3-­‐deoxy-­‐5-­‐acetamido-­‐D-­‐glycero-­‐D-­‐galacto-­‐nonulosonic	  acid	  and	  2-­‐keto-­‐3-­‐deoxy-­‐D-­‐galacto-­‐nonulosonic	   acid,	   more	   simply	   called	   N-­‐acetylneuraminic	  acid	  or	  Neu5Ac	  and	  KDN,	  respectively	  (Angata	  and	  Varki,	  2002,	  Vimr	  et	  al.,	  2004)	  (Figure	  1.1).	  Substitutions	  at	  positions	  C4,	  C5,	  C7,	  C8	  and	  C9	  by	  acetate,	  lactate,	  sulphate	  and	  methyl	  or	  phosphate	  esters	  lead	  to	  the	  production	  of	  more	  than	  50	  discrete	  members	  of	   this	  chemical	   family	  making	   it	  one	  of	   the	  most	   diverse	   sugar	   families	   known	   (Angata	   and	   Varki,	   2002).	   The	   most	  ubiquitous	   sialic	   acid	   is	   Neu5Ac,	  which	   differs	   from	   the	   second	  most	   common	  sialic	  acid,	  Neu5Gc,	  only	  by	  the	  addition	  of	  a	  hydroxyl	  to	  the	  N-­‐acetyl	  group	  at	  the	  C5	  position	  of	  Neu5Ac	   (Vimr	   et	   al.,	   2004)	   (Figure	  1.1).	   	  Neu5Ac	  was	  originally	  isolated	   from	   the	   bovine	   submaxillary	   gland	   in	   1936	   closely	   followed	   by	   the	  isolation	   of	   Neu5Gc	   from	   the	   porcine	   submaxillary	   gland	   in	   1955	   (Blix	   et	   al.,	  1955).	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frame	  (Angata	  and	  Varki,	  2004).	  The	  most	  common	  sialic	  acids,	  KDN,	  Neu5Ac	  and	  Neu5Gc,	  differ	  only	  at	  the	  C5	  position.	  	  Free	  sialic	  acids	  are	  hydrophilic	  because	  of	  their	  negatively	  charged	  carboxylate.	  The	  pyranose	  ring	  of	  the	  majority	  of	  sialic	  acids	  adopt	  a	  2C5	  chair	  conformation	  in	  solution.	   Sialic	   acid	   is	   most	   commonly	   found	   as	   the	   terminal	   sugar	   in	  glycoconjugates,	   forming	   glycosidic	   linkages	   via	   its	   C2	   in	   the	   energetically	  favorable	   α-­‐configuration,	   in	   which	   the	   C7	   is	   in	   a	   cis	   position	   relative	   to	   C1	  (Angata	   and	   Varki,	   2002).	   The	   most	   common	   sialic	   acid	   glycoconjugates	   have	  sialic	  acid	  joined	  via	  a	  α-­‐2,3	  linkage	  to	  galactose	  (Spiro,	  1964),	  or	  a	  α-­‐2,6	  linkage	  to	  galactose	  or	  N-­‐acetylgalactosamine	  (Sadler	  et	  al.,	  1979).	  Slightly	  less	  common	  are	  α-­‐2,9-­‐linkages	   and	  α-­‐2,8	   linkages	   to	   other	   sialic	   acids	   (Bhattacharjee	   et	   al.,	  1975;	   Egan	   et	   al.,	   1977).	   Additional	   linkages	   do	   exist,	   including	   α-­‐2,4-­‐linkages	  with	  galactose	  (Takasaki	  et	  al.,	  1979),	  however	  they	  are	  not	  as	  frequently	  found	  in	  nature	  (Angata	  and	  Varki,	  2002).	  	  	  Until	   recently	   it	   was	   understood	   that	   sialic	   acid	  was	   only	   produced	   by	   higher	  organisms	   that	   utilised	   its	   chemistry	   primarily	   in	   cell	   signalling	   (Angata	   and	  Varki,	  2002).	  	  Cell	  surface	  proteins	  in	  higher	  eukaryotes	  are	  often	  decorated	  with	  numerous	  sugars	  which	  are	  strictly	  controlled	  by	  numerous	  enzymes,	  of	  which	  4	  are	   sialidases	   (Varki	   and	  Varki,	   2007).	  Due	   to	   its	  negative	   charge	  and	   its	   often	  terminal	  position	  on	  glycoconjugates,	  sialic	  acid	  can	  act	  as	  an	  excellent	  signalling	  molecule	  (Etzioni	  et	  al.,	  1992;	  Hartnell	  et	  al.,	  2001;	  Jin	  et	  al.,	  2002).	  The	  primary	  sialic	  acid	  in	  humans	  is	  Neu5Ac	  after	  an	  evolutionary	  development	  where	  Homo	  
sapiens	   lost	   the	   ability	   to	   utilise	   Neu5Gc	   (Chou	   et	   al.,	   1998).	   Neu5Ac	   is	   found	  prolifically	   in	   the	   lungs	   and	   is	   predominantly	   α-­‐2,6-­‐linkaged	   in	   the	   upper	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respiratory	  tract	  and	  α-­‐2,3-­‐linkaged	  in	  the	  lower	  respiratory	  tract	  (Shinya	  et	  al.,	  2006).	   Further,	   to	   this	   α-­‐2,8-­‐linked	   poly	   sialic	   acid	   is	   more	   abundant	   on	  proliferating	   cells	   and	   has	   been	   strongly	   linked	   with	   the	   developing	   nervous	  system	   (Landmesser	   et	   al.,	   1990).	   Neuronal	   cell	   adhesion	   molecules	   on	   the	  surface	  of	  neurons	  are	  coated	  in	  α-­‐2,8-­‐linked	  poly	  sialic	  acid	  and	  it	   is	  this	  sialic	  acid	   that	   is	   responsible	   for	   neuronal	   plasticity	   (Rutishauser	   and	   Landmesser,	  1996).	  This	  demonstrated	   that	  both	   the	  presence	   and	   the	   linkage	  of	   sialic	   acid	  are	  important	  in	  the	  role	  of	  sialic	  acid	  function.	  	  	  Neu5Ac	  is	  found	  throughout	  the	  body	  and	  is	  not	  limited	  to	  the	  tissues	  previously	  mentioned.	   Similarly	   the	   sialic	   acid	   KDN	   is	   found	   throughout	   the	   body	   but	  generally	   at	   far	   lower	   concentrations	   (Inoue	   et	   al.,	   1996).	   KDN	   is	   common	   in	  developing	  tissues	  and	  is	  elevated	  in	  the	  foetal	  cord	  red	  blood	  cells	  (Inoue	  et	  al.,	  1998).	   KDN	   is	   also	   a	   marker	   of	   oncodevelopment	   and	   is	   present	   in	   similar	  linkages	  to	  Neu5Ac	  (Yabu	  et	  al.,	  2013;	  Qu	  et	  al.,	  1996).	  	  	  The	   majority	   of	   non-­‐eukarya	   do	   not	   utilize	   sialic	   acid.	   Therefore	   sialic	   acid	  represents	   a	   fantastic	   homing	   beacon	   for	   pathogenic	   bacteria	   to	   unsuspecting	  hosts.	   	   Scores	   of	   pathogens	   including	   the	   influenza	   virus,	   Streptococcus	  
pneumoniae	  and	  Vibrio	  cholerae	  possess	  a	  sialidase	  as	  a	  virulence	  factor	  (Taylor,	  1996).	   The	   influenza	   virus	   binds	   to	   sialic	   acid	   on	   the	   surface	   of	   host	   cells	   and	  uses	   a	   sialidase	   to	   facilitate	   its	   release	   such	   that	   it	   can	   spread	   to	  neighbouring	  host	  cells.	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Many	  bacteria	  and	  fungi	  can	  metabolise	  sialic	  acid	  as	  an	  energy	  source	  (Vimr	  and	  Troy,	   1985;	   Vimr	   et	   al.,	   2004).	   Cleavage	   of	   host	   sialic	   acid	   presents	   a	   carbon	  source	   for	   pathogens	   and	   commensal	   microbes	   (Chang	   et	   al.,	   2004).	   Further	  studies	   revealed	   that	   some,	   notably	   pathogenic,	   bacteria	   could	   also	   synthesize	  the	  sugar	  and	  yet	  more	  could	  sequester	  it	  from	  the	  environment	  and	  evade	  host	  detection	   by	   presenting	   Neu5Ac	   on	   their	   cell	   surface	   (Bortolussi	   et	   al.,	   1979;	  Edwards	  et	  al.,	  1982).	  	  The	  parasite	  Trypanosoma	  cruzi	  (T.	  cruzi)	  responsible	  for	  South	  American	  trypanosomiasis	  possesses	  a	  trans-­‐sialidase	  that	  can	  cleave	  and	  transfer	  sialic	  acid	  from	  the	  presenting	  host	  to	  their	  own	  cell	  surface,	  aiding	  its	  evasion	   of	   the	   host	   immune	   system	   (Schenkman	   et	   al.,	   1991).	   Neisseria	  
meningitides	   also	   coats	   itself	   in	   sialic	   acid,	   namely	  α-­‐2,8-­‐linked	  poly	   sialic	   acid,	  which	  aids	  its	  resistance	  to	  the	  host	  immune	  system	  (Kahler	  et	  al.,	  1998).	  	  The	  importance	  of	  sialic	  acid	  and	  its	  metabolism	  in	  the	  realm	  of	  glycobiology	  is	  irrefutable.	  	  Neu5Ac	  in	  particular	  has	  achieved	  much	  attention,	  not	  only	  because	  it	   is	   the	   most	   abundant	   sialic	   acid,	   more	   abundant	   than	   its	   fellow	   family	  members,	   but	   because	   of	   its	   relevance	   in	   human	   disease.	   Thus	   it	   follows	   that	  sialidases,	  enzymes	  that	  cleave	  sialic	  acid	  from	  glycoconjugates,	  should	  also	  play	  important	  roles	  in	  various	  diseases;	  from	  genetic	  disorders	  such	  as	  cancers	  and	  lysosomal	   storage	   diseases,	   to	   infections	   such	   as	   influenza	   and	   cholera.	   The	  targeted	  control	  of	  sialidases	  may	  present	  an	  effective	  method	  of	  disease	  control.	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1.2	  Sialidases	  	  	  Sialidases,	   known	   synonymously	   as	   neuraminidases,	   catalyse	   the	   cleavage	   of	  sialic	  acids	  from	  sugar	  chains	  whilst	  retaining	  the	  anomeric	  configuration	  in	  the	  product	   (Taylor,	   1996).	   Sialidases	   are	   primarily	   classified	   in	   the	   enzyme	  commission	   group	   E.C.	   3.2.1.18	   based	   on	   substrate	   specificity	   (Hancock	   and	  Withers,	   2007).	   However,	   endosialidases	   are	   classified	   separately	   as	   E.C	  3.2.1.129	  owing	  to	  their	  inability	  to	  catalyse	  the	  hydrolysis	  of	  single	  sialic	  acids	  and	   intramolecular	   trans-­‐sialidase	   (IT)	   sialidases	   as	   E.C	   4.2.2.15	   due	   to	   their	  formation	  of	  the	  anhydro	  form	  of	  sialic	  acid	  (http://www.expasy.ch/enzyme/).	  	  Sialidase	  activity	  was	  first	  detected	  in	  the	  early	  1940s	  by	  the	  agglutination	  of	  red	  blood	  cells	   (Hirst,	  1941).	   It	  was	  not	  until	   the	   late	  1940s	   that	   it	  was	  removal	  of	  sugars,	   specifically	   sialic	   acid,	   on	   the	   surface	   of	   the	   red	   blood	   cells	   that	   was	  determined	  to	  be	  responsible	  for	  their	  agglutination	  (Gottschalk	  and	  Lind,	  1949,	  Howe	   et	   al.,	   1957).	   The	   first	   sialidase	   crystal	   structure	   of	   the	   influenza	  neuraminidase	   N2	   subtype	   was	   elucidated	   in	   1983	   (Varghese	   et	   al.,	   1983;	  Coleman	  et	  al.,	  1983).	  To	  date,	  there	  is	  an	  accepted	  mechanism	  and	  a	  wealth	  of	  crystal	  structures	  of	  sialidases	  allowing	  an	  intricate	  analysis	  of	  the	  function	  and	  properties	  of	  sialidases.	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1.2.1	  Sialidase	  structure	  
	  
Figure	   1.2.	   Sialidases	   from	   Vibrio	   cholerae	   (A),	   an	   influenza	   virus	   (B)	   and	   Streptococcus	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The	   tertiary	   structure	   of	   the	   sialidase	   family	   is	   very	   distinctive	   and	   largely	  conserved.	  Anti-­‐parallel	  beta-­‐sheets	  containing	  four	  strands	  form	  six	   ‘propeller’	  like	  structures,	  which	  form	  a	  canonical	  topology	  with	  six-­‐fold	  pseudo	  symmetry	  (Figures	   1.2	   &	   1.3).	   The	   active	   site	   is	   found	   at	   the	   centre	   of	   this	   canonical	  structure.	  Comparison	  of	  the	  X-­‐ray	  structures	  of	  sialidases	  demonstrate	  that	  the	  central	  canonical	  domain	   is	  conserved	  but	  can	  vary	  greatly	  (Figure	  1.2).	  The	  β-­‐propellers	   can	   fluctuate	   in	   length	   and	   angle	   between	   sialidases	   and	   extended	  loops,	   even	   large	   insertions,	   are	   common.	  Through	   the	   centre	  of	   this	   canonical	  structure	  there	  is	  a	  conserved	  water	  accessible	  channel	  that	  is	  almost	  continuous	  from	  the	  active	  site	  to	  the	  opposing	  face	  of	  the	  protein	  and	  is	  hypothesised	  to	  be	  important	  in	  enzyme	  activity	  (Paul	  Braer,	  personal	  communication)	  (Figure	  1.4).	  Ancillary	   carbohydrate	   binding	   modules	   (CBM)	   are	   also	   present	   in	   some	  sialidases.	  	  	   	  
	  
Figure	  1.3.	  The	  tertiary	  structure	  of	  all	   sialidases	   is	   that	   of	   a	   6	  antiparallel	   β-­‐sheet	   propeller	  canonical	  topology.	  Shown	  here	  is	  a	  human	   sialidase,	   Neu2	   (PDB	   code	  1VCU,	  Chavas	  et	  al.,	  2005),	  depicted	  with	   each	   of	   the	   6	   β-­‐sheet	  propellers	   in	   a	   different	   colour.	   A	  single	   propeller	   is	   highlighted	   by	   a	  blue	  triangle.	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The	  surface	  of	  the	  protein	  is	  not	  uniformly	  charged;	  excreted	  bacterial	  sialidases	  such	   as	   NanB	   from	   Streptococcus	   pneumoniae	   (Xu	   et	   al.,	   2008b),	   NanI	   from	  
Clostridium	  perfringens	   (Newstead	   et	   al.,	   2008)	   and	  NanH	   from	  Vibrio	  cholerae	  (Moustafa	   et	   al.,	   2004)	   use	   negatively	   charged	   residues	   on	   the	   face	   of	   the	  opposing	  side	  of	  the	  sialidase	  to	  the	  active	  site	  to	  orient	  the	  active	  site	  to	  face	  the	  negatively	  charged	  substrate	  (Figure	  1.5).	  	  
Figure	   1.4.	   Through	   the	  centre	   of	   the	   canonical	  topology	  of	   sialidases	   is	  a	  water	   accessible	   channel.	  This	   channel	   extends	  from	   the	   active	   to	   the	  opposite	   face	   of	   the	  protein.	   Here	   is	   shown	  
TrSA	   (PDB	   code	   1N1S,	  Amaya	   et	   al.,	   2003),	   the	  sialidase	   from	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At	  the	  sequence	  level,	  there	  are	  only	  two	  conserved	  sequence	  motifs,	  the	  Asp-­‐box	  and	  RXP	  motif.	   Structural	   analyses	   have	   identified	   additional	   conserved	   amino	  acids	  involved	  in	  catalysis.	  These	  motifs	  will	  now	  be	  discussed.	  	  
Figure	   1.5.	  The	  surface	  potential	  of	  NanB	   from	  Streptococcus	  pneumoniae,	  calculated	   in	  PyMol,	  (PDB	   code	   2VW1,	   Xu	   et	   al.,	   2008b)	   is	   not	   uniform.	   The	   surface	   charge	   of	   NanB	   (shown	   here,	  where	   red	   denotes	   a	   negative	   charge	   and	   blue	   denotes	   a	   positive	   charge)	   is	   predominantly	  positively	   charged	   on	   the	   surface	   containing	   the	   active	   site	   (A)	   and	   negatively	   charged	   on	   the	  opposite	  face	  of	  the	  protein	  (B)	  to	  orient	  the	  protein	  toward	  the	  negatively	  charged	  substrate.	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motif	   is	   also	   conserved	   in	   a	   plethora	   of	   protein	   families	   many	   of	   which	   have	  extremely	  different	  functions	  (Quistgaard	  and	  Thirup,	  2009;	  Copley	  et	  al.,	  2001).	  	  
Figure	   1.6.	   The	  structure	   of	   the	  sialidase	   from	  
Trypanosoma	   rangeli,	  1N1S	   (Amaya	   et	   al.,	  2003),	   is	   depicted	   as	  cartoon.	   This	   sialidase	  possesses	   3	   ‘Asp-­‐boxes’	   (highlighted	   in	  red).	  	  	  	  	  	  	  	  The	  primary	  sequence	  of	  the	  Asp-­‐box	  has	  recently	  been	  defined	  as	  X-­‐X-­‐Ser(Thr)-­‐X-­‐Asp(Asn)-­‐X-­‐Gly-­‐X-­‐Thr(Ser)-­‐Trp(Phe/Tyr),	  where	  X	  denotes	  a	  variable	  residue	  and	   the	   amino	   acids	   in	   brackets	   denote	   the	   most	   common	   substitutions	  (Quistgaard	   and	   Thirup,	   2009).	   The	   sequence	   deviations	   notwithstanding,	   the	  secondary	   structure	   of	   the	  Asp-­‐box	  motif	   is	   extremely	  well	   preserved,	   not	   just	  between	  sialidases	  but	  between	  protein	   families;	   the	  Asp-­‐box	  of	  chitinase	   from	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only	   0.33Å	   from	   the	   sialidase	   of	   Micromonospora	   viridifaciens	   (Russell,	   1998).	  The	  Asp-­‐box	  forms	  a	  hairpin	  turn	  and	  is	  usually	  found	  between	  the	  3rd	  and	  4th	  β-­‐strands	   of	   each	   blade	   of	   the	   6-­‐fold	   pseudosymmetrical	   propellers	   (Figure	   1.6).	  The	   hairpin	   mainly	   relies	   on	   hydrogen	   bond	   contacts	   between	   its	   conserved	  residues	  and	  a	  highly	  conserved	  water	  molecule	  (Quistgaard	  and	  Thirup,	  2009;	  Copley	   et	   al.,	   2001).	   The	  majority	   of	   Asp-­‐box	   containing	   proteins	   are	   secreted	  lending	   to	   the	   possibility	   that	  Asp-­‐boxes	   signal	   excretion,	   however	   there	   are	   a	  number	  of	  recorded	  cytosolic	  sialidases	  that	  also	  possess	  Asp-­‐boxes	  (Quistgaard	  and	  Thirup,	  2009).	  	  	  It	   is	   generally	   accepted	   that	   in	   sialidases	   the	  Asp-­‐box	   functions	   as	   a	   structural	  motif,	   conserved	   for	   its	   importance	   in	   the	   formation	   and	   orientation	   of	   the	   β-­‐propellers.	   Substantiating	   this	   theory,	   several	   other	   proteins	   with	   similar	   β-­‐propellers	   maintain	   Asp-­‐boxes	   in	   relative	   regions	   between	   the	   propellers	   as	  found	   in	   sialidases	   (Quistgaard	   and	   Thirup,	   2009).	   The	   importance	   of	   this	  hairpin	   structure	  was	   demonstrated	   in	   a	   study	   of	   the	   human	   genetic	   disorder	  called	   sialodosis,	   where	   more	   than	   50%	   of	   recorded	   mutations	   in	   the	   human	  sialidase	   Neu1	   causing	   it	   to	   malfunction	   were	   located	   in	   one	   of	   its	   Asp-­‐boxes	  (Bonten	   et	   al.,	   2000).	  Moreover,	   experimentally	   induced	  mutations	   in	   the	  Asp-­‐boxes	   of	   NanI	   sialidase	   from	   Clostridium	   perfringens	   cause	   conformational	  changes	  leading	  to	  significant	  reduction	  in	  activity	  (Chien	  et	  al.,	  1996).	  The	  Asp-­‐box	   is	   not	   found	   in	   viral	   sialidases,	   with	   the	   notable	   exception	   of	   the	   K1	  
Escherichia	  coli	  bacteriophage	  (Crennell	  et	  al.,	  1993;	  Amaya	  et	  al.,	  2004),	  hence	  it	  appears	   that	   although	   strictly	   conserved	   in	   most	   non-­‐viral	   sialidases	   it	   is	   not	  essential	   for	   the	   formation	  of	   the	  characteristic	   sialidase	   topology.	   	  Although	   it	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should	   be	   noted	   that	   the	   influenza	   neuraminidase	   is	   tetrameric	   and	   the	  association	  of	  monomers	  may	  compensate	  for	  the	  structural	  requirement	  of	  the	  Asp-­‐box.	  	  
1.2.3 The	  ‘RXP’	  motif	  Primary	   sequence	   analysis	   exposed	   another	   conserved	   motif	   in	   bacterial	  sialidases;	   the	   ‘FRIP	   region’	   (Roggentin	   et	   al.,	   1993).	   Found	   towards	   the	   N-­‐terminus	  of	  bacterial	  sialidases,	  the	  FRIP	  region	  is	  an	  acronym	  for	  the	  residues	  it	  contains,	   Phe-­‐Arg-­‐Ile-­‐Pro,	   the	   arginine	   and	   proline	   of	   which	   are	   the	   most	  conserved	   (Figure	   1.7).	   Mutation	   of	   the	   arginine	   of	   the	   FRIP	   region	   reduces	  binding	  affinity	  of	  the	  substrate	  and	  thus	  lowers	  catalytic	  activity	  (Roggentin	  et	  al.,	  1993;	  Chien	  et	  al.,	  1996).	  
Figure	  1.7.	   	  The	  RXP,	  or	  FRIP	  domain,	  (green)	  of	  the	  leech	  intramolecular	  trans-­‐sialidase	  (1SLI,	  Luo	   et	   al.,	   1999).	   The	   arginine	   of	   the	   FRIP	   domain	   hydrogen	   bonds	   (dashed	   lines)	   with	   the	  carboxylic	  acid	  of	  the	  substrate,	  or	  in	  this	  case	  the	  substrate	  transition	  state	  analogue	  Neu5Ac2en	  (yellow	  carbons).	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  Other	  than	  the	  arginine	  and	  proline,	  the	  remaining	  residues	  of	  this	  motif	  can	  be	  quite	  varied.	   It	   is	  not	  uncommon	  for	  a	   tyrosine	  to	  replace	  the	  phenylalanine	  or	  leucine	  for	  the	   isoleucine,	  both	  of	  which	  are	  conservative	  substitutions.	   In	  viral	  sialidases	   the	   FRIP	   region	   is	   termed	   instead	   the	   REP	   region	   owing	   to	   the	  substitution	   of	   the	   isoleucine	   with	   a	   glutamate	   (Gaskell	   et	   al.,	   1995).	   This	  substitution	  is	  less	  commonly	  found	  in	  nature	  (Henikoff	  and	  Henikoff,	  1992).	  The	  arginine	  and	  proline	  are	  the	  most	  strongly	  conserved;	  hence	  across	  the	  domains	  of	  life	  this	  region	  can	  be	  summarized	  as	  the	  RXP	  motif.	  	  	  Congruent	   with	   Roggentin’s	   hypothesis,	   structural	   studies	   confirmed	   that	   the	  arginine	  of	  the	  RXP	  domain	  was	  involved	  in	  substrate	  binding	  as	  can	  be	  seen	  in	  Figure	  7	  (Roggentin	  et	  al.,	  1993).	  The	  conservation	  of	  the	  proline	   is	  most	   likely	  due	   to	   the	  unique	   structural	   properties	   of	   this	   residue:	   the	  backbone	   is	   forced	  into	  a	  tight	  turn	  by	  the	  cyclical	  nature	  of	  its	  side	  chain	  and	  hence	  any	  mutation	  of	  the	  proline	  would	  certainly	  cause	  a	  shift	  in	  the	  positioning	  of	  the	  arginine.	  	  
1.2.4	  Carbohydrate	  binding	  domains	  	  	  Some	  sialidases	  utilize	  carbohydrate	  binding	  modules	  (CBMs)	  to	  increase	  affinity	  of	   the	   protein	   for	   the	   substrate.	   It	   is	   hypothesized	   that	   CBMs	   bind	   to	   the	  substrate	  and	  orient	  the	  enzyme	  toward	  high	  concentrations	  of	  substrate.	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Figure	   1.8.	  The	  sialidase	  NanH	  from	  Vibrio	  cholerae	  (A)	  (PDB	  code	  1KIT,	  Crennell	  et	  al.,	  1994)	  possesses	   2	   carbohydrate	   binding	   modules	   (CBMs,	   green).	   The	   ligand	   for	   one	   of	   the	   CBMs	   is	  known	  to	  be	  Neu5Ac	  (yellow)	  which	  is	  shown	  binding	  to	  the	  CBM	  (2W68,	  Connaris	  et	  al.,	  2009)	  in	  the	  foreground	  (B)	  (hydrogen	  bonds	  shown	  as	  dashed	  lines).	  	  	  CBMs	   are	   distal	   to	   the	   active	   site	   and	   structurally	   distinct	   from	   the	   catalytic	  subunit;	  CBMs	  are	  identified	  as	  being	  different	  from	  a	  secondary	  binding	  site	  on	  the	   catalytic	   subunit.	   X-­‐ray	   crystallography	   has	   elucidated	   the	   structures	   of	  sialidases	  with	  a	  single	  CBM	  and	  2	  CBMs	  (Figure	  1.8).	  The	  CBMs	  are	  found	  on	  the	  N	  or	  C	  terminus,	  or	  both,	  or	  even	  formed	  from	  an	  extended	  loop	  between	  the	  β-­‐sheets	  of	   the	  sialidase	  propellers	   flanking	  the	  catalytic	  subunit.	  Consistent	  with	  the	  hypothesis	  that	  CBMs	  aid	  orientation	  to	  high	  concentrations	  of	  substrate,	  the	  
!"#
$"#
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CBMs	  of	  the	  NanH	  sialidase	  from	  V.	  cholerae	  and	  NanA	  of	  S.	  pneumoniae	  bind	  to	  the	   sialic	   acid	   Neu5Ac,	   its	   substrate	   (Figure	   1.8).	   The	   Kd	   of	   the	   V.	   cholerae	  sialidase	  CBM	  for	  sialic	  acid	  is	  only	  30	  μM	  (Connaris	  et	  al.,	  2009).	  This	  being	  said	  not	  all	   sialidase	  CBMs	  are	   specific	   to	   sialic	  acid;	   the	  CBM	  of	   the	  M.	  viridifaciens	  sialidase	   binds	   galactose	   specifically	   (Newstead	   et	   al.,	   2005).	   C.	   perfringens	  possesses	  2	  CBMs	  which	  bind	  galactose	  or	  N-­‐acetylgalactosamine	  and	  sialic	  acid	  respectively	  (Borston	  et	  al.,	  2007).	  	  	  
1.3	  The	  sialidase	  active	  site	  	  As	   previously	   mentioned,	   there	   is	   low	   sequence	   identity	   between	   sialidases.	  Despite	   this,	   the	   active	   site	   of	   the	  majority	   of	   sialidases	   contain	   six	   conserved	  residues.	  	  These	  residues	  have	  all	  been	  demonstrated	  to	  have	  important	  roles	  in	  functionality:	   three	  arginines	   that	   form	  an	   ‘arginine	   triad’,	  an	  aspartic	  acid	   that	  acts	  as	  an	  acid/base,	  a	  nucleophilic	  tyrosine	  and	  an	  associated	  glutamic	  acid.	  Of	  these	   six	   residues	   the	   arginines	   are	   responsible	   for	   binding	   and	   orienting	   the	  substrate	   in	   the	   active	   site	   whilst	   the	   other	   three	   are	   directly	   involved	   in	   the	  catalytic	  mechanism	  (Figure	  1.9).	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Figure	   1.9.	   	  Stereo	   image	  of	   transition	  state	  analogue	  Neu5Ac2en	  (yellow)	  bound	   in	   the	  active	  site	   of	   the	   sialidase	   from	   Salmonella	   typhimurium	   (PDB	   code	   2SIM,	   Crennell	   et	   al.,	   1996).	  Neu5Ac2en	  makes	  multiple	   interactions	   with	   the	   protein	   and	   those	   that	   are	   conserved	   in	   the	  majority	   of	   sialidases	   are	   highlighted	   here	   (dashed	   lines).	   	   The	   carboxylic	   acid	   of	   the	   ligand	   is	  stabilised	  by	  3	  arginines;	  in	  this	  sialidase	  the	  arginine	  triad	  is	  composed	  of	  Arg37,	  246	  and	  309.	  The	  catalytic	  tyrosine,	  Tyr342	  is	  primed	  for	  nucleophilic	  attack	  on	  the	  C2	  of	  the	  ligand	  by	  Glu231.	  The	   acid/base	   catalyst	   in	   this	   sialidase	   is	   Asp62.	   Asp62	   protonates	   the	   leaving	   sugar	   and	   co-­‐ordinates	  a	  water	  molecule	  to	  nucleophilically	  attack	  the	  C2	  of	  sialic	  acid.	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Sialidases	  also	  possess	  a	  hydrophobic	  pocket	  which	  accommodates	  the	  N-­‐acetyl	  group.	  There	  is	  much	  sequence	  variation	  in	  this	  pocket,	  however	  the	  majority	  of	  the	   residues	   are	   composed	   of	   side	   chains	   of	   aromatic	   residues	   which	   act	   to	  anchor	   the	  substrate	   in	   the	  active	  site	   in	  conjunction	  with	   the	  arginine	   trial	  on	  the	   opposing	   wall	   of	   the	   active	   site	   (Newstead	   et	   al.,	   2008;	   Xu	   et	   al.,	   2008a;	  Amaya	  et	  al.,	  2004).	  Although	  the	  residues	  in	  this	  pocket	  are	  not	  well	  conserved	  this	  pocket	  is	  common	  to	  the	  majority	  of	  sialidases.	  	  
	  
1.3.2	  Mechanism	  	  Sialidases	   are	   a	   member	   of	   the	   glycosidase	   family	   of	   enzymes	  (http://www.cazy.org/Glycoside-­‐Hydrolases.html).	   Glycoside	   hydrolases	  possess	  2	  acidic	   residues	   in	   their	  active	  site,	   the	   first	  of	  which	   is	  known	  as	   the	  acid	  base	  catalyst	  protonates	  the	  oxygen	  of	  the	  leaving	  group	  of	  the	  donor	  sugar.	  The	  absence	  of	  the	  glycosidic	  bond	  at	  the	  C2	  of	  sialic	  acid	  distorts	  the	  sugar	  ring	  from	   a	   chair	   conformation	   to	   the	   higher	   energy	   oxocarbenium	   halfchair	   or	  envelope	   conformation.	   In	   the	   oxocarbenium	   ion	   transition	   state	   the	   anomeric	  carbon	   and	   endocyclic	   oxygen	   now	   maintains	   a	   positive	   dipole.	   Glycoside	  hydrolases	  can	  function	  whilst	  retaining	  or	  inverting	  the	  anomeric	  configuration	  of	  the	  product	  with	  respect	  to	  the	  substrate	  (Davies	  and	  Henrissat	  1995;	  Zechel	  and	  Withers,	  2000).	  In	  inverting	  glycosidase	  hydrolases	  the	  distance	  between	  the	  catalytic	  acids	  is	  usually	  ≈	  9.5	  Å	  allowing	  space	  for	  the	  second	  acidic	  residue	  to	  orient	   a	   water	   molecule	   such	   that	   negative	   dipole	   of	   the	   water’s	   oxygen	   can	  attack	   the	   anomeric	   carbon.	   In	   retaining	   sialidases,	   however	   the	   distance	  between	  the	  catalytic	  acids	  is	  usually	  less	  than	  ≈	  5	  Å.	  At	  this	  distance	  the	  second	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acidic	   residue	   forms	   a	   transient	   covalent	   bond	   with	   the	   anomeric	   carbon	  facilitating	  the	  cleavage	  of	  the	  glycosidic	  bond	  (Burmeister	  et	  al.,	  1993;	  Wang	  et	  al.,	  1994).	  Once	  cleaved,	  the	  donor	  sugar	  dissociates	  and	  is	  replaced	  by	  a	  water	  molecule	  which	  attacks	  the	  anomeric	  carbon,	  facilitated	  by	  the	  first	  catalytic	  acid,	  and	  thus	  the	  anomeric	  configuration	  of	  the	  sugar	  is	  retained.	  	  	  Sialidases	   are	   retaining	  glycoside	  hydrolases,	   however,	   only	  possess	  one	  acidic	  residue	  in	  the	  active	  site.	  	  	  	  	  
	  
Figure	  1.10.	  The	  universal	  transition	  state	  analogue	  for	  sialidases	  is	  Neu5Ac2en.	  	  The	  removal	  of	  the	  C2	  hydroxyl	  of	  Neu5Ac	  creates	  a	  double	  bond	  between	  the	  C2	  and	  C3	  and	  forces	  the	  pyranose	  ring	  into	  a	  half-­‐chair	  conformation.	  In	  attempts	  to	  trap	  the	  transient	  covalent	  bond	  between	  the	  catalytic	  tyrosine	  and	  the	  C2	  of	  the	  substrate,	  the	  C2	  hydroxyl	  and	  the	  C3	  proton	  were	  replaced	  by	  fluorines	  creating	  2,3-­‐difluoro-­‐Neu5Ac.	  The	  fluorines	  are	  more	  electronegative	  than	  the	  atoms	  they	   replaced,	   increasing	   the	   positive	   charge	   on	   the	   C2	   of	   the	   ligand	   and	   prolonging	   the	  breakdown	  of	  the	  intermediate	  that	  is	  covalently	  linked	  to	  the	  catalytic	  tyrosine	  long	  enough	  to	  be	  seen	  in	  X-­‐ray	  crystallography.	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In	   1993,	   the	   X-­‐ray	   structure	   was	   solved	   of	   Neu5Ac2en	   in	   the	   active	   site	   of	  influenza	  virus	  B	  neuraminidase.	  Kinetic	  studies	  demonstrated	  that	  Neu5Ac2en,	  also	  known	  as	  DANA,	  is	  an	  inhibitor	  of	  sialidases	  and	  has	  higher	  affinity	  for	  the	  sialidase	  active	  site	  than	  Neu5Ac	  and	  was	  thus	  hypothesised	  to	  be	  an	  analogue	  of	  a	   sialic	   acid	   transition	   state	   (Miller	   et	   al.,	   1978).	  Neu5Ac2en	  differs	   chemically	  from	  Neu5Ac	  only	  in	  the	  removal	  of	  a	  hydroxyl	  group	  at	  the	  C2	  position	  however	  is	   structurally	   quite	   different	   (Kiefel	   and	   von	   Itzstein,	   2002;	   Burmeister	   et	   al.,	  1993).	  The	  removal	  of	  the	  C2	  hydroxyl	  results	  in	  a	  double	  bond	  between	  the	  C2	  and	  C3	  of	  the	  pyranose	  ring	  driving	  it	  from	  the	  2C5	  chair	  conformation	  of	  Neu5Ac	  into	  a	  half	  chair	  conformation	  similar	  to	  the	  predicted	  oxocarbenium	  transition	  state	   in	   other	   glycosidases	   (Figure	   1.10).	   It	  was	   thus	   theorised	   that	  DANA	  has	  greater	   affinity	   for	   the	   sialidase	   active	   site	   because	   it	   is	   capable	   of	   making	  comparable	  interactions	  with	  active	  site	  residues	  as	  Neu5Ac	  but	  does	  not	  require	  the	  energy	  to	  distort	  its	  pyranose	  ring	  (Miller	  et	  al.,	  1978).	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From	   these	  data	   it	  was	  hypothesised	   that	   the	   glycosidic	   oxygen	   atom	  between	  the	   sialic	   acid	   and	   its	   leaving	   group	   would	   initially	   be	   protonated	   by	   the	  conserved	  aspartic	  acid	  residue	  at	  the	  C2	  position	  severing	  the	  bond.	  Burmeister	  et	  al.	  (1993)	  noted	  that	  in	  place	  of	  a	  second	  acidic	  residue	  there	  was	  a	  tyrosine,	  now	  known	  to	  be	  totally	  conserved	  in	  the	  sialidase	  family.	  The	  hydroxyl	  group	  of	  this	   tyrosine	  was	  expected	   to	  be	  more	  electronegative	  due	   to	  a	  hydrogen	  bond	  with	   a	   highly	   conserved	   glutamate.	   This	   effectively	   acts	   as	   a	   negative	   charge	  relay	  from	  glutamate	  through	  tyrosine	  to	  stabilise	  the	  attack	  of	  the	  nucleophillic	  tyrosine	   on	   the	   positive	   dipole	   now	   imposed	   on	   C2.	   A	   water	   molecule	  coordinated	  by	  the	  catalystic	  aspartic	  acid	  also	  attacks	  the	  C2	  from	  the	  opposing	  side	   forming	   Neu5Ac	  whist	   retaining	   the	   anomeric	   configuration	   of	   the	   sugar.	  The	   tyrosine	   in	   Burmeister’s	   model	   is	   roughly	   3.2Å	   from	   C2	   and	   was	  hypothesised	   to	   be	   too	   distant	   to	   covalently	   attack	   the	   oxocarbenium	   ion	  (Burmeister	  et	  al.,	  1993).	  It	  was	  therefore	  proposed	  that	  the	  pyranose	  ring	  of	  the	  transition	  state	  of	  sialidases	  maintains	  a	  half	  chair	  configuration	   forcing	  the	  C2	  closer	   to	   the	   catalytic	   tyrosine.	   The	   electronegative	   phenolate	   of	   the	   catalytic	  tyrosine	  effectively	  stabilised	   this	  configuration	  by	  charge-­‐charge	   type	  bonding	  with	   the	  C2	  of	   the	  pyranose	  ring.	  The	  hypothesis	   that	   the	  nucleophilic	   tyrosine	  acted	   in	   a	   similar	   fashion	   to	   the	   second	   acidic	   residue	   found	   in	   glycoside	  hydrolases	  was	   substantiated	   by	  mutational	   studies;	   it	  was	   demonstrated	   that	  the	   substitution	   of	   the	   nucleophilic	   tyrosine	   resulted	   in	   a	   catalytically	   active	  enzyme,	  which	  however	  resulted	  in	  the	   inversion	  of	  the	  anomeric	  centre	  of	  the	  pyranose	  ring	  (Watson	  et	  al.,	  2003).	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In	   glycoside	   hydrolases	   the	   substrate	   is	   hypothesised	   to	   make	   a	   transient	  covalent	   bond	   with	   the	   enzyme.	   Formation	   and	   degradation	   of	   the	   covalent	  intermediate	   in	   sialidases	   is	   much	   too	   fast	   to	   be	   trapped	   by	   X-­‐ray	  crystallography.	   	   Shrewd	   chemistry	   removed	   this	   barrier	   by	   the	   addition	   of	  fluorine	  at	  positions	  C2	  and	  C3	  of	  Neu5Ac’s	  pyranose	  ring	  creating	  2,3-­‐difluoro-­‐N-­‐acetylneuraminic	  acid	  (Watts	  et	  al.,	  2003)	  (Figure	  10).	  The	  electronegativity	  of	  the	   fluorine	   on	   the	   C3	   of	   2,3-­‐difluoro-­‐N-­‐acetylneuraminic	   acid	   increased	   the	  positive	  dipole	  on	  the	  anomeric	  carbon	  increasing	  the	  interaction	  between	  it	  and	  the	   nucleophilic	   tyrosine	   and	   the	   substrate	   effectively	   trapping	   it	   in	   the	   active	  site.	   Mass	   spectrometry	   indicated	   that	   this	   compound	   was,	   like	   other	  glycosidases	  covalently	  bonded	  to	  the	  protein	  via	  the	  active	  site	  tyrosine	  rather	  than	   an	   acidic	   residue	   as	   in	   other	   glycosidases	   (Watts	   et	   al.,	   2003).	   This	  hypothesis	  was	  substantiated	  by	  a	  crystal	  structure	  of	  the	  trapped	  intermediate	  covalently	  bonded	  to	  the	  active	  site	  tyrosine	  via	  C2	  (Amaya	  et	  al.,	  2004).	  For	  this	  to	   occur	   the	   pyranose	   ring	  must	   be	   forced	   into	   a	  B2,5	   conformation	   placing	   C2	  closer	   to	   the	   attacking	   tyrosine	   and	   the	   tyrosine	   itself	   must	   move	   to	   form	   a	  covalent	   bond	   with	   C2	   forming	   the	   sialo-­‐enzyme	   complex	   as	   is	   seen	   in	   the	  structure	   of	   the	   trans	   sialidase	   from	   Trypanosom	   cruzi	   	   in	   complex	   with	   2,3-­‐difluoro-­‐N-­‐acetylneuraminic	  acid.	   	  This	  allows	  the	  pyranose	  ring	  to	  return	  to	  the	  lower	   energy	   2C5	   chair	   conformation	   and	   the	   hydrogen	   bonding	   between	   the	  catalytic	   residues	   tyrosine	   and	   glutamate	   is	   broken	   and	   glutamate	   forms	   a	  similar	  bond	  with	  a	  water	  molecule	  (Figure	  1.11).	  	  Structures	  of	  the	  sialidase	  from	  Trypanosoma	  rangeli	  (Watts	  et	  al.,	  2003;	  Watts	  et	  al.,	   2006)	   as	   well	   as	   from	   non-­‐trypanosomal	   organisms	   such	   as	   C.	   perfringens	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(Newstead	   et	   al.,	   2008)	   were	   also	   solved	   in	   complex	   with	   2,3-­‐difluoro-­‐N-­‐acetylneuraminic	  acid	  all	   trapping	  the	  transient	  covalent	  bond.	  Current	  opinion	  supports	   the	  hypothesis	   that	  all	   sialidases	   form	  a	   transient	  covalent	  bond	  with	  sialic	   acid,	   however	   as	   2,3-­‐difluoro-­‐N-­‐acetylneuraminic	   acid	   is	   not	   the	   natural	  substrate	   for	   this	   family	  of	  proteins,	   the	   covalent	  bond	  may	  be	  an	  effect	  of	   the	  modifications	  to	  the	  substrate.	  	  	  	  
1.3.3	  Unique	  sialidase	  mechanisms	  	  
1.3.3.1	  Endosialidases:	  a	  new	  mechanism	  entirely?	  	  Recently,	   the	   first	   structure	   of	   an	   endosialidase	   was	   published	   revealing	   yet	  another	   means	   to	   cleave	   sialic	   acid.	   The	   endosialidase	   from	   E.	   coli	   K1	  bacteriophage,	   known	   as	   endoNF,	   catalyses	   the	   removal	   of	   α-­‐2,8-­‐glycosidically	  linked	   polysialic	   acid	   (PSA)	   chains	   composed	   of	   4	   or	  more	   sugar	   units	   and	   in	  contrast	  to	  other	  sialidases	  is	   inverting	  (Morley	  et	  al.,	  2009)	  (Figure	  1.12).	  This	  intriguing	  member	  of	  the	  sialidase	  family	  conforms	  to	  the	  canonical	  β-­‐propeller	  motif	   and	   includes	   Asp-­‐boxes	   characteristic	   of	   bacterial	   and	   eukaryotic	  sialidases,	   however	   on	   close	   inspection	   Stummeyer	   et	   al.	   (2005)	  noted	   several	  conserved	   residues	   were	   omitted	   in	   the	   active	   site,	   including	   the	   acid/base	  aspartic	  acid	  and	  the	  nucleophilic	  tyrosine.	  	  	  Less	   remarkably,	   but	   still	   unusual,	   the	   distinctive	   arginine	   triad	   is	   lacking	   a	  member,	  which	  would	  be	  expected	  to	  cause	  some	  destabilisation	  of	  sialic	  acid	  in	  the	  active	  site.	  The	  hydrophobic	  pocket	  too	  is	  significantly	  displaced	  in	  NF;	  taken	  together	   this	   suggests	   that	   the	   sialic	   acid	   targeted	   for	   cleavage	   is	   held	   in	   an	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altered	   orientation	   relative	   to	   exosialidases.	   This	   change	   in	   orientation	   may	  impact	   on	   the	   placement	   of	   the	   catalytic	   residues,	   thus	   to	   ensure	   that	   the	  remaining	   3	   predicted	   active	   site	   residues	   were	   still	   involved	   in	   the	   catalysis,	  mutational	   studies	   were	   undertaken	   (Stummeyer	   et	   al.,	   2005;	   Morley	   et	   al.,	  2009).	  These	  studies	  showed	  that	  mutation	  of	  any	  one	  of	  the	  remaining	  glutamic	  acid	  or	  two	  arginines	  resulted	  in	  more	  than	  95%	  decrease	  in	  activity.	  	  
	  
Figure	  1.12.	  (A	  &	  B)	  The	  endo	  sialidase	  from	  E.	  coli	  bacteriophage	  Φ1F,	  endoNF	  (PDB	  code	  1V0E,	  Stummeyer	  et	  al.,	  2005).	  The	  quaternary	  structure	  comprises	  a	  trimer	  of	  endoNF	  (grey	  cartoon)	  each	   with	   a	   sialidase	   domain	   (highlighted	   in	   pink,	   purple	   and	   navy).	   (C)	   The	   surface	   charge	  representation	  of	  endoNF	  showing	  the	  active	  site	  (green	  box).	  The	  active	  site	   is	   in	  an	  extended	  positively	  charge	  groove	  to	  accommodate	  the	  poly	  sialic	  acid	  chain.	  	  
!"# $"#
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  A	  vague	  mechanistic	  proposal	  is	  emerging	  for	  endoNF.	  In	  solution,	  PSA	  chains	  of	  4	  or	  more	  sialic	  acid	  units	  form	  a	  helical	  secondary	  structure	  that	  demonstrates	  non-­‐random	  self-­‐cleavage	   (Manzi	  et	  al.,	  1994).	  Dilution	  of	  PSA	   in	  solution	  does	  not	   decrease	   the	   rate	   of	   breakdown	   of	   the	   chains,	   and	   since	   the	   internal	  glycosidic	   bonds	   of	   PSA	   are	  more	   vulnerable	   to	   cleavage	   it	   has	   been	  proposed	  that	  the	  carboxylate	  of	  sialic	  acid	  is,	  in	  this	  conformation,	  capable	  of	  attacking	  the	  adjacent	  glycosidic	  oxygen	  to	   form	  the	  oxocarbenium	  transition	  state	   typical	  of	  sialidase	  induced	  catalysis	  (Manzi	  et	  al.,	  1994).	  Since	  the	  nucleophilic	  tyrosine	  is	  absent	   in	   the	   structural	   model	   of	   endoNF	   it	   was	   thus	   inferred	   that	   sialic	   acid	  acted	  as	  its	  own	  acid	  catalyst,	  and	  the	  conserved	  glutamic	  acid	  acted	  to	  attack	  the	  C2	  of	  the	  induced	  oxocarbenium	  transition	  state.	  Substantiating	  this	  hypothesis	  endoNF	   has	   been	   demonstrated	   to	   bind	   PSA	   in	   its	   helical	   form	   and	   can	   only	  cleave	  chains	  of	  4	  sugar	  moieties	  or	  more,	  which	  is	  presumably	   long	  enough	  to	  form	  the	  required	  secondary	  structure	  (Haselhorst	  et	  al.,	  2006).	  However	  recent	  studies	   advocate	   that	   the	   carboxylate	   of	   sialic	   acid	   is	   incapable	   of	   acting	   as	   its	  own	  acid	  catalyst	  (Morley	  et	  al.,	  2009),	  and	  the	  glutamate	  is	  proposed	  as	  the	  acid	  catalyst	  and	  the	  carboxylate	  of	  sialic	  acid	  as	  the	  acid/base	  catalyst	  in	  the	  place	  of	  the	   missing	   aspartic	   acid.	   Clearly	   further	   research	   is	   needed	   to	   build	   a	   more	  reliable	  model	  of	  the	  endosialidase	  mechanism.	  	  Due	   to	   the	   nature	   of	   endosialidases	   binding	   to	   PSA	   chains,	   it	   has	   not	   yet	   been	  possible	  to	  collect	  x-­‐ray	  data	  with	  either	  Neu5Ac	  or	  Neu5Ac2en	  in	  the	  active	  site	  (Stummeyer	   et	   al.,	   2005).	  The	   crystal	   structure	  of	   an	   endosialidase	   in	   complex	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with	   PSA	   is	   eagerly	   waited	   and	   will	   hopefully	   further	   elucidate	   their	   novel	  mechanism.	  	  	  	  	  	  
1.3.3.2	  The	  intramolecular	  sialidase:	  is	  it	  even	  a	  sialidase?	  	  	  To	  date	   there	  are	  only	   two	  known	  IT	  sialidases;	   the	   IT	  trans-­‐sialidase	   from	  the	  leech	  Macrobdella	  decora,	  NanL,	  and	   the	   IT	   sialidase	  NanB	   from	  S.	  pneumoniae	  (Luo	   et	   al.,	   1998;	   Xu	   et	   al.,	   2008b;	   Gut	   et	   al.,	   2008).	   IT	   trans-­‐sialidases	   cleave	  terminal	   sialic	   acid	  moieties	   producing	   2,7-­‐anhydroNeu5Ac	   (Figure	   1.13).	   The	  structures	   of	   both	   enzymes	   have	   been	   solved	   and	   form	   the	   basis	   of	   our	  mechanistic	  understanding	  of	   these	  proteins.	  Both	  known	  IT	  sialidases	  possess	  the	   Asp-­‐box,	   FRIP	   domains	   and	   maintain	   the	   conventional	   β-­‐propeller	   fold	   of	  sialidases	   (Luo	   et	   al.,	   1998;	   Xu	   et	   al.,	   2008b).	   The	   difference	   between	   the	   IT	  sialidase	  and	  general	  sialidases	  lies	  in	  the	  active	  site.	  	  
Figure	   1.13.	   	   The	   active	   site	   of	   the	   leech	   intramolecular	   trans-­‐sialidase,	   in	   surface	   charge	  representation,	  in	  complex	  with	  transition	  state	  analogue	  Neu5Ac2en	  (A,	  yellow)	  (PDB	  code	  1SLI,	  Luo	  et	  al.,	  1998)	  and	  the	  enzyme	  product	  2,7-­‐anhydro-­‐Neu5Ac	  (B,	  yellow)	  (PDB	  code	  2SLI,	  Luo	  et	  al.,	  1999).	  	  
!"# $"#
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  Investigation	   of	   NanL	   revealed	   that	   this	   IT	   trans-­‐sialidase	   posseses	   the	   6	  aforementioned	   conserved	   active	   site	   residues	  within	   a	   0.8Å	  RMSD	   of	   all	   non-­‐hydrogen	  atoms	  when	  compared	  to	  the	  same	  residues	  from	  the	  sialidase	  from	  M.	  
viridifaciens	   (Luo	  et	   al.,	   1998).	  The	  hydrophobic	  pocket	   is	  discreetly	  altered	  by	  the	  inclusion	  of	  a	  threonine	  residue	  which	  protrudes	  out	  into	  the	  pocket.	  In	  the	  reduced	  size	  pocket,	  the	  Cγ	  of	  the	  threonine	  clashes	  sterically	  with	  where	  O8	  of	  Neu5Ac	  would	   be	   in	   the	   sialidase,	   forcing	   it	   into	   the	   axial	   position	   by	   rotation	  around	  C6.	  TAs	  deduced	  from	  x-­‐ray	  crystallography	  the	  initial	  acid	  catalysis	  then	  proceeds	  as	  usual;	  the	  conserved	  aspartic	  acid	  protonates	  the	  glycosidic	  oxygen	  atom	   and	   the	   pyranose	   ring	   takes	   on	   the	   boat	   conformation.	   However,	   the	  nucleophilic	   tyrosine	  merely	  stabilises	  the	  oxocarbenium	  transition	  state	  and	  it	  is	   the	   O7	   of	   Neu5Ac	   which	   acts	   as	   a	   base	   catalyst.	   The	   C7	   hydroxyl	   makes	   a	  hydrogen	   bond	   with	   a	   glutamic	   acid	   instigating	   a	   negative	   dipole	   on	   the	   O7	  which,	   from	   its	   now	   axial	   position,	   can	   attack	   the	   positive	   dipole	   on	   the	   C2	  forming	   the	   covalent	   bond	   in	   2,7-­‐anhydroNeu5Ac	   (Luo	   et	   al.,	   1998;	   Luo	   et	   al.,	  1999)	  (Figure	  1.14).	  	   	  
	  
Figure	   1.14.	   The	   chemical	   structure	   of	   2,7-­‐anhydroNeu5Ac.	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Structural	   studies	   by	   Xu	   et	   al.	   (2008b)	   confirmed	   that	   the	   IT	   sialidase,	   NanB,	  worked	   by	   a	   similar	  means.	   The	   scarcity	   of	   these	   sialidases	   has	   prevented	   the	  large	  comparative	  studies	  required	  to	  substantiate	  this	  mechanistic	  theory.	  	  	  
1.3.4	  Active	  site	  specificity	  
1.3.4.1	  Acceptor/donor	  specificity	  	   	  
Figure	  1.15.	  The	  active	  site	  of	  the	  sialidase	   from	   Trypanosoma	  
rangeli	   	   (PDB	   code	   1MZ6,	  Buschiazzo	   et	   al.,	   2000)	   in	  complex	   with	   transition	   state	  analogue	   Neu5Ac2en	   (yellow).	  This	  is	  overlaid	  with	  the	  structure	  of	   the	   active	   site	   of	   the	   sialidase	  from	   Trypnosoma	   rangeli	   	   (PDB	  code	   1WCS,	   Paris	   et	   al.,	   2005)	  with	   5	   mutations	   (cyan)	   that	  confer	  trans	  sialidase	  activity.	  	  	  Sialidases	   can	   be	   selective	   to	   sialic	   acid	   form,	   type	   of	   glycosidic	   linkage,	   sugar	  donor	   and,	   in	   the	   case	   of	   trans-­‐sialidases,	   the	   accepting	   sugar.	  Trans-­‐sialidases	  cleave	   terminal	   sialic	   acids	   by	   identical	  means	   to	   exosialidases.	   The	   active	   site	  however	  is	  a	  longer,	  larger	  cavity	  than	  seen	  in	  typical	  sialidases	  to	  accommodate	  the	  donor	  and	  acceptor	  sugars.	  Mutational	  studies	  achieved	  the	   transformation	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of	   an	   exosialidase	   to	   a	   trans-­‐sialidase	   and	   in	   so	   doing	   ascertained	   the	   primary	  residues	  responsible	   for	   the	   formation	  of	   the	  acceptor-­‐binding	  pocket	   (Paris	  et	  al.,	   2005).	   The	   exosialidase,	   T.	   rangeli	   sialidase	   (TrSA),	   is	   a	   conventional	  exosialidase	   which	   shares	   70%	   identity	   with	   TcTS,	   the	   trans-­‐sialidase	   from	  
Trypanosoma	  cruzi.	  TrSA	  required	   five	  point	  mutations	   in	   the	  active	   site	   to	   the	  equivalent	  residues	  from	  TcTS	  (Figure	  1.15)	  before	  TrSA	  would	  demonstrate	  any	  
trans-­‐sialidase	   activity.	   A	   sixth	   mutation	   of	   either	   Ile37Leu	   or	   Gly342Ala	  enhanced	  the	  catalytic	  capacity	  of	  this	  mutant	  to	  10%	  of	  wild	  type	  TcTS.	  Notably,	  none	   of	   these	   mutations	   were	   of	   the	   catalytic	   residues	   and	   as	   such	   the	  mechanism	  is	  identical	  to	  that	  of	  other	  sialidases.	  	  
1.3.4.2	  Glycosidic	  linkage	  specificity	  	  As	  previously	  discussed	  the	  most	  common	  sialic	  acid	  conjugates	  are	  α-­‐2,3-­‐linked,	  α-­‐2,6-­‐linked	   and	   α-­‐2,8-­‐linked.	   From	   studies	   of	   the	   endoNF	   sialidase	   it	   is	   clear	  that	   cleavage	   of	   α-­‐2,8	   linked	   PSA	   requires	   a	   much	   adapted	   active	   site.	  Comparisons	  between	  α-­‐2,3	  and	  α-­‐2,6	  specific	  sialidases	  highlighted	  an	  absence	  of	   a	   bulky	   tryptophan	   residue	   in	   the	   active	   site	   of	   α-­‐2,3	   specific	   sialidases.	  Mutation	  of	  this	  residue	  in	  TcTS	  and	  TrSA	  to	  an	  alanine	  allowed	  the	  hydrolysis	  of	  both	  linkages	  (Paris	  et	  al.,	  2005).	  	  	  
1.3.4.3	  Sialic	  acid	  specificity	  	  Neu5Ac	  is	  the	  substrate	  for	  the	  majority	  of	  sialidases	  however	  there	  are	  notable	  exceptions.	   KDN	   specific	   sialidases	   from	   Bacteroides	   fragilis	   and	  
Sphingobacterium	  multivorum	  have	  been	  cloned,	  expressed	  and	  studied	  (Tanaka	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et	   al.,	   1994;	   Nishino	   et	   al.,	   1996).	   Importantly,	   KDNases	   possess	   the	   Asp	   box	  motif	   implying	   it	   conforms	   to	   the	   same	   β-­‐propeller	   structure	   of	   the	   sialidases	  (Pavlova	   et	   al.,	   1999).	   Furthermore,	   analogous	   to	   the	   inhibition	   of	   standard	  sialidases	  by	  Neu5Ac2en,	  the	  KDNase	  from	  S.	  multivorum	  is	  inhibited	  by	  KDN2en	  	  (Terada	  et	   al.,	   1997).	   Interestingly	   this	  KDNase	   is	  not	   inhibited	  by	  Neu5Ac2en,	  hence	  it	  would	  appear	  that	  the	  active	  site	  cannot	  accommodate	  Neu5Ac.	  KDN2en	  differs	   from	  Neu5Ac2en	  by	  substitution	  of	   the	  C5	  N-­‐acetyl	  group	  by	  a	  hydroxyl	  (figure	  1.16),	  thus	  Terada	  et	  al.	  (1997)	  propose	  that	  the	  active	  site	  selectivity	  for	  KDN	  is	  based	  on	  recognition	  of	  the	  C5	  hydroxyl.	  	  	  	  	  	  
	  
Figure	  1.16.	  The	  chemical	  structures	  of	  Neu5Ac2en	  and	  KDN2en.	  	  	  Specificity	  of	  sialidases	  toward	  sialic	  acids	  other	  than	  Neu5Ac	  has	  been	  reported,	  however	   the	   mechanism	   for	   such	   specificity	   has	   not	   been	   structurally	  determined.	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1.4	  The	  sialidases	  in	  this	  thesis	  	  
1.4.1	  The	  sialidase	  from	  Aspergillus	  fumigatus,	  AfS	  	  Fungi	   from	   the	   family	   Aspergillus	   are	   common	   moulds	   to	   which	   the	   immune	  system	   is	   continuously	   exposed.	   In	   immunocompromised	   individuals	   such	   as	  solid	   organ	   transplant	   patients,	   patients	   undergoing	   chemotherapy	   and	   HIV	  sufferers,	   Aspergillus	   exposure	   can	   cause	   chronic	   and	   acute	   Invasive	  Aspergillosis	  (IA).	  IA	  is	  the	  most	  common	  form	  of	  aspergillosis	  and	  is	  primarily	  an	  infection	  of	  the	  lungs,	  although	  infection	  can	  occur	  in	  the	  sinus	  or	  nose,	  skin,	  brain	   and	   gastrointestinal	   tract	   (Denning,	   1998;	   Denning	   et	   al.,	   1998).	   The	  majority	  of	  aspergillosis	  cases	  are	  caused	  by	  a	  single	  member	  of	  the	  Aspergillus	  family,	   A.	   fumigatus	   (Denning	   et	   al.,	   1998;	   Ribaud	   et	   al.,	   1999;	   Marr	   et	   al.,	  2002)(Figure	   1.17),	   despite	   not	   being	   the	  most	   common	   environmental	   strain	  (Shelton	   et	   al.,	   2002).	   If	   untreated	   or	   if	   diagnosis	   is	   significantly	   delayed	   the	  mortality	   rate	   is	   almost	  100%	   for	  acute	  Aspergillosis	   (Aisner	  et	   al.,	   1977).	  The	  severity	   and	   velocity	   of	   disease	   progression	   coupled	   with	   poor	   diagnostic	  methods	  and	  increasing	  drug	  resistance	  mean	  that	  the	  prescription	  of	  Azoles,	  the	  preferred	  treatment,	  has	  limited	  effectiveness	  (Howard	  et	  al.,	  2010).	   	   	  Mortality	  rates	  from	  IA	  range	  greatly	  depending	  on	  underlying	  condition,	  time	  to	  diagnosis	  and	  treatment	  strategy.	  It	  is	  generally	  accepted	  that	  the	  mortality	  rate	  is	  roughly	  60-­‐80%	   although	   combinational	   therapies	   are	   improving	   on	   this	   (Marr	   et	   al.,	  2004;	  Denning	  et	  al.,	  1998;	  Ribaud	  et	  al.,	  1999;	  Gallien	  et	  al.,	  2008).	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Figure	   1.17.	   Scanning	  electron	   micrograph	   of	   the	  phialides	   and	   conidia	   of	  
Aspergillus	   fumigatus	  (Wellcome	  images,	  2013).	  	  	  	  The	   initial	   infection	   occurs	   when	   A.	   fumigatus	   conidia	   enter	   the	   lungs	   and	  germinate.	  The	  conidia	  are	  coated	  in	  sialic	  acid	  α2,6	  linked	  to	  galactose.	  Removal	  of	   this	  sialic	  acid	  sheath	  reduces	  conidia	  binding	  to	  human	  extracellular	  matrix	  proteins	   (Warwas	   et	   al.,	   2007).	   Non-­‐pathogenic	   strains	   of	   Aspergillus	   notably	  present	   less	  sialic	  acid	  on	  their	  conidia	  (Wasylnka	  et	  al.,	  2001).	  Examination	  of	  the	  A.	  fumigatus	  genome	  shows	  no	  homologues	  to	  known	  sialic	  acid	  biosynthetic	  machinery	   thus	   the	   origin	   of	   the	   sialic	   acid	   coating	   the	   conidia	   is	   still	   being	  investigated	   (Tiralongo	   et	   al.,	   2009).	   Other	   pathogens,	   such	   as	   the	   parasite	  
Trypanosoma	   cruzi,	   use	   sialidases	   to	   sequester	   sialic	   acid	   from	   their	   hosts	   to	  present	  on	  their	  surface	  giving	  a	   false	   ‘self’	   signal	   to	  evade	  detection	   from	  host	  immune	   systems	   (Schenkman	   et	   al.,	   1991).	   The	   A.	   fumigatus	   genome	   does	  encode	   a	   putative	   sialidase,	   and	   this	   has	   been	   cloned	   and	   characterized.	   This	  sialidase,	   AfS,	   possesses	   a	   single	   Asp-­‐box	   and	   a	   FRIP	   domain	   (Warwas	   et	   al.,	  2010).	  AfS	  is	  relatively	  poor	  at	  cleaving	  the	  substrate	  4-­‐methylumbelliferyl	  α-­‐D-­‐N-­‐acetylneuraminic	  acid.	  It	  has	  a	  preference	  for	  α2,3-­‐linked	  sialic	  acids	  and	  has	  no	  trans-­‐sialidase	  activity	  (Warwas	  et	  al.,	  2010).	  AfS	  may	  harvest	  the	  sialic	  from	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the	  extracellular	  matrix	  although	  the	  means	  by	  which	  sialic	  acid	  is	  transferred	  to	  the	  conidia	  surface	  is	  still	  unknown.	  The	  expression	  of	  AfS	  is	  up-­‐regulated	  in	  the	  presence	   of	   human	   serum	   however	   it	   has	   not	   yet	   been	   validated	   by	   knockout	  studies	  as	  a	  virulence	  factor.	  	  	  
1.4.2	  Trypanosoma	  cruzi	  trans-­‐sialidase	  	  
T.	  cruzi	   is	   the	  etiological	   agent	  of	  Chaga	  disease	   (Figure	  1.18)	  which	   infects	   an	  estimated	  7-­‐8	  million	  people	   around	   th	   globe	   (WHO,	  2013).	   	   Chagas	  disease	   is	  endemic	   to	   South	   America	   but	   is	   fast	   becoming	   a	   global	   infection	   aided	   by	  increased	  host	  migration	   (Schmunis,	   2007).	  Of	   those	   infected	  with	  T.	  cruzi	   10-­‐30%	  will	  present	  with	  acute	  Chagas	  disease,	  with	  children	  between	  1	  and	  5	  years	  being	  at	   the	  greatest	  danger	   (Klein	  et	  al.,	  2013).	  The	  approximate	  morbidity	  of	  acute	   Chagas	   disease	   is	   10%	   caused	   by	   cardiac	   failure	   or	   encephalomyelitis	  (Prata,	   2001).	   Of	   those	   that	   survive	   the	   acute	   phase	   of	   the	   infection,	  approximately	   30-­‐40%	   of	   untreated	   individuals	   progress	   to	   present	   with	   the	  chronic	   form	  of	  the	  disease	  (Rassi	  et	  al.,	  2010;	  Klein	  et	  al.,	  2013).	  An	  estimated	  30%	  of	  chronic	  infections	  result	  in	  gastrointestinal	  lesions	  and	  10%	  with	  cardiac	  lesions	  which	  can	  progress	  to	  heart	   failure	  (WHO,	  2013).	  An	  estimated	  11,	  000	  people	   die	   from	   Chagas	   disease	   per	   annum	   (WHO,	   2013).	   Furthermore	   the	  estimated	   economic	   impact	   of	   Chagas	   disease	   in	   endemic	   countries	   totals	   $8	  billion	  (Klein	  et	  al.,	  2013).	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Figure	  1.18.	  Selection	  of	  images	  of	  the	  T.	  cruzi	  parasite	  (Terry	  Smith,	  personal	  communication).	  	  The	   current	   treatments	   have	   limited	   effectiveness	   if	   not	   administered	   early	   in	  the	   disease	   progression	   and	   are	   plagued	   by	   severe	   and	   common	   side	   effects	  (Jackson	   et	   al.,	   2010;	   Perez-­‐Molina	   et	   al.,	   2009).	   As	   such	   there	   is	   currently	   no	  drug	  treatment	  for	  Chagas	  disease	  that	  is	  FDA	  approved	  and	  treatments	  are	  only	  available	   in	   the	   USA	   for	   research	   purposes	   (Center	   for	   Disease	   Control	   and	  Prevention,	   2013).	   	   In	   endemic	   countries	   benznidazole	   and	   nifurtimox	   are	  available	  for	  the	  treatment	  of	  Chagas	  disease.	  These	  treatments	  should	  be	  taken	  3	  times	  daily	  for	  60-­‐90	  days	  and	  as	  such	  are	  expensive	  and	  have	  poor	  adherence	  (Rassi	  et	  al.,	  2010).	  	  Both	  treatments	  are	  associated	  with	  wide	  ranging	  and	  often	  serious	   side	   effects	   (Castro	   et	   al,	   2006).	   Because	   of	   the	   poor	   efficacy,	   safety	  profile	  and	  high	  cost	  there	  is	  a	  need	  for	  new	  treatments	  for	  Chagas	  disease.	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Figure	   1.19.	   The	   life	   cycle	   of	   Trypanosoma	   cruzi	   (adapted	   from	   the	   CDC	   report	   on	   American	  trypanosomiasis,	  http://www.cdc.gov/parasites/chagas/biology.html).	  	  The	  T.	  cruzi	  parasite	  possesses	  a	   trans-­‐sialidase	   that	   is	   selectively	  expressed	  at	  various	   points	   in	   the	   parasite’s	   lifecycle,	   namely	   during	   the	   infection	   of	   the	  mammalian	   host	   (Schenkman	  &	  Eichinger,	   1993)	   (Figure	   1.19).	   Trypanosomes	  that	   are	   not	   expressing	   trans-­‐sialidase	   are	   significantly	   less	   virulent	   than	   sub	  populations	   of	   trypanosomes	   that	   are	   expressing	   the	   protein	   (Pereira	   et	   al.,	  1996).	  The	  trans-­‐sialidase	  is	  GPI	  anchored	  to	  the	  surface	  of	  trypanosomes	  as	  well	  as	   being	   shed	   releasing	   free	   enzyme	   into	   the	   surrounding	   environment.	  Treatment	  of	  mouse	  host	  infection	  sites	  with	  the	  trans-­‐sialidase	  prior	  to	  infection	  increases	   mortality	   from	   infection	   from	   0	   to	   100%	   of	   mice	   after	   25	   days	  (Chuenkova	  and	  Pereira,	  1995).	  The	  recognition	  of	  sialic	  acids	  on	  the	  host	  cells	  by	   GPI	   anchored	   TcTS	   leads	   to	   adhesion	   of	   the	   parasite	   to	   the	   host	   and	  desialylation	   of	   the	   host	   cell	   which	   improves	   the	   efficacy	   of	   the	   T.	   cruzi	   pore	  forming	   virulence	   factor	   aiding	   entry	   into	   cells	   (Schenkman	   et	   al.,	   1991).	   The	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trypanosome	   is	   incapable	  of	   synthesizing	   sialic	   acid	   itself	   and	   transfer	  of	   sialic	  acid	   from	   the	   host	   to	   its	   surface	   helps	   the	   parasite	   to	   evade	   the	   complement	  immune	  system	  (Tomlinson	  et	  al.,	  1994).	  The	  mediocre	  inhibition	  of	  this	  enzyme	  with	   preliminary	   inhibitors	   effectively	   reduced	   T.	   cruzi	   infection	   in	   Vero	   cell	  cultures	   by	   up	   to	   27%	   (Agusti	   et	   al.,	   2004).	   Due	   to	   its	  multiple	   and	   important	  roles	   in	   infection	   this	   enzyme	   provides	   an	   exciting	   prospect	   as	   a	   therapeutic	  target	  for	  chagas	  disease.	  	  The	  enzyme	  itself	  bears	  all	  the	  hallmarks	  of	  a	  sialidase	  topologically	  (Buschiazzo	  et	   al.,	   2000).	   The	   trans-­‐sialidase	   active	   site	   includes	   the	   conserved	   residues	  (covered	   in	   Chapter	   1.3)	   that	   overlay	   well	   with	   the	   sialidase	   from	  
Micromonospora	   viridifaciens	   (MvS)	   (Gaskell	   et	   al.,	   1995).	   Given	   its	   structural	  homology	   to	  MvS	   it	   is	   a	   relatively	   poor	   sialidase.	   The	  poor	   sialidase	   activity	   is	  hypothesized	  to	  be	  due	  to	  the	  dual	  function	  of	  this	  sialidase;	  the	  trans-­‐sialidase	  cleaves	  sialic	  acid	  as	  well	  as	  transferring	  it	  to	  acceptor	  sugars	  on	  the	  parasite	  cell	  surface.	   The	   presence	   of	   a	   tyrosine,	   Tyr119,	   in	   the	   active	   site	   helps	   form	   the	  binding	   site	   for	   the	   acceptor	   and	   donor	   lactose	   molecules	   that	   are	   covalently	  bound	   to	   sialic	   acid	   via	   2,3	   glycosidic	   linkage.	   In	   the	   absence	   of	   the	   donor	   or	  acceptor	   sugar	   the	   bound	   Neu5Ac,	   or	   transition	   state	   analogue	   Neu5Ac2en,	  causes	   Tyr119	   to	   flip	   into	   the	   active	   site	   clashing	   with	   the	   glycerol	   moiety	   of	  Neu5Ac	  which	  forces	  the	  substrate	  deeper	  into	  the	  active	  site	  (Figure	  1.20).	  The	  binding	   of	   Neu5Ac	   or	   Neu5Ac2en	   is	   therefore	   strained,	   making	   them	   a	   poor	  substrate	   and	   inhibitor	   respectively	   (Amaya	   et	   al.,	   2003;	   Amaya	   et	   al.,	   2004;	  Paris	  et	  al.,	  2005).	  Given	  its	  target	  potential,	  there	  have	  been	  extensive	  attempts	  to	   identify	  effective	   inhibitors	   for	  Tcts.	  Taking	   into	  account	   the	  poor	  binding	  of	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Neu5Ac2en,	   attempts	   to	   design	   inhibitors	   based	   on	   lactose,	   the	   donor	   sugar,	  have	  demonstrated	   inhibition	   in	  vitro	   as	  well	   as	   in	  vivo	   (Agusti	   et	   al.,	   2004).	   A	  number	   of	   potent	   reversible	   and	   non-­‐reversible	   inhibitors	   based	   on	   the	  substrate	   have	   been	   published	   and	   are	   in	   ongoing	   trials	   (Buchini	   et	   al.,	   2008;	  Carvalho	  et	  al.,	  2010).	  The	  search	  for	  novel	  inhibitors	  has	  identified	  compounds	  with	  IC50s	  as	  low	  as	  0.6	  μM	  (Kim	  et	  al.,	  2009).	  Despite	  the	  identification	  of	  these	  inhibitors	  there	  are	  only	  6	  TcTS-­‐inhibitor	  complexes	  in	  the	  PDB,	  of	  which	  4	  are	  Neu5Ac2en	  or	  difluoro-­‐Neu5Ac.	  The	  majority	  of	  these	  studies	  rely	  on	  computer	  modeling	  and	  fluorescent	  assays	  for	  the	  identification	  of	  these	  inhibitors	  (Neres	  et	  al.,	  	  2007;	  Neres	  et	  al.,	  	  2009).	  These	  methods	  are	  extremely	  valuable	  however	  are	  subject	  to	  false	  positives.	  In	  the	  identification	  and	  design	  of	  potent	  inhibitors	  x-­‐ray	   crystallography	   is	   seen	   as	   the	   gold	   standard	   and	   it	   is	   disappointing	   how	  few	  inhibitors	  have	  been	  validated	  by	  this	  technique.	  
Figure	   1.20.	   The	   active	   site	   of	   the	   trans-­‐sialidase	   from	   Trypanosoma	   cruzi	   (grey,	   cartoon)	   in	  complex	   with	   2,3-­‐sialyllactose	   (A,	   yellow,	   sticks)	   (PDB	   code	   1S0I,	   Amaya	   et	   al.,	   2004)	   and	  Neu5Ac2en	   (B,	   yellow,	   sticks)	   (PDB	   code	   1MS1,	   Buschiazzo	   et	   al.,	   2000).	   Tyrosine	   119	   (green,	  sticks)	  is	  seen	  in	  only	  one	  conformation,	  the	  ‘open’	  conformation,	  when	  sialyllactose	  is	  bound	  and	  
!"# $"#
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in	  two	  conformations,	  ‘open’	  and	  ‘closed’,	  when	  Neu5Ac2en	  is	  bound.	  In	  the	  closed	  conformation	  Tyr119	   clashes	  with	   the	   glycerol	  moiety	  of	  Neu5Ac2en	  distorting	   its	  binding	   in	   the	   active	   site.	  This	  clash	  makes	  Neu5Ac2en	  a	  poor	  inhibitor	  of	  TcTS.	  	  
Aims	  
To	   further	   our	   understanding	   of	   sialidases	   this	   thesis	   aims	   to	   present	   the	  structure	  of	  the	  first	   fungal	  sialidase,	  AfS,	   from	  Aspergillus	   fumigatus.	  Herin	  we	  present	   a	   mechanism	   for	   substrate	   selectivity	   of	   AfS	   for	   KDN	   as	   opposed	   to	  Neu5Ac	  using	  mutational	  studies	  and	  X-­‐ray	  crystallography.	  	  	  This	  thesis	  also	  aims	  to	  identify	  small	  molecule	  inhibitors	  of	  the	  trans-­‐sialidase,	  
TcTS	  from	  T.	  cruzi.	  Using	  a	  high	  throughput	  florescence	  assay,	  NMR	  and	  in	  silico	  we	   identify	   a	   number	   of	   small	   molecule	   inhibitors.	   By	   means	   of	   X-­‐ray	  crystallography	   of	   these	   molecules	   in	   complex	   with	   TcTs	   we	   validate	   these	  molecules	   and	   explore	   possible	   substituents	   to	   improve	   inhibition	   by	   these	  molecules.	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2.	  Structural	  determination	  and	  
substrate	  specificity	  of	  AfS,	  the	  
sialidase	  from	  Aspergillus	  fumigatus	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2.1	  Summary	  	  Members	   of	   the	   Aspergillus	   family	   of	   fungi	   are	   the	   etiological	   agents	   of	  Aspergillosis,	   a	   severe	   disease	   primarily	   affecting	   the	   lungs	   of	  immunocompromised	   persons.	   The	   conidia	   of	  Aspergillus	   fungi	   are	   decorated	  with	   glycoproteins	   and	   recent	   research	   suggests	   that	   species	   with	   high	  concentrations	   of	   sialic	   acid	   are	   better	   equipped	   to	   infect	   the	   human	   lung	  (Wasylnka	  et	  al.,	  2000;	  Wasylnka	  et	  al.,	  2001).	  The	  conidia	  of	  A.	  fumigatus	  do	  not	  possess	  any	  known	  sialic	  acid	  biosynthesis	  genes	  suggesting	  that	  the	  fungi	  must	  sequester	  the	  sugar	  from	  an	  environmental	  source.	  However	  A.	  fumigatus	  conidia	   are	   unable	   to	   utilize	   exogenous	   addition	   of	   Neu5Ac	   or	   the	   building	  block	   for	   Neu5Ac,	   ManNAc	   (Trialongo,	   2009).	   A.	   fumigatus	   does	   however	  possess	   a	   sialidase	   that	   has	   been	   cloned	   and	   characterized,	   here	   termed	  AfS.	  Herein	   is	   presented	   the	   expression,	   purification,	   crystallization	   and	   structure	  determination	  of	  AfS.	  	  The	  structure	  of	  apo	  AfS	  residues	  21	  -­‐	  406	  was	  solved	  to	  1.84	  Å.	  	  As	  molecular	  replacement	   using	   other	   bacterial	   sialidase	   models	   was	   unsuccessful,	  selenomethionine	  incorporation	  and	  subsequent	  data	  collection	  at	  the	  selenium	  absorption	   peak	   was	   used	   to	   derive	   phases	   with	   density	   modification	   being	  used	   to	   break	   the	   phase	   ambiguity.	   The	   sialidase	   from	   Micromonospora	  
viridifaciens	  (MvS)	  is	  the	  closest	  known	  homologue	  of	  AfS	  with	  an	  rmsd	  of	  only	  1.44	   Å	   over	   309	   Cα	   despite	   sharing	   only	   29	   %	   sequence	   identity.	   The	  positioning	  of	  the	  key	  catalytic	  residues	  in	  the	  active	  site	  are	  indistinguishable	  between	   the	   two	   sialidases,	   however	   it	  was	  not	   possible	   to	   obtain	   a	   complex	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structure	  with	   the	  predicted	  Neu5Ac	  product.	   In	   contrast	   to	   the	  active	   site	  of	  
MvS,	   AfS	   exhibits	   a	   reduced	   hydrophobic	   cavity,	   a	   cavity	   common	   to	   known	  sialidases	   used	   to	   accommodate	   the	   N-­‐acetyl	   substituent	   of	   Neu5Ac.	   A	   less	  ubiquitous	   member	   of	   the	   sialic	   acid	   family	   of	   sugars	   is	   KDN,	   which	   has	   a	  hydroxyl	  in	  place	  of	  the	  N-­‐acetyl	  substituent	  at	  the	  C5	  position	  of	  Neu5Ac,	  and	  we	  hypothesized	   that	  AfS	  was	  capable	  of	  binding	   this	   sugar.	  KDN	  was	   soaked	  into	  crystals	  and	  the	  complex	  structure	  solved	  to	  1.45	  Å.	  AfS	   is	  shown	  to	  be	  a	  KDN	  specific	  sialidase	  and	  is	  the	  first	  fungal	  sialidase	  and	  the	  first	  KDN	  specific	  sialidase,	   or	   KDNase,	   to	   have	   its	   structure	   elucidated.	   To	   affirm	   that	   the	  catalytic	   mechanism	   remains	   unchanged	   despite	   the	   substrate	   specificity,	  structures	  of	  AfS	  were	  obtained	  with	  the	  transition-­‐state	  analogue	  KDN2en	  to	  1.84	   Å,	   and	   a	   fluorinated	   substrate	   2,3-­‐difluoro-­‐KDN,	   here	   termed	   KDF,	   that	  allowed	  a	  covalent	  glycosyl-­‐enzyme	  intermediate	  to	  be	  trapped	  and	  observed	  at	  1.5	  Å	  resolution.	  	  	  Surprisingly,	   the	  structures	  of	  AfS	   in	  complex	  with	  KDN,	  KDN2en	  and	  KDF	  all	  showed	  several	  binding	  sites	  for	  each	  ligand.	  A	  secondary	  binding	  site	  adjacent	  to	   the	   active	   site,	   together	  with	   a	   positively-­‐charged	   surface	   groove,	   suggests	  that	  the	  natural	  substrate	  may	  be	  polyKDN.	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2.2	  Methods	  
2.2.1	  Expression	  and	  purification	  of	  AfS	  	  The	  AfS	   gene	  was	   identified	   in	   the	   genome	  of	   the	  A.	   fumigatus	   clinical	   isolate	  Af293	  by	  collaborators	  in	  Vancouver	  (Warwas	  et.	  al.,	  2010).	  The	  AfS	  gene,	  not	  including	  the	  20	  amino	  acid	  signal	  sequence,	  was	  amplified	  and	  ligated	  into	  the	  pET28A+	   (EMD	  Chemicals	   Inc.,	   San	  Diego,	  CA)	  vector	  as	  previously	  described	  (Warwas	  et.	  al.,	  2010).	  	  	  Tuner	  (DE3,	  Novagen)	  or	  BL21	  (DE3,	  Novagen)	  strains	  of	  Escherichia	  coli	  were	  transformed	  by	  addition	  of	  0.5	  μl	  of	  230	  ng/μl	  AfS/PET28A+	  plasmid	  to	  22	  μl.	  The	   plasmid/cell	   mixture	   was	   incubated	   on	   ice	   for	   30	   mins	   before	   heat	  shocking	  the	  cells	  for	  30	  s	  at	  42	  °C.	  Cells	  expressing	  the	  AfS/PET28A+	  plasmid	  were	  selected	  for	  by	  plating	  on	  to	  kanamycin	  plates	  and	  incubated	  overnight	  at	  37	   °C.	   Colonies	   expressing	   the	   AfS/PET28A+	   plasmid	   were	   grown	   in	   Luria	  Broth	   (LB)	  with	  50	  μg/ml	  kanamycin	   at	   37	   °C,	   shaking	   at	   220	   rpm.	  Once	   the	  culture	  OD600	  had	   reached	  0.9,	  AfS	  expression	  was	   induced	  by	  addition	  of	  0.5	  mM	   isopropyl	   thio-­‐β-­‐D-­‐galactopyranoside	   (IPTG)	   and	   incubated	   overnight	   at	  37	  °C.	  Cells	  were	  then	  harvested	  by	  centrifugation	  at	  16,780	  X	  g	  for	  25	  mins	  and	  re-­‐suspended	   in	   phosphate	   buffered	   saline	   (PBS)	   (50mM	   NaH2PO4,	   300	   mM	  NaCl,	  pH	  8)	  containing	  EDTA-­‐free	  protease	  inhibitor	  cocktail	  (one	  tablet	  per	  25	  ml	  of	  solution;	  Roche	  Diagnostics)	  and	  DNase	   I	   (Sigma,	   final	  concentration	  20	  μg/	  ml).	  The	   lysate	  was	  sonicated	   five	  times	   for	  30	  s	  at	  10	  mA.	  The	  sonicated	  culture	  was	   centrifuged	   to	   remove	   insoluble	   cell	   debris	   at	   37,000	   X	  g	   for	   30	  mins.	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Figure	  2.1:	   (A)	  SDS-­‐PAGE	  gel	  showing	  the	  results	  from	  HisTrap	  affinity	  chromatography	  of	  AfS.	  Even	  in	  the	  whole	  cell	  pellet	  (WC)	  a	  band	  corresponding	  to	  AfS	  can	  clearly	  be	  seen	  at	  ~44	  kDa	  showing	  AfS	   is	  expressed	  extremely	  well.	  The	  same	  band	  can	  be	   seen	   in	   the	  soluble	  fraction	  post	  sonication	  (Son)	  but	  not	  in	  the	  HisTrap	  flow	  through	  (FT)	  and	  is	  thus	  soluble	  and	  binds	  well	  to	  the	  column.	  Some	  AfS	  is	  evident	  in	  the	  wash	  fractions	  (W1-­‐3).	  AfS	  is	   clearly	   the	   dominant	   protein	   in	   the	   elution	   fractions	   (E1-­‐3),	   however	   there	   are	   still	  significant	  contaminants	  including	  a	  strong	  band	  at	  roughly	  97	  kDa	  which	  was	  confirmed	  to	  be	  AfS	  also.	  (B)	  Post	  gel	  filtration	  AfS	  is	  pure	  with	  evidence	  of	  AfS	  at	  97	  kDa	  also.	  	  The	  supernatant	  was	  filtered	  through	  a	  0.22	  μm	  pore	  syringe	  driven	  filter	  before	   being	   loaded	   onto	   a	   5	   ml	   HisTrap	   column	   (GE	   Healthcare)	  equilibrated	   with	   PBS.	   The	   bound	   protein	   was	   washed	   with	   five	   column	  volumes	  of	  150	  mM	  imidazole	  in	  PBS	  and	  eluted	  with	  five	  column	  volumes	  of	   300	   mM	   imidazole	   in	   PBS.	   The	   eluted	   fraction	   was	   subjected	   to	   size	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exclusion	   chromatography	   by	   loading	   onto	   a	   120ml	   Sephacryl	   S-­‐200	  column	   (GE	   Healthcare)	   equilibrated	  with	   50	  mM	   Tris-­‐HCl,	   100mM	  NaCl	  pH8	  (Figures	  2.1	  &	  2.2).	  Fractions	  containing	  AfS	  were	  identified	  and	  purity	  assessed	   by	   SDS-­‐PAGE	   and	   matrix-­‐assisted	   laser	   desorption/ionisation	  time-­‐of-­‐flight	  mass	   spectrometry	   (MALDI-­‐TOF	  MS)	   (Figure	  2.3).	   Fractions	  containing	  a	  high	  purity	  of	  AfS	  were	  pooled,	  concentrated	  and	  stored	  at	  -­‐20	  °C.	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Figure	   2.3.	   The	   sequence	   for	   expressed	   AfS.	   The	   protein	   was	   subjected	   to	   trypsin	  digestion	  and	  analysed	  by	  matrix-­‐assisted	  laser	  desorption/ionisation	  time-­‐of-­‐flight	  mass	  spectrometry.	  The	  peptide	  masses	  identified	  following	  trypsin	  digest	  (shown	  here	  in	  red)	  span	  more	  than	  60%	  of	  the	  protein.	  	  	  
2.2.2.	  Selenomethionine	  incorporation	  	  Tuner	  E.	  coli	  cells	  expressing	  the	  AfS/PET28A+	  plasmid	  were	  grown	  in	  150	  ml	   LB	  with	  50	  μg/ml	   kanamycin	   at	   37	   °C,	   shaking	   at	   220	   rpm	  overnight.	  Cells	  were	  harvested	  by	  centrifugation	  at	  4000	  rpm	  for	  20	  mins	  at	  4	  °C.	  The	  supernatant	  was	  discarded	  and	  the	  pellet	  was	  re-­‐suspended	  in	  100	  ml	  PBS	  and	  centrifuged	  again	  the	  supernatant	  was	  discarded,	  and	  the	  pellet	  was	  re-­‐suspended	   in	   4	  ml	   PBS	   and	   added	   to	   1	   L	   sterile	   selenomethionine	  media	  (17	  mM	  NH4Cl,	  22	  mM	  KH2PO4,	  6	  mM	  Na2HPO47H2O,	  25	  μM	  Fe2(SO4)3	  and	  30	   μM	   thiamine,	   20%	   w/v	   glucose,	   0.3%	   w/v	   MgSO4).	   50mg	   of	  selenomethionine	   and	   kanamycin	   (50μg/ml)	   were	   added	   using	   a	   sterile	  technique	   to	   the	   selenomethionine	  minimal	  media.	  The	   culture	   incubated	  at	  37	  °C,	  shaking	  at	  200	  rpm,	  until	  the	  OD600	  reached	  0.9	  and	  AfS	  expression	  was	  induced	  by	  0.5	  mM	  IPTG	  and	  incubated	  overnight	  at	  37	  °C.	  Cells	  were	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harvested	  and	  AfS	  extracted,	  purified	  and	  crystallized	  as	  described	  with	  the	  native	   structure.	   Selenomethionine	   incorporation	   was	   confirmed	   by	  MALDI-­‐TOF	  MS	  at	  sites	  M43	  and	  M223	  of	  the	  6	  possible	  sites	  (Figure	  2.4).	  This	   does	   not	   exclude	   the	   incorporation	   of	   selenomethionine	   in	   other	  positions	  due	  to	  the	  limitation	  in	  peptide	  mass	  coverage	  in	  the	  MALDI-­‐TOF	  MS	  experiments.	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2.2.3.	  Protein	  crystallization	  	  The	   optimal	   AfS	   concentration	   for	   crystallization	   trials	   was	   determined	   as	  ≈13.7	   mg/ml	   by	   a	   pre-­‐crystallization	   assay	   according	   to	   manufacturers	  instructions	   (Hampton	   Research).	   Sitting	   drop,	   vapour	   diffusion	   plates	  (Molecular	   dimensions),	   incubated	   at	   20	   °C	   were	   used	   for	   all	   crystallization	  experiments.	   To	   ascertain	   crystallization	   conditions	   for	   AfS,	   commercial	  screens	  Cryo	  I	  and	  II	  (Emerald	  Biosystems),	  Crystal	  screens	  I	  and	  II	  (Hampton	  Research),	   Index	   (Hampton	   Research),	   PEG	   screen	   (Qiagen)	   and	   Wizard	  (Emerald	   Biosystems)	   were	   used.	   150	   μl	   of	   purified	   AfS	   was	   added	   to	   each	  screen	  condition	  in	  a	  1:1	  ratio	  by	  the	  high	  throughput	  Rhombix	  Screen®	  robot	  (Rhombix).	   Crystals	   from	   the	   PEG	   screen	   (Qiagen),	   containing	   20	   %	   (w/v)	  polyethylene	  glycol	  (PEG)	  3350	  and	  0.2	  M	  sodium	  nitrate,	  appeared	  after	  four	  days	  and	  did	  not	  require	  any	  optimisation	  (Figure	  2.5).	  The	  AfS	  structure	  with	  selenomethionine	   incorporated	   crystallized	   in	   identical	   conditions.	   The	  structures	   of	   AfS	   in	   complex	   with	   KDN,	   KDN2en	   and	   KDF	   were	   achieved	   by	  soaking	   AfS	   crystals	   following	   addition	   of	   1	   μl	   of	   70	   mM	   KDN-­‐MU,	   100	   mM	  KDN2en	  or	  500	  mM	  KDF	  to	  a	  4	  μl	  well	  containing	  a	  1:1	  ratio	  of	  13.7	  mg/ml	  AfS	  and	  20	  %	  (w/v)	  PEG	  3350	  and	  0.2	  M	  sodium	  nitrate	  and	  leaving	  for	  20	  mins.	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Figure	   2.5.	   AfS	   crystal	   mounted	   in	   a	   0.7	   mm	   loop.	   The	   crystal	   was	   cryoprotected	   in	  crystallization	  buffer	  with	  20%	  (w/v)	  glycerol.	  	  	  	  
2.2.4.	  Data	  collection	  	  Crystals	   were	   cryoprotected	   by	   transfer	   to	   a	   drop	   containing	   20%	   (w/v)	  glycerol	  in	  crystallization	  buffer	  for	  a	  few	  seconds	  prior	  to	  placement	  in	  liquid	  nitrogen.	  Native	  data	  were	  collected	  at	  100	  K	  in	  house	  (Rigaku-­‐MSC	  Micromax-­‐007	   X-­‐ray	   generator	   and	   Saturn	   944+	   CCD	   detector).	   Selenomethionine	  incorporated	   crystals	   were	   sent	   to	   the	   ESRF	   in	   Grenoble	   for	   remote	   multi-­‐wavelength	  data	   collection.	  MOSFLM	   (Leslie,	   2006)	  was	  used	   to	   integrate	   the	  data	  and	  POINTLESS	  in	  the	  CCP4	  suite	  (Winn	  et	  al.,	  2011)	  determined	  the	  space	  group	  to	  be	  P21.	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2.2.5.	  Structure	  determination	  and	  refinement	  	  The	   structure	   determination	   of	   AfS	   was	   done	   using	   data	   collected	   at	   the	  selenium	   absorption	   peak.	   The	   selenium	   peak	   itself	   was	   0.9794	   Å,	   as	  determined	   by	   a	   fluorescence	   scan	   performed	   on	   the	   crystal	   at	   the	   ESRF,	  Grenoble.	  The	  data	  were	  integrated	  and	  scaled	  using	  HKL2000	  (Otwinowski	  &	  Minor,	   1997)	   and	   processed	   using	   SHELXC	   to	   calculate	   the	   heavy	   atom	  structure	   factor	   estimates	   from	   the	   anomalous	   differences	   (Table	   2.1).	   Using	  SHELXD	   with	   data	   to	   2.4	   Å	   the	   location	   of	   the	   selenium	   sites	   within	   the	  asymmetric	   unit	   were	   derived	   (Table	   2.2).	   There	   were	   10	   selenium	   sites	  identified	  by	  SHELXD	  from	  the	  anomalous	  differences.	  	  	  	  	  
	  Table	  2.1.	  Structure	  factor	  estimates,	  by	  resolution,	  as	  determined	  using	  SHELXC	  from	  the	  anomalous	  differences.	  	  	  	  	  	  	  























N(data)	   892	   1223	   1511	   3396	   3411	   4532	   3254	   4341	   5803	   7988	   8394	  
I/sigI	   18.9	   18.2	   17.4	   19.8	   18.9	   17.7	   15.8	   14.2	   13.0	   11.8	   10.4	  
Completeness	  (%)	   96.1	   99.9	   99.8	   99.3	   99.6	   99.8	   99.8	   99.9	   99.9	   99.9	   99.1	  
d"/Sig	   1.40	   1.32	   1.15	   1.03	   0.93	   0.93	   0.94	   0.90	   0.86	   0.81	   0.77	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Selenium	  
site	  
x	   y	   z	   Occupancy	  
1	   0.1947170	   0.513657	   0.354412	   1	  
2	   -­‐0.0461040	   0.271523	   0.170002	   0.9967	  
3	   0.4038390	   0.329254	   0.536167	   0.9599	  
4	   0.0349200	   0.558983	   0.521083	   0.9292	  
5	   -­‐0.4189610	   0.482971	   0.068607	   0.95	  
6	   -­‐0.1919020	   0.314224	   -­‐0.04488	   0.896	  
7	   -­‐0.140556	   0.43557	   0.032474	   0.6908	  
8	   0.135094	   0.389526	   0.411823	   0.5844	  
9	   -­‐0.340294	   0.611885	   -­‐0.045491	   0.4495	  
10	   0.331345	   0.210114	   0.399776	   0.3829	  
Table	  2.2.	  Heavy	  atoms	  identified	  by	  SHELXC	  and	  their	  predicted	  positions	  in	  the	  unit	  cell.	  	  	  SHELXE	   was	   used	   to	   resolve	   the	   phase	   ambiguity	   and	   to	   apply	   15	   cycles	   of	  density	   modification,	   and	   was	   run	   a	   second	   time	   with	   the	   heavy	   atom	  coordinates	  inverted	  to	  determine	  the	  correct	  hand	  of	  the	  solution.	  SHELXE	  also	  applied	  2-­‐fold	  non-­‐crystallographic	  symmetry	  and	  the	  phases	  were	  extended	  to	  1	  Å	  using	  the	  “free	  lunch”	  algorithm	  which	  resulted	  in	  an	  outstanding	  map	  with	  a	  clear	  protein/solvent	  boundary	  (Sheldrick,	  2010)	  (Figure	  2.6A).	  Using	  this	  map	  SHELXE	  also	  performed	  6	  cycles	  of	  autotracing	  to	  produce	  a	  polyalanine	  trace	  of	  the	   structure	   which	   included	   690	   alanine	   residues	   (Figure,	   6B	   &	   C).	   The	   free	  lunch	  algorithm	  is	  a	  powerful	  tool	  and	  from	  the	  map	  produced	  it	  was	  possible	  to	  interpret	  the	  map	  and	  produce	  a	  fairly	  accurate	  model	  (Figure	  2.6B).	  It	  should	  be	  noted	   however	   that	   the	   phases	   produced	   by	   the	   free-­‐lunch	   algorithm	   are	   an	  extension	  of	  the	  experimentally	  derived	  data	  but	  are	  not	  experimentally	  derived	  themselves.	   Hence	   the	   experimentally	   derived	   phases	   to	   2.15	   Å	   from	   SHELXE	  were	  used	  in	  Phenix	  (Adams	  et	  al.,	  2002).	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Figure	   2.6.	   2Fo-­‐Fc	   map	   generated	   by	   the	   ‘free-­‐lunch’	   algorithm	   in	   SHELXE	   which	   extends	  experimental	  phases	  to	  1	  Å	  (A,	  B	  &	  C).	  From	  the	  map	  there	  is	  a	  clear	  protein/solvent	  boundary	  (A)	   and	   even	   the	   side	   chains	   of	   most	   residues	   are	   discernable	   (B).	   SHELXE	   also	   produced	   a	  polyalanine	  model	  of	  AfS	  (C).	  	  Given	   the	   sequence	   of	   the	   AfS,	   Phenix	   performed	   8	   cycles	   of	   autobuilding	   by	  breaking	   the	   sequence	   down	   into	   fragments	   and	  modelling	   them	   individually.	  The	   final	   model	   produced	   included	   760	   residues,	   380	   amino	   acids	   for	   each	  monomer	  in	  the	  asymmetric	  unit,	  a	  meagre	  5	  residues	  less	  than	  the	  final	  model.	  
!"# $"#
%"#
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After	  3	  refinement	  cycles	  in	  phenix	  the	  Rwork	  and	  Rfree	  for	  this	  model	  were	  0.21	  and	  0.25	   respectively.	  This	  model	  was	   refined	   in	  REFMAC5	   initially	  using	   rigid	  body	  refinement	  followed	  by	  rounds	  of	  restrained	  refinement	  (Murshudov	  et	  al.,	  1997)	   using	   the	   native	   data	   to	   1.84	   Å.	   The	   model	   was	   manually	   fitted	   and	  improved	   with	   Coot	   (Emsley	   and	   Cowtan,	   2004).	   The	   resulting	   model	   was	  validated	  by	  Coot	  and	  MolProbity	  (Lovell	  et	  al.,	  2003)	  before	  submission	  to	  the	  PDB,	  accession	  code	  2XCY.	  	  The	  model	  2XCY	  was	  refined	  in	  REFMAC5	  against	  data	  collected	  for	  each	  of	  the	  complexes	  AfS-­‐KDN,	  AfS-­‐KDN2en	  and	  AfS-­‐KDF.	  2D	  Chemdraw	  representations	  of	  ligands	  were	  submitted	  to	  the	  PRODRG	  server	  (Schuttelkopf	  &	  van	  Aalten,	  2004)	  to	   produce	   appropriate	   3D	   representations	   including	   geometric	   constraints	  which	  are	  essential	  for	  modelling	  purposes.	  Manual	  modelling	  of	  the	  protein	  and	  the	  soaked	   ligands	  was	  carried	  out	   in	  Coot	  and	   further	  refined	  with	  REFMAC5.	  Again	   the	   resulting	  model	  was	   validated	  by	  Coot	   and	  MolProbity	   (Lovell	   et	   al.,	  2003)	  before	  submission	  to	  the	  PDB.	  	  	  
2.2.6	  Protein	  databank	  accession	  codes	  	  Refined	  structures	  were	  deposited	  in	  the	  Protein	  Data	  Bank	  and	  given	  accession	  codes	  2XCY	   (apo	  structure),	  2XZI	   (KDN	  complex),	  2XZJ	   (KDN2en	  complex)	  and	  2XZK	  (KDF	  complex).	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   SeMet	  2.15	   SeMet	  1.84	   KDN	  complex	   KDN2en	  
complex	  
Covalent	  	  	  	  	  	  	  	  	  
intermediate	  
Data	  collection	  a	   	   	   	   	   	  
X-­‐ray	  source	   ID23-­‐1	   In	  house	   	  	  	  	  	  	  ID29	   In	  house	   ID14-­‐1	  
X-­‐ray	  wavelength	  (Å)	   0.9794	   1.542	   	  	  	  	  	  	  0.979	   1.542	   0.934	  
Resolution	  (Å)	   58.2-­‐2.15	  (2.26-­‐2.15)	   12.4-­‐1.84	  (1.94-­‐1.84)	   37.3-­‐1.45	  (1.53-­‐1.45)	   12.4-­‐1.84	  (1.94-­‐1.84)	   31.1-­‐1.50	  (1.54-­‐1.50)	  
Unit	  cell	  dimensions	   	   	   	   	   	  
a(Å)	   76.1	   75.9	   75.8	   75.8	   75.6	  
b(A)	   58.2	   58.2	   58.0	   58.1	   58.1	  
c	  (Å)	   94.7	   94.7	   94.8	   94.4	   94.4	  
β 	  (°)	  	   100.0	   100.0	   100.1	   99.92	   100.0	  
No.	  observations	   318,537	   228,526	   504,295	   214,982	   342,750	  
Redundancy	   7.1	  (6.9)	   3.1	  (3.0)	   3.5	  (3.4)	   3.1	  (2.8)	   3.1	  (2.8)	  
Completeness(%)	   99.9	  (99.7)	   84.2	  (64.8)	   99.5	  (97.6)	   98.8	  (95.0)	   86.2	  (47.0)	  
Rmerge	  (%)	  b	   9.9	  (13.7)	   3.0	  (19.6)	   8.1	  (24.5)	   8.6	  (15.3)	   5.6	  (29.0)	  
I/σI	   14.6	  (10.2)	   15.6	  (64.8)	   9.4	  (4.3)	   9.8	  (5.3)	   12.9	  (3.5)	  
Refinement	   	   	   	   	   	  
Reflections	  used	   	   61,943	   142,319	   97,843	   105,520	  
No.	  atoms	   	   7,000	   7,287	   7,184	   7,265	  
Number	   of	   protein	  
atoms	  
	   5,940	   6,021	   5,935	   6,000	  
Number	  of	  water	  	  
molecules	  
	   1,055	   1,159	   1,201	   1,095	  
Number	   of	   ligand	  
atoms	  
	   N/A	   72	   34	   133	  
Average	  B-­‐factor	  (Å2)	   	   11.6	   12.2	   5.3	   13.9	  
Protein	   	   9.5	   9.5	   5.4	   11.3	  
Water	   	   23.5	   25.7	   6.4	   27.5	  
Ligand	   	   N/A	   18.7	   4.9	   18.2	  
R-­‐factor	  c	   0.17	   0.153	   0.180	   0.1967	   0.1792	  
R-­‐free	  d	   0.208	   0.194	   0.205	   0.2593	   0.2138	  
Root	  mean	  square	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
deviation	  in	  bond	  length	  
(Å)	  
0.009	   0.009	   0.009	   0.010	   0.009	  
Root	  mean	  spuare	  
deviation	  in	  bond	  
angles	  (°)	  
1.16	   1.13	   1.29	   1.32	   1.26	  
PDB	  code	   	   2XCY	   2XZI	   2XZJ	   2XZK	  
Table	  2.3.	  Data	  collection	  and	  refinement	  statistics	  	  a	  =	  Values	  in	  parenthesis	  correspond	  to	  the	  highest	  resolution	  shell.	  b	  =	  Rmerge	  =	  ∑hkl	  ∑i	  |Ihkl,	  i	  –	  〈	  Ihkl	  〉|	  /	  ∑hkl	  〈	  Ihkl	  〉	  c	  &	  d	  =	  R-­‐factor	  and	  R-­‐free	  =	  (Σ	  |	  |Fo|	  -­‐	  |Fc|	  |)/(Σ	  |Fo|),	  where	  the	  Rfree	  was	  calculated	  from	  5%	  of	  reflections	  excluded	  from	  refinement.	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2.3	  Results	  and	  discussion	  	  
2.3.1.	  AfS	  primary	  sequence	  analysis	  	  Bioinformatic	  analysis	  using	  Target	  P	  (Emanuelsson	  et	  al.,	  2007)	  of	  the	  primary	  sequence	  of	  AfS	  in	  the	  Fungal	  Secretory	  Database	  indicates	  the	  presence	  of	  a	  20	  amino	   acid	   signal	   sequence.	   The	   signal	   sequence	   is	   predicted	   to	   target	  AfS	   for	  extracellular	  secretion	  similar	  to	  sialidases	  NanA	  and	  NanB	  from	  S.	  pneumoniae.	  In	  this	  way,	  AfS	  would	  be	  perfectly	  targeted	  to	  remove	  sialic	  acid	  from	  the	  fungal	  environment	  or	  act	  as	  a	  virulence	  factor	  as	  in	  the	  case	  of	  NanA.	  	  
2.3.2.	  AfS	  architecture	  	  There	   are	   two	   monomers	   of	   AfS	   in	   the	   asymmetric	   unit.	   The	   rmsd	   of	   the	   Cα	  chains	   of	   the	   two	  monomers	   is	   0.5	   Å	   and	   no	   significant	   structural	   differences	  were	   identified	   between	   them.	   Analysis	   of	   the	   interface	   between	   the	   two	  monomers	   by	   PDBePISA	   (Krissinel	   and	   Henrick	   2007)	   measure	   the	   buried	  surface	   area	  between	   the	   two	  monomers	   to	  be	  882.8	  A2	  which	   represents	   less	  than	   3%	   of	   the	   solvent	   accessible	   area.	   Due	   to	   the	   minimal	   protein	   contacts	  between	   the	   two	   monomers	   it	   is	   unlikely	   to	   form	   a	   dimer	   in	   vivo.	   The	   local	  atomic	  density,	  as	  calculated	  in	  Proface	  as	  the	  average	  number	  of	  atoms	  within	  a	  12	   Å	   radius	   of	   any	   given	   atom	   in	   the	   defined	   interface	   between	   the	   two	  monomers	   (Bahadur	   et	   al.,	   2004;	   Saha	   et	   al.,	   2006),	   is	   22.26	   and	   24.75	   for	  monomer	  A	  and	  B	  respectively.	  Crystal	  packing	  interfaces	  have	  an	  average	  local	  atomic	  density	  of	  <32,	  however	  genuine	  homodimers	  average	  a	   local	  density	  of	  >44	   (Bahadur	   et	   al.,	   2004).	   The	   local	   density	   of	  AfS	   is	   significantly	   lower	   than	  that	  of	  a	  typical	  homodimer	  thus	  is	  unlikely	  to	  exist	  as	  dimer	  in	  solution.	  This	  is	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Organism	   Reference	  
2XCY	   B	   0.5	   100	   KDNase	   AfS	   A.	  fumigatus	   Telford	  et	  
al.,	  2010	  
2VK7	   B	   1.8	   24	   Sialidase	   NanI	   C.	  perfringens	   Newstead	  
et	  al.,	  2008	  
1W8N	   A	   2	   29	   Sialidase	   MvS	   M.	  viridifaciens	   Watson	  et	  
al.,	  2003	  
2VVZ	   A	   2.1	   25	   Sialidase	   NanA	   S.	  pneumoniae	   Xu	  et	  al.,	  
2008a	  
4FJ6	   B	   2.1	   24	   Putative	  
sialidase	  
N/A	   P.	  distasoris	   Unpublish
ed	  
2SLL	   A	   2.1	   19	   intramolecular	  
trans-­‐sialidase	  
NanL	   M.	  decora	   Luo	  et	  al.,	  
1999	  
2VW2	   A	   2.1	   18	   Sialidase	   Nan	  B	   S.	  pneumoniae	   Xu	  et	  al.,	  
2008b	  
1VCU	   A	   2.6	   25	   Sialidase	   Neu2	   Homo	  sapiens	   Chavas	  et	  
al.,	  2005	  
2AGS	   A	   2.3	   20	   Sialidase	   TrSA	   T.	  rangeli	   Watts	  et	  
al.,	  2006	  
1MS3	   A	   2.4	   21	   trans-­‐sialidase	   TcTS	   T.	  cruzi	   Buschiazzo	  
et	  al.,	  2002	  
	  Table	  2.4.	  	  Top	  unique	  structures	  with	  best	  structural	  homology	  to	  AfS.	  As	  would	  be	  expected	  all	  structures	  identified	  to	  have	  structural	  homology	  to	  AfS	  are	  sialidases.	  Despite	  all	  having	  sequence	  identity	  of	  less	  than	  24%,	  the	  rmsd	  between	  the	  Cα	  chain	  is	  as	  low	  as	  1.8	  Å.	  	  	  Despite	  29%	  sequence	  identity	  and	  significant	  structural	  homology	  it	  was	  not	  possible	  to	  solve	  the	  phase	  problem	  by	  molecular	  replacement	  with	  MvS	  (Protein	  Data	  Bank	  codes	  1EUR	  and	  1EUS)	  (Gaskell	  et	  al.,	  1995),	  the	  closest	  known	  primary	  sequence	  homologue	  to	  AfS.	  MvS	  and	  AfS	  have	  an	  rmsd	  of	  1.44Å	  across	  309	  Cα	  atoms.	  	  	  
AfS	  possesses	  2	  bacterial	  neuraminidase	  repeats	  also	  referred	  to	  as	  BNRs	  or	  ASP-­‐boxes.	  The	  structure	  of	  AfS	  is	  most	  similar	  to	  NanI	  from	  C.	  perfringens	  and	  MvS	  from	  M.	  viridifaciens	  (Table	  2.4).	  Taken	  together	  these	  data	  suggests	  that	  AfS	  may	  have	  been	  acquired	  through	  horizontal	  gene	  transfer	  from	  a	  bacterial	  origin,	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however	  structural	  data	  on	  eukaryotic	  sialidases	  is	  too	  limited	  to	  provide	  a	  large	  enough	  data	  set	  to	  state	  this	  conclusively.	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which	   is	  more	   electron	   dense	   and	  would	   be	   expected	   to	   have	   a	  much	   greater	  electron	   density.	   	   To	   confirm	   this,	   the	  model	  was	   refined	  with	   calcium	   in	   this	  position	   and	   the	   resulting	   difference	   map	   displayed	   negative	   electron	   density	  suggesting	   that	   there	   is	   insufficient	   electron	   density	   to	   support	   the	   binding	   of	  calcium.	  The	  binding	  of	  sodium	  is	  consistent	  with	  the	  presence	  of	  sodium	  in	  the	  buffer.	   From	   the	   electron	   density	   alone	   it	   is	   not	   possible	   to	   rule	   out	   that	   this	  metal	  ion	  is	  in	  fact	  calcium	  with	  a	  lower	  occupancy.	  The	  metal	  ion	  is	  co-­‐ordinated	  by	   the	   side	   chain	   carbonyls	   of	   Asp87	   and	   Asn89	   as	   well	   as	   the	   backbone	  carbonyls	  of	  Gly116	  and	  Gly118.	  Two	  water	  molecules	  either	   side	  of	   the	  metal	  ion	  complete	  the	  octahedral	  co-­‐ordination	  of	  the	  ion.	  	  
2.3.3.	  AfS	  Active	  site;	  Protein-­‐substrate	  complexes	  	  Sialidases	   are	   atypical	   retaining	  glycoside	  hydrolases.	  They	  are	   atypical	   in	   that	  although	  they	  also	  use	  acid/base	  catalysis	  to	  hydrolyze	  the	  glycosidic	  bond,	  the	  nucleophile	   in	   this	   mechanism	   is	   actually	   a	   tyrosine.	   The	   tyrosine	   is	   made	  nucleophilic	  by	  a	  conserved	  glutamic	  acid.	  The	  nucleophilic	  tyrosine	  attacks	  the	  anomeric	   carbon	   and	   the	   catalysis	   is	   completed	   by	   protonation	   of	   the	   leaving	  group	  by	  the	  catalytic	  aspartic	  acid,	  Asp84.	  Mutation	  of	   these	  residues	  severely	  perturbs	   the	   catalytic	   mechanism	   leading	   to	   lower	   activity	   or	   an	   alternative	  product.	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Figure	   2.10.	   Overlay	   of	   the	   AfS	   active	   site	   (green)	   with	   the	   active	   site	   of	   the	   sialidase	   from	  
Micromonospora	  viridifaciens	  (blue).	  The	  amino	  acids	  essential	  to	  efficient	  catalysis	  are	  shown	  in	  stick	   format.	   These	   highly	   conserved	   residues	   are	   in	   almost	   identical	   positions	   relative	   to	   the	  enzyme	  products	  Neu5Ac	  (blue)	  and	  KDN	  (yellow).	  	  The	   active	   site	   of	   AfS	   possesses	   all	   of	   the	   essential	   amino	   acids	   for	   efficient	  catalysis;	  the	  nucleophilic	  tyrosine	  (Tyr358),	  glutamic	  acid	  (Glu249)	  and	  aspartic	  acid	   (Asp84).	   Overlay	   of	   the	   AfS	   active	   site	   with	  MvS	   shows	   that	   there	   is	   no	  significant	   difference	   in	   the	   positions	   of	   the	   active	   site	   residues	   relative	   to	   the	  sialic	   acid	   product	   (Figure	   2.10).	   Similarly,	   the	   characteristic	   arginine	   triad	  involved	  in	  binding	  and	  stabilisation	  of	  the	  carboxylic	  acid	  of	  sialic	  acid	  is	  in	  an	  almost	  identical	  position	  in	  AfS	  as	  in	  MvS.	  Despite	  repeated	  soaking	  attempts	  at	  co-­‐crystallization	  with	  Neu5Ac	  no	  structure	  of	  AfS	  in	  complex	  with	  Neu5Ac	  was	  obtained.	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Further	   inspection	   of	   the	   AfS	   active	   site	   revealed	   that	   the	   pocket	   that	   would	  usually	   accommodate	   the	   N-­‐acetyl	   group	   on	   the	   C5	   of	   Neu5Ac	   was	   unusually	  charged	   and	   very	   shallow.	   Generally	   sialidases	   have	   a	   hydrophobic	   cavity	   that	  accommodates	   the	   N-­‐acetyl	   group	   of	   Neu5Ac	   as	   can	   be	   seen	   in	  MvS	   (Figure	  2.11A).	  Overlay	  of	  the	  structure	  of	  the	  MvS-­‐Neu5Ac2en	  complex,	  1EUS,	  with	  AfS	  suggests	   that	  AfS	  does	  not	  possess	  such	  a	  cavity	  and	  would	  be	  too	  shallow	  and	  charged	  to	  allow	  binding	  of	  Neu5Ac	  (figure	  2.11B).	  In	  AfS	  the	  equivalent	  pocket	  contains	  an	  arginine	  (Arg171),	  which	  would	  be	  predicted	  to	  be	  only	  1.7	  Å	  from	  the	   methyl	   of	   the	   N-­‐acetyl	   substituent	   of	   Neu5Ac.	   The	   ketone	   of	   the	   N-­‐acetyl	  substituent	   is	   predicted	   to	   be	   only	   2.3	   Å	   from	   the	   side	   chain	   of	   Trp202.	   The	  hydrophobic	  environment	  created	  by	  this	  tryptophan	  is	  unfavourable	  for	  binding	  of	  the	  hydrophilic	  ketone.	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possesses	   a	  modest	   hydroxyl	   (Figure	  2.12).	   It	  was	  hypothesised	   therefore	   that	  KDN	  with	  its	  smaller	  C5	  group	  would	  be	  capable	  of	  binding	  in	  this	  tighter	  cavity.	  
	  
Figure	   2.12.	   The	   chemical	   structures	   of	   Neu5Ac,	   KDN,	   KDN2en	   and	   KDF.	   The	   more	   common	  sialic	  acid	  Neu5Ac	  only	  differs	  from	  its	  family	  member	  KDN	  by	  the	  presence	  of	  an	  N-­‐acetyl	  group,	  rather	  than	  a	  hydroxyl,	  on	  the	  C5	  of	  the	  pyranose	  ring.	  KDN2en	  is	  the	  transition	  state	  analogue	  of	  the	  sialidase	  catalysed	  hydrolysis	  of	  KDN.	  The	  substitution	  of	  the	  C2	  hydroxyl	  and	  the	  C3	  proton	  for	   more	   electronegative	   fluorines	   allows	   the	   trapping	   of	   the	   enzyme-­‐substrate	   transient	  covalent	  bond.	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2.3.4.	  AfS	  complexes	  
2.3.4.1	  AfS-­‐KDN	  complex	  	  
	  







Figure 1.9 The structure of the covalent-forming compound 2, 3F-Neu5Ac. Formula: C11H17F2NO8; 
















Figure 1.10 The currently proposed mechanism for sialidase catalysis. Modified from a previously 
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is	   poised	   above	   the	   O2	   of	   KDN	   on	   the	   opposite	   side	   to	   Tyr358.	   Interactions	  between	  Arg78	  and	  the	  hydroxyl	  on	  the	  C4	  of	  KDN	  increase	  binding	  affinity;	  as	  do	   interactions	  mediated	  by	  water	  molecules	  between	  Glu56	  and	  Asn104	  with	  the	   hydroxyls	   of	   the	   C4	   and	   C5	   of	   KDN	   respectively.	   KDN	   binding	   is	   further	  enhanced	  by	  hydrogen	  bond	  interactions	  between	  hydroxyls	  on	  the	  C7	  and	  C9	  of	  the	   glycerol	  moiety	   of	  KDN	  with	  Gln128	   from	   the	   cap	   region	   (Figure	   2.14).	   As	  predicted,	  the	  cavity	  accommodating	  the	  C5	  hydroxyl	  of	  KDN	  is	  very	  limited.	  The	  C5	  hydroxyl	  sits	  only	  3.4	  Å	  from	  Trp202	  and	  4.5	  Å	  from	  Arg171	  at	  their	  closest	  points	  and	  thus	  addition	  of	  an	  N-­‐acetyl	  at	  this	  position,	  as	  in	  Neu5Ac,	  would	  be	  too	  large	  and	  prevent	  binding.	  	  
Figure	  2.14.	  Stereo	  diagram	  of	  the	  Michalis	  complex	  of	  the	  AfS	  (green	  carbons)	  product	  KDN	  (yellow	  carbons)	  with	  the	  active	  site.	  Hydrogen	  bonds	  are	  indicated	  with	  dashed	  lines	  and	  water	  molecules	  by	  red	  spheres.	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interactions	  with	   the	  AfS	   active	   site.	   The	   pyranose	   ring	   of	   KDF	   is	   bound	   in	   an	  unstrained	  2C5	  conformation,	  as	  opposed	  to	  the	  B2,5	  boat	  of	  KDN,	  which	  is	  similar	  to	  that	  seen	  in	  other	  sialidases	  with	  2,3-­‐difluoro-­‐Neu5Ac	  (Watts	  et	  al.,	  2003).	  In	  this	   structure	   the	   C2	   is	   only	   1.75	   Å	   from	   the	   oxygen	   of	   the	   Tyr358	   hydroxyl	  which	   is	  clearly	  too	  small	  a	  distance	  to	  be	  sterically	  tolerated	  unless	  a	  covalent	  bond	   is	   formed.	   Further	   to	   this	   there	   is	   clear	   electron	   density	   between	   the	   C2	  and	   catalytic	   tyrosine	   even	  when	   the	   2Fo-­‐Fc	  map	   is	   contoured	   at	   1	   sigma,	   that	  demonstrates	   the	  presence	  of	   the	   covalent	  bond	   (Figure	  2.15).	  The	   typical	  C-­‐O	  bond	   length	   is	   only	   1.4	   Å,	   as	   can	   be	   measured	   elsewhere	   in	   the	   structure	  including	   between	   the	   CZ	   and	   OH	   of	   the	   catalytic	   tyrosine.	   The	   increased	   C-­‐O	  bond	   length	   between	   the	   OH	   of	   the	   catalytic	   tyrosine	   and	   the	   C2	   of	   the	   KDF	  substrate	  in	  this	  complex	  structure	  is	  likely	  the	  result	  of	  the	  fleeting	  and	  unstable	  nature	  of	  this	  covalent	  bond	  even	  with	  the	  added	  influence	  of	  the	  fluorines	  at	  the	  3	  position	  of	  the	  pyranose	  ring.	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2.3.4.3	  AfS-­‐KDN2en	  complex	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on	   the	   C5	   of	   the	   pyranose	   ring	   that	   would	   be	   unable	   to	   fit	   in	   the	   modest	  hydrophobic	   cavity	   in	   AfS.	   Collaborators	   Prof	   Andrew	   Bennet	   and	   Dr	   Milton	  Kiefel	  from	  Simon	  Fraser	  University	  and	  Griffith	  University,	  respectively,	  kindly	  provided	   2,3-­‐didehydro-­‐2,3-­‐	   dideoxy-­‐D-­‐glycero-­‐D-­‐galacto-­‐nonulosonic	   acid	  (KDN2en)	  which	  is	  to	  KDN	  as	  Neu5Ac2en	  is	  to	  Neu5Ac	  (Figure	  12).	  The	  structure	  of	   AfS	   in	   complex	   with	   KDN2en	   was	   solved	   to	   1.84	   Å.	   In	   this	   structure	   the	  KDN2en	  binds	  in	  the	  active	  site	  in	  an	  almost	  identical	  position	  as	  KDN	  and	  KDF	  (Figure	   2.16).	   Once	   again	   it	   is	   the	   conformation	   of	   the	   ring	   that	   defines	   the	  difference	  between	  these	  structures.	  The	  removal	  of	  the	  hydroxyl	  from	  the	  C2	  of	  KDN	   to	   produce	   KDN2en	  mimics	   the	   catalytic	   process	   and	   the	   formation	   of	   a	  double	  bond	  between	  the	  C2	  and	  C3	  carbons	   is	  analogous	  of	   the	  pyranose	  ring	  conformation	  post	  cleavage	  of	  the	  glycosidic	  bond.	  In	  this	  structure	  the	  pyranose	  ring	   is	   in	   a	   4H5	   half	   chair	   conformation	   bringing	   the	   C2	   only	   2.8	   Å	   from	   the	  catalytic	   tyrosine	   in	   comparison	   with	   the	   3.2	   Å	   seen	   in	   the	   KDN	   complex	  structure	  (Figure	  2.16).	  	  	  	  	  	  	  	  	  	  	  
	   75	  
Figure	  2.17.	  The	  apo	  active	  site	  of	  AfS	  (grey)	  overlaid	  with	  the	  active	  sites	  in	  complex	  with	  AfS-­‐KDN	  (A,	  blue),	  KDN2en	  (B,	  purple)	  and	  KDF	  (C,	  green).	  	  There	  is	  no	  movenet	  in	  the	  side	  chains	  of	  the	  active	  site	  residues	  except	  that	  of	  the	  catalytic	  aspartic	  acid	  in	  the	  AfS-­‐KDF	  complex	  structure	  (C).	   Interestingly	   there	   is	  greater	  agreement	  between	  the	  asymmetric	  unit	  monomer	  A	  of	   the	  4	  
AfS	  structures	  than	  between	  the	  A	  and	  B	  monomers	  of	  the	  same	  asymmetric	  unit.	  This	  highlights	  that	  the	  structures	  are	  more	  alike	  than	  the	  2	  monomers	  in	  the	  asymmetric	  unit	  (D).	  	  	  There	  is	  little	  change	  to	  the	  overall	  structure	  of	  AfS	  upon	  binding	  of	  KDN,	  KDF	  or	  KDN2en	  (Figure	  2.17).	  This	  is	  particularly	  notable	  by	  the	  fact	  that	  the	  rmsd	  of	  the	  Cα	  chain	  between	  monomers	  A	  and	  B	  of	  apo-­‐AfS	   is	  higher	  than	  for	  monomer	  A	  and	  any	  of	  the	  complex	  structures	  (Figure	  2.17D).	  As	  the	  hydrolysis	  progresses	  the	   conformation	   of	   the	   substrate	   changes,	   however	   the	   active	   site	   residues	  show	   no	   significant	   alteration	   in	   positioning	   between	   the	   apo	   and	   complex	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structures.	  The	  exception	  to	  this	  is	  the	  catalytic	  aspartic	  acid,	  Asp84,	  which	  is	  in	  a	  dual	   conformation	   in	   the	  AfS-­‐KDF	   structure.	   This	   is	   also	   reported	   for	  Asp1266	  from	  NanI,	  the	  sialidase	  from	  C.	  perfringens	  (Newstead	  et	  al.,	  2008)	  and	  may	  be	  a	  feature	   of	   a	   number	   of	   sialidases	   that	   is	   not	   frequently	   captured	   in	   X-­‐ray	  structures.	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
Figure	  2.18.	  The	  overlay	  of	  the	  active	  site	  of	  AfS	  from	  each	  of	  the	  complex	  structures	  AfS-­‐KDN,	  
AfS-­‐KDN2en	   and	  AfS-­‐KDF.	   	   The	   positions	   of	   the	   active	   site	   residues	   remains	   the	   same	   in	   all	   3	  complex	   structures	   with	   the	   exception	   of	   the	   catalytic	   aspartic	   acid	   which	   is	   seen	   a	   dual	  conformation	  in	  the	  AfS-­‐KDF	  structure.	  The	  substrate	  KDN	  (green)	  binds	  in	  a	  boat	  conformation;	  it’s	  C2	  is	  3.2	  Å	  from	  the	  hydroxyl	  of	  the	  catalytic	  tyrosine.	  The	  attack	  of	  the	  nucleophilic	  tyrosine	  is	   captured	  with	   substrate	   analogue	  KDF	   (magenta)	   trapping	   the	   transient	   covalent	   bond	  with	  length	   1.7	  Å.	   The	   pyranose	   ring	   of	   KDF	   is	   forced	   into	   a	   chair	   conformation	   upon	   attack	   of	   the	  nucleophilic	  tyrosine.	  KDN2en,	  the	  transitions	  state	  analogue,	  is	  in	  a	  half	  chair	  conformation	  with	  the	  C2	  of	  the	  pyranose	  ring	  2.8	  Å	  from	  the	  hydroxyl	  of	  the	  catalytic	  tyrosine.	  
!
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  The	  conformation	  of	   the	  pyranose	  ring	   is	  distorted	  during	  the	  catalytic	  process	  (Figure	   2.18).	   As	   mentioned	   previously	   the	   substrate	   KDN	   exists	   in	   a	   2C5	   in	  solution	   however	   is	   distorted	   by	   the	   active	   site	   into	   a	   B2,5	  boat	   conformation	  were	  the	  C2	  is	  3.2	  Å	  from	  the	  catalytic	  tyrosine.	  	  This	  distance	  shortens	  to	  1.7	  Å	  upon	   binding	   of	   the	   substrate	   analogue	   KDF.	   This	   distance	   is	   indicative	   of	  formation	   of	   a	   covalent	   bond	   between	   the	   C2	   of	   the	   pyranose	   ring	   and	   the	  catalytic	  tyrosine.	  	  	  The	   leaving	   group	   is	   protonated	  by	  Asp84	   resulting	   in	   the	   formation	  of	   a	   high	  energy	  transition	  state.	  This	  transition	  state	  has	  a	  partial	  double	  bond	  between	  the	   C2	   and	   C3	   similar	   to	   the	   full	   double	   bond	   seen	   in	   the	   transition	   state	  analogue	  KDN2en.	  The	  pyranose	  ring	  of	  KDN2en	  is	  in	  a	  half	  chair	  conformation	  increasing	  the	  distance	  from	  the	  catalytic	  tyrosine	  to	  2.8	  Å.	  The	  catalytic	  process	  is	   completed	   by	   the	   attack	   of	   the	   C2	   by	   a	   water	   molecule	   that	   has	   been	  deprotonated	  by	  Asp84.	  	  	  
2.3.5.	  Further	  substrate	  binding	  sites	  
2.3.5.1	  The	  secondary	  binding	  site	  	  In	  the	  AfS-­‐KDN	  and	  AfS-­‐KDF	  complex	  structures	  there	  was	  a	  secondary	  binding	  site	   evident.	   This	   secondary	   binding	   site	   was	   located	   adjacent	   to	   the	   active	  site/primary	  binding	  site.	  The	  carboxylic	  acid	  of	  the	  KDN	  in	  this	  secondary	  site	  forms	  hydrogen	  bonds	  with	  the	  backbone	  nitrogen	  of	  Arg322	  that	  is	  located	  2.8	  Å	  away	  (Figure	  2.19).	  The	  C4	  and	  C5	  hydroxyls	  hydrogen	  bond	  with	  Arg323	  and	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Asp	  376	  respectively.	  	  It	  should	  be	  noted	  that	  this	  secondary	  site	  is	  so	  close	  to	  the	  active	   site	   that	   the	   residue	   Arg322	   is	   responsible	   for	   the	   stabilisation	   of	   the	  carboxylic	  acid	  of	  both	  the	  KDN	  in	  the	  active	  site	  and	  the	  secondary	  binding	  site	  (Figure	  2.19).	  The	  secondary	  site	  is	  predominantly	  positively	  charged	  and	  is	  part	  of	  a	  long	  groove	  that	  extends	  across	  the	  protein.	  Interestingly,	  in	  the	  AfS-­‐KDN2en	  structure	  there	  is	  only	  one	  molecule	  of	  KDN2en	  bound	  per	  molecule	  of	  AfS	  in	  the	  asymmetric	  unit.	  The	  KDN2en	  binds	  only	  in	  the	  active	  site	  cavity	  suggesting	  that	  the	   secondary	   site	   is	   unable	   to	   accommodate	   the	   altered	   conformation	   of	   the	  pyranose	  ring	  and	  is	  thus	  selective	  for	  KDN.	  No	  density	  for	  Neu5Ac2en,	  Neu5Ac	  or	  KDN2en	  was	  ever	  seen	  in	  the	  secondary	  site	  despite	  multiple	  soakings.	  	  The	  purpose	  of	  this	  secondary	  site	  may	  be	  to	  target	  AfS	  to	  high	  concentrations	  of	  KDN	   as	   is	   the	   case	   with	   carbohydrate	   binding	   modules	   (CBMs),	   which	   are	  common	   domains	   to	   sialidases	   (Boraston	   et	   al.,	   2007).	   The	   CBM	   domain	   of	   S.	  
pneumoniae	   NanA	   is	   an	   entirely	   separate	   domain	   from	   the	   catalytic	   domain	  linked	   by	   a	   disordered	   loop	   (Xu	   et	   al.,	   2008a).	   AfS	   is	   unusual	   in	   that	   the	  secondary	  KDN	  binding	  site	  is	  not	  located	  on	  a	  CBM	  distal	  from	  the	  active	  site.	  In	  the	  structures	  presented	  here	  there	  is	  only	  5.4	  Å	  from	  the	  carboxylic	  acid	  of	  the	  active	   site	   KDN	   to	   the	   C9	   of	   the	   KDN	   in	   the	   secondary	   site	   (Figure	   2.18).	   The	  close	  proximity	  of	  the	  secondary	  binding	  site	  might	  help	  to	  target	  and	  orient	  the	  active	   site	   to	   areas	   abundant	   in	   KDN	   and	   may	   act	   in	   a	   conveyer	   belt-­‐type	  mechanism	  in	  vivo.	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Figure	  2.19.	  Stereo	  image	  of	  the	  active	  site	  cavity	  and	  adjoining	  secondary	  binding	  site	  for	  KDN	  from	   the	   AfS-­‐KDN	   complex	   structure.	   Interactions	   less	   than	   3.5	   Å	   are	   depicted	   by	   the	   black	  broken	  lines.	  There	  are	  no	  direct	  interactions	  between	  the	  2	  KDN	  molecules	  in	  the	  active	  site	  and	  secondary	   site	   however	   there	   is	   only	   5.4	   Å	   between	   them	   at	   their	   closest	   point.	   Interestingly,	  glycerol	   in	   the	   cavity	  between	   these	   two	   sites	   interacts	  with	   the	  C2	  hydroxyl	   of	   the	   active	   site	  KDN.	  	  	  In	   the	   AfS-­‐KDN	   complex	   structure	   there	   is	   also	   density	   for	   several	   glycerol	  molecules,	   including	   one	   close	   to	   both	   the	   active	   site	   and	   secondary	   site	   KDN	  molecules.	  This	  glycerol	  hydrogen	  bonds	  both	  with	  AfS	  and	  with	  the	  active	  site	  KDN.	  The	  primary	  hydroxyl	  of	   the	  glycerol	   sits	  2.7	  Å	  above	   the	  C2	  hydroxyl	  of	  KDN.	   The	   glycerol	   is	   within	   hydrogen	   bonding	   distance	   of	   Asp84,	   Asn82	   and	  Arg388	   which	   act	   to	   stabilise	   its	   binding	   (Figure	   2.19).	   Glycerol	   is	   a	   common	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cryoprotectant	  and	  as	   such	   it	   is	   frequently	   seen	   in	  crystal	   structures,	   including	  active	  sites.	  	  The	  presence	  of	  this	  particular	  glycerol	  however	  is	  hypothesised	  to	  mimic	  the	  binding	  of	  a	  glycerol	  moiety	  associated	  with	  a	  third	  KDN	  molecule	  in	  this	  cavity.	  Taken	  together	  with	  the	  proximity	  of	  the	  two	  KDN	  binding	  sites	  it	  is	  hypothesised	  that	  AfS	  may	  be	  specialised	  for	  the	  cleavage	  of	  poly	  KDN.	  PolySialic	  acid	  had	  been	  characterised	  as	  α2,8	  and	  α2,9	  linked	  Neu5Ac	  as	  well	  as	  chains	  of	  alternating	   α2,8	   and	   α2,9	   linkages	   (Barry,	   1958;	   Bhattacharjee	   et	   al.,	   1975;	  McGowen	   et	   al.,	   2001).	   Thus	   far	   Poly-­‐KDN	   has	   only	   been	   described	   in	   the	  literature	  as	  2,8	  linked	  (Sato	  et	  al.,	  1993).	  However,	  studies	  into	  poly-­‐sialic	  acid	  are	   still	   in	   their	   infancy	   and	   few	   published	   methods	   adequately	   distinguish	  between	  Neu5Ac	  and	  KDN	  chains,	  thus	  we	  strongly	  suspect	  the	  chains	  of	  both	  2,8	  and	  2,9	  linked	  poly-­‐KDN	  are	  common	  in	  nature.	  	  	  	  Further	  evidence	  to	  support	  the	  hypothesis	  that	  AfS	  is	  specialised	  for	  poly	  KDN	  hydrolysis	  can	  be	  seen	  in	  the	  AfS-­‐KDF	  complex	  structure.	  The	  AfS-­‐KDF	  complex	  structure	   contained	   two	   further	   KDF	   molecules	   resulting	   a	   total	   of	   four	   KDF	  molecules	   in	   monomer	   B	   of	   the	   asymmetric	   unit	   and	   3	   sites	   in	   monomer	   A	  (Figure,	  2.20).	  It	  should	  be	  acknowledged	  that	  KDF	  is	  a	  synthetic	  KDN	  analogue	  and	   is	   not	   the	  natural	   substrate	   and	   these	  binding	   sites	  were	  not	   found	   in	   the	  
AfS-­‐KDN	  structure.	   It	   is	  possible	  however	   that	   these	  sites	  were	  not	   seen	   in	   the	  
AfS-­‐KDN	  structure	  as	  the	  KDN	  in	  this	  structure	  resulted	  from	  soaking	  with	  KDN-­‐Mu	   and	   not	   KDN.	   The	   hydrophobic	   fluorescent	   addition	   to	   KDN	   may	   have	  prevented	   binding	   at	   these	   additional	   sites.	   To	   obtain	   the	   AfS-­‐KDF	   complex	  structure,	   crystals	  were	   soaked	   in	   100	  mM	   compound,	  which	   is	   likely	   to	   be	   in	  
	   81	  
excess	  of	   in	  vivo	  concentrations.	  Regardless	  it	   is	  surprising	  to	  see	  this	  substrate	  analogue	  binding	  at	  so	  many	  sites.	  
2.3.5.2.	  The	  tertiary	  binding	  site	  (site	  3)	  
Figure	   2.20.	   Binding	   sites	   for	   the	   substrate	   analogue	   KDF	   identified	   in	   the	   AfS-­‐KDF	   complex	  structure.	  AfS	  is	  shown	  as	  cartoon	  (A	  and	  B)	  and	  as	  a	  surface	  topology	  model	  (C	  and	  D).	  	  	  In	  the	  tertiary	  binding	  site	  the	  KDF	  molecule	  is	  stabilised	  by	  interaction	  of	  the	  C5	  hydroxyl	   with	   Asp332	   (Figure	   2.21A).	   The	   C4	   hydroxyl	   of	   KDN	   is	   within	  hydrogen	   bonding	   distance	   of	   both	   the	   backbone	   carbonyl	   of	   Lys337	   and	   the	  backbone	  amine	  of	  Tyr331.	  The	  C3	  fluorine	  is	  also	  capable	  of	  interacting	  with	  the	  
!
	   A.	   B.	  
C.	   D.	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backbone	  carbonyl	  of	  Lys337,	  however	  this	  interaction	  would	  not	  be	  seen	  in	  the	  natural	  substrate	  KDN.	  The	  glycerol	  group	  does	  not	  make	  any	  interactions	  with	  
AfS	  in	  this	  binding	  site	  and	  appears	  to	  adopt	  slightly	  different	  conformations	  in	  each	  monomer	   in	  the	  asymmetric	  unit.	  The	  average	  B-­‐factor	   for	   the	  KDF	  in	  the	  tertiary	   binding	   site	   is	   23.8	   Å2,	   marginally	   higher	   than	   that	   of	   the	   KDF	   in	   the	  secondary	  site,	  which	  has	  a	  B	  factor	  of	  21.1	  Å2.	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2.3.5.3	  The	  quaternary	  binding	  site	  	  The	   active	   site	   of	  AfS	   sits	   at	   the	  mouth	   of	   the	   β-­‐propeller	   and	   the	   quaternary	  binding	   site	   is	   located	   in	   a	   cavity	   formed	   at	   the	   opposite	   end	   of	   the	   barrel	  between	   the	   two	   monomers	   in	   the	   asymmetric	   unit	   (Figure	   2.21C).	   The	  quaternary	   binding	   site	   is	   unusual	   in	   that	   because	   of	   its	   position	   between	   the	  two	  monomers	   in	   the	   asymmetric	   unit	   the	   KDF	   in	   this	   site	   forms	   interactions	  with	   both	   monomers	   A	   and	   B	   and	   thus	   there	   are	   7	   molecules	   of	   KDF	   in	   the	  asymmetric	  unit.	  The	  KDF	   in	   the	  quaternary	  binding	  site	  has	  a	  B-­‐factor	  of	  only	  18.3	  Å2	  making	  it	  the	  most	  stable	  of	  the	  three	  non-­‐catalytic	  binding	  sites	  thus	  it	  is	  surprising	   that	   it	   is	   not	   seen	   in	   both	  monomers.	   However	  modelling	   KDF	   into	  monomer	  A	  in	  an	  identical	  position	  to	  that	  seen	  in	  monomer	  B	  demonstrates	  that	  the	   two	   KDF	  molecules	  would	   overlap	   and	   thus	   only	   one	   can	   bind	   at	   any	   one	  time.	   No	   density	   was	   seen	   for	   the	   binding	   of	   KDF	   in	   a	   similar	   position	   in	  monomer	   A	   of	   the	   asymmetric	   unit.	   It	   is	   unclear	   why	   there	   is	   such	   a	   strong	  preference	  for	  the	  binding	  of	  KDF	  in	  the	  quaternary	  site	  of	  B	  rather	  than	  A.	  There	  is	  little	  to	  no	  difference	  in	  the	  backbone	  and	  side	  chains	  of	  the	  important	  amino	  acids	  however	  as	  there	  are	  subtle	  differences	  between	  the	  2	  monomers	  resulting	  in	   the	   presence	   of	   two	   monomers	   in	   the	   asymmetric	   unit.	   Perhaps	   the	  summation	  of	  these	  subtle	  differences	  is	  sufficient	  to	  bias	  the	  binding	  of	  KDF	  to	  the	  quaternary	  binding	  site	  of	  monomer	  B	  over	  A.	  Alternatively,	  the	  accessibility	  of	  the	  binding	  sites	  constrained	  by	  crystal	  packing	  may	  predispose	  the	  binding	  of	  KDF	  to	  monomer	  B.	  	  	  The	  carboxylic	  acid	  of	  the	  KDF	  in	  the	  quaternary	  site	  is	  within	  hydrogen	  bonding	  distance	  with	  Tyr303	  of	  AfS	  monomer	  B	  of	  the	  asymmetric	  unit	  (Figure	  2.21B).	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The	  C4	  and	  C5	  hydroxyls	  likewise	  hydrogen	  bond	  with	  Arg310.	  Unlike	  the	  KDF	  in	  the	   tertiary	   site,	   the	   glycerol	   moiety	   of	   the	   KDF	   in	   the	   quaternary	   site	   is	  stabilised	   by	   multiple	   interactions;	   the	   C7	   hydroxyl	   is	   within	   2.6	   Å	   of	   the	  carboxylic	  acid	  of	  Asp306	  and	  the	  εN	  of	  Lys363	  is	  situated	  2.8	  Å	  and	  3.0	  Å	  from	  the	  C8	   and	  C9	  hydroxyls	   respectively.	   The	  KDF	   in	   this	   binding	   site	   also	  makes	  interactions	  with	  two	  amino	  acids	  in	  monomer	  A	  of	  the	  asymmetric	  unit;	  the	  C2	  fluorine	  interacts	  with	  Cβ	  of	  Pro24	  and	  the	  C9	  hydroxyl	  forms	  interactions	  with	  Ala307.	   It	   should	  be	  noted	   that	   the	   former	   interaction	  would	  not	  be	   seen	  with	  binding	  of	  the	  natural	  substrate	  KDN.	  	  	  
Substrate	  targeting	  	  The	  sialidases	  NanA,	  NanB	  from	  S.	  pneumoniae,	  NanH	  from	  V.	  cholerae	  and	  NanI	  from	  M.	  viridifaciens	  all	  have	  a	  negatively	  charged	  surface	  on	  the	  opposite	  side	  of	  the	  protein	  from	  the	  active	  site.	  It	  is	  hypothesised	  that	  this	  aids	  orientation	  of	  the	  active	  site	  toward	  the	  substrate	  by	  repelling	  forces	  caused	  by	  the	  negative	  charge	  of	  sialic	  acid	  at	  the	  rear	  face	  of	  the	  protein	  and	  attractive	  forces	  of	  the	  positively	  charged	  active	   site	   (Xu	  et	  al.,	  2009).	   	  Not	  only	   is	   the	   rear	   face	  of	  AfS	  positively	  charged	   but	   there	   is	   also	   a	   possible	   KDN	   binding	   site	   in	   this	   cavity.	   We	  hypothesise	  that	  this	  is	  another	  indication	  that	  AfS	  is	  specialised	  for	  the	  cleavage	  of	   polyKDN	   over	   terminal	   KDN	   sugars	   as	   well	   as	   being	   capable	   of	   cleaving	  terminal	  KDN.	  In	  this	  proposed	  model,	  the	  protein	  has	  evolved	  to	  bind	  or	  wrap	  itself	  in	  chains	  of	  poly-­‐KDN,	  and	  cleave	  its	  way	  out.	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Figure	  2.22.	  The	  binding	  sites	  of	  KDF	  (green	  carbons)	  and	  glycerol	  (green	  carbons)	  in	  the	  AfS-­‐KDF	   complex	   structure	   (surface	   charge	   were	   red	   denotes	   negative	   charge	   and	   blue	   denotes	  positively	  charged	  as	  calculated	  in	  Pymol)	   looking	  directly	  at	  the	  active	  site	  (A)	  and	  turned	  90°	  (B).	   Interestingly,	   the	  glycerol	  binding	  sites	  are	  roughly	  evenly	  spaced	  and	   lead	  from	  the	  active	  site	  cavity	  to	  the	  tertiary	  and	  quaternary	  KDF	  binding	  sites.	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active	  site	  of	  AfS	  is	  part	  of	  a	  seemingly	  larger	  channel	  across	  the	  protein	  which,	  in	  the	  AfS-­‐KDF	   structure,	   includes	   three	   additional	   glycerol	   binding	   sites.	   Two	   of	  these	  sites	  are	  conserved	  in	  both	  monomers	  of	  the	  asymmetric	  unit	  of	  both	  the	  
AfS-­‐KDN	   and	  AfS-­‐KDF	   structures	  with	   the	   exception	   that	   in	  monomer	  A	   of	   the	  
AfS-­‐KDF	  structure	  one	  of	  these	  sites	  contains	  a	  nitrate	  in	  place	  of	  a	  glycerol.	  It	  is	  hypothesised	  that	  this	  channel	  as	  marked	  out	  by	  these	  glycerol-­‐binding	  sites	  may	  be	  ideal	  for	  the	  binding	  of	  poly-­‐KDN.	  The	  three	  glycerol	  molecules	  in	  this	  channel	  sit	   7.3	   Å	   and	   8.4	   Å	   from	   one	   another,	   however,	   the	   irregular	   surface	   of	   the	  protein	  suggests	  that	  the	  distance	  between	  the	  three	  sites	  is	  very	  similar	  (Figure	  2.22).	  The	  distance	  uniformity	  between	   these	   sites	  may	   indicate	   that	   there	  are	  three	  possible	  sites	   for	   the	  binding	  of	  polar	  molecules	  with	  a	  regular	  and	   fixed	  distance	  between	  them.	   It	   is	   tantalising	  to	  hypothesise	  that	   this	  molecule	  could	  be	  polyKDN.	  	  	  
2.3.6	  Poly	  KDN	  modelling	  	  Purification	   of	   poly-­‐KDN	   from	   known	   sources	   is	   challenging	   and	   very	   limited	  amounts	  can	  be	  obtained	  and	  as	  such	   it	  was	  not	  possible	   to	  conduct	  successful	  soaking	   experiments	   on	   inactive	  mutants.	   Here	   presented	   are	   possible	  models	  for	  the	  binding	  of	  α-­‐2,8-­‐	  and	  α-­‐2,9-­‐	  poly-­‐KDN	  based	  on	  the	  manual	  modelling	  of	  a	  KDN	   molecule	   between	   the	   confirmed	   binding	   sites	   in	   the	   active	   site	   and	  secondary	   site.	   Both	  models	  were	   created	   based	   on	   the	   following	   criteria:	   the	  glycosidic	  bond	  length	  should	  be	  roughly	  1.4	  Å	  and	  there	  is	  no	  steric,	  charge	  or	  other	  repellent	  clashes	  (Figure	  2.23).	  Both	  models	  predict	  multiple	  interactions	  with	   the	  protein.	  The	  α-­‐2,9-­‐polyKDN	  model	   in	  particular	  utilises	   the	   space	  and	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interactions	  displayed	  by	  the	  glycerol	  and	  is	  hypothesised	  to	  be	  a	  better	  model	  of	  binding.	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2.4	  Conclusions	  
AfS	  is	  a	  KDN	  specific	  sialidase.	  This	  is	  the	  first	  structure	  of	  a	  fungal	  sialidase	  and	  the	   first	   structure	   of	   a	   KDN	   specific	   sialidase.	   The	   tertiary	   structure	   of	   AfS	   is	  typical	   of	   a	   sialidase	   and	   possesses	   all	   the	   catalytic	   machinery	   to	   be	   active.	  Despite	  this	  AfS	  is	  poor	  at	  catalyzing	  the	  hydrolysis	  of	  the	  sialic	  acid	  Neu5Ac.	  The	  structure	  of	  AfS	  presented	  here	  demonstrates	   that	   the	   active	   site	   cavity	  where	  the	  N-­‐acetyl	  group	  of	  Neu5Ac	  usually	  binds	  AfS	  is	  shallower	  than	  other	  members	  of	   the	   saialidase	   family	   of	   enzymes	   preventing	   the	   binding	   of	   Neu5Ac.	   KDN	   is	  another	  sialic	  acid	  that	  differs	  from	  Neu5Ac	  by	  replacement	  of	  the	  N-­‐acetyl	  group	  by	   a	   hydroxyl.	   It	  was	  not	   possible	   to	   attain	   a	   structure	   of	  AfS	   in	   complex	  with	  Neu5Ac.	  The	  structure	  of	  AfS	  in	  complex	  with	  KDN	  was	  solved	  to	  and	  identified	  a	  secondary	   binding	   site.	   	   Two	   further	   binding	   sites	   were	   identified	   in	   the	  structure	  of	  AfS	   in	  complex	  with	   the	  substrate	  analogue	  KDF	  bringing	   the	   total	  binding	  sites	  to	  four.	  The	  surface	  of	  AfS	  is	  primarily	  positively	  charged	  and	  taken	  together	   with	   the	   four	   possible	   bindings	   sites	   suggests	   that	   the	   preferred	  substrate	  is	  poly-­‐KDN.	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3.	  AfS	  kinetic	  analysis	  and	  mutational	  
studies	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3.1	  Summary	  	  The	   catalytic	  mechanism	  of	   sialidases	  has	  been	  well	   established.	   Sialidases	   are	  retaining	   glycosyl	   hydrolases,	   which	   universally	   employ	   acid/base	   catalysis	   to	  cleave	   their	   substrate.	   Sialidases	   however	   are	   unusual	   retaining	   glycosyl	  hydrolases	  in	  that	  the	  nucleophile	  in	  this	  catalytic	  process	  is	  a	  tyrosine.	  A	  charge	  relay	  between	  the	  hydroxyl	  of	   this	   tyrosine	  and	  the	  carboxylic	  acid	  moiety	  of	  a	  conserved	   glutamic	   acid	   negatively	   polarizes	   the	   hydroxyl,	   priming	   it	   for	  nucleophilic	   attack	   on	   the	   C2	   of	   sialic	   acid.	   Also	   important	   to	   catalysis	   is	   an	  aspartic	  acid	  positioned	  on	  the	  opposite	  side	  of	  the	  C2	  of	  sialic	  acid	  that	  donates	  a	   proton	   to	   the	   leaving	   group.	   Once	   deprotonated	   the	   aspartic	   acid	   acquires	   a	  proton	   from	   a	   water	   molecule	   producing	   a	   hydroxyl	   ion	   which	   then	  nucleophilically	   attacks	   the	   C2	   breaking	   the	   covalent	   intermediate	   from	   the	  nucleophilic	  tyrosine	  and	  completing	  the	  reaction.	  	  	  Binding	  of	  the	  sialic	  acid	  substrate	  is	  facilitated	  by	  three	  conserved	  arginines	  that	  act	   to	   stabilize	   the	   carboxylic	   acid	   group	   of	   sialic	   acid.	   There	   is	   a	   hydrophobic	  cavity	   to	   accommodate	   the	   acetyl	   moiety	   on	   the	   C5	   on	   Neu5Ac	   that	   is	  characteristic	   of	   this	   family	   of	   proteins.	  Despite	   the	   conservation	  of	   this	   cavity	  within	   the	   sialidase	   family	   the	   residues	   that	   line	   this	   cavity	   are	   less	   well	  conserved.	  	  
1H	   NMR	   spectroscopy	   of	   AfS	   with	   KDN-­‐Mu,	   a	   fluorescent	   substrate	   analogue,	  demonstrated	  that	  the	  mechanism	  of	  product	  formation	  was	  identical	  to	  that	  of	  traditional	   sialidases.	   From	   the	   AfS-­‐KDN	   and	   AfS-­‐KDF	   structures	   it	   appears	  evident	   that	   the	   catalytic	   tyrosine	   and	   aspartic	   acid	   are	  Tyr358	   and	  Asp84.	  As	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proof	   of	   principle	   we	   mutated	   these	   residues	   to	   a	   histidine	   and	   an	   alanine	  respectively	  and	  witnessed	  a	  drastic	   reduction	   in	   the	  activity	  of	   the	  enzyme	  as	  would	   be	   expected.	   The	   structure	   of	   these	   mutants	   showed	   no	   significant	  perturbations	  in	  the	  active	  site	  residues	  and	  much	  less	  in	  the	  overall	  structure	  of	  the	  protein	  and	  hence	  we	  concluded	  that	  Tyr358	  and	  Asp84	  are	  the	  key	  catalytic	  residues.	  	  The	   structure	   of	   AfS	   in	   complex	   with	   KDN,	   KDN2en	   and	   KDF	   highlighted	   the	  absence	  of	  a	  hydrophobic	  cavity	  to	  allow	  the	  binding	  of	  Neu5Ac,	  Neu5Ac2en	  or	  2,3-­‐difluro-­‐Neu5Ac.	   Arg171	   and	   Trp202	   were	   identified	   as	   the	   residues	  responsible	   for	   restricting	   the	   substrate	   specificity	   to	   KDN.	   The	   mutation	   of	  Arg171	   to	   leucine	   increased	   the	  activity	  of	  AfS	   for	  Neu5Ac	  substrate	  analogues	  over	   the	  wild	   type	   enzyme,	   however	   it	   is	   still	   significantly	   less	   active	   than	   the	  activity	  of	  the	  wild	  type	  enzyme	  toward	  KDN	  substrate	  analogues.	  A	  structure	  of	  
AfSR171L	   in	   complex	  with	  Neu5Ac2en	  was	   solved	   to	   1.8	  Å.	   This	  model	   revealed	  that	  Neu5Ac2en	  binds	   similarly	   to	  KDN2en.	  The	  N-­‐acetyl	   is	   twisted	  away	   from	  Trp202	  which	  is	  3	  Å	  apart	  at	  their	  closest	  point.	  Furthermore,	  Trp202	  remains	  in	  an	  identical	  position	  in	  all	  aforementioned	  structures	  apart	  from	  AfS	  R171L	  where	  it	  is	  forced	  away	  from	  the	  N-­‐acetyl	  group	  by	  0.8	  Å.	  It	  is	  apparent	  from	  the	  meagre	  increase	   in	  activity	  of	  AfSR171L	  compared	  with	  the	  wild	  type	  using	  the	  substrate	  Neu5Ac-­‐Mu	   that	   Arg171	   is	   not	   solely	   responsible	   for	   the	   selectivity	   of	  AfS	   for	  KDN.	   Taken	   together	   with	   the	   displacement	   of	   Trp202	   upon	   binding	   of	  Neu5Ac2en	   it	   is	   clear	   that	  Trp202	   is	   also	   involved	   in	   substrate	   selectivity.	  The	  structure	  of	  AfSR171L,W202V	  revealed	  a	  larger	  cavity	  and	  predicts	  no	  impediment	  to	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the	   binding	   of	  Neu5Ac.	   Unfortunately	   issues	  with	   protein	   stability	   and	   activity	  prevented	  verifying	  this	  kinetically	  in	  this	  study.	  
3.2	  Materials	  and	  Methods	  
3.2.1	  Site	  directed	  mutagenesis	  	  	  The	   AfS	   gene	   ligated	   into	   the	   pET28A+	   (EMD	   Chemicals	   Inc.,	   San	   Diego,	   CA)	  vector	  as	  previously	  described	  (Warwas	  et.	  al.,	  2010)	  was	  used	  as	  the	  template	  for	  all	  site	  directed	  mutagenesis	  experiments.	  Using	  the	  experimentally	  derived	  model	  the	  catalytic	  tyrosine	  Tyr358	  and	  aspartic	  acid	  Asp84	  were	  identified	  for	  mutation	   to	   a	   histidine	   and	   alanine	   respectively.	   Residues	  Arg171	   and	  Trp202	  were	  identified	  from	  the	  structure	  as	  possibly	  being	  responsible	  for	  the	  inability	  of	  AfS	  to	  utilize	  Neu5Ac	  as	  a	  substrate.	  Arg171	  was	  mutated	  to	  a	  leucine	  and	  this	  construct	  was	  used	  as	  a	  template	  for	  the	  mutation	  of	  Trp202	  to	  valine	  creating	  a	  double	  mutant.	  All	  mutations	  were	  performed	  using	  the	  Stratagene	  Quikchange	  site-­‐directed	   mutagenesis	   kit	   in	   accordance	   with	   manufacturer’s	   instructions.	  Template	   DNA	   plasmids	   used	   to	   design	   primers	   suitable	   for	   mutagenesis	   and	  primers	  were	   obtained	   from	   Integrated	  DNA	  Technologies.	  E.	  coli	  (DH5α)	   cells	  were	   transformed	   with	   the	   mutated	   DNA	   and	   plated	   onto	   LB	   agar	   plates	  containing	   50μg/ml	   kanamycin	   and	   incubated	   overnight	   at	   37	   °C.	   The	  transformation	  was	  done	  by	  addition	  of	  1μl	  of	  site	  direted	  mutagenisis	  product	  to	  cells	  and	  heat	  shocking	  the	  mixture	  for	  30s	  at	  42°C	  before	  placing	  on	  ice	  for	  2	  mins.	   Selected	   colonies	   were	   amplified	   in	   5	   ml	   LB	   with	   50	   μg/ml	   kanamycin,	  mini-­‐prepped	  (Qiagen)	  according	   to	  manufacturers	   instructions	  and	  sequenced	  (GATC	  Biotech)	  to	  ensure	  that	  the	  mutation	  had	  been	  incorporated.	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3.2.2	  Protein	  expression	  and	  purification	  	  Plasmids	   incorporating	   mutations	   AfSD84A	   and	   AfSY358H	   were	   transformed,	  expressed	   and	   purified	   as	   described	   in	   Chapter	   2.	   Plasmids	   incorporating	  mutations	  AfS	  R171L	  and	  AfSR171L,W202V	  were	  transformed	  into	  E.	  coli	  (BL21	  GOLD)	  and	   successfully	   transformed	   bacteria	   were	   selected	   by	   plating	   onto	   LB	   agar	  plates	  containing	  50	  μg/ml	  kanamycin	  and	  incubated	  overnight	  at	  37	  °C.	  A	  single	  colony	  was	  amplified	   in	  20	  ml	  LB	  with	   shaking	  at	  200	   rpm	  at	  37	   °C.	   From	   the	  overnight	   culture	   5	   ml	   was	   added	   to	   1	   L	   of	   auto	   induction	   media	  (http://www.formedium.com/uk/EscherichiaColi/EscherichiaColi_6.htm#AIM%C2%A0_-­‐_Terrific_Broth_Base_including_Trace_elements,	   ForMedium)	   with	   100	  μg/ml	  kanamycin	  and	  left	  shaking	  at	  250	  rpm	  at	  37	  °C	  for	  2	  hrs.	  After	  this	  time	  the	   temperature	   was	   lowered	   to	   16	   °C	   and	   were	   incubated	   for	   48-­‐60	   hrs.	  All	  mutant	  proteins	  were	  harvested	  and	  purified	  as	  in	  Chapter	  2.2.1.	  	  
	  
3.2.3	  Protein	  soaking	  and	  crystallization	  	  Crystals	   of	   all	  mutants	   formed	   identically	   to	  wild	   type	   as	   discussed	   in	  Chapter	  2.2.3.	  	  	  The	   structure	  of	  AfSR171L	   in	   complex	  with	  Neu5Ac2en	  was	  achieved	  by	   soaking	  
AfSR171L	  crystals	  by	  addition	  of	  1	  μL	  of	  500	  mM	  Neu5Ac2en	  to	  4	  μL	  crystallization	  drop	  containing	  1:1	  ratio	  of	  13.7	  mg/ml	  AfSR171L	  and	  20	  %	  (w/v)	  PEG	  3350	  and	  0.2	   M	   sodium	   nitrate.	   The	   crystal	   was	   soaked	   for	   20	   mins.	   Crystals	   were	  cryoprotected	   by	   transfer	   to	   20%	   (w/v)	   glycerol	   in	   crystallization	   buffer	   for	   a	  few	  seconds	  prior	  to	  placement	  in	  liquid	  nitrogen.	  All	  data	  were	  collected	  at	  100	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K	   in	   house	   (Rigaku-­‐MSC	  Micromax-­‐007	   X-­‐ray	   generator	   and	   Saturn	   944+	   CCD	  detector).	  MOSFLM	  (Leslie,	  2006)	  was	  used	  to	  integrate	  the	  data	  and	  POINTLESS	  in	  the	  CCP4	  suite	  (Evans,	  2006)	  confirmed	  the	  space	  group	  as	  P21.	  	  The	   apo	   wild	   type	   enzyme	   model,	   2XCY,	   including	   both	   monomers	   in	   the	  asymmetric	   unit	   was	   modified	   by	   removal	   of	   water	   molecules	   for	   use	   in	  molecular	   replacement.	   The	   modified	   2XCY	   model	   was	   used	   in	   rigid	   body	  refinement	  by	  REFMAC5	  against	  data	  collected	  for	  each	  of	  the	  mutant	  structures	  
AfSY358H,	   AfSD84A,	   AfSR171L	   and	   AfSR171L,W202V.	   Further	   restrained	   refinements	   in	  REFMAC5	   were	   used	   to	   improve	   the	   model	   and	   insert	   watermolecules.	   2D	  ChemDraw	   representation	   of	   Neu5Ac2en	   was	   submitted	   to	   the	   Prodrg	   server	  (Schuttelkopf	   &	   Aalten,	   2004)	   to	   produce	   appropriate	   3D	   representations	  including	   geometric	   constraints	   which	   are	   essential	   for	   modelling	   purposes.	  Manual	  modelling	  of	  the	  protein	  and	  the	  soaked	  ligands	  was	  carried	  out	  in	  Coot	  and	  further	  refined	  with	  REFMAC5	  (Table	  3.1).	  Again	  the	  resulting	  models	  were	  validated	  by	  Coot	  and	  MolProbity	  (Lovell	  et	  al.,	  2003).	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Data	  collection	  a	   	   	   	   	  
X-­‐ray	  source	   In	  house	   In	  house	   In	  house	   In	  house	  
X-­‐ray	  wavelength	  (Å)	   1.542	   1.542	   1.542	   1.542	  
Resolution	  (Å)	   12.4-­‐1.84	  	  (1.94-­‐1.84)	   12.4-­‐1.84	  	  (1.94-­‐1.84)	   12.4-­‐1.84	  	  (1.94-­‐1.84)	   12.4-­‐1.84	  	  (1.94-­‐1.84)	  
Unit	  cell	  dimensions	   	   	   	   	  
a(Å)	   75.9	   75.9	   75.9	   75.9	  
b(A)	   57.8	   58.1	   58.0	   57.7	  
c	  (Å)	   94.6	   94.4	   94.6	   94.5	  
β 	  (°)	  	   99.9	   99.9	   99.9	   100.0	  
No.	  observations	   273,633	   274,759	   302,861	   274,546	  
Redundancy	   2.0	  (1.8)	   2.2	  (1.9)	   2.2	  (2.0)	   2.0	  (1.9)	  
Completeness	  (%)	   98.9	  (94.4)	   98.5	  (92.0)	   99.2	  (96.9)	   98.8	  (95.0)	  
Rmerge	  (%)	  b	   5.5	  (14.2)	   8.8	  (21.2)	   8.6	  (27.8)	   8.6	  (15.3)	  
I/σI	   18.2	  (7.5)	   11.0	  (5.0)	   13.8	  (4.2)	   18.7	  (8.2)	  
Refinement	   	   	   	   	  
Reflections	  used	   70,126	   65,819	   66,869	   63,006	  
No.	  atoms	   7,201	   7,158	   7,253	   7,184	  
Number	   of	   protein	  
atoms	  
6,039	   5,981	   6,010	   5,977	  
Number	  of	  water	  	  
molecules	  
1,162	   1,165	   1,396	   973	  
Number	   of	   ligand	  	  	  	  	  	  	  	  	  
atoms	  
N/A	   N/A	   20	   N/A	  
Average	  B-­‐factor	  (Å2)	   9.9	   9.9	   12.1	   11.3	  
Protein	   7.5	   7.6	   9.5	   8.9	  
Water	   22.4	   21.8	   28.9	   23.9	  
Ligand	   N/A	   N/A	   13.5	   N/A	  
R-­‐factor	  c	   0.143	   0.173	   0.155	   0.143	  
R-­‐free	  d	   0.178	   0.224	   0.194	   0.285	  
Root	   mean	   square	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
deviation	   in	   bond	  
length	  (Å)	  
0.009	   0.010	   0.009	   0.010	  
Root	   mean	   square	  
deviation	   in	   bond	  
angles	  (°)	  
1.14	   1.24	   1.19	   1.25	  
Table	  3.1.	  Data	  collection	  and	  refinement	  statistics	  	  a	  =	  Values	  in	  parentheses	  correspond	  to	  the	  highest	  resolution	  shell.	  b	  =	  Rmerge	  =	  ∑hkl	  ∑i	  |Ihkl,	  i	  –	  〈	  Ihkl	  〉|	  /	  ∑hkl	  〈	  Ihkl	  〉	  c	  &	  d	  =	  R-­‐factor	  and	  R-­‐free	  =	  (Σ	   |	  |Fo|	  -­‐	  |Fc|	  |)/(Σ	   |Fo|),	  were	   the	  Rfree	  was	  calculated	   from	  5%	  of	  reflections	  excluded	  from	  refinement.	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3.2.4	  Kinetic	  characterisation	  of	  AfS	  	  Sialidase	   activity	   was	  measured	   by	   release	   of	   4-­‐methylumbelliferyl	   (Mu)	   from	  artificial	   substrates	   2’-­‐(4-­‐methylumbelliferyl)-­‐α-­‐D-­‐N-­‐acetylneuraminic	   acid	  (Neu5Ac-­‐Mu)	   or	   2’-­‐(4-­‐methylumbelliferyl)-­‐α-­‐D-­‐2-­‐keto-­‐3-­‐deoxy-­‐D-­‐glycero-­‐D-­‐galactonononic	  acid	  (KDN-­‐Mu).	  The	  release	  of	  this	  fluorogenic	  molecule,	  Mu,	  was	  monitored	   by	   excitation	   at	   365	   nm	   and	   recording	   of	   the	   emission	   at	   450	   nm	  using	   a	   Molecular	   Devices	   SPECTRAmax	   GEMINI	   XPS	   fluorimeter.	   All	  experiments	  were	  repeated	  in	  triplicate	  and	  average	  values	  calculated.	  	  In	  order	  to	  calculate	  the	  molar	  equivalent	  to	  the	  fluorescence	  released,	  Mu	  was	  added	  to	  the	  buffer	  used	  in	  each	  experiment	  in	  concentrations	  of	  0,	  0.1	  μM,	  1	  μM,	  10	  μM,	  100	  μM,	  1	  mM,	  5	  mM	  and	  10	  mM.	  The	  measured	  fluorescence	  was	  plotted	  against	  the	  concentration	  of	  Mu	  to	  create	  formulae	  relative	  to	  each	  experiment	  to	  calculate	  the	  concentration	  of	  Mu	  released	  relative	  to	  the	  fluorescence	  measured.	  Since	   1	   molecule	   of	   Mu	   released	   is	   equal	   to	   1	   KDN	  molecule	   it	   is	   possible	   to	  calculate	  the	  number	  of	  moles	  of	  KDN	  hydrolyzed	  from	  Mu.	  
3.2.4.1	  Michalis-­‐Menten	  Kinetics	  	  Assay	  conditions	  were	  optimized	  to	  contain	  10	  ng/ml	  of	  AfS,	  final	  concentration,	  in	  50	  mM	  Hepes,	  100	  mM	  NaCl	  at	  pH	  4.5,	  100μl	  final	  volume.	  Assays	  were	  run	  in	  triplicate	  in	  a	  96-­‐well	  format.	  To	  begin	  the	  reaction,	  concentrations	  of	  KDN-­‐Mu	  at	  2	  μM,	  20	  μM,	  50	  μM,	  125	  μM,	  250	  μM,	  500	  μM,	  1	  mM	  and	  2	  mM	  were	  added	  to	  each	   well	   and	   the	   reaction	   was	   mixed	   and	   the	   florescence	   measured	   by	   the	  Spectra	  max	  M2	  fluorimeter	  (Molecular	  Dimensions)	  at	  room	  temperature.	  The	  Michalis-­‐Menten	  parameters	  were	  determined	  by	  GraFit	  (Erithacus	  Software).	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3.2.4.2	  Inhibitor	  studies	  	  The	  calculation	  of	   the	   IC50	  of	  KDN2en	  for	  AfS	  was	  calculated	  by	  addition	  of	  10	  μM,	   100	   μM,	   400	   μM,	   2	   mM	   and	   10	   mM	   KDN2en	   to	   10	   μg/ml	   of	   AfS,	   final	  concentration,	   in	  50	  mM	  Hepes,	   100	  mM	  NaCl	   at	   pH	  4.5.	  After	  5	  mins	  200	  μM	  KDN-­‐Mu	  was	  added	  brininging	  the	  final	  volume	  to	  100μl.	  The	  reaction	  was	  mixed	  and	   the	   florescence	   measured	   by	   the	   Spectra	   max	   M2	   fluorimeter	   (Molecular	  Dimensions)	   at	   room	   temperature.	   The	   fluorescence	   data	  were	   processed	   and	  the	  IC50	  calculated	  using	  the	  statistical	  software	  GraFit	  (Erithacus	  Software).	  	  
3.2.5	  NMR	  experiments	  	  1H	   NMR	   spectroscopy	   was	   used	   to	   examine	   product	   formation	   from	   the	  hydrolysis	   of	   KDN-­‐Mu	   by	   AfS	   and	   to	   test	   for	   trans-­‐sialidase	   activity.	   Reaction	  mixtures	  included	  15	  μl	  23	  mg/ml	  AfS	  and	  15	  μl	  33	  mg/ml	  KDN	  in	  2H20.	  In	  the	  case	   of	   the	   trans-­‐sialidase	   assay,	   15	   μl	   20	   mg/ml	   galactose	   or	   N-­‐acetylgalactosamine	  in	  2H20	  was	  also	  added.	  The	  reaction	  mixture	  was	  made	  up	  to	   600	   μl	   with	   PBS	   pH	   7	   in	   2H20	   and	   placed	   in	   a	   5	   mm	   NMR	   tube.	   Reaction	  mixtures	  were	  incubated	  at	  room	  temperature	  and	  spectra	  recorded	  at	  0,	  0.5,	  1,	  5,	  12	  and	  24	  hours.	  All	  NMR	  spectra	  were	  recorded	  at	  298	  K	  using	  a	  500	  MHz	  Bruker	   spectrometer	   taking	   64	   scans	   with	   a	   2	   s	   relaxation	   delay.	   During	   the	  relaxation	  delay	  the	  remaining	  water	  signal	  was	  suppressed	  by	  continuous	   low	  power	  irradiation.	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3.3	  Results	  and	  Discussion	  	  
3.3.1.	  AfS	  substrate	  specificity	  	  The	  Michaelis-­‐Menten	  parameters	  for	  AfS	  were	  calculated	  by	  plotting	  the	  rate	  of	  KDN-­‐Mu	  cleavage	  at	  different	  concentrations	  of	  substrate.	  The	  Km	  of	  AfS	  for	  KDN-­‐Mu	   is	  2.46	  ±	  0.20	  mM	  (Figure	  3.1).	  Due	   to	   restrictions	   in	   substrate	   availability	  only	   two	   readings	   at	   each	   concentration	  were	   taken.	  This	  may	   account	   for	   the	  disagreement	   between	   the	   Michaelis-­‐Menten	   kinetics	   calculated	   here	   and	   the	  results	  accumulated	  by	  our	  collaborators	  in	  Canada	  who	  measure	  the	  Km	  at	  0.23	  ±	  0.02	  mM	  (Juliana	  Yeung,	  personal	  communication).	  As	  predicted	  by	  the	  crystal	  structure	  the	  Km	  for	  AfS	  of	  the	  substrate	  Neu5Ac-­‐Mu	  is	  significantly	  higher	  than	  KDN-­‐Mu.	  The	  Km	   is	  more	   than	  25	   fold	  higher	  with	  Neu5Ac-­‐Mu	   than	   that	  of	   the	  substrate	  KDN-­‐Mu	  with	  a	  Km	  of	  5.8	  ±	  1.7	  mM	  (J.	  Yeung,	  personal	  communication).	  The	  Km	  is	  an	  measure	  of	  the	  affinity	  of	  the	  enzyme	  for	  the	  substrate	  and	  thus	  the	  higher	  Km	  for	  Neu5Ac	  demonstrates	  the	  poor	  affinity	  for	  this	  substrate.	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site	  and	  preventing	  the	  binding	  and	  cleavage	  of	  KDN-­‐Mu.	  This	  was	  expected	  from	  the	   numerous	   failed	   attempts	   to	   attain	   a	   crystal	   structure	   complex.	   Just	   as	  Neu5Ac2en	   is	   an	   inhibitor	   of	   traditional	   sialidases	   we	   hypothesized	   that	   the	  restricted	   hydrophobic	   pocket	   in	   AfS	   around	   the	   C5	   of	   where	   Neu5Ac	   and	  Neu5Ac2en	   would	   bind	   suggest	   KDN2en	   as	   a	   possible	   inhibitor.	   At	   10	   mM	  KDN2en	  showed	  94	  %	  inhibition	  of	  AfS	  (Figure	  3.2),	  however	  the	  standard	  error	  was	  too	  poor	  to	  calculate	  an	  accurate	  IC50	  for	  KDN2en	  for	  AfS.	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leaving	  group	   it	  exists	   in	   the	  the	  high-­‐energy	  α-­‐conformation.	  KDN	  relaxes	   into	  the	   lower	   energy	   state	   β-­‐conformation	   in	   solution	   by	   mutarotation.	   NMR	  experiments	   demonstrated	   no	   trans-­‐sialidase	   activity	   when	   galactose	   or	   N-­‐acetylgalactosamine	  were	  used	  as	  possible	  acceptors.	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The	   active	   site	   of	   AfS	   is	   an	   extended	   cavity	   that	   is	   capable	   of	   binding	   2	   KDN	  molecules	   simultaneously.	   1H	   NMR	   demonstrated	   the	   hydrolysis	   of	   KDN	   from	  KDN-­‐Mu	  however	  did	  not	  indicate	  any	  other	  product	  formation	  such	  as	  polyKDN.	  	  
	  These	   results	   confirm	   that	   AfS	   is	   capable	   of	   catalysing	   the	   hydrolysis	   of	   both	  Neu5Ac	  and	  KDN	  from	  the	  Mu	  leaving	  group	  however	  AfS	  has	  a	  clear	  preference	  for	   KDN.	   Since	   Neu5Ac2en	   is	   unable	   to	   inhibit	   the	   activity	   of	   AfS	   it	   can	   be	  concluded	   it	   is	   incapable	   of	   binding	   in	   the	   active	   site.	   KDN	   is	   found	   in	   human	  tissue,	  however	  it	  is	  mainly	  limited	  to	  developing	  tissues	  and	  cancerous	  cells	  and	  is	   far	   less	  abundant	   in	   the	  primary	  sites	  of	   infection	   than	  Neu5Ac.	  Thus	  due	   to	  the	   preference	   for	   KDN	   of	  AfS	   it	   is	   not	   likely	   that	   the	   primary	   purpose	   of	   this	  protein	  is	  a	  virulence	  factor.	  	  	  The	  ability	  of	  AfS	  to	  cleave	  Neu5Ac	  containing	  substrates	   is	  still	  significant	  and	  may	   aid	   infection.	   A.	   fumigatus	   is	   an	   opportunistic	   pathogen	   where	   hosts	   are	  often	  immunocompromised	  however	  its	  primary	  habitat	  is	  the	  soil	  (Mullins	  et	  al.,	  1976).	  A.	  fumigatus	  can	  utilize	  KDN	  as	  a	  carbon	  source	  but	  not	  Neu5Ac	  (Figure	  3.4).	  Thus	  it	  is	  likely	  that	  AfS	  is	  used	  in	  the	  harvesting	  of	  KDN	  from	  the	  soil	  as	  a	  carbon	  source	  for	  the	  fungus	  (J.	  Yeung,	  personal	  communication).	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Figure	   3.4.	  The	  ability	  of	  A.	  fumigatus	   to	  utilise	  KDN,	  Neu5Ac	  and	  mannose	  as	  carbon	  sources.	  	  (Figure	   supplied	   by	   J.	   Yeung,	   personal	   communication).	   A.	   fumigatus	   was	   cultured	   in	   Kafer’s	  medium,	  here	  denoted	  as	  K,	  with	  the	  addition	  of	  glucose	  (Glu),	  KDN,	  mannose	  (MAN)	  or	  Neu5Ac	  (SA).	   All	   sugars	   were	   added	   to	   a	   final	   concentration	   of	   25	   mM	   except	   K(+0.05Man),	   which	  contained	   1.25	  mM	  mannose	  which	  was	   used	   as	   a	   control	   for	   the	   addition	   of	   KDN	  which	  may	  contain	  residual	  mannose	  at	  that	  concentration.	  A.	  fumigatus	  is	  incapable	  of	  utilising	  Neu5Ac	  as	  a	  carbon	  source	  as	  growth	  is	  very	  poor	  and	  similar	  to	  the	  carbon	  source	  free	  control,	  K(-­‐Glu).	  KDN	  however	  was	   capable	   of	   being	   utilised	   as	   a	   carbon	   source	   although	   not	   to	   the	   same	   extent	   as	  glucose	  and	  mannose.	  This	  figure	  and	  supporting	  information	  was	  provided	  by	  J.	  Yeung	  (personal	  communication).	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3.3.2	  Mutation	  of	  the	  catalytic	  residues	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activity	  of	  AfS.	  This	  was	  further	  validated	  by	  the	  AfS-­‐KDF	  complex	  structure	  that	  trapped	   the	   transient	   covalent	   bond	   created	   by	   the	   attack	   of	   the	   nucleophilic	  tyrosine	  on	  the	  C2	  of	  KDF	  and	  by	  extension	  KDN.	  Here	  we	  mutate	   the	  catalytic	  tyrosine	   to	   a	   histidine,	   AfSY358H,	   and	   the	   catalytic	   aspartic	   acid	   to	   an	   alanine,	  
AfSD84A.	  	  	  The	  mutation	  of	  the	  catalytic	  aspartic	  acid	  almost	  completely	  abolished	  catalytic	  activity	  (Figure	  3.5).	  The	  Kcat	  of	  AfSD84A	   is	  2050	  RFU.min-­‐1.mg	  of	  AfS,	  more	  than	  218	  times	  slower	  than	  the	  wild	  type.	  From	  the	  structure	  of	  AfSD84A	  it	  is	  clear	  that	  there	   are	   no	   other	   perturbations	   in	   the	   overall	   structure	   or	   the	   active	   site	  residues	   other	   than	   the	  mutated	   aspartic	   acid	   (Figure	  3.6A	  &	  C).	   In	   one	   of	   the	  monomers	  in	  the	  asymmetric	  unit	  there	  are	  2	  possible	  conformations	  for	  Arg171	  (Figure	   3.6C).	   Overlay	   of	   AfSD84A	   with	   the	   AfS-­‐KDN	   complex	   structure	  demonstrates	  that	  both	  conformations	  maintain	  a	  single	  interaction	  with	  the	  C5	  hydroxyl	  of	  KDN	  mediated	  through	  a	  water	  molecule	  as	  is	  the	  case	  with	  the	  wild	  type	  enzyme.	  One	  of	  the	  conformations	  seen	  in	  the	  AfSD84A	  structure	  is	  the	  same	  as	  seen	  in	  the	  wild	  type.	  The	  dual	  conformation	  of	  Arg171	  would	  have	  little	  effect	  on	  the	  interactions	  made	  by	  AfS	  with	  the	  substrate	  and	  thus	  is	  unlikely	  to	  have	  any	  effect	  on	  activity.	  Overlaying	  the	  wild	  type	  AfS-­‐KDN	  complex	  with	  the	  AfSD84A	  structure	  it	  is	  clear	  that	  the	  alanine	  is	  too	  distal	  to	  the	  KDN	  molecule	  to	  directly	  interact	   with	   it	   (Figure	   3.6E).	   Asp84	   helps	   mediate	   a	   water	   molecule	   that	  nucleophilically	   attacks	   the	   C2	   of	   KDN.	   In	   contrast	   to	   aspartic	   acid	   the	   alanine	  residue	   is	   hydrophobic	   and	   is	   incapable	   of	   coordinating	   this	   essential	   water	  molecule.	  This	  mutation	   therefore	   confirms	   that	  Asp84	   is	   the	   catalytic	   aspartic	  acid.	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The	  mutation	  of	  the	  catalytic	  tyrosine	  has	  been	  studied	  in	  a	  number	  of	  sialidases.	  The	   removal	   of	   this	   highly	   conserved	   residue	   results	   in	   either	   profoundly	  diminished	   activity	   or	   transformation	   of	   the	   retaining	   glycosidase	   into	   an	  inverting	  enzyme.	  In	  the	  case	  of	  MvS	  the	  mutation	  of	  this	  residue	  to	  an	  aspartic	  acid,	   threonine	   or	   asparagine	   significantly	   decreased	   enzyme	   activity	   and	   also	  turned	  MvS	  from	  a	  retaining	  glycosidase	  into	  an	  inverting	  enzyme	  (Watson	  et	  al.,	  2003).	  The	  T.	  cruzi	  genome	  possesses	  more	  than	  140	  copies	  of	  the	  trans-­‐sialidase	  gene,	  of	  which	  an	  estimated	  70	  genes	  encode	  inactive	  enzymes.	  The	  majority	  of	  these	   have	   a	   histidine	   in	   place	   of	   the	   catalytic	   tyrosine	   (Frasch,	   2000).	   The	  mutation	  of	  the	  catalytic	  tyrosine	  in	  TcTS	  reduces	  enzyme	  activity	  by	  more	  than	  three	   orders	   of	   magnitude	   and	   increases	   the	   enzyme’s	   propensity	   to	   act	   as	   a	  lectin	  (Oppezzo	  et	  al.,	  2011).	  	  Here	  the	  catalytic	  tyrosine	  of	  AfS	  was	  mutated	  to	  a	  histidine.	  As	  was	   the	   case	  with	   the	  aspartic	   acid	  point	  mutation	   there	  were	  no	  significant	   alterations	   in	   the	  protein	   structure	  of	  AfSY358H	   (Figure	  3.6A,	  B	  &	  D).	  The	   imidazole	   ring	   of	   the	   histidine	   superimposes	   on	   the	   phenyl	   ring	   of	   the	  tyrosine	  it	  replaces.	  There	  is	  little	  change	  in	  the	  active	  site	  residues	  including	  the	  glutamic	  acid	  that	  primes	  the	  catalytic	  tyrosine	  for	  nucleophilic	  attack	  on	  the	  C2	  of	   the	   substrate	   (Figure	   3.6D).	   The	   Glu249	   is	   2.6	   Å	   from	   the	   hydroxyl	   of	   the	  Tyr358	   side	   chain	   in	   the	   wild	   type	   enzyme	   and	   4	   Å	   from	   the	   histidine	   in	   the	  
AfSY358H	  structure	  and	  therefore	  does	  not	  significantly	  interact	  with	  the	  histidine.	  Interestingly,	  Arg265	  is	  seen	  in	  a	  dual	  conformation.	  In	  the	  wild	  type	  enzyme	  the	  guanidinium	   of	   Arg265	   is	   2.8	   Å	   from	   the	   hydroxyl	   of	   Tyr358.	   In	   the	   AfSY358H	  construct	   the	  histidine	   is	  3.4	  Å	   from	  the	  closest	  conformation	  of	  Arg265	  and	   is	  thus	  incapable	  of	  hydrogen	  bonding	  leading	  to	  the	  two	  conformers	  seen.	  Arg265	  is	  also	  important	  in	  substrate	  binding	  in	  the	  wild	  type	  enzyme	  by	  stabilization	  of	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the	  carboxylic	  acid	  of	  KDN,	  although	  one	  of	  the	  conformations	  in	  AfSY358H	  is	  the	  same	  as	  that	  seen	  in	  the	  wild	  type	  and	  thus	  it	  is	  not	  prevented	  from	  binding	  the	  substrate.	   It	   is	   unclear	   to	   what	   extent	   the	   increased	   flexibility	   of	   this	   residue	  accounts	  for	  the	  decrease	  in	  enzyme	  activity.	  	  The	   activity	   of	   AfSY358H	   is	   66	   times	   lower	   than	   wild	   type	   with	   a	   Kcat	   of	   6800	  RFU.min-­‐1.mg	  AfSY358H.	   	  The	  same	  mutation	  in	  MvS	  and	  TcTS	  also	  revealed	  some	  residual	   catalytic	   ability.	   This	   was	   hypothesized	   to	   be	   mediated	   by	   a	   water	  molecule	   serving	   as	   a	   nucleophile	   in	   place	   of	   the	   catalytic	   tyrosine,	   however	  these	  enzymes	  were	  now	  inverting	  sialidases	  (Oppezzo	  et	  al.,	  2011;	  Watson	  et	  al.,	  2003).	   Research	   by	   our	   collaborators	   demonstrated	   that	   the	   meagre	   enzyme	  activity	   of	   AfSY358H	   was	   that	   of	   a	   retaining	   enzyme	   (Yeung,	   personal	  communication).	   This	   suggests	   that	   there	   is	   no	   water	   molecule	   in	   the	   correct	  position	   to	   nucleophilically	   attack	   the	  C2	   of	  KDN	   in	  AfSY358H.	   This	   is	   consistent	  with	  the	  crystal	  structure,	  which	  predicts	  a	  distance	  of	  4.2	  Å	  between	  His358	  and	  the	  C2	  of	  KDN2en	  in	  the	  overlay	  of	  AfSY358H	  and	  the	  AfS-­‐KD2en	  complex	  structure	  thus	  it	  is	  unlikely	  to	  accommodate	  a	  water	  molecule	  in	  this	  space	  (Figure	  3.7).	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Figure	   3.7.	   The	   overlay	   of	   KDN2en	  from	   the	   AfS-­‐KDN2en	   complex	  (yellow)	   structure	   with	   AfSY358H	  (green).	  There	  is	  4.2	  Å	  between	  the	  C2	  of	  KDN2en	  and	  the	  histidine	  imidazole	  ring	   thus	   it	   is	   unlikely	   that	   a	   water	  molecule	   would	   be	   able	   to	   fit	   in	   this	  cavity.	   The	   inability	   of	   a	   water	  molecule	   to	   fit	   in	   this	   cavity	   is	  consistent	  with	  this	  mutant’s	  retaining	  sialidase	  activity.	  	  	  	  	  
3.3.3	  Mutating	  AfS	  from	  a	  KDNase	  to	  a	  sialidase	  	  The	  absence	  of	  a	  hydrophobic	  cavity	   to	  accommodate	   the	  C5	  N-­‐acetyl	  group	  of	  Neu5Ac	  is	  hypothesized	  to	  account	  for	  the	  selectivity	  of	  AfS	  to	  the	  substrate	  KDN	  over	  Neu5Ac.	  As	  previously	  mentioned	  KDN	  has	  only	  a	  hydroxyl	  group	  at	  the	  C5	  position	  and	  is	  capable	  of	  binding	  in	  this	  reduced	  size	  cavity.	  From	  the	  AfS-­‐KDN,	  KDN2en	   and	   KDF	   structures	   it	   appears	   that	   Arg171	   extends	   into	   this	  hydrophobic	  cavity	  and	  would	  clash	  with	  the	  N-­‐acetyl	  group	  of	  Neu5Ac.	  In	  MvS,	  which	   cleaves	   Neu5Ac,	   there	   is	   a	   leucine	   residue	   in	   the	   relative	   position	   to	  Arg171	  of	  AfS.	  The	  mutation	  of	  Arg171	  in	  AfS	  to	  leucine	  would	  open	  up	  the	  active	  site	  cavity	  and	  should	  mimic	  the	  hydrophobic	  cavity	  of	  a	  typical	  sialidase.	  	  	  
AfSR171L	  was	  more	  prone	   to	  precipitation	   than	   the	  wild	   type	  AfS	  or	  AfSD84A	   and	  
AfSY358H	   mutations	   and	   required	   expression	   at	   a	   lower	   temperature,	   however	  expressed	  well	   in	  auto	   induction	  media	  at	  16	  °C.	  Despite	   this,	  AfSR171L	  was	  100	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fold	  better	  at	  cleaving	  Neu5Ac-­‐Mu	  than	  the	  wild	  type.	  The	  R171L	  mutation	  also	  resulted	   in	   an	   8000	   fold	   decrease	   in	   activity	   toward	   the	   substrate	   KDN-­‐Mu	   (J.	  Yeung	  personal	  communication).	  The	  removal	  of	  Arg171	  therefore	  improves	  the	  ability	  of	  AfS	  to	  utilize	  Neu5Ac	  as	  a	  substrate,	  however	  had	  a	  detrimental	  effect	  on	  binding	  the	  substrate	  KDN.	  	  The	  complex	  structure	  of	  AfS	  R171L	  with	  Neu5Ac2en	  was	  solved	  to	  1.8	  Å	  in	  house	  (Figure	  3.8).	  There	  were	  no	  significant	  alterations	  in	  the	  overall	  structure	  or	  the	  active	   site	   residues	   (Figure	   3.8)	   when	   compaired	   to	   wild	   type	   AfS.	   It	   is	  unsurprising	   therefore	   that	   soaking	   AfSR171L	   crystals	   with	   Neu5Ac	   and	  Neu5Ac2en	   required	   high	   concentrations	   of	   ligands	   and	   was	   successful	   in	   a	  limited	  number	  of	  experiments.	  Furthermore,	  there	  was	  limited	  evidence	  for	  the	  binding	   of	  Neu5Ac2en	   in	   the	   active	   site	   of	  monomer	  B	   of	   the	   asymmetric	   unit	  and	   the	   occupancy	   of	   the	   bound	   Neu5Ac2en	   in	  monomer	   B	  was	  modelled	   0.6	  emphasizing	   the	  weak	  binding	  of	   this	   compound	   (Figure	  3.9).	  There	  was	   some	  density	  suggesting	  the	  presence	  of	  Neu5Ac2en	  in	  monomer	  A	  of	  the	  asymmetric	  unit	   however	   this	   density	   was	   saticfied	   by	   water	   molecules.	   Neu5Ac2en	   was	  bound	  in	  the	  active	  site	  cavity	   in	  an	  almost	   identical	  position	  to	  KDN2en	  in	  the	  
AfS-­‐KDN2en	   complex	   (Figure	   3.10).	   As	   expected	   the	   N-­‐acetyl	   group	   of	  Neu5Ac2en	   extends	   into	   this	   newly	   enlarged	   cavity.	   It	   is	   most	   likely	   that	   the	  methyl	  of	  the	  N-­‐acetyl	  group	  of	  Neu5Ac2en	  is	  orientated	  up	  and	  out	  of	  the	  active	  site	  and	  the	  carboxyl	  is	  directed	  down	  into	  the	  active	  site	  cavity	  as	  indicated	  by	  the	  proximity	  of	  water	  molecules	  in	  hydrogen	  bonding	  distance	  of	  the	  carboxyl.	  The	   methyl	   is	   twisted	   away	   from	   Trp202	   relative	   to	   the	   binding	   position	   of	  Neu5Ac2en	  in	  the	  MvS	  active	  site	  suggesting	  some	  repulsive	  forces	  (Figure	  3.10).	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Figure	   3.8.	   (A	   and	  B)	   Images	   of	   the	   overlay	   of	  AfSR171L	   (yellow),	  AfSR171L,W202V	   (green)	   and	   the	  wild	   type	   AfS	   (grey)	   in	   two	   orientations.	   There	   is	   no	   significant	   difference	   in	   the	   active	   site	  residues	  in	  the	  active	  site	  of	  either	  AfSR171L	  (C)	  or	  AfSR171L,W202V	  (D).The	  overlay	  of	  AfSR171L	  (E)	  and	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The	  methyl	  of	  the	  C5	  N-­‐acetyl	  group	  is	  3	  Å	  from	  the	  benzene	  ring	  of	  Trp202	  at	  its	  closest	  point	  (Figure	  3.11).	  We	  hypothesize	  that	  it	  is	  a	  clash	  between	  the	  Trp202	  and	   the	  N-­‐acetyl	  group	   that	   forces	  a	   twisting	   in	   the	  Neu5Ac2en	  N-­‐acetyl	  group	  which	   is	  not	   favourable	  to	  binding.	   In	  the	  apo	  structure	  of	  AfS	  wild	  type	  and	  in	  complex	  with	  KDN,	  KDN2en,	  and	  KDF	  the	  position	  of	  Trp202	  is	  identical	  (Figure	  3.11).	   Comparing	   these	   structures	   and	   the	  AfSR171L	   structure	  however,	   the	   side	  chain	  of	  Trp202	  is	  0.8	  Å	  from	  its	  position	  in	  the	  apo	  structure	  despite	  there	  being	  less	  than	  a	  0.2	  Å	  deviation	  in	  the	  Cα	  position	  of	  Trp202	  (Figure	  3.11).	  	  
Figure	  3.10.	  (A)	  The	  overlay	  of	  Neu5Ac2en	  (yellow)	  as	  bound	  in	  the	  AfSR171L	  structure	  with	  the	  KDN2en	   (green)	   of	   the	   AfS-­‐KDN2en	   structure.	   The	   structures	   overlay	   well	   and	   there	   is	   no	  perturbation	  in	  the	  binding	  of	  the	  pyranose	  ring.	  (B)	  Similar	  overlay	  with	  Neu5Ac2en	  bound	  in	  the	  active	  site	  of	  MvS	  (green)	  from	  the	  structure	  1EUS	  (Gaskell	  et	  al.,	  1995)	  with	  the	  Neu5Ac2en	  from	   the	  AfSR171L	   structure	   overlaid	   (yellow).	   	   The	  N-­‐acetyl	   group	   of	   Neu5Ac2en	   bound	   in	   the	  
AfSR171L	   structure	   is	   tilted	   away	   from	   Trp202	   as	   opposed	   to	   toward	   it	   as	   is	   the	   case	   with	  Neu5Ac2en	  bound	  in	  MvS.	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Figure	  3.11.	   	  The	  overlay	  of	  AfS	  wild	  type	  (green),	  AfS-­‐KDN2en	  complex	  (cyan)	  and	  the	  AfSR171L	  structure	   (yellow).	  Trp202	   is	   in	   an	   identical	   position	   in	   the	  AfS	  wild	   type	   and	   the	  AfS-­‐KDN2en	  structures,	  however	  is	  0.8	  Å	  from	  the	  same	  position	  in	  the	  AfSR171L	  structure.	  This	  is	  hypothesized	  to	  be	  due	  to	  repulsive	  forces	  with	  the	  N-­‐acetyl	  group	  of	  Neu5Ac2en	  with	  Trp202	  which	  is	  forced	  away	  from	  the	  inhibitor.	  	  It	  is	  evident	  from	  the	  AfSR171L	  structure	  that	  Arg171	  is	  not	  solely	  responsible	  for	  the	  selectivity	  of	  AfS	  for	  KDN	  over	  Neu5Ac	  and	  that	  Trp202	  is	  also	   involved.	   In	  
MvS	   the	   residue	   in	   the	   equivalent	   position	   to	   Trp202	   is	   Phe155,	   which	   is	  orientated	   away	   from	   the	  N-­‐acetyl	   group	  of	  Neu5Ac2en	   as	   opposed	   to	  Trp202	  which	   is	   orientated	   toward	   the	   transition	   state	   analogue.	   Attempts	   to	   mutate	  Trp202	   to	   phenylalanine	   proved	   unsuccessful	   at	   the	   site	   directed	  mutagenisis	  stage	   and	   a	   secondary	   attempt	   to	   mutate	   Trp202	   to	   a	   valine	   was	   pursued	  instead.	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The	  mutation	  of	  Trp202	  to	  valine	  was	  applied	  to	  the	  AfSR171L	  construct	  creating	  a	  double	  mutant,	  AfSR171L,W202V.	  The	  structure	  of	  AfSR171L,W202V	  was	  solved	  to	  1.8	  Å	  resolution	   with	   data	   collected	   in	   house.	   Again,	   like	   the	   other	   point	   mutations	  there	  was	   little	   effect	   on	   the	   overall	   structure	   of	  AfS	   and	   no	   alterations	   in	   the	  active	  site	  residues	  outwith	  the	  point	  mutations	  (Figure	  3.8).	  It	  is	  predicted	  from	  the	   overlay	   of	   AfSR171L,W202V	  with	  MvS	   in	   complex	   with	   Neu5Ac2en	   that	   there	  would	  be	  no	  clash	  with	  the	  N-­‐acetyl	  of	  Neu5Ac2en	  (Figure	  3.12).	  Unfortunately,	  due	   to	   solubility	   issues	   of	   this	   enzyme	   it	   was	   not	   possible	   to	   attain	   reliable	  kinetics	   for	   this	   mutant,	   but	   we	   predict	   that	   AfSR171L,W202V	   would	   be	   better	   at	  utilizing	   Neu5Ac	   as	   a	   substrate	   compared	   with	   the	   wild	   type	   and	   AfSR171L	  enzymes.	  	  
3.4	  Conlusions	  
The	   catalysis	   of	   KDN-­‐Mu	   by	  AfS	   proceeds	   by	   an	   identical	  mechanism	   to	   other	  members	   of	   the	   sialidase	   family.	   The	   selectivity	   of	  AfS	   for	   KDN	   as	   opposed	   to	  Neu5Ac	   is	   partially	  mediated	   by	   reduction	   in	   the	   active	   site	   cavity	   by	   residue	  R117.	  The	  protrustion	  of	  this	  residue	  into	  the	  active	  site	  is	  hypothesized	  to	  clash	  with	   the	   N-­‐acetyl	   group	   of	   Neu5Ac	   as	   demonstrated	   by	   the	   mutation	   of	   this	  residue	   to	   a	   leucine,	   which	   allowed	   the	   binding	   of	   Neu5Ac.	   A	   second	   residue,	  W202,	  also	  protrudes	  into	  the	  active	  site	  in	  the	  same	  pocket.	  Future	  work	  should	  include	   the	   mutation	   of	   this	   residue	   to	   a	   residue	   with	   a	   smaller	   sidechain	   to	  enlarge	  this	  cavity	  and	  improve	  the	  binding	  of	  Neu5Ac.	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4.	  Fragment	  based	  drug	  discovery	  on	  
the	  trans-­‐sialidase,	  TcTS,	  from	  
Trypanosoma	  cruzi.	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4.1	  Summary	  	  
T.	  cruzi	  is	  the	  etiological	  agent	  of	  Chagas	  disease	  which	  infects	  an	  estimated	  7-­‐8	  million	  people	  around	  the	  globe.	  An	  estimated	  30	  %	  of	  chronic	  infections	  result	  in	  gastrointestinal	  lesions	  and	  10	  %	  cardiac	  lesions	  which	  can	  progress	  to	  heart	  failure	   (WHO,	   2013).	   The	   current	   treatments	   have	   limited	   effectiveness	   if	   not	  administered	   early	   in	   the	   disease	   progression	   and	   are	   plagued	   by	   severe	   and	  common	   side	   effects	   (Jackson	   et	   al.,	   2010;	   Perez-­‐Molina	   et	   al.,	   2009).	   As	   such	  there	  is	  currently	  no	  drug	  treatment	  for	  Chagas	  disease	  that	  is	  FDA	  approved	  and	  treatments	   are	   only	   available	   in	   the	   USA	   for	   research	   purposes	   (Center	   for	  Disease	  Control	  and	  Prevention,	  2013).	  	  	  The	  T.	  cruzi	  parasite	  possesses	  a	  trans-­‐sialidase	  that	  protects	   the	  parasite	   from	  lysis	   by	   the	   complement	   cascade	   (Tomlinson	   et	   al.,	   1994)	   as	   well	   as	   being	  involved	   in	   host	   cell	   recognition	   and	   cell	   invasion	   (Schenkman	   et	   al	   1991).	  Furthermore,	   inhibition	   of	   this	   enzyme	   with	   preliminary	   inhibitors	   effectively	  reduced	   infection	   in	  Vero	  cell	   cultures	  by	  up	   to	  27%	  (Agusti	   et	   al.,	   2004).	  This	  chapter	  details	  the	  initial	  search	  for	  small	  molecule	  inhibitors	  against	  the	  T.	  cruzi	  
trans-­‐sialidase	  by	  fragment-­‐based	  screening.	  	  In	  the	  search	  for	   initial	   fragments	  an	   in-­‐house	   library	  of	  672	  compounds	  based	  on	  the	  Maybridge	  Ro3	  500	  library	  was	  used.	  447	  compounds	  were	  tested	  by	  the	  1H	   NMR	   techniques	   water-­‐LOGSY	   and	   saturation	   transfer	   difference	   (STD),	   of	  which	   24	   and	   0	   fragments,	   respectively,	  were	   identified	   as	   possible	   binders.	   A	  further	  672	   fragments	  were	   tested	  by	   inhibition	   assay	   resulting	   in	  66	  possible	  fragment	   inhibitors.	   Significantly,	   water-­‐LOGSY	   identified	   the	   only	   two	   known	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inhibitors,	   tetrahydropyran-­‐2-­‐carboxylic	   acid	   and	   tetrahydro-­‐2-­‐furancarboxylic	  acid,	   in	   the	   fragments	   screened	  adding	   credence	   to	   the	  other	  hits	   identified	  by	  this	   screening	   technique.	   There	   was	   no	   binding	   identified	   by	   STD	   due	   to	   the	  experimental	  settings	  necessary	  for	  efficient	  screening.	  Unfortunately,	  despite	  an	  overlap	   of	   424	   fragments	   screened	   by	   the	   different	  methods	   there	   is	   only	   one	  successful	   compound	   common	   to	   water-­‐LOGSY	   and	   the	   inhibition	   assay;	   2-­‐(4-­‐methoxyphenyl)acetonitrile.	   The	   inhibition	   assay	   suffers	   from	   a	   number	   of	  caveats	  but	  despite	  this	  identified	  several	  classes	  of	  related	  compounds	  that	  may	  inhibit	  TcTS.	  	  In	  an	  attempt	   to	  validate	   the	  hits	   identified	  by	  water-­‐LOGSY	  and	   the	   inhibition	  assay,	   these	   compounds	   were	   analyzed	   by	   GOLD	   software	   and	   used	   in	  crystallization	  studies	  with	  TcTS.	  The	  ten	  fragments	  with	  the	  best	  docking	  scores	  were	  distributed	  equally	  between	  the	  two	  experimental	  techniques.	  Of	  these	  ten	  fragments,	  nine	  possessed	  a	   carboxylic	  acid	   that	  bound	   to	   the	  arginine	   triad	  of	  
TcTS	   in	   an	   almost	   identical	   conformation	   to	   the	   sialic	   acid	   substrate,	  which	   is	  encouraging	  for	  the	  validity	  of	  these	  hits.	  Furthermore	  GOLD	  correctly	  identified	  the	   binding	   mode	   of	   a	   known	   inhibitor,	   3-­‐piperidinic	   acid.	   GOLD	   identified	  several	   possible	   docking	   solutions	   for	   fragments	   in	   the	   donor/acceptor	   sugar	  binding	  pocket	  allowing	  for	  the	  design	  of	  inhibitors	  that	  could	  potentially	  exploit	  more	   interactions	   than	   in	   traditional	   sialidases	   as	  well	   as	   inhibitors	   specific	   to	  
TcTS.	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4.2	  Materials	  and	  Methods	  	  
4.2.1	  Site	  directed	  mutagenesis	  	  The	   pTrcHis	   plasmid	   containing	   the	   mutated	   TcTS	   construct	   described	   in	  Buschiazzo	  et	  al.,	  2002	  was	  kindly	  provided	  by	  collaborator	  Prof.	  Pedro	  M.	  Alzari	  from	  Unité	  de	  Biochimie	  Structurale,	  Institut	  Pasteur	  and	  is	  henceforth	  referred	  to	  as	  TcTS	  Fr.	   	  This	  construct	  contains	  7	  mutations	  that	  did	  not	  demonstrate	  any	  detrimental	   effect	   on	   enzyme	   activity	   but	   did	   facilitate	   crystallization	  (Buschiazzo	  et	  al.,	  2002).	  	  One	  of	  these	  mutations,	  Asn58Phe,	  is	  located	  adjacent	  to	  the	  catalytic	  residue	  Asp59.	  Site	  directed	  mutagenesis	  of	  this	  residue	  back	  to	  the	   wild	   type	   Asn58	   was	   performed	   using	   the	   Stratagene	   Quikchange	   site-­‐directed	   mutagenesis	   kit	   in	   accordance	   with	   manufacturer’s	   instructions.	  Template	  DNA	  was	  used	  to	  design	  primers	  suitable	  for	  mutagenesis,	  which	  were	  obtained	   from	   Integrated	  DNA	  Technologies	   (see	  appendix).	  E.	  coli	  (DH5α)	   cell	  were	  transformed	  with	  the	  mutated	  DNA	  plasmid	  and	  plated	  onto	  LB-­‐agar	  plates	  containing	   100μg/ml	   L-­‐ampicillin	   plates	   and	   incubated	   overnight	   at	   37	   °C.	  Selected	   colonies	   were	   amplified	   in	   5	  ml	   LB	   with	   100	   μg/ml	   L-­‐ampicillin	   and	  DNA	  plasmids	  extracted	  by	  mini-­‐prep	  (Qiagen)	  and	  sequenced	  (GATC	  Biotech)	  to	  ensure	   that	   the	   mutation	   had	   been	   incorporated.	   This	   plasmid	   was	   named	  
TcTSSco.	  	  	  
4.2.2	  Expression	  and	  Purification	  of	  TcTS	  	  Purified	   TcTSSco	   plasmid	   was	   used	   to	   transform	   E.	   coli	   (BL21	   GOLD)	  (transformation	  protocol	  as	  in	  Chapter	  3.2.2)	  that	  were	  then	  selected	  by	  plating	  on	  to	  LB-­‐agar	  plates	  containing	  100	  μg/ml	  L-­‐Ampicillin	  plates	  and	  incubated	  at	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37	  °C	  overnight.	  A	  single	  colony	  was	  amplified	  in	  20	  ml	  LB	  shaking	  at	  200	  rpm	  at	  37	   °C	   overnight.	   From	   the	   overnight	   culture	   5	   ml	   was	   added	   to	   1	   L	   of	   auto	  induction	   media	   (Terrific	   broth	   base	   with	   trace	   elements,	   ForMedium,	  http://www.formedium.com/uk/EscherichiaColi/EscherichiaColi_6.htm#AIM%C2%A0_-­‐_Terrific_Broth_Base_including_Trace_elements)	   with	   100	   μg/ml	   L-­‐ampicillin	   and	   left	   shaking	   at	   250	   rpm	   at	   37	   °C	   for	   2	   hrs.	   After	   this	   time	   the	  temperature	   was	   lowered	   to	   16	   °C	   for	   48-­‐60	   hrs,	   and	   briefly	   stopped	   for	   the	  addition	  of	  a	  further	  50	  μg/ml	  L-­‐ampicillin	  after	  30	  hrs.	  Cells	  were	  harvested	  by	  centrifugation	   at	   9,000	   rpm	   for	   25	  mins	   and	   stored	   at	   -­‐80	   °C	   overnight.	   Cells	  were	   then	   thawed	   and	   re-­‐suspended	   in	   Tris	   buffer	   (50	  mM	  Tris,	   pH	   7.5)	  with	  EDTA-­‐free	   protease	   inhibitor	   cocktail	   (one	   tablet	   per	   25	  ml	   of	   solution;	   Roche	  Diagnostics)	   and	   DNase	   I	   (Sigma,	   final	   concentration	   20	   μg/ml).	   Once	   fully	  homogenised	   the	   cell	   suspension	   was	   lysed	   by	   a	   cell	   disruptor	   (Constant	  Systems).	   	  The	  solution	  was	  then	  centrifuged	  to	  remove	  insoluble	  cell	  debris	  at	  20,	  000	  rpm	  for	  30	  mins.	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4.2.3	  NMR	  	  1H	   NMR	   experiments,	   water-­‐LOGSY	   and	   saturation	   transfer	   difference	   (STD)	  NMR,	  were	  performed	  on	  TcTSFr	  with	  cocktails	  of	  fragments	  from	  the	  Maybridge	  Ro3	   500	   fragments	   library	   to	   ascertain	   binders.	   54	   cocktails	   of	   8	   soluble	  fragments	  and	  a	  single	  cocktail	  of	  4	   fragments	  with	  a	  clean	  spectra	  (436)	  were	  recorded	   so	   that	   the	   spectra	   of	   each	   compound	   could	   be	   identified.	   Using	   a	  Bruker	  Avance	  500	   the	   two	  NMR	  experiments	  were	  performed	  sequentially	  on	  solutions	  containing	  20	  μM	  TcTSFr	  in	  50	  mM	  phosphate	  buffer,	  pH	  7,	  with	  10	  %	  D2O.	   To	   each	   reaction	   cocktails	   of	   8	   compounds	   were	   added	   to	   a	   final	  concentration	   of	   1	   mM.	   Spectra	   were	   processed	   with	   Topspin	   2	   and	   AMIX	   to	  identify	  fragment	  binding.	  	  	  Further	   STD	   experiments	   with	   1mM	   L-­‐proline	   were	   performed	   on	   a	   Bruker	  Avance	   600	   on	  TcTSFr	   in	   10	  mM	   phosphate	   buffer,	   pH	   7,	   in	   100	  %	   D2O	   in	   an	  attempt	  to	  reduce	  the	  water	  signal.	  Experiments	  were	  repeated	  with	  the	  addition	  of	  20,	  400	  and	  600	  μg	  of	  TcTSFr	  with	  512	  scans.	  Experiments	  were	  also	  repeated	  with	  2K	  scans	  and	  a	  spinlock	  filter	  in	  order	  to	  enhance	  the	  proline	  binding	  signal.	  	  	  
4.2.4	  High	  throughput	  assay	  	  Assay	  conditions	  were	  optimized	  to	  contain	  10	  ng/μl	  TcTSSco,	  final	  concentration,	  in	  50	  mM	  Hepes,	  100	  mM	  NaCl	  at	  pH	  7.5.	  Assays	  were	  run	  in	  triplicate	  in	  a	  96-­‐well	   format.	   Each	   reaction	   contained	   80	   μl	   of	   TcTSSco	   in	   buffer	   that	   was	   pre-­‐incubated	  with	   10	   μl	   of	   20	  mM	   of	   a	   single	   fragment	   in	   10%	  DMSO	   in	   50	  mM	  Hepes,	   100	   mM	   NaCl	   at	   pH	   7.5	   for	   10	   mins	   at	   room	   temperature.	   The	   final	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concentration	   of	   fragment	   in	   the	   assay	   was	   2	  mM	   in	   1%	   DMSO.	   To	   begin	   the	  reaction,	  10	  μl	  of	  2	  mM	  Neu5Ac-­‐Mu	  was	  added	  to	  each	  well	  and	  the	  reaction	  was	  mixed	   and	   the	   fluorescence	   measured	   by	   the	   Spectra	   max	   M2	   fluorometer	  (Molecular	  Dimensions)	  at	  room	  temperature.	  The	  excitation	  wavelength	  in	  this	  experiment	  was	  365	  nm	  and	  the	  fluorescence	  emitted	  measured	  at	  450	  nm	  with	  a	  420	  nm	  cutoff.	  The	  final	  concentrations	  in	  the	  assay	  were	  8	  ng/μl	  TcTSSco,	  2	  mM	  fragment,	  1%	  DMSO	  and	  200	  μM	  Neu5Ac-­‐Mu.	  	  	  	  8	   reactions	   per	   plate	   were	   reserved	   for	   a	   control	   which	   contained	   10	   μl	   1%	  DMSO	  in	  50	  mM	  Hepes,	  100	  mM	  NaCl	  at	  pH	  7.5	  in	  place	  of	  the	  fragment	  solution.	  The	   mean	   value	   of	   the	   8	   controls	   was	   calculated	   along	   with	   the	   standard	  deviation	   from	   the	  mean.	   Compounds	   that	   lowered	   the	   reaction	   rate	   by	  more	  than	   1	   standard	   deviation	   in	   2	   or	   more	   of	   the	   repetitions	   were	   selected	   as	  provisional	  hits.	  A	   separate	   second	  control	  plate	  was	   set	  up	   containing	  50	  mM	  Hepes,	   100	   mM	   NaCl	   at	   pH	   7.5,	   2	   mM	   fragment,	   1%	   DMSO	   and	   200	   μM	  methylumbelliferone.	   A	   single	   reading	  was	   taken	   to	   ascertain	   if	   the	   fragments	  were	  absorbing	  the	  fluorescence	  and	  giving	  a	  false	  positive.	  Again	  there	  were	  8	  fragment-­‐less	   controls	   from	   which	   a	   mean	   and	   standard	   deviation	   was	  determined.	  Any	  fragment	  that	  showed	  absorbance	  of	  the	  fluorescence	  of	  greater	  than	  1	  standard	  deviation	  in	  2	  or	  more	  of	  the	  3	  repetitions	  was	  discarded	  from	  the	  list	  of	  positive	  hits.	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4.2.5.	  In	  silico	  fragment	  screening	  	  Fragments	  identified	  by	  the	  assay	  and	  water-­‐LOGSY	  as	  possible	  inhibitors	  were	  screened	   by	   virtual	   docking.	   Protein	   Data	   Bank	   co-­‐ordinates	   of	   82	   of	   the	   83	  fragments	  were	  produced	  in	  Prodrg	  (Schüttelkopf	  and	  van	  Aalten	  2004).	  A	  single	  compound,	   2-­‐methylbicyclohept-­‐5-­‐ene-­‐2-­‐carboxylic	   acid,	   was	   unable	   to	   be	  processed	  by	  Prodrg	  and	  was	  not	  included	  in	  the	  screening.	  These	  PDB	  files	  were	  reformatted	  to	  mol2	  files	  and	  protonated	  at	  pH	  7	  by	  Babel	  (Open	  Eye	  scientific	  software).	  The	  TcTSSco-­‐proline	   complex	   structure	   (discussed	   further	   in	  Chapter	  5)	   was	   used	   as	   the	   template	   for	   the	   virtual	   screen	   in	   Hermes	   and	   GOLD.	   All	  ligands	   were	   removed	   from	   the	   structure	   and	   the	   solvent	   accessible	   cavity	  within	  10	  Å	  of	  the	  bound	  proline	  was	  identified	  as	  the	  target	  for	  screening.	  The	  fragments	   were	   screened	   in	   silico	   by	   GOLD	   and	   their	   veracity	   assessed	   by	  Goldscore.	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4.3	  Results	  and	  Discussion	  	  
4.3.1	  NMR	  	  The	  1H	  NMR	  techniques	  STD	  and	  water-­‐LOGSY	  were	  performed	  on	  cocktails	  of	  fragments	   in	   the	   presence	   of	   TcTSFr	   to	   identify	   binding.	   Only	   water-­‐LOGSY	  identified	   24	   possible	   binding	   fragments	   (Table	   4.1),	   whereas	   STD	   identified	  zero	  hits.	  	  	   Molecular	  weight	  	   Fragment	  	   Structure	  	  	  	  	  115.2	  
	  	  	  4-­‐piperidinemethanol	  
	  	  116.1	   	  	  tetrahydro-­‐2-­‐furancarboxylic	  acid	  
	  	  	  120.2	   	  	  3-­‐(1H-­‐pyrrol-­‐1-­‐yl)propanenitrile	  
	  	  	  130.1	   	  	  tetrahydropyran-­‐2-­‐carboxylic	  acid	  
	  	  	  132.2	   	  	  2-­‐amino-­‐4-­‐methylbenzonitrile	  
	  	  	  137.2	   	  	  Thiobenzamide	  
	  	  	  139.2	   	  	  (1,3,5-­‐trimethyl-­‐1H-­‐pyrazol-­‐4-­‐yl)methylamine	  
	  
	  	  144.2	   	  	  3-­‐phenyl-­‐1H-­‐pyrazole	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  146.6	   	  	  3-­‐chloro-­‐4-­‐fluorophenol	  
	  	  	  147.2	   	  	  2-­‐(4-­‐methoxyphenyl)acetonitrile	  
	  	  	  151.2	   	  	  methyl	  3-­‐aminobenzoate	  
	  	  	  	  153.2	  
	  	  	  methyl	  2,5-­‐dimethyl-­‐1H-­‐pyrrole-­‐3-­‐carboxylate	  
	  	  	  	  154.2	  
	  	  	  3-­‐[(tetrahydrofuran-­‐2-­‐ylmethyl)amino]propanenitrile	  
	  	  	  	  165.2	  
	  	  	  N-­‐(1,3-­‐benzodioxol-­‐5-­‐ylmethyl)-­‐N-­‐methylamine	  
	  	  	  	  166.2	  
	  	  	  2,3-­‐dihydro-­‐1,4-­‐benzodioxin-­‐2-­‐ylmethanol	  
	  	  	  	  166.2	  
	  	  	  2-­‐(1,3-­‐benzodioxol-­‐5-­‐yl)ethanol	  
	  	  	  	  166.3	  
	  	  	  N-­‐methyl-­‐N-­‐phenylthiourea	  
	  	  	  173.2	   	  	  1-­‐methyl-­‐3-­‐phenyl-­‐1H-­‐pyrazol-­‐5-­‐amine	  
	  	  	  	  177.2	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  179.2	  
	  	  	  ethyl	  2-­‐(4-­‐aminophenyl)acetate	  
	  	  	  	  182.2	  
	  	  	  methyl	  2-­‐(phenylthio)acetate	  
	  	  	  	  186.2	  
	  	  	  4-­‐phenoxyphenol	  
	  	  	  	  193.2	  
	  	  	  (2-­‐morpholinophenyl)methanol	  
	  	  	  	  194.2	  
	  	  	  ethyl	  3-­‐(4-­‐hydroxyphenyl)propanoate	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TcTSFr	   inhibitors.	   However,	   their	   identification	   as	   hits	   by	   water-­‐LOGSY	   is	  encouraging	  as	  it	  validates	  the	  method	  as	  a	  suitable	  for	  hit	   identification.	  Other	  known	   hits,	   L-­‐proline,	   1,3-­‐thiazolane-­‐2-­‐carboxylic	   acid	   and	   nipecotic	   acid	  (discussed	  further	  in	  Chapter	  5)	  were	  not	  included	  in	  the	  NMR	  fragment	  screens. 	  There	   is	   little	   obvious	   commonality	   between	   the	  hits,	  which	   is	   less	   reassuring.	  Furthermore	  there	  is	  little	  overlap	  between	  the	  water-­‐LOGSY	  hits	  and	  the	  assay	  results.	   Ligand-­‐based	   NMR	   binding	   experiments	   can	   only	   detect	   binding	   and	  cannot	  be	  used	  to	  determine	  whether	  or	  not	  a	  fragment	  is	  binding	  in	  the	  active	  site.	  These	   fragments	  may	  be	  binding	   to	   the	  protein	  at	  different	  sites	   therefore	  accounting	   for	   the	   different	   hits	   between	   the	   techniques.	   Water-­‐LOGSY	   is	  marginally	  biased	  toward	  the	  identification	  of	  hydrophilic	  hits	  as	  it	  relies	  on	  the	  displacement	  of	  irradiated	  water	  molecules	  to	  produce	  a	  signal	  and	  thus	  signals	  tend	   to	   originate	   in	   hydrophilic	   water	   filled	   cavities	   (Dalvit	   et	   al.,	   2001).	   The	  active	  site	  is	  primarily	  hydrophilic	  favouring	  water-­‐LOGSY	  as	  a	  detection	  method	  for	  fragment	  binding	  to	  TcTSFr.	  	  	  Water-­‐LOGSY	  alone	  is	  insufficient	  to	  substantiate	  fragment	  binders.	  Compounds	  identified	   by	   both	  water-­‐LOGSY	   and	   STD	   are	   generally	   considered	   to	   be	  more	  reliable	   than	   compounds	   identified	   by	   one	   of	   these	   techniques	   alone.	  Unfortunately,	   STD	   NMR	   screening	   was	   unsuccessful	   and	   did	   not	   identify	   any	  hits.	   STD	   relies	   on	   saturating	   the	   protein	   at	   a	   frequency	   that	   will	   not	   directly	  irradiate	  the	  fragments.	  This	  frequency,	  the	  on-­‐resonance,	  was	  set	  at	  around	  -­‐1	  ppm,	   a	   chemical	   shift	   observed	   for	  methyl	   protons	  of	   hydrophobic	   buried	   side	  chains.	   Saturation	   is	   transferred	   from	  protein	   to	   binding	   fragments	   by	   nuclear	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overhauser	   effects	   to	   create	   a	   signal	   and	   thus	   is	   marginally	   biased	   toward	  hydrophobic	  fragment	  binding.	  Given	  the	  hydrophilicity	  of	  the	  TcTSFr	  active	  site,	  STD	  is	  less	  likely	  to	  be	  capable	  of	  identifying	  compounds	  that	  bind	  in	  this	  cavity.	  	  The	   known	   inhibitors	   Neu5Ac2en	   and	   proline	   were	   tested	   under	   the	   high	  throughput	  settings	  used	  on	  the	  rest	  of	  the	  in	  house	  library	  and	  did	  not	  show	  any	  evidence	  of	  binding	  with	  STD.	  One	  caveat	  of	  STD	  NMR	  is	  that	  it	  is	  only	  capable	  of	  identifying	   weak	   binders	   as	   it	   relies	   on	   detection	   of	   the	   loss	   of	   the	   fragment	  signal	  in	  solution.	  For	  this	  reason	  it	  may	  not	  have	  been	  capable	  of	  identifying	  the	  binding	  of	  Neu5Ac2en,	  however	  this	  caveat	  is	  unlikely	  to	  affect	  the	  identification	  of	  fragment	  binders,	  such	  as	  proline,	  which	  are	  unlikely	  to	  be	  strong	  binders.	  	  	  Clearly	   STD	   is	   not	   applicable	   as	   a	   high	   throughput	   method	   for	   identifying	  inhibitors	   of	   TcTSFr	   as	   it	   cannot	   identify	   even	   known	   inhibitors	   such	   as	  Neu5Ac2en	  or	  proline.	  With	  an	   increased	  number	  of	   scans	   from	  128	   to	  512	  or	  2000,	   using	   a	   spinlock	   filter	   and	  performing	   experiments	   in	   100%	  D2O,	   it	  was	  possible	   to	   show	   evidence	   of	   binding	   of	   L-­‐proline	   (Figure	   4.2).	   STD	   is	   an	  excellent	  technique,	  however	  the	  settings	  required	  to	  identify	  binding	  fragments	  are	  not	  conducive	  to	  high	  throughput	  screening	  for	  the	  protein	  TcTSFr.	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4.3.2.	  Fragment	  screening	  assay	  	  	  A	  number	  of	  studies	  have	  had	  success	  in	  identifying	  drug	  fragments	  that	  bind	  to	  their	   respective	   proteins	   using	   fragment	   screening	   assays	   (Murray	   and	   Rees,	  2009;	   Rees	   et	   al.	   2004).	   As	   TcTSSco	   is	   a	   trans-­‐sialidase,	   optimally	   a	   high	  throughput	   trans-­‐sialidase	   assay	   would	   be	   used	   to	   identify	   small	   molecule	  inhibitors.	  A	  few	  methods	  for	  trans-­‐sialidase	  assays	  have	  been	  published	  to	  date	  however	   due	   to	   caveats	   in	   time,	   cost	   and	   toxicity	   here	  we	   opted	   to	   adopt	   the	  established	  sialidase	  assay	  for	  this	  purpose.	  This	  method	  is	  well	  established,	  fast,	  repeatable	   and	   reliable.	   Any	   fragment	   that	   inhibits	   in	   the	   standard	   sialidase	  assay	  will	   inhibit	   the	   trans-­‐sialidase	   activity	   of	  TcTSSco,	   however	   by	   using	   only	  this	  assay	  format	  there	  is	  a	  bias	  for	  identifying	  fragments	  that	  inhibit	  by	  binding	  in	  the	  sialic	  acid	  binding	  site	  and	  not	  the	  donor/acceptor	  sugar	  binding	  site.	  This	  limitation	  is	  outweighed	  by	  the	  reliability	  and	  ease	  of	  this	  technique	  and	  does	  not	  preclude	  the	  extension	  of	  these	  fragments	  into	  the	  donor/acceptor	  sugar	  binding	  site.	  	  	  From	   the	   672	   compounds	   tested	   by	   this	   method,	   57	   fragments	   demonstrated	  inhibition	  (See	  Appendix).	  Disappointingly	  in	  this	  study	  none	  of	  the	  structurally	  validated	   compounds	   discussed	   in	   Chapter	   5	   or	   tetrahydropyran-­‐2-­‐carboxylic	  acid	  were	  identified	  by	  this	  screen.	  The	  concentration	  of	  substrate	  in	  this	  assay	  was	  200	  μM,	  as	  based	  on	  published	  work	  (Arioka	  et	  al.,	  2010;	  Amaya	  et	  al.,	  2004)	  which	  is	  only	  10	  times	  more	  dilute	  than	  the	  concentration	  of	  the	  fragments.	  Thus	  fragments	   that	  would	  demonstrate	   inhibition	   in	   this	  method	  must	  have	  a	  Kd	   in	  the	  range	  of	  roughly	  10-­‐fold	  less	  than	  that	  of	  Neu5Ac-­‐Mu,	  which	  is	  unlikely	  to	  be	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achieved	  by	  such	  small	  fragments.	  Larger	  compounds,	  of	  a	  size	  more	  comparable	  to	   a	   drug,	  may	   be	  more	   appropriate	   for	   this	   high	   throughput	   assay	  method	   as	  they	   are	   capable	   of	   making	   more	   interactions	   than	   fragments	   and	   thus	   can	  achieve	  a	   lower	  Kd.	  The	  drawback	  of	   screening	   larger	   compounds	   is	   that	   there	  are	  fewer	  hits	  due	  to	  size	  constraints,	  however	  hits	  are	  capable	  of	  making	  more	  interactions	  and	  are	  often	  tight	  binders.	  	  	  The	   sialidase	   assay	   described	   here	   measures	   the	   hydrolysis	   of	  methylumbelliferone	   (Mu)	   from	   Neu5Ac-­‐Mu	   by	  measuring	   the	   fluorescence	   of	  the	   released	   Mu.	   Control	   assays	   to	   ascertain	   which	   compounds	   absorb	   the	  fluorescence	   in	   this	   range	   of	   wavelengths	   were	   run	   and	   resulting	   compounds	  discarded.	  Positive	  hits	  may	  have	  been	  discarded	  due	  to	  their	  absorbance	  in	  this	  range.	   Of	   the	   672	   compounds	   assayed	   342	   were	   discarded	   for	   absorbing	   the	  flourecence.	   This	   means	   that	   effectively	   over	   51%	   of	   the	   screen	   were	   not	  considered	  due	  to	  them	  being	  discarded	  from	  the	  screen.	  The	  high	  a	  proportion	  of	  the	  fragments	  absorbing	  the	  fluorescence	  may	  be	  explained	  poor	  solubility	  of	  the	  fragments	   in	  the	  assay	  buffer.	  Precipitation	  of	  the	  fragments	  would	  occlude	  flourecence	   in	   the	  well.	  Furthermore	   the	  condition	  of	   the	   fragment	  screen	  may	  have	   deteriorated	   due	   to	   long	   periods	   in	   storage	   resulting	   inprecipitation	   or	  breakdown.	  	  
4.3.3	  In	  silico	  modeling	  of	  fragment	  binding	  	  GOLD	  software	  was	  used	  to	  screen	  the	  possible	  inhibitors	  identified	  in	  the	  NMR	  and	   assay	   screens	   in	   silico.	   	   GOLD	   uses	   a	   genetic	   algorithm	   that	   makes	   small	  modifications	  to	  possible	  binding	  modes	  of	  ligands	  in	  a	  selected	  protein	  in	  order	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to	   determine	   the	   best	   binding	   conformation.	   For	   each	   conformation	   GOLD	  calculates	  a	  fitness	  score	  by	  the	  summation	  of	  calculated	  hydrogen	  bond	  energy	  of	   the	  protein-­‐ligand	  complex,	   the	  steric	  energy	  of	   the	   interaction	  of	   the	   ligand	  with	  the	  protein	  and	  the	  internal	  energy	  of	  the	  ligand	  (Jones	  et	  al.,	  1997).	  Using	  this	   fitness	   function	   GOLD	   averaged	   a	   71%	   success	   rate	   at	   predicting	   ligand	  binding	  mode	  of	  100	  known	  complex	  structures	  (Jones	  et	  al.,	  1997).	  The	  fitness	  function	  however	  does	  not	   address	  hydrophobic	   interactions	   and	   is	   limited	  by	  structure	  resolution.	  The	  resolution	  of	  TcTSSco	  is	  1.9	  Å	  and	  is	  not	  a	  limiting	  factor	  for	   GOLD	   docking.	   The	   active	   site	   is	   primarily	   hydrophilic	   and	   therefore	   is	   an	  ideal	  candidate	  for	  GOLD	  docking.	  	  	  GOLD	   identified	   472	   possible	   binding	  modes	   from	   the	   82	   fragments	   screened.	  GOLD	   can	   correctly	   identify	   binding	   mode	   in	   81%	   of	   drug-­‐like	   molecules	  (Verdonk	   et	   al.,	   2003),	   although	   it	   is	  marginally	   less	   accurate	  when	   predicting	  fragment	   binding	   and	   like	   other	   screening	   methods	   should	   be	   validated	   by	  another	   experimental	   method.	   Pleasingly,	   GOLD	   correctly	   identified	  tetrahydropyran-­‐2-­‐carboxylic	   acid	   and	   predicted	   tetrahydro-­‐2-­‐furancarboxylic	  acid	  binding	  in	  the	  TcTSSco	  active	  site.	  Furthermore,	  all	  nine	  of	  the	  carboxylic	  acid	  containing	  fragments	  screened	  by	  GOLD	  were	  among	  the	  top	  10	  solutions	  (Table	  4.2).	   GOLD	   predicted	   that	   all	   of	   these	   fragments	   would	   bind	   to	   the	   TcTSSco	  arginine	  triad	  as	  would	  be	  expected.	  	  	  	  	  	  







at	  	  2	  mM	   Compound	  name	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Structure	  
79.8	   Assay	   11.7	  ±	  5.4	  
	  	  	  3-­‐(1H-­‐indol-­‐3-­‐yl)propanoic	  acid	  
76.6	   Assay	   78.0	  ±	  2.1	  
	  	  	  2,3-­‐dimethyl-­‐1H-­‐indole-­‐5-­‐carboxylic	  acid	  
73.4	   Assay	   32.7	  ±	  2.4	  
	  	  	  2,2-­‐dimethyl-­‐2,3-­‐dihydro-­‐1-­‐benzofuran-­‐7-­‐carboxylic	  acid	  	  	  	  70.1	  
	  	  	  Assay	  
	  	  	  16.8	  ±	  0.8	  
	   	  	  5-­‐chloro-­‐2-­‐methoxybenzoic	  acid	  
67.7	   Assay	   51.1	  ±	  34.7	  
	  	  	  	  2-­‐(2-­‐hydroxyphenyl)acetic	  acid	  
61.2	   Assay	   12.8	  ±	  7.2	  
	  	  	  	  isonicotinic	  acid	  
59.3	   Assay	   2.6	  ±	  0.5	  
	  	  	  	  thiophene-­‐2-­‐carboxylic	  acid	  	  	  	  	  	  58.8	  
	  	  	  NMR	  
	  	  	  	  	  	  	  	  	  	  n/a	  
	  	  	   	  	  	  tetrahydropyran-­‐2-­‐carboxylic	  acid	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Table	  4.2.	  	  The	  top	  10	  fragments	  with	  the	  best	  ranked	  binding	  solutions	  as	  predicted	  by	  GOLD.	  	  The	   fragments	   that	   were	   identified	   as	   possible	   inhibitors	   by	   either	   NMR	  techniques	   or	   the	   assay	   screeneing	   were	   tested	   in	   silico.	   Of	   the	   fragments	  assessed	   by	   in	   silico	   methods	   80%	   of	   the	   top	   10	   fragment	   solutions	   were	  identified	  in	  the	  inhibition	  assay	  and	  20%	  by	  water-­‐LOGSY.	  This	  is	  similar	  to	  the	  composition	   of	   the	   screen	   (73%	   from	   assay	   hits	   and	   27%	   from	  water-­‐LOGSY)	  and	   indicates	   that	   both	   screens	   may	   be	   equally	   useful	   in	   the	   identification	   of	  fragments	  that	  bind	  in	  the	  active	  site.	  Both	  water-­‐LOGSY	  and	  the	  inhibition	  assay	  identified	   2-­‐(4-­‐methoxyphenyl)acetonitrile	   as	   a	   possible	   inhibitor.	   However,	  disappointingly,	   in	  silico	  docking	  of	   this	  compound	  could	  not	   identify	  a	  suitable	  solution	  with	   the	   best	   solution	   resulting	   in	   a	   relatively	   poor	  Goldscore	   of	   only	  48.8.	  GOLD	  docks	  the	  electrophilic	  nitrile	  of	  2-­‐(4-­‐methoxyphenyl)acetonitrile	  3	  Å	  away	   from	   the	  nucleophilic	   tyrosine	  and	  Arg245	  and	  314	  of	   the	  arginine	   triad.	  GOLD	   predicts	   that	   the	  methoxyphenyl	   group	   of	   this	   compound	   π	   stacks	  with	  Tyr119	  and	  Trp312	  of	  the	  lactose	  binding	  pocket	  (Figure	  4.3).	  
	  57.6	   	  Assay	   	  28.6	  ±	  7.0	   	  (4-­‐pyrid-­‐2-­‐ylphenyl)methanol	  
55.4	   NMR	   n/a	  
	  	  	  tetrahydro-­‐2-­‐furancarboxylic	  acid	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Figure	  4.3.	  (A)	  The	  predicted	  binding	  of	  2-­‐(4-­‐methoxyphenyl)acetonitrile	  (yellow	  carbons,	  white	  lone	  pairs)	   from	  GOLD	  docking	  with	  TcTSSco	  	   (surface	  representation).	   	   (B)	  The	  binding	  of	  2-­‐(4-­‐methoxyphenyl)acetonitrile	  by	  GOLD	  predicts	  that	  the	  nitrile	  interacts	  with	  Arg	  245	  and	  314	  of	  the	  arginine	  triad	  (hydrogen	  bonds	  are	  represented	  as	  dashed	  lines).	  The	  phenyl	  group	  π	  stacks	  with	  Tyr119	  and	  Trp312	  in	  the	  donor/acceptor	  binding	  site	  of	  TcTSSco	  (green	  carbons	  from	  PDB	  structure	   1SOI).	   (C)	   The	   overlay	   of	   sialylactose	   (green	   carbons)	   binding	   in	   the	   active	   site	   of	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bind	  in	  the	  active	  site	  as	  it	  is	  the	  most	  reactive	  area	  of	  the	  protein.	  Perhaps	  a	  little	  surprisingly,	  although	  all	  nine	  of	  the	  carboxylic	  acid	  based	  top	  10	  hits	  bind	  to	  the	  arginine	  triad,	  the	  remainder	  of	  fragment	  is	  then	  modelled	  extending	  out	  of	  the	  active	  site	  cavity	  and	  into	  a	  hydrophobic	  pocket	  usually	  reserved	  for	  the	  binding	  of	  the	  donor/acceptor	  sugar.	  A	  prime	  example	  of	  this	   is	  the	  docking	  solution	  of	  	  3-­‐(1H-­‐indol-­‐3-­‐yl)propanoic	   acid	   which	   was	   predicted	   as	   the	   best	   docking	  solution	   identified	   (Table	   4.2	   and	   Figure	   4.4).	   3-­‐(1H-­‐indol-­‐3-­‐yl)propanoic	   acid	  binds	  to	  the	  arginine	  triad	  via	  its	  carboxylic	  acid	  and	  its	  indol	  ring	  extends	  into	  the	  lactose	  binding	  cavity	  (Figure	  4a	  and	  b).	  This	  cavity	   is	   lined	  by	  Trp314	  and	  Try119	   and	   the	   indol	   ring	   is	   predicted	   to	   bind	   inbetween	   the	   phenyl	   rings	   of	  these	  residues.	  The	  predicted	  binding	  of	  3-­‐(1H-­‐indol-­‐3-­‐yl)propanoic	  acid	  is	  ideal	  for	  π	  stacking	  with	  these	  residues.	  The	  amine	  of	  3-­‐(1H-­‐indol-­‐3-­‐yl)propanoic	  acid	  is	  predicted	  to	  hydrogen	  bond	  with	  the	  hydroxyl	  of	  the	  Tyr119	  side	  chain	  (Figure	  4.4a).	  	  
TcTS	  differs	   from	  traditional	   sialidases	  by	   the	  presence	  of	  a	  binding	  pocket	   for	  the	  donor/acceptor	   sugar	   in	   addition	   to	   the	   sialic	   acid	   binding	   site.	   Fragments	  that	   bind	   in	   this	   pocket	   allow	   the	   exploitation	   of	   more	   interactions	   and	   may	  confer	  specificity	  to	  TcTS.	  For	  the	  design	  of	  potential	  drugs	  this	  in	  turn	  may	  lead	  to	  lower	  effective	  doses	  and	  fewer	  side	  effects.	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Figure	   4.5.	   The	   experimentally	   derived	   binding	   modes	   of	   Neu5Ac2en	   (A,	   yellow)	   and	   3-­‐piperidinic	   acid	   (B,	   yellow)	   and	   their	   predicted	   binding	   as	   calculated	   by	   GOLD	   (green).	   GOLD	  struggles	  to	  replicate	  the	  experimentally	  derived	  binding	  mode	  of	  Neu5Ac2en,	  but	  has	  far	  greater	  success	  with	  3-­‐piperidinic	  acid.	  	  	  
In	   silico	   fragment	   docking	   is	   a	   powerful	   tool	   and	   appears	   the	  most	   promising	  screening	  method	  used	   in	   this	   study,	  however	   this	   technique	   is	  not	  without	   its	  shortcomings.	   Attempted	   docking	   of	   known	   binders	   Neu5Ac2en	   and	   3-­‐piperidinic	  acid	  (discussed	  further	  in	  Chapter	  5)	  resulted	  in	  models	  that	  shared	  similar	  binding	  modalities	   to	   the	  experimentally	  derived	  models	  however	  with	  notable	   differences.	   The	   carboxylic	   acids	   of	   both	   compounds	   bind	   in	   X-­‐ray	  structures	   in	   almost	   identical	   positions	   to	   the	  models	   estimated	  by	  GOLD.	   The	  binding	   of	   Neu5Ac2en	   is	   close	   to	   the	   active	   site	   cavity	   wall,	   however	   GOLD	  estimates	  that	  Neu5Ac2en	  extends	  out	  of	  the	  active	  site	  (Figure	  4.5a).	  Similarly,	  in	  the	  GOLD	  model	  of	  3-­‐piperidinic	  acid	  binding	  the	  carboxylic	  acid	  is	  predicted	  perfectly.	  However,	  the	  piperidinic	  ring	  is	  tilted	  away	  from	  the	  active	  site	  cavity	  in	  GOLD	  relative	  to	  the	  experimentally	  derived	  model	  (Figure	  4.5b).	  It	  should	  be	  noted	  that	  Neu5Ac2en	  is	  a	  poor	   inhibitor	  of	  TcTS	  due	  to	  a	  steric	  clash	  with	  the	  
!"# $"#
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catalytic	   tyrosine.	  The	   catalytic	   tyrosine	   is	   forced	   to	  move	   slightly	   to	   avoid	   the	  clash	  upon	  binding	  Neu5Ac2en	  (Buschiazzo	  et	  al.,	  2002),	  a	  movement	   that	  was	  not	   accounted	   for	   in	   the	   GOLD	   docking.	   The	   docking	   of	   3-­‐piperidinic	   acid	   is	  impressively	  accurate	  and	   is	  a	  promising	   indicator	   for	   the	  veracity	  of	   the	  other	  docking	   estimations	   provided	   by	   GOLD.	   The	   Goldscores	   for	   Neu5Ac2en	   and	  piperidinic	   acid	  were	  85.9	   and	  60.2	   respectively.	  The	   top	  6	   fragment	   solutions	  calculated	   by	   GOLD	   have	   scores	   higher	   than	   3-­‐piperidinic	   acid	   tentatively	  suggesting	   that	   they	  may	   in	   fact	   bind	   better	   than	   3-­‐piperidinic	   acid.	   Given	   the	  results	   calculated	   by	   GOLD	   here	   we	   anticipate	   that	   the	   evolution	   of	   in	   silico	  fragment	  screening	  and	  drug	  design	  will	  make	  it	  a	  progressively	  invaluable	  drug	  design	  tool.	  
4.4	  Conclusions	  	  Only	   one	   compound	  was	   identified	   as	   a	   possible	   hit	   as	   a	   possible	   inhibitor	   of	  
TcTS	   in	   both	   the	   NMR	   and	   assay	   screening	   techniques:	   2-­‐(4-­‐methoxyphenyl)acetonitrile.	   The	   low	   congruence	   between	   these	   screening	  methods	   is	   disappointing.	   In	   silico	   fragment	   screening	   however	   seems	   very	  promising.	   The	   identification	   of	   3-­‐(1H-­‐indol-­‐3-­‐yl)propanoic	   acid	   by	   the	  inhibition	   assay	   was	   calculated	   to	   have	   a	   good	   GOLD	   prediction	   score.	   The	  predicted	   docking	   of	   this	   compound	   and	   8	   others	   utilised	   the	   binding	   of	  carboxylic	  acid	   in	  the	  arginine	  triad.	  This	  highlights	  the	  benefits	  conferred	  by	  a	  carboxylic	  acid	  in	  potential	  inhibitors.	  All	  of	  the	  acids	  identified	  either	  by	  NMR	  or	  inhibition	   assay	   were	   among	   the	   top	   10	   hits	   identified	   by	   GOLD	   docking.	  Excitingly,	   these	   compounds	   extended	   into	   the	   binding	   pocket	   for	   the	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donor/acceptor	  sugar,	   indicating	  methods	   for	   the	  design	  of	  potential	   inhibitors	  that	  are	  specific	  to	  TcTS.	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5.	  Crystallography	  of	  TcTS	  in	  complex	  
with	  fragment	  hits	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5.1	  Summary	  	  More	  than	  seven	  mutations	  were	  required	  to	  crystallize	  TcTS	  (Buschiazzoet	  al.,	  2002),	  herein	  referred	  to	  as	  TcTSFr.	  The	  mutations	  are	  concentrated	  in	  the	  CBM	  domain	  of	  TcTS,	  distal	   from	   the	  active	   site,	   and	  a	   single	  mutation	  Asn58Phe	   in	  the	   catalytic	   subunit.	   Upon	   solving	   the	   structure	   it	   was	   realized	   that	   this	  mutation	  was	  located	  beside	  the	  catalytic	  residue	  Asp59.	  This	  mutation	  did	  not	  affect	   the	   activity	   of	   the	   enzyme	   and	   thus	   it	   was	   hypothesized	   it	   made	   no	  difference	  to	  the	  overall	  structure	  (Buschiazzo	  et	  al.,	  	  2002;	  Amaya	  et	  al.,	  2004).	  	  	  In	  this	  chapter	  we	  present	  two	  further	  crystallization	  conditions	  for	  TcTS.	  From	  the	   structure	   it	   can	  be	   concluded	   that	  mutation	  Asn58Phe	   is	  not	  necessary	   for	  crystallization	  and	  that	  its	  removal	  may	  provide	  a	  truer	  platform	  for	  drug	  design.	  Thus	   the	   mutation	   was	   removed	   and	   the	   resulting	   protein	   TcTSSco	   was	  crystallized	   and	   used	   for	   all	   further	   crystallographic	   studies.	   All	   compounds	  identified	  in	  the	  NMR	  and	  high	  throughput	  assays	  were	  used	  in	  co-­‐crystallization	  trials	  or	  soaking	  experiments.	  Unfortunately	  very	  few	  of	  the	  hits	  were	  validated	  by	   this	   method	   highlighting	   the	   caveats	   of	   false	   positives	   in	   high	   throughput	  fragment	   screening	   and	   conversely	   the	   occurrence	   of	   false	   negatives	   in	   X-­‐ray	  crystallography.	  	  
	  Herein	  we	   present	   the	   structures	   of	   five	   compounds,	   identified	   either	   through	  high	   throughput	   screening	  or	  hypothesis	  based	  on	   the	  knowledge	  of	   the	  active	  site,	   in	  complex	  with	  TcTSSco.	  All	   five	  of	   the	  compounds	  share	  a	  carboxylic	  acid	  that	   interacts	  with	  the	  arginine	  triad	  almost	   identically	  to	  the	  natural	  substrate	  Neu5Ac.	   Small	   amino	   acids	   proline,	   serine	   and	   valine	   and	   compounds	   1,3-­‐
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thiazolane-­‐2-­‐carboxylic	   acid	   and	  3-­‐piperidinic	   acid	   bound	   in	   the	   active	   site	   via	  their	  carboxylic	  acid	  and	  the	   interaction	  of	   their	  amine	  (or	   imine	   in	   the	  case	  of	  proline,	   1,3-­‐thiazolane-­‐2-­‐carboxylic	   acid	   and	   3-­‐piperidinic	   acid)	   with	   the	  catalytic	   aspartic	   acid.	   The	   commonality	   of	   these	   two	   moieties	   to	   the	   five	  fragments	   that	   were	   successfully	   crystallized	   highlights	   their	   importance	   for	  binding.	   The	   ring	   structures	   of	   proline	   and	   3-­‐piperidinic	   acid	   provide	   an	  excellent	  structure	  on	  which	  to	  extend	  these	  compounds	  in	  to	  potential	  drugs.	  	  	  Unlike	   traditional	   sialidases,	   TcTS	   presents	   a	   much	   larger	   active	   site	   to	  accommodate	  the	  donor	  and	  acceptor	  sugar	  chains	  from	  the	  host	  and	  pathogen.	  The	   exploitation	   of	   this	   cavity	   by	   extension	   of	   currently	   available	   drugs	   or	  validated	  sialidase	  inhibitors	  such	  as	  Neu5Ac2en	  would	  prove	  challenging	  due	  to	  the	  double	  bond	  in	  their	  ring	  structures.	  Addition	  of	  a	  substituent	  to	  exploit	  this	  cavity	  would	  remove	  this	  double	  bond	  and	  alter	  ring	  puckering	  and	  thus	  binding	  efficiency.	   This	   would	   not	   be	   a	   problem	   for	   lead	   compounds	   proline	   and	   3-­‐piperidinic	   acid	   identified	   here	   as	   they	   do	   not	   possess	   double	   bonds	   in	   their	  respective	   ring	   structures	  and	   thus	  may	  prove	  excellent	   starting	  points	   for	   the	  development	  of	  drugs	   capable	  of	   exploiting	   the	  entire	   active	   site.	   Interestingly,	  other	   buffer	   and	   cryoprotectant	   components	   highlight	   other	   exploitable	  interactions	  in	  both	  the	  sialic	  acid	  and	  lactose	  binding	  pocket.	  There	  is	  electron	  density	  visible	  in	  the	  structures	  for	  DMSO,	  Tris	  and	  a	  tetrahedral	  ion	  in	  the	  long	  active	  site	  cleft	  highlighting	  3	  druggable	  sites.	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5.2	  Materials	  and	  Method	  	  	  
TcTSSco	  and	  TcTSFr	  were	  expressed	  and	  purified	  as	   in	  Chapter	  4	   (Chapter	  4.2.1,	  p117).	  	  	  
5.2.1	  Site	  directed	  mutation	  	  The	   pTrcHis	   plasmid	   containing	   the	   mutated	   TcTS	   construct	   described	   in	  Buschiazzo	  et	  al.,	  2002	  was	  kindly	  provided	  by	  collaborator	  Prof.	  Pedro	  M.	  Alzari	  from	  Unité	  de	  Biochimie	  Structurale,	  Institut	  Pasteur	  and	  is	  henceforth	  referred	  to	  as	  TcTS	  Fr.	   	  This	  construct	  contains	  7	  mutations	  that	  did	  not	  demonstrate	  any	  detrimental	   effect	   on	   enzyme	   activity	   but	   did	   facilitate	   crystallization	  (Buschiazzo	  et	  al.,	  2002).	  	  One	  of	  these	  mutations,	  Asn58Phe,	  is	  located	  adjacent	  to	  the	  catalytic	  residue	  Asp59.	  Site	  directed	  mutagenesis	  of	  this	  residue	  back	  to	  the	   wild	   type	   Asn58	   was	   performed	   using	   the	   Stratagene	   Quikchange	   site-­‐directed	   mutagenesis	   kit	   in	   accordance	   with	   manufacturer’s	   instructions.	  Template	  DNA	  was	  used	  to	  design	  primers	  suitable	  for	  mutagenesis,	  which	  were	  obtained	   from	   Integrated	  DNA	  Technologies	   (see	  appendix).	  E.	  coli	  (DH5α)	   cell	  were	  transformed	  with	  the	  mutated	  DNA	  plasmid	  and	  plated	  onto	  LB-­‐agar	  plates	  containing	   100μg/ml	   L-­‐ampicillin	   plates	   and	   incubated	   overnight	   at	   37	   °C.	  Selected	   colonies	   were	   amplified	   in	   5	  ml	   LB	   with	   100	   μg/ml	   L-­‐ampicillin	   and	  DNA	  plasmids	  extracted	  by	  mini-­‐prep	  (Qiagen)	  and	  sequenced	  (GATC	  Biotech)	  to	  ensure	   that	   the	   mutation	   had	   been	   incorporated.	   This	   plasmid	   was	   named	  
TcTSSco.	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5.2.2	  Protein	  Crystallization	  	  Sitting	  drop,	  vapour	  diffusion	  plates	  (Crystalclear	  D	  strips	  with	  depressions	  from	  Douglas	   Instruments	   Ltd.),	   were	   incubated	   at	   20	   °C	   in	   all	   crystallization	  experiments.	  To	  ascertain	  new	  crystallization	  conditions	  for	  TcTSFr,	  commercial	  screens	  Cryo	   I	   and	   II	   (Emerald	  Biosystems),	  Crystal	   screens	   I	   and	   II	   (Hampton	  Research),	   Index	   (Hampton	   Research),	   PEG	   screen	   (Qiagen)	   and	   Wizard	  (Emerald	   Biosystems)	   were	   used.	   300	   nl	   of	   purified	   TcTSFr	   at	   10	   mg/ml	   was	  added	   to	   each	   screen	   condition	   in	   a	  1:1	   ratio	  by	   the	  high	   throughput	  Rhombix	  Screen®	   robot	   (Rhombix).	   Large	   cube-­‐like	   crystals	   appeared	   in	   the	   Hampton	  Research	  Index	  condition	  containing	  200	  mM	  L-­‐Proline,	  100	  mM	  Hepes	  and	  10%	  PEG	  3350	  within	  a	  week	  (Figure	  5.1).	  Similar	  crystals	  appeared	  in	  the	  condition	  10%	  PEG	  8	  K	  and	  100	  mM	  Tris	  pH	  8.5	  after	  3	  weeks.	  Crystals	   in	  this	  condition	  were	  hard	   to	   replicate	  without	   seeding.	  For	   seeding	  experiments	  a	   single	  drop	  containing	  a	  crystal	  was	  aspirated	  and	  diluted	  with	  50	  μL	  of	  crystallization	  buffer	  in	   a	   seed	   bead	   tube	   (Hampton	   Research)	   and	   vortexed	   for	   60	   s.	   The	  crystallization	  drops	  were	  set	  up	  as	  before	  and	  the	  crystal	  seeds	  deposited	  using	  a	   cat	  whisker	   dipped	   into	   the	   seed	   solution	   and	   then	   steaked	  directly	   into	   the	  crystallization	  drop	  before	   the	  plates	  were	   re-­‐sealed.	   Post	   solving	   and	   refining	  the	   structure	  of	  TcTSFr,	   analysis	  of	   the	   crystal	  packing	   suggested	   that	  mutation	  Asn58Phe	   was	   not	   necessary	   for	   crystallization.	   Subsequently	   TcTSSco	   	   was	  crystallized	  in	  identical	  conditions.	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Figure	  5.1.	  Image	  of	  a	  TcTSSco	  crystal	  in	  a	  0.4	   μm	   loop.	   The	   crystals	   are	   large	  cuboids.	  
	  	  	  	  	  	  	  	  	  
5.2.3	  Crystal	  soaks	  and	  co-­‐crystallization	  	  Hits	   from	   the	   high	   throughput	   screens,	   identified	   by	   NMR	   and	   the	   high	  throughput	   assay,	   described	   in	   the	   previous	   chapter	   were	   used	   to	   attempt	  cocrystallization	  with	  TcTSSco	  by	  substitution	  of	  200	  mM	  proline	  present	   in	   the	  crystallization	   condition	   with	   200	  mM	   of	   the	   respective	   hit.	   Compounds	   were	  stored	  at	  2	  M	   in	  100%	  DMSO.	  The	  DMSO	  diluted	   into	   the	  crystallization	  buffer	  resulted	  in	  a	  final	  concentration	  was	  10%.	  	  There	  was	  no	  DMSO	  in	  the	  conditions	  were	   proline	   was	   substituted	   with	   other	   amino	   acids	   as	   all	   amino	   acid	   stock	  solutions	  were	  made	  to	  1	  M	  in	  deionized	  water.	  	  	  Furthermore,	  crystals	  were	  grown	  in	  10%	  PEG	  8K	  and	  100	  mM	  Tris	  pH	  8.5	  were	  used	  in	  soaking	  experiments	  with	  compounds	  so	  as	  to	  prevent	  competition	  with	  proline.	  All	   soaks	  were	   conducted	  by	  addition	  of	  1	  μl	  of	  200	  mM	  compound	   in	  100%	  DMSO	  to	  the	  4	  μl	  crystalization	  drop	  and	  left	  at	  room	  temperature	  for	  3-­‐5	  minutes	  before	  placement	  on	  the	  goniometer	  in	  a	  stream	  of	  nitrogen	  at	  100	  K.	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5.2.4	  Data	  collection,	  structure	  determination	  and	  refinement	  	  Crystals	   were	   cryo-­‐protected	   with	   either	   20%	   glycerol	   (w/v),	   30%	   PEG	   400	  (w/v)	   or	   30%	   DMSO	   in	   crystallization	   buffer	   for	   a	   few	   seconds	   prior	   to	  placement	  in	  liquid	  nitrogen.	  This	  was	  not	  necessary	  for	  crystals	  used	  in	  soaking	  experiments	  which	  were	  cryoprotected	  by	  the	  addition	  of	  1	  μl	  of	  the	  compound	  in	   100%	   DMSO	   to	   the	   4	   μL	   drop	   containing	   the	   crystals	   giving	   the	   final	  concentration	  of	  20%	  DMSO.	  All	  data	  were	  collected	  at	  100	  K	  in	  house	  (Rigaku-­‐MSC	  Micromax-­‐007	   X-­‐ray	   generator	   and	   Saturn	   944+	   CCD	   detector).	   MOSFLM	  (Leslie,	  2006)	  was	  used	  to	   integrate	  the	  data	  and	  POINTLESS	   in	  the	  CCP4	  suite	  (Bailey,	  1994)	  determined	  the	  space	  group	  to	  be	  P21.	  	  The	  data	  were	  scaled	  using	  SCALA.	  Since	  the	  unit	  cell	  was	  adequately	  similar	  to	  that	  of	  previously	  published	  structures	   2AH2,	   1SOI,	   1SOJ	   and	   1SOK	   (Amaya	   et	   al.,	   2004)	   these	   were	   used	  directly	   for	   refinement	   using	   REFMAC5	   (Murshudov	   et	   al.,	   1997)	   using	   native	  data	   (or	   data	   collected	   on	   soaked	   or	   co-­‐crystallized	   crystals).	   All	   non-­‐protein	  atoms	  were	   removed	   from	   these	  models	  prior	   to	   ridged	  body	   refine	  ment	   and	  later	  restrained	  refinement	  in	  REFMAC5	  and	  manually	  fitted	  and	  improved	  with	  Coot	   (Emsley	   and	   Cowtan,	   2004).	   Coordinate	   and	   crystallographic	   information	  files	   (CIF	   files)	   for	   ligands	   were	   created	   using	   Prodrg	   (Schüttelkopf	   and	   van	  Aalten,	   2004).	   For	   structures	   where	   the	   resulting	   Fo-­‐Fc	   map	   indicated	   the	  presence	   of	   the	   ligand,	   those	   files	   were	   used	   to	   fit	   the	   ligand	   in	   Coot	   before	  further	   refinement.	  The	   resulting	  model	  was	  validated	  by	  Coot	  and	  MolProbity	  (Lovell	  et	  al.,	  2003).	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X-­‐ray	  source	   In	  house	   In	  house	   In	  house	   In	  house	   In	  house	   In	  house	  
X-­‐ray	  wavelength	  (Å)	   1.542	   1.542	   1.542	   1.542	   1.542	   1.542	  
Resolution	  (Å)	   12.4-­‐1.84	  (1.94-­‐1.84)	   13.8-­‐1.9	  (2.0-­‐1.9)	   13.9-­‐1.96	  (2.01-­‐1.97)	   15.5-­‐2.09	  (2.2-­‐2.09)	   15.4-­‐2.09	   (2.2-­‐2.09)	   15.5-­‐2.0	   (2.1-­‐2.0)	  
Unit	  cell	  dimensions	   	   	   	   	   	   	  
a(Å)	   63.4	   53.8	   54.5	   54.4	   54.2	   54.1	  
b(A)	   129.4	   129	   129.9	   129.8	   128	   129.8	  
c	  (Å)	   87.1	   54.1	   54.5	   54.4	   54.2	   54.4	  
b	  (°)	  	   91.0	   107.5	   107.6	   108.4	   102.8	   108.5	  
No.	  observations	   376718	  (120227)	   119327	  (12185)	   123243	  (14599)	   100257	  (12088)	   75687	  	  (10040)	   135167	  (10859)	  
Redundancy	   3.1	  (2.7)	   2.3	  (1.9)	   2.6	  (2.1)	   2.4	  (2.2)	   2.0	  (2.0)	   3.0	  (2.3)	  
Completeness	  (%)	   98.4	  (94.8)	   93.6	  (79.0)	   90.9	  (92.1)	   97.2	  (91.6)	   88.3	  (83.5)	   94.6	  (69.1)	  
Rmerge	  (%)	  b	   7.2	  (17.9)	   4.8	  (8.9)	   5.0	  (11.6)	   5.2	  (15.2)	   9.2	  (21.2)	   5.0	  (15.1)	  
I/σI	   11.5	  (5.4)	   13.9	  (7.6)	   14.0	  (6.6)	   12.2	  (5.1)	   6.2	  (3.3)	   15.1	  (5.1)	  Refinement	   	   	   	   	   	   	  
Reflections	  used	   121837	   55085	   51601	   42140	   42490	   47782	  
N.	  atoms	   5208	   5584	   5361	   5379	   5286	   5419	  
Number	   of	   protein	  
atoms	  
4927	   4927	   4854	   4917	   4879	   4927	  
Number	  of	  water	  	  
molecules	  
281	   616	   496	   777	   372	   846	  
Number	   of	   ligand	  
atoms	  
0	   8	   7	   8	   8	   9	  Average	   B-­‐factor	  (Å2)	   28.2	   16.2	   21.2	   25.7	   20.8	   21.2	  
Protein	   28.2	   13.1	   20.6	   25.1	   20.1	   20.4	  
Water	   28.3	   25.3	   27.3	   31.2	   28.9	   29.9	  
Ligand	   n/a	   11.7	   13.7	   22.2	   25.6	   14.9	  
DMSO	   n/a	   23.4	   35.7	   n/a	   20.0	   n/a	  
Tris	   n/a	   n/a	   n/a	   35.0	   n/a	   n/a	  
Tetrahedral	  ion	   n/a	   39.0	   n/a	   n/a	   n/a	   n/a	  
R-­‐factor	  c	   0.171	   0.163	   0.211	   0.191	   0.187	   0.196	  
R-­‐free	  d	   0.204	   0.204	   0.274	   0.251	   0.229	   0.248	  
Root	   mean	   square	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
deviation	   in	   bond	  
length	  (Å)	  
0.008	   0.01	   0.009	   0.01	   0.009	   0.009	  
Root	   mean	   square	  
deviation	   in	   bond	  
angles	  (°)	  
1.1	   1.23	   1.18	   1.2	   1.18	   1.2	  
Table	  5.1.	  a	  =	  Values	  in	  parenthesis	  correspond	  to	  the	  highest	  resolution	  shell.	  b	  =	  Rmerge	  =	  ∑hkl	  ∑i	  |Ihkl,	  i	  –	  〈	  Ihkl	  〉|	  /	  ∑hkl	  〈	  Ihkl	  〉	  c	  &	  d	  =	  R-­‐factor	  and	  R-­‐free	  =	  (Σ	  |	  |Fo|	  -­‐	  |Fc|	  |)/(Σ	  |Fo|),	  where	  the	  Rfree	  was	  calculated	  from	  5%	  of	  reflections	  excluded	  from	  refinement.	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5.3	  Results	  and	  Discussion	  	  	  
5.3.1	  Removal	  of	  mutation	  Asn59Phe	  	  After	   a	   long	   and	   robust	   search	   for	   the	   crystallization	   conditions	   of	   TcTS,	  Buschiazzo	   et	   al.	   published	   a	   crystallization	   method	   involving	   seven	   site	  mutations,	   the	  production	  of	  microcrystals	  and	  their	  subsequent	  seeding	   into	  a	  different	   condition	   (Buschiazzo	   et	   al.	   2002).	   Taking	   the	   same	   construct	   here,	  describe	   a	   single	   step	   process	   for	   the	   crystallization	   of	   TcTSFr	   in	   2	   separate	  conditions:	  200	  mM	  L-­‐Proline,	  100	  mM	  Hepes	  and	  10%	  PEG	  3350;	  and	  100	  mM	  Tris	   pH	   8.5	   and	   10%	   PEG	   8	   K.	   The	   large	   number	   of	   possible	   crystallization	  conditions	   tested	   may	   have	   led	   to	   the	   discovery	   of	   these	   more	   efficient	   and	  reliable	  crystallization	  methods.	  However,	  it	  is	  likely	  that	  the	  absence	  of	  salt	  and	  detergent	   as	   in	   the	   published	   crystallization	   conditions	   significantly	   increased	  the	  propensity	  of	  this	  protein	  to	  crystallization	  (Buschiazzo	  et	  al.	  2002).	  
	  The	   crystal	   packing	   and	   hence	   the	   unit	   cell	   are	   almost	   identical	   to	   those	  previously	   published	   (Buschiazzo	   et	   al.	   2002).	   Close	   analysis	   of	   the	   crystal	  contacts	  suggested	  that	  one	  of	  the	  seven	  mutations	  inserted	  into	  the	  TcTS	  gene	  to	   facilitate	   crystallization	  was	   not	   involved	   in	   crystal	   packing.	   This	  mutation,	  Asn58Phe,	   is	   located	  adjacent	  to	  the	  catalytic	  aspartic	  acid,	  Asp59.	  Examination	  of	  crystal	  packing	  shows	  that	  the	  closest	  point	  to	  the	  neighbouring	  monomer	  is	  the	  backbone	  carbonyl	  of	  Asp624.	  The	  phenyl	  side	  chain	  of	  Phe58	  is	  7.2	  Å	  from	  the	   carbonyl	   of	   the	   Asp624	   backbone	   and	   thus	   is	   not	   capable	   of	   forming	  interactions	  that	  would	  affect	  crystal	  packing	  (Figure	  5.2).	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Although	  this	  mutation	  does	  not	  interact	  with	  the	  native	  substrate	  or	  impede	  the	  catalytic	   efficiency	   of	   the	   enzyme	   (Buschiazzo	   et	   al.,	   2002)	   it	   does	   alter	   the	  charge	  and	  shape	  of	   the	  active	  site	  cleft.	   	   In	   this	  study	  we	  probe	  the	  active	  site	  cleft	  to	  exploit	  a	  number	  of	  interactions	  with	  the	  aim	  of	  creating	  an	  inhibitor	  with	  sufficient	   activity	   to	   become	   a	   possible	   drug.	   Many	   drugs	   utilize	   interactions	  outwith	  the	  catalytic	  residues	  and	  extend	  into	  parts	  of	  the	  active	  site	  that	  do	  not	  interact	  directly	  with	  the	  substrate.	  	  
Figure	   5.3.	   Overlay	   of	   TcTSSco	   (blue)	   with	   the	   previously	   published	   TcTSFr-­‐Neu5Ac	   complex	  (green)	  (PDB	  code	  2AH2,	  Alzari	  2004).	  There	  is	  no	  significant	  difference	  in	  overall	  structure	  (A)	  or	  the	  position	  of	  the	  catalytic	  Asp59	  (B	  and	  C).	  	  
!"#
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The	   aberration	   of	   the	   active	   site	   cleft	   by	   mutation	   Asn58Phe	   may	   not	   affect	  catalytic	  efficiency	  but	  may	  incorrectly	  bias	  and	  hinder	  drug	  discovery	  methods.	  The	   mutation	   of	   this	   residue	   back	   to	   the	   wild	   type	   Asn58	   did	   not	   prevent	  crystallization	  and	  provides	  a	  truer	  construct	  for	  drug	  discovery	  studies.	  	  There	  is	  little	  to	  no	  effect	  on	  the	  overall	  structure	  from	  the	  Asn58Phe	  mutation	  nor	   is	   there	   any	  meaningful	   difference	   in	   the	   position	   of	   the	   catalytic	   residues	  (Figures	  5.3	  and	  Table	  5.2).	  The	  side	  chain	  of	  Phe58	  in	  the	  TcTSFr	  structure	  does	  not	  interact	  with	  any	  of	  the	  surrounding	  amino	  acids	  and	  density	  can	  be	  seen	  for	  two	  conformations.	  The	  Asn58	  of	  TcTSSco	  is	  only	  seen	  in	  one	  position	  and	  the	  side	  chain	  forms	  a	  salt	  bridge	  with	  the	  backbone	  amide	  of	  the	  catalytic	  aspartic	  acid.	  Despite	   the	  meagre	  effect	  of	   this	  mutation	   it	   is	  still	   favorable	  to	  use	  TcTSSco	   for	  drug	  design	  studies,	  as	  it	  is	  more	  reflective	  of	  the	  native	  protein.	  	  
Table	   5.2.	   The	   rmsd	   (Å)	   of	   the	  structures	  presented	  here	  with	  1SOJ	  (Amaya	   et	   al.,	   2004).	   There	   is	   no	  significant	   difference	   between	   the	  structures.	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TcTSSco	   to	   1.9	   Å	   resolution.	   Interestingly,	   this	   structure	   contains	   two	   proline	  molecules	   including	   one	   bound	   in	   the	   active	   site.	   To	   obtain	   the	   structures	  published	   previously	   the	   crystals	   required	   the	   pre-­‐incubation	   of	  TcTSFr	  with	   2	  mM	  of	  the	  inhibitor	  Neu5Ac2en	  to	  aid	  nucleation.	  Although	  ligand	  binding	  in	  the	  active	   site	   is	   not	   necessary	   for	   crystal	   formation,	   these	   results	   suggest	   the	  stabilization	  of	   the	  active	  site	   is	  beneficial	   to	  TcTSFr	  and	  TcTSSco	   crystallization.	  The	   active	   site	   is	   not	   directly	   involved	   in	   crystal	   contacts	   nor	   does	   it	   alter	   the	  protein	   conformation	   as	   determined	   by	   comparing	  with	   apo	   structures	   (Table	  5.2),	   thus	   the	   binding	   of	   proline	   or	   Neu5Ac2en	   in	   the	   active	   site	   is	   likely	   to	  facilitate	  crystallization	  through	  stabilization	  of	  the	  protein.	  	  	  The	  carboxylic	  acid	  of	  proline	  in	  the	  active	  site	  binds	  in	  the	  same	  position	  as	  the	  carboxylic	   acid	   of	   the	   substrate	   Neu5Ac.	   Like	   Neu5Ac	   the	   carboxylic	   acid	   of	  proline	  forms	  multiple	  hydrogen	  bonds	  with	  the	  arginine	  triad	  (Arg35,	  Arg	  245	  and	   Arg314)	   and	   catalytic	   tyrosine	   (Tyr342)	   (Figure	   5.4).	   The	   proline	   ring	   is	  bound	   in	   an	   envelope	   conformation,	   and	   the	   nitrogen	   in	   the	   pyrridole	   ring	   of	  proline	  is	  capable	  of	  hydrogen	  bonding	  with	  the	  catalytic	  aspartic	  acid	  (Asp59).	  The	   exogenous	   proline	   has	   a	   B-­‐factor	   of	   only	   11.7	  Å2,	  which	   is	   lower	   than	   the	  average	  B-­‐factor	  of	  13.1	  Å2	  of	  the	  protein,	  suggesting	  that	  at	  200	  mM	  the	  proline	  is	  stably	  bound.	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several	  well-­‐conserved	  waters	  forming	  a	  charge	  relay	  with	  εN	  of	  Trp120.	  The	  ion	  is	  3.5	  Å	  from	  the	  guanidinium	  of	  Arg245	  with	  which	  it	  may	  form	  a	  salt	  bridge.	  	  	  
Figure	   5.5.	  The	  binding	  of	  DMSO	  (A)	  and	  a	   tetrahedral	   ion	  (B)	  present	   in	   the	  active	  site	  of	   the	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5.3.3	  Binding	  of	  other	  amino	  acids	  	  	  Given	  the	  ability	  of	  proline	  to	  bind	  in	  the	  active	  site	  of	  TcTSSco,	  a	  range	  of	  other	  amino	  acids	  were	  used	  in	  co-­‐crystallization	  trials.	  Only	  conditions	  that	  included	  serine	  or	  valine	  successfully	  yielded	  crystals;	   these	  trials	  were	  completed	  prior	  to	  the	  expression	  of	  TcTSSco	  and	  as	  such	  TcTSFr	  was	  used.	  The	  larger	  amino	  acids	  may	  be	  prevented	  from	  binding	  due	  to	  spatial	  constraints	  in	  the	  active	  site.	  For	  the	  successful	  crystal	  formation	  of	  TcTSFr	  or	  TcTSSco	  in	  10%	  PEG	  8K	  and	  100	  mM	  Tris	   pH	   8.5,	   the	   crystallization	   buffer	   must	   also	   contain	   200	  mM	   L-­‐Proline	   or	  other	  amino	  acid	  capable	  of	  binding	  in	  the	  active	  site.	  Many	  of	  the	  larger	  amino	  acids	   were	   not	   soluble	   to	   this	   concentration	   in	   the	   crystallization	   buffer	   and	  therefore	  it	  is	  possible	  that	  they	  are	  capable	  of	  binding,	  but	  were	  unable	  to	  due	  to	  the	  limitations	  of	  the	  experimental	  parameters.	  	  	  
	  
Figure	  5.7.	  Stereo	  image	  of	  the	  binding	  of	  exogenous	  serine	  (yellow	  carbons)	  in	  the	  active	  site	  of	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The	   valine-­‐TcTSFr	   and	   serine-­‐TcTSFr	   structures	   were	   solved	   to	   2.1	   Å	   and	   2	   Å	  resolution	  respectively.	  Unsurprisingly,	  both	  of	  these	  small	  amino	  acids	  bind	  in	  a	  similar	   mode	   to	   proline.	   The	   carboxylic	   acid	   group	   of	   all	   three	   amino	   acids	  mimics	   the	  binding	  of	   the	   carboxylic	  acid	  of	   the	  natural	   substrate	   sialyllactose.	  The	  amine	  group	  of	  serine	  and	  valine	  sits	  2.6	  Å	   from	  the	  catalytic	  aspartic	  acid	  similar	   to	   the	   secondary	   amine	   of	   proline	   which	   sits	   2.8	   Å	   from	   the	   catalytic	  aspartic	   acid	   (Figure	   5.7	   and	   5.8).	   The	   hydroxyl	   of	   the	   exogenous	   serine	   is	  capable	  of	  hydrogen	  bonding	  with	  the	  hydroxyl	  of	  the	  catalytic	  tyrosine	  as	  well	  as	  providing	  a	  good	  platform	  for	  modifications	  and	  extension	  (Figure	  5.7).	  	  	  In	   the	   active	   site	   of	   the	  TcTSFr-­‐serine	   complex	   there	   is	   also	   a	   DMSO	  molecule	  present.	   The	  DMSO	  moiety	  bound	   in	   the	   active	   site	   of	   both	   the	  TcTSSco-­‐proline	  and	   the	   TcTS-­‐serine	   structures	   are	   in	   almost	   identical	   positions.	   The	   DMSO	  molecules	   interact	   with	   the	   protein	   in	   the	   same	   manner	   and	   both	   are	   within	  hydrogen	  bonding	  distance	  of	  the	  amine	  of	  their	  respective	  ligand	  (Figure	  5.7).	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interactions	  of	  both	  the	  lactose	  and	  sialic	  acid	  binding	  sites.	  The	  most	  successful	  sialidase	  inhibitors	  to	  date	  are	  based	  on	  the	  transition	  state	  analogue	  Neu5Ac2en	  and	  achieve	  this	  by	  the	  presence	  of	  a	  double	  bond	  between	  the	  C2	  and	  C3,	  as	  is	  the	  case	  with	  zanamivir,	  or	  between	  C2	  and	  C7	  as	   is	   the	  case	  with	  oseltamivir.	  The	  addition	  of	   substituents	  at	   this	  C2	  position	  would	  mean	   loss	  of	   the	  double	  bond,	   significantly	   disrupting	   the	   ring	   puckering	   and	   effectively	   removing	   any	  benefits	   gained	   from	   their	   mimicry	   of	   the	   transition	   state.	   The	   addition	   of	  substituents	  to	  exploit	  the	  lactose	  binding	  cavity	  at	  the	  C2	  of	  Neu5Ac2en	  or	  other	  known	   sialidase	   inhibitors	   based	   on	   Neu5Ac2en	   would	   therefore	   presumably	  face	   the	   same	   problem.	   This	   however	   is	   not	   a	   problem	   for	   fragments	   such	   as	  proline,	   serine,	  valine	  and	  3-­‐piperidinic	  acid	  covered	   in	   this	  chapter	  as	   they	  do	  not	   rely	   on	   the	   presence	   of	   a	   double	   bond	   in	   this	   position	   and	   would	   allow	  utilization	  of	  both	  the	  sialic	  acid	  and	  lactose	  binding	  sites.	  	  
Figure	   5.9.	   The	   binding	   of	  Tris	   in	   the	   active	   site	   of	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Amino	   acids	   valine	   and	   serine	   bind	   in	   a	   small	   portion	   of	   the	   Neu5Ac	   binding	  pocket	  allowing	  for	  possible	  extension	  into	  the	  sialic	  acid	  binding	  site.	  The	  sialic	  acid	  binding	  site	  is	  primarily	  polar	  which	  is	  emphasized	  by	  the	  binding	  of	  either	  phosphate	  or	  sulfate	  in	  the	  TcTSSco-­‐proline	  structure	  and	  also	  by	  binding	  of	  Tris	  in	   a	   similar	   position	   in	   the	   TcTSFr-­‐valine	   complex.	   The	   Tris	   molecule	   in	   this	  structure	  makes	  multiple	  hydrogen	  bonding	  interactions	  with	  the	  protein	  and	  is	  bound	   in	   a	   similar	   site	   to	   the	   glycerol	   moiety	   of	   sialic	   acid	   (Figure	   5.9).	   The	  amine	  of	  Tris	  does	  not	  make	  any	  interactions	  with	  the	  protein	  and	  thus	  it	  would	  be	  expected	  that	  the	  hydroxyls	  of	  Tris	  would	  bind	  in	  a	  similar	  position	  to	  that	  of	  the	  glycerol	  moiety	  in	  the	  substrate	  sialic	  acid.	  However	  this	  is	  not	  the	  case,	  the	  hydroxyls	  of	  the	  Tris	  make	  different	  interactions	  to	  the	  natural	  substrate	  in	  the	  same	   binding	   site.	   The	   glycerol	   moiety	   of	   the	   Neu5Ac	   product	   only	   interacts	  directly	   with	   the	   protein	   via	   hydrogen	   bonding	   with	   the	   secondary	   amine	   of	  Trp120	   and	   interacts	   with	   several	   other	   amino	   acids	   mediated	   by	   water	  molecules.	   The	   Tris	   molecule	   sits	   closer	   to	   the	   active	   site	   wall	   making	   more	  direct	  interactions.	  Most	  likely	  the	  glycerol	  moiety	  of	  Neu5Ac	  is	  restricted	  by	  the	  interactions	  made	  by	  the	  rest	  of	  the	  Neu5Ac	  ligand.	  Like	  Neu5Ac,	  Tris	  hydrogen	  bonds	   with	   Trp120,	   but	   unlike	   Neu5Ac	   it	   also	   is	   within	   hydrogen	   bonding	  distance	   of	   Gln195,	   Asp96	   and	   Glu230	   (Figure	   5.9).	   The	   presence	   of	   Tris	   or	   a	  tetrahedral	   ion	   in	   the	   same	   pocket	   as	   where	   the	   substrate’s	   glycerol	   moiety	  highlights	  the	  polar	  contacts	  to	  be	  exploited	  in	  this	  site.	  At	  its	  closest	  point	  one	  of	  the	   Tris	   hydroxyl	   group	   is	   only	   3.3	   Å	   from	   the	   methyl	   group	   of	   the	   valine	  pointing	  to	  exciting	  avenues	  for	  drug	  design.	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5.3.4	  High	  throughput	  crystallography	  	  A	   large	   number	   of	   hits	   for	   inhibition	   of	   TcTS	   were	   generated	   through	   high	  throughput	   screening	   methods	   (see	   chapter	   4.).	   High	   throughput	   screening	   is	  prone	  to	  false	  positives,	  as	  well	  as	   false	  negatives,	  which	  is	  particularly	  evident	  from	   the	   lack	   of	   consistency	   between	   the	   hits	   identified	   in	   each	   screening	  method.	  In	  an	  attempt	  to	  ascertain	  the	  validity	  of	  the	  82	  hits	  from	  the	  NMR	  and	  and	   the	  assay	   screens,	   all	  hits	  were	   soaked	   into	  TcTSSco	   crystals	  or	  used	   in	   the	  crystallization	   conditions	   as	   a	   substitute	   for	   proline.	   Compounds	   from	   the	  fragment	  library	  that	  possessed	  a	  carboxylic	  acid	  were	  also	  tested	  based	  on	  the	  binding	   of	   the	   aforementioned	   amino	   acids	   and	   the	   substrate	   which	  demonstrates	   that	   the	   binding	   of	   carboxylic	   acid	   to	   the	   arginine	   triad	   is	   a	   key	  interaction.	  Frustratingly,	  very	  few	  hits	  were	  validated	  by	  X-­‐ray	  crystallography,	  however	  this	  does	  not	  preclude	  the	  possibility	  that	  more	  of	  the	  high	  throughput	  hits	  are	  true	  hits	  as	  one	  of	  the	  caveats	  of	  X-­‐ray	  crystallography	  is	  that	   it	  can	  be	  prone	   to	   false	   negatives.	   Crystallography	   is	   also	   time	   consuming	   and	   thus	  multiple	  repeats	  were	  not	  always	  feasible.	  	  	  	  Fragments	  are	  limited	  in	  how	  many	  interactions	  they	  can	  make	  with	  the	  protein	  due	   to	   their	   limited	   size	   and	   as	   such	   they	   may	   not	   be	   seen	   in	   the	   structures	  unless	  soaked	  or	  co-­‐crystallized	  at	  high	  concentrations.	  This	  in	  turn	  has	  its	  own	  constraints	  that	  may	  lead	  to	  false	  negatives	  as	  high	  concentrations	  of	  compounds	  may	  interfere	  with	  the	  formation	  of	  crystals	  by	  altering	  the	  pH,	  hydrophobicity,	  crystal	   contacts	   as	   well	   as	   other	   strictly	   controlled	   variables	   involved	   in	  crystallization.	  Furthermore,	  all	  compounds	  were	  dissolved	  in	  100%	  DMSO	  and	  increasing	   the	   concentration	   of	   the	   compound	   causes	   an	   increase	   in	   the	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concentration	  of	  DMSO	  which	  is	  known	  to	  damage	  both	  fully	  formed	  crystals	  and	  forming	   crystals.	   Finally,	   many	   of	   the	   compounds	   are	   insoluble	   in	   the	  crystallization	   buffer	   thus	   they	   are	   unable	   to	   be	   soaked	   into	   the	   crystal,	  particularly	   at	   the	   high	   concentrations	   required,	   and	   thus	   crystallography	   is	  often	  biased	  toward	  polar	   fragments.	   	  Given	  these	   limitations	   it	   is	  unsurprising	  that	   this	  method	  revealed	  very	   few	  structures	  with	  compound	  bound,	  however	  hits	   validated	   by	   crystallography	   can	   be	   trusted	   and	   are	   essential	   for	   logical	  extension	  to	  form	  better	  inhibitors.	  	  	  
	  
Figure	  5.11.	  The	  structures	  of	  proline	  (A),	  1,3-­‐thiazolane-­‐2-­‐carboxylic	  acid	  (B)	  and	  nipecotic	  acid	  (C).	  All	  three	  structures	  possess	  a	  secondary	  amine	  and	  a	  carboxylic	  acid.	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This	  study	  highlights	  the	  necessity	  of	  multiple	  screening	  and	  validation	  methods	  in	  drug	  discovery.	  Only	   two	  compounds	  were	  validated	  using	  this	  method:	  1,3-­‐thiazolane-­‐2-­‐carboxylic	  acid	  and	  nipecotic	  acid	  (Figure	  5.11).	  	  
5.3.5	  1,3-­‐thiazolane-­‐2-­‐carboxylic	  acid	  –	  TcTSSco	  	  complex	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bound	   in	   the	   structure.	   Both	   isomers	   are	   capable	   of	   fitting	  within	   the	   electron	  density	  seen	  in	  the	  structure	  however	  when	  isomer	  R	  is	  fitted	  the	  difference	  map	  indicates	   that	   there	   is	   insufficient	  electron	  density	   to	  support	   the	  sulfur	  at	   this	  position	  in	  the	  ring	  and	  too	  much	  electron	  density	  to	  be	  satisfied	  by	  the	  nitrogen	  (Figure	   5.13).	   Sulfur	   is	  more	   electron	   dense	   than	   nitrogen	   and	   thus	   it	   is	   clear	  from	  the	  electron	  density	  that	  isomer	  S	  is	  bound	  (Figure	  5.13).	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	   5.13.	  The	  2Fo-­‐Fc	  (grey	  mesh)	  and	  the	  Fo-­‐Fc	  map	  (green	  mesh	   for	  positive	  difference	   in	  the	  electron	  density	  map	  and	  red	  mesh	  for	  negative	  difference)	  of	  (R)1,3-­‐thiazolane-­‐2-­‐carboxylic	  acid	  in	  the	  active	  site	  of	  TcTSSco.	  The	  Fo-­‐Fc	  map	  indicates	  that	  there	  is	  more	  electron	  density	  than	  in	  the	  model	  around	  the	  nitrogen	  of	  the	  thiazolane	  ring	  and	  less	  around	  the	  sulfur	  indicating	  the	  position	   of	   the	   ring	   is	   incorrect.	   This	   is	   not	   seen	   for	   the	   (S)	   1,3-­‐thiazolane-­‐2-­‐carboxylic	   acid	  isomer.	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(S)	  1,3-­‐thiazolane-­‐2-­‐carboxylic	  acid	  is	  bound	  in	  a	  twisted	  conformation	  with	  the	  nitrogen	  of	   the	  5-­‐membered	   ring	   facing	   into	   the	  active	   site	   cleft	   and	   the	   sulfur	  facing	  out	  of	  the	  active	  site.	  Like	  proline	  the	  amine	  of	  1,3-­‐thiazolane-­‐2-­‐carboxylic	  acid	  hydrogen	  bonds	  with	  the	  catalytic	  aspartic	  acid.	  The	  sulfur	  fails	  to	  make	  any	  interactions	   with	   the	   protein.	   This	   is	   unsurprising	   given	   that	   sulfur	   is	   less	  electronegative	   than	  nitrogen	   and	   as	   such	   is	   poorer	   at	   hydrogen	  bonding	   than	  nitrogen,	  and	  prefers	  a	  hydrophobic	  environment.	  The	  thiazolane	  ring	  is	  bound	  in	  a	  hydrophilic	  cavity	  and	  it	  is	  unlikely	  that	  having	  a	  sulfur	  in	  the	  5-­‐membered	  ring	   confers	   improved	   inhibition.	   Since	   the	   sulfur	   fails	   to	  make	  any	   interaction	  with	   the	   protein	   it	   can	   be	   concluded	   that	   proline	   is	   the	   minimum	   binding	  fragment.	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DMSO	   is	   seen	   in	   the	   structure	   in	   an	   almost	   identical	   position	   to	   the	   DMSO	  molecules	   in	   the	   active	   site	  of	   the	  TcTSFr-­‐serine	   and	  TcTSSco-­‐proline	   complexes	  (Figure	  5.14).	  Oddly	  there	  is	  also	  a	  DMSO	  bound	  in	  the	  same	  site	  as	  the	  Tris	  and	  tetrahedral	   ion	   seen	   in	   the	   valine	   and	  proline	   complex	   structures	   respectively.	  This	  is	  the	  first	  incidence	  of	  a	  partially	  hydrophobic	  molecule	  binding	  in	  this	  site.	  The	  polar	   oxygen	  hydrogen	  bonds	  with	  Trp120,	   an	   interaction	   common	   to	   the	  binding	   of	   Neu5Ac	   and	   Tris	   (Figure	   5.14).	   The	   methyl	   groups	   are	   distal	   from	  most	   amino	   acids	   preventing	   a	   significant	   clash.	   The	   juxtaposition	   of	   the	  hydrophobic	  methyl	   groups	   in	   this	   hydrophilic	   cavity	   can	   be	   explained	   by	   the	  high	  concentration	  of	  DMSO	  in	  the	  cryoprotectant.	  	  	  
5.3.6	  Nipecotic	  acid-­‐TcTSSco	  	  complex	  	  	  
	  
Figure	   5.15.	   The	   stereo	   image	   of	   (R)-­‐3-­‐Piperidinic	   acid	   (yellow	   carbons)	   in	   the	   active	   site	   of	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acid	  demonstrated	  its	  binding	  in	  the	  active	  site.	  The	  structure	  of	  nipecotic	  acid-­‐
TcTSSco	   was	   solved	   to	   2.0	   Å	   resolution.	   Nipecotic	   acid	   was	   selected	   from	   the	  library	   of	   compounds	   for	   its	   similarity	   to	   the	   already	   validated	   hit	   proline.	   As	  with	   all	   of	   the	   previously	   identified	   hits,	   the	   carboxylic	   acid	   of	   nipecotic	   acid	  binds	  to	  the	  arginine	  triad.	  Nipecotic	  acid	  is	  synonymous	  with	  3-­‐piperadinic	  acid,	  however	   henceforth	   we	   use	   nipecotic	   acid	   to	   describe	   the	   mixture	   of	   the	   3-­‐piperidinic	   enantiomers	   and	   refer	   to	   the	   individual	   enantiomers	   of	   piperidinic	  acid	  as	  (S)-­‐3-­‐piperidinic	  acid	  and	  (R)-­‐3-­‐piperidinic	  acid.	  After	  soaking	  crystals	  in	  nipecotic	  acid,	  only	  density	  for	  (R)-­‐3-­‐piperidinic	  acid	  is	  evident.	  This	  allows	  the	  amine	  group	  of	  the	  piperidine	  ring	  to	  face	  into	  the	  active	  site	  cleft	  and	  toward	  the	  catalytic	  aspartic	  acid	  (Figure	  5.15).	  The	  piperidine	  ring	  of	  (R)-­‐3-­‐piperidinic	  acid	  is	  present	  in	  a	  half	  chair	  conformation	  bringing	  the	  amine	  group	  2.7	  Å	  away	  from	  the	  catalytic	  aspartic	  acid	  to	  which	  it	  hydrogen	  bonds.	  Despite	  the	  density	  quite	  clearly	  demonstrating	  that	  (R)-­‐3-­‐piperidinic	  acid	  was	  bound	  in	  the	  active	  site	  it	  does	   not	   preclude	   the	   binding	   of	   (S)-­‐3-­‐piperidinic	   acid.	   The	   ratio	   of	   the	   two	  isoforms	   is	   unknown	   and	   furthermore	   (R)-­‐3-­‐piperidinic	   acid	   may	   bind	   more	  effectively	  than	  (S)-­‐3-­‐piperidinic	  acid	  but	  not	  exclusively.	  	  	  	  Piperidinic	   acid	   has	   proved	   a	   useful	   lead	   compound	   in	   the	   design	   of	   glycosyl	  hydrolase	  inhibitors	  (Nishimura	  et	  al.,	  2000;	  Nishimura	  2009).	  The	  interaction	  of	  the	  amine	  with	  the	  catalytic	  acid	  in	  the	  universal	  acid/base	  catalytic	  mechanism	  supports	  binding	  and	  a	  similarity	  in	  ring	  puckering	  to	  the	  sugar’s	  pyranose	  ring.	  Addition	   of	   substituents	   that	   extend	   into	   the	   catalytic	   pocket	   in	   a	   similar	  orientation	  to	  the	  substrate	  aids	  binding.	  This	  however	  is	  not	  the	  case	  for	  (R)-­‐3-­‐piperidinic	   acid	   which	   appears	   in	   a	   half	   chair	   conformation	   in	   this	   structure	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however	   is	   bound	   in	   a	   different	   orientation	   to	   the	   substrate.	   The	   amine	   of	   the	  ring	  still	  interacts	  with	  the	  catalytic	  aspartic	  acid,	  however	  due	  to	  the	  differential	  puckering,	   the	   ring	   substituents	   will	   extend	   into	   the	   active	   site	   cavity	   in	  alternative	  orientations	  to	  the	  natural	  substrate.	  While	  this	  may	  lead	  to	  exciting	  possible	  avenues	  for	  drug	  design	  it	  may	  also	  prove	  more	  challenging.	  Moreover,	  the	  greater	  the	  divergence	  of	  a	  drug	  from	  the	  substrate	  is	  related	  to	  an	  increased	  incidence	  of	  resistance	  in	  the	  pathogen.	  	  The	  TcTSSco-­‐(R)-­‐3-­‐piperidinic	   acid	   complex	   is	   the	   only	   structure	   not	   to	   include	  other	   fragments	   in	   either	   of	   the	   sites	   previously	  mentioned.	   This	   is	   surprising	  given	  their	  consistent	  appearance	  in	  the	  previous	  complex	  structures.	  	  	  
5.4	  Conclusions	  	  The	  use	  of	  crystallography	  as	  a	  high	  throughput	  screen	  for	  fragment	  based	  drug	  discovery	  is	  ill-­‐advised.	  The	  number	  of	  fragments	  screened	  is	  not	  reflected	  in	  the	  number	   of	   validated	   hits.	   It	   is	   hypothesized	   that	  more	   fragments	   bind	   to	  TcTS	  than	  were	  identified	  by	  crystallography	  and	  that	  the	  experimental	  limitations	  of	  this	   technique	   precluded	   an	   unknown	   number	   of	   true	   hits	   from	   being	  authenticated	  by	   this	  method.	  Despite	   its	   drawbacks	   it	   is	   essential	   for	   rational	  design	  of	  inhibitors	  and	  remains	  the	  ‘gold	  standard’	  of	  hit	  validation.	  	  	  The	   compounds	   shown	   in	   these	   structures	   all	   share	   two	   notable	   features:	   a	  primary	  or	  secondary	  amine	  that	  hydrogen	  bonds	  with	  the	  catalytic	  aspartic	  acid	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and	  a	  carboxylic	  acid	  that	  binds	  to	  the	  arginine	  triad	  consistent	  with	  the	  binding	  of	  the	  substrate.	  	  These	  fragments	  present	  excellent	  scaffolds	  for	  drug	  design.	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6.	  Improving	  fragment	  inhibitors	  of	  
TcTS	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6.1	  Summary	  	  	  In	   the	   search	   and	   design	   of	   future	   drugs,	   one	   approach	   is	   to	   find	   and	   then	  develop	   minimal	   binding	   fragments.	   The	   minimal	   binding	   fragment	   is	  determined	   by	   stripping	   a	   known	   inhibitor	   back	   to	   the	   smallest	   possible	  substituent	  without	  compromising	  binding	  interactions.	  In	  this	  way	  it	  is	  possible	  to	   identify	   the	   crucial	   interactions	   involved	   in	   ligand	   binding	   and	   extend	   the	  fragment	   from	   there	   (Brear	   et	   al.,	   2013).	   The	   minimal	   binding	   fragments	   for	  
TcTSSco	  determined	  here	  were	  proline,	  serine,	  valine	  and	  nipecotic	  acid.	  	  Despite	   similar	   interactions	   with	   TcTSSco,	   nipecotic	   acid	   demonstrated	  considerably	   better	   inhibition	   than	   D-­‐proline	   as	   determined	   by	   fluorescence	  assay.	  Nipecotic	  acid,	  or	  3-­‐piperidinic	  acid,	  is	  a	  mixture	  of	  two	  enantiomers	  of	  3-­‐piperidinic	  acid,	  R	  and	  S,	  however	  when	  crystallized	  in	  the	  active	  site	  of	  TcTSSco	  only	   the	   R	   was	   seen.	   The	   binding	   mode	   of	   (R)-­‐3-­‐piperidinic	   acid	   bears	  resemblance	   to	   other	   glycosidase	   inhibitors	   that	   are	   hypothesized	   to	   use	   a	  piperidine	  ring	  as	  a	   transition	  state	  mimic	  such	  as	  nojirimycin.	  The	  protonated	  amine	   is	   hypothesized	   to	   increase	   binding	   affinity	   by	   mimicking	   the	  oxocarbenium	  ion	  of	  the	  transition	  state	  or	  is	  at	  least	  advantageous	  to	  inhibitor	  binding	  by	  interaction	  with	  the	  catalytic	  acids	  (Lopez	  et	  al.,	  2013;	  Lammerts	  van	  Bueren	  et	  al.,	  2010;	  Gloster	  et	  al.,	  2004).	  	  	  Here	  we	  report	  that	  (S)-­‐3-­‐piperidinic	  acid,	  the	  other	  enantiomer	  of	  3-­‐piperidinic	  acid,	  has	  a	  similar	  inhibitory	  capability	  to	  (R)-­‐3-­‐piperidinic	  acid.	  Interestingly,	  it	  is	  bound	  in	  two	  possible	  positions	  in	  complex	  with	  TcTSSco:	  the	  first	  is	  similar	  to	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(R)-­‐3-­‐piperidinic	   acid	   and	   in	   the	   second	   conformation	   the	   carboxylic	   acid	   also	  binds	  to	  the	  arginine	  triad,	  however	  the	  amine	  of	  the	  piperidine	  ring	  points	  out	  of	  the	  TcTSSco	  active	  site,	  away	  from	  the	  catalytic	  machinery	  toward	  the	  lactose	  binding	  site.	  In	  this	  binding	  mode	  the	  amine	  hydrogen	  bonds	  with	  Tyr119,	  which	  is	   also	   seen	   in	   two	   conformations.	   Tyr119	   swings	   into	   the	   active	   site,	   into	   a	  closed	   position,	   upon	   cleavage	   of	   sialic	   acid	   from	   sialyllactose	   (Amaya	   et	   al.,	  2003).	   In	   the	  closed	  position	  Tyr119	  clashes	  with	   the	  glycerol	  backbone	  of	   the	  transition	  state	  analogue	  and	  universal	  sialidase	  inhibitor	  Neu5Ac2en,	  making	  it	  a	   very	   poor	   inhibitor	   for	   this	   enzyme.	   Despite	   Tyr119	   being	   in	   the	   closed	  position	  upon	  binding	  of	  (S)-­‐3-­‐piperidinic	  acid	  there	  is	  no	  evidence	  of	  a	  clash.	  	  Since	   both	   enantiomers	   of	   nipecotic	   acid	   have	   similar	   inhibitory	   capacities	  despite	   different	   binding	   interactions	  with	  TcTSSco,	   attempts	   to	   combine	   these	  interactions	  by	  testing	  (R)	  and	  (S)	  2-­‐piperazine	  carboxylic	  acid	  were	  carried	  out.	  Surprisingly,	  in	  the	  crystal	  structure	  of	  the	  compounds	  in	  complex	  with	  TcTSSco,	  neither	   piperazine	   carboxylic	   acid	   made	   any	   interactions	   with	   Tyr119,	   which	  remained	   in	   the	   open	   position	   in	   both	   structures.	   However,	   both	   enantiomers	  did	   interact	  with	   the	   catalytic	   aspartic	   acid,	   Asp59.	   (S)-­‐2-­‐piperazine	   carboxylic	  acid	   makes	   similar	   interactions	   as	   (R)-­‐3-­‐piperidinic	   acid	   and	   as	   such	  demonstrates	   similar	   inhibition	   of	   TcTSSco.	   (R)-­‐2-­‐piperazine	   carboxylic	   acid	  makes	  additional	  interactions	  with	  TcTSSco	  and	  is	  consequently	  a	  better	  inhibitor	  with	  an	  IC50	  of	  12.6	  ±	  0.9	  mM.	  	  Interestingly	   there	   is	   a	   known	   sialidase	   inhibitor	   isolated	   from	   Streptomyces	  that	   is	   based	   on	   3-­‐piperidinic	   acid	   (Umezawa	   et	   al.,	   1974).	   This	   inhibitor,	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siastatin	  B,	  is	  a	  potent	  inhibitor	  of	  the	  sialidase	  from	  Clostridium	  perfringens	  and	  other	  bacterial	  sialidases	  (Umezawa	  et	  al.,	  1974),	  but	  is	  less	  potent	  against	  viral	  sialidases	   such	   as	   the	   influenza	   virus	   neuraminidase	   (Shitara	   et	   al.,	   2000).	  Siastatin	   B	   is	   hypothesized	   to	   inhibit	   glycosidases	   by	   mimicking	   the	  oxocarbenium	  ion	  of	  the	  transition	  state	  (Nishimura,	  2009).	  Here	  we	  report	  the	  first	   structure	   of	   siastatin	  B	   in	   complex	  with	   a	   glycosidase,	  TcTSSco.	   The	   amine	  does	  not	  mimic	  the	  glycopyranosyl	  cation,	  but	  instead	  binds	  to	  Tyr119	  which	  is	  seen	  in	  the	  closed	  position.	  The	  addition	  of	  10	  mM	  of	  siastatin	  B	  and	  Neu5Ac2en	  resulted	   in	   a	   67.8	   ±	   2.0	   %	   and	   59.2	   ±	   0.6	   %	   decrease	   in	   activity	   of	   TcTS,	  respectively.	  	  Although	  the	  IC50s	  of	  the	  aforementioned	  compounds	  remain	  poor,	  siastatin	  B	  is	  a	  better	  inhibitor	  than	  Neu5Ac2en.	  The	  importance	  of	  an	  amine-­‐acid	  interaction	  with	   Asp59	   for	   the	   inhibition	   of	   TcTS	   is	   highlighted	   by	   the	   nipecotic	   acid	  enantiomers	   and	   the	   piperazine	   carboxylic	   acid	   enantiomers.	   With	   this	  knowledge	  and	  the	  reactive	  sites	  identified	  in	  Chapter	  5	  it	  should	  be	  possible	  to	  design	  significantly	  improved	  inhibitors.	  	  	  	  	  	  	  	  	  	  
	   183	  
6.2	  Materials	  and	  Methods	  
6.2.1	  Protein	  purification	  and	  crystallization	  	  	  
TcTSSco	   was	   expressed,	   purified	   and	   crystallized	   as	   decribed	   in	   Chapter	   4.2.2	  (p116)	  and	  Chapter	  5.2.2	  (p140).	  	  
6.2.2	  Crystal	  soaking	  	  	  
TcTSSco	  crystals	  were	  soaked	  by	  addition	  to	  a	  1	  μL	  dropof	  500	  μM	  of	  compounds	  D-­‐Proline,	   nipecotic	   acid,	   (R)-­‐3-­‐piperidinic	   acid,	   (S)-­‐3-­‐piperidinic	   acid,	   (R)-­‐2-­‐piperazine	   carboxylic	   acid,	   (S)-­‐2-­‐piperazine	   carboxylic	   acid	   and	   siastatin	   B	  dissolved	   in	   dH2O.	   Crystals	   were	   soaked	   for	   2	   mins	   at	   room	   temperature.	  Crystals	  were	   cryo-­‐protected	  with	   20%	  glycerol	   (w/v)	   in	   crystallization	   buffer	  for	  a	  few	  seconds	  prior	  to	  placement	  in	  liquid	  nitrogen.	  	  
6.2.3	  Data	  collection	  and	  refinement	  	  Data	   collection	   and	   refinement	   was	   performed	   as	   described	   in	   Chapter	   5.2.4	  (p142)	  
6.2.4	  Inhibition	  kinetics	  	  Assay	  conditions	  were	  optimized	  to	  10	  μg/ml	  TcTSSco,	  final	  concentration,	  in	  50	  mM	   Hepes	   at	   pH	   7.5.	   Assays	   were	   run	   in	   triplicate	   in	   a	   96-­‐well	   format.	   Each	  reaction	  contained	  80	  μl	  of	  TcTSSco	  in	  buffer	  that	  was	  pre-­‐incubated	  with	  10	  μl	  of	  a	  single	  compound	  at	  varying	  concentrations	  (for	  details	  please	  see	   figures	  6.1,	  6.2	   and	   6.7)	   in	   50	  mM	  Hepes	   at	   pH	   7.5	   for	   10	  mins	   at	   room	   temperature.	   To	  begin	   the	   reaction,	  10	  μl	   of	  2	  mM	  Neu5Ac-­‐Mu	  was	  added	   to	   each	  well	   and	   the	  reaction	   was	   mixed	   and	   the	   fluorescence	   measured	   by	   the	   Spectra	   Max	   M2	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Data	  collection	  a	   	   	  
X-­‐ray	  source	   In	  house	   In	  house	  
X-­‐ray	  wavelength	  (Å)	   1.542	   1.542	  
Resolution	  (Å)	   13.9-­‐1.96	  	  (2.07-­‐1.96)	   15.4-­‐2.09	  (2.09-­‐2.2)	  
Unit	  cell	  dimensions	   	   	  
a(Å)	   54.1	   53.9	  
b(A)	   129.4	   128.9	  
c	  (Å)	   54.4	   54.3	  
β 	  (°)	  	   108.0	   109.2	  
No.	  observations	   182,270	   90,692	  
Redundancy	   3.6	  (3.2)	   2.3	  (1.9)	  
Completeness	  (%)	   98.4	  (90.8)	   93.8	  (87.9)	  
Rmerge	  (%)	  b	   4.9	  (12.9)	   4.0	  (8.3)	  
I/σI	   17.1	  (7.7)	   15.8	  (8.9)	  
Refinement	   	   	  
Reflections	  used	   50,643	   41,218	  
Number	  of	  atoms	   5,492	   5,662	  
Number	  of	  protein	  atoms	   4,951	   4,934	  
Number	  of	  water	  	  
molecules	  
532	   710	  
Number	  of	  ligand	  atoms	   9	   9	  
Average	  B-­‐factor	  (Å2)	   24.1	   16.5	  
Protein	   23.3	   15.0	  
Water	   31.5	   26.6	  
Ligand	   21.0	   27.9	  
R-­‐factor	  c	   0.228	   0.152	  
R-­‐free	  d	   0.287	   0.205	  
Root	   mean	   square	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
deviation	  in	  bond	  length	  (Å)	  
0.009	   0.010	  
Root	  mean	  square	  deviation	  in	  bond	  
angles	  (°)	  
1.19	   1.24	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   TcTSSco-­‐(R)-­‐2-­‐
piperazine	  





carboxylic	   acid	  
complex	  
	  
TcTSSco-­‐Siastatin	   B	  
complex	  
Data	  collection	  a	   	   	   	  
X-­‐ray	  source	   In	  house	   In	  house	   In	  house	  
X-­‐ray	  wavelength	  (Å)	   1.542	   1.542	   1.542	  
Resolution	  (Å)	   13.9-­‐1.96	  (2.1-­‐1.96)	   15.4-­‐2.09	  (2.2-­‐2.09)	   15.5-­‐2.09	  (2.2-­‐2.09)	  
Unit	  cell	  dimensions	   	   	   	  
a(Å)	   54.1	   54.1	   54.0	  
b(A)	   129.7	   129.4	   128.9	  
c	  (Å)	   54.5	   54.3	   54.3	  
β 	  (°)	  	   108.8	   108.8	   108.9	  
No.	  observations	   180,356	   148,873	   124,050	  
Redundancy	   3.6	  (1.6)	   3.6	  (3.1)	   3.0	  (2.5)	  
Completeness	  (%)	   99.2	  	  (96.8)	   99.2	  (96.2)	   98.6	  (97.3)	  
Rmerge	  (%)	  b	   3.8	  (8.3)	   6.3	  (11.2)	   4.4	  (8.1)	  
I/σI	   22.8	  (11.2)	   14.2	  (8.1)	   17.6	  (9.8)	  
Refinement	   	   	   	  
Reflections	  used	   50,797	   41,631	   41,757	  
Number	  of	  atoms	   5,548	   5,329	   5,409	  
Number	  of	  protein	  atoms	   4,912	   4,924	   4,912	  
Number	  of	  water	  	  
molecules	  
621	   396	   476	  
Number	  of	  ligand	  atoms	   9	   9	   15	  
Average	  B-­‐factor	  (Å2)	   21.7	   24.6	   20.5	  
Protein	   19.7	   24.2	   19.9	  
Water	   30.0	   29.7	   26.9	  
Ligand	   17.2	   23.4	   18.2	  
R-­‐factor	  c	   0.189	   0.193	   0.176	  
R-­‐free	  d	   0.240	   0.247	   0.229	  
Root	   mean	   square	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
deviation	   in	   bond	   length	  
(Å)	  
0.009	   0.010	   0.009	  
Root	   mean	   square	  
deviation	   in	   bond	   angles	  
(°)	  
1.16	   1.22	   1.17	  
Table	  6.1.	  a	  =	  Values	  in	  parentheses	  correspond	  to	  the	  highest	  resolution	  shell.	  b	  =	  Rmerge	  =	  ∑hkl	  ∑i	  |Ihkl,	  i	  –	  〈	  Ihkl	  〉|	  /	  ∑hkl	  〈	  Ihkl	  〉	  c	  &	  d	  =	  R-­‐factor	  and	  R-­‐free	  =	  (Σ	  |	  |Fo|	  -­‐	  |Fc|	  |)/(Σ	  |Fo|),	  where	  the	  Rfree	  was	  calculated	  from	  5%	  of	  reflections	  excluded	  from	  refinement.	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6.3	  Results	  and	  Discussion	  
6.3.1	  Kinetics	  of	  lead	  fragments	  D-­‐Proline	  and	  nipecotic	  acid	  	  D-­‐proline	   and	   nipecotic	   acid	   were	   identified	   as	   possible	   lead	   compounds	   for	  inhibition	  of	  TcTSSco	  by	  crystallographic	  and	  in	  silico	  screening	  (Chapters	  4	  &	  5).	  Both	   proline	   and	   (R)-­‐3-­‐piperidinic	   acid	   interact	   with	   the	   arginine	   triad	   and	  catalytic	   aspartic	   acid	  of	  TcTSSco.	  The	  amine	  of	  nipecotic	   acid	   is	  2.7	  Å	   from	   the	  catalytic	   aspartic	  acid,	  Asp59.	  The	  amine	  of	  D-­‐proline	   in	   contrast	   is	  3.1	  Å	   from	  Asp59	  and	  thus	  may	  weaken	  the	   interaction	  resulting	   in	  poorer	   inhibition.	  The	  amine	   of	   nipecotic	   acid	   also	   hydrogen	   bonds	   with	   a	   water	   molecule	   which	  mediates	  interactions	  with	  Arg53	  and	  Asp96.	  The	  amine	  of	  D-­‐proline	  also	  makes	  an	  additional	  hydrogen	  bond	   to	   a	  DMSO	  molecule	  which	  mediates	   interactions	  with	  Arg35.	  Overall,	  D-­‐proline	  makes	  fewer	  interactions	  with	  the	  protein	  which	  may	  explain	  why	  it	  is	  a	  poorer	  inhibitor	  of	  TcTSSco	  than	  (R)-­‐3-­‐piperidinic	  acid.	  	  	  The	  IC50	  of	  nipecotic	  acid	  is	  68.8	  ±	  5.2	  mM,	  which	  is	  lower	  than	  the	  IC50	  of	  proline	  which	   is	  ≈	  211.5	  ±	  54.4	  mM	  (Figure	  6.1).	  Due	   to	   the	  poor	   inhibition	  by	  proline	  the	  error	  on	  the	  IC50	  was	  greater	  than	  10%	  and	  thus	  not	  statistically	  reliable.	  The	  addition	  of	  100	  mM	  nipecotic	  acid	  and	  D-­‐proline	  inhibited	  the	  ability	  of	  TcTSSco	  to	  hydrolyze	  Neu5Ac-­‐Mu	  by	  59.7	  ±	  1.1	  %	  and	  40.2	  ±	  1.2	  %	  respectively.	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6.3.2	  Inhibition	  by	  the	  Nipecotic	  acid	  isomers	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mean	  that	  statistically	  the	  difference	  between	  these	  fragments	  is	  not	  significant.	  Addition	  of	  100	  mM	  of	   the	  R	  and	  S	  enantiomers	   to	  TcTSSco	   reduced	  activity	  by	  69.1	  ±	  1.1	  and	  54.1	  ±	  1.4	  %	  respectively,	   suggesting	   that	   (R)-­‐3-­‐piperidinic	  acid	  may	  be	  a	  better	  inhibitor.	  Taken	  together,	  these	  data	  suggest	  that	  there	  is	  little	  to	  distinguish	  between	  the	  inhibitory	  capabilities	  of	  these	  two	  isomers	  of	  nipecotic	  acid.	  	  
	  
Figure	   6.3.	   (A	  &	  B)	  The	  overlay	  of	   (R)-­‐3-­‐piperidinic	  acid	   (green)	  with	  sialyllactose	   (yellow)	  as	  they	  bind	   in	   the	  active	  site	  of	  TcTSSco.	  The	  carboxylic	  acids	  of	  both	   ligands	  bind	   to	   the	  arginine	  triad,	  however	  the	  6-­‐membered	  ring	  of	  (R)-­‐3-­‐piperidinic	  acid	  and	  sialic	  acid	  do	  not	  overlay	  well.	  (B	  &	  C)	  The	  overlay	  of	  (R)-­‐3-­‐piperidinic	  acid	  in	  complex	  with	  TcTSSco	  as	  seen	  when	  soaked	  in	  on	  its	  own	  (green)	  or	  as	  a	  mixture	  in	  nipecotic	  acid	  (yellow).	  	  	  
!"# $"#
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Each	  enantiomer	  of	  nipeotic	  acid	  was	  soaked	  separately	  into	  TcTSSco	  crystals	  and	  the	   structure	  of	   the	  TcTSSco-­‐(R)-­‐3-­‐piperidinic	   acid	   and	  TcTSSco-­‐(S)-­‐3-­‐piperidinic	  acid	  complexes	   	  were	  determined	  to	  1.96	  Å	  and	  2.09	  Å	  resolution,	  respectively.	  Interestingly	  the	  piperidine	  ring	  of	  the	  (R)-­‐3-­‐piperidinic	  acid	  enantiomer	  adopts	  a	  different	  conformation	  to	  that	  seen	  for	  the	  same	  species	  when	  nipicotic	  acid	  is	  soaked	  into	  crystals	  (Figure	  6.3).	  	  	  Glycosidase	  inhibitors	  based	  on	  a	  piperidine	  ring	  have	  proven	  successful	  against	  a	   number	   of	   enzymes	   including	   α-­‐L-­‐fucosidase	   from	   Bacteroides	  
thetaiotaomicron,	  glucosylceramidase	  from	  Homo	  sapiens	  and	  the	  neuraminidase	  from	  the	   influenza	  virus	  (Shitara	  et	  al.,	  2000;	  Lammerts	  van	  Buren	  et	  al.,	  2010;	  Brumshtein	   et	   al.,	   2009).	   The	   imino	   sugars	   are	   hypothesized	   to	   act	   as	  glycomimetics	   with	   the	   piperidine	   ring	   mimicking	   the	   pyranose	   ring	   of	   the	  transition	  state	  analogue.	  The	  protonated	  amine	  is	  hypothesised	  to	  mimic	  the	  ion	  like	   oxocarbonium	   of	   the	   transition	   state.	   	   The	   piperidine	   ring	   of	   (R)-­‐3-­‐piperidinic	  acid	  is	  capable	  of	  forming	  a	  boat	  or	  chair	  conformation	  similar	  to	  the	  conformation	   of	   the	   sialic	   acid	   pyranose	   ring	   in	   the	   previously	   published	  complex	   of	   TcTSFr	   with	   sialyllactose	   (Amaya	   et	   al.,	   2004).	   Despite	   the	   6-­‐membered	  rings	  of	   sialyllactose	  and	  (R)-­‐3-­‐piperidinic	  acid	  possessing	  a	  similar	  conformation,	   and	   the	   carboxylic	   acids	   binding	   in	   an	   identical	   position,	   the	  ligands	  do	  not	  overlap	  well.	   	  The	  boat	  conformation	  of	  (R)-­‐3-­‐piperidinic	  acid	   is	  flipped	   180°	   relative	   to	   the	   boat	   conformation	   of	   the	   pyranose	   ring	   of	  sialyllactose	   (Figure	   6.3).	   The	   interaction	   of	   the	   amine	   with	   Asp84	   forces	   the	  piperidine	   ring	   away	   from	   the	   position	   of	   the	   pyranose	   ring	   seen	   for	  sialyllactose.	   	  The	  amine	   interacts	  with	  Asp84	  but	   is	  not	  bound	  in	  a	  position	  to	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mimic	   the	   oxocarbenium	   ion-­‐like	   transition	   state	   (Figure	   6.4).	   Thus,	   (R)-­‐3-­‐piperidinic	  acid	  is	  a	  fragment	  binder	  and	  not	  a	  substrate	  mimic.	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distance	  of	  3.2	  Å,	  consistent	  with	  the	  amine	  being	  present	  at	  this	  position	  in	  the	  ring	  (Figure	  6.5A	  &	  B).	  The	  binding	  of	  (S)-­‐3-­‐piperidinic	  acid	  is	  similar	  to	  (R)-­‐3-­‐piperidinic	   acid	   with	   density	   for	   the	   amine	   group	   in	   a	   similar	   position.	   The	  density	  for	  the	  rest	  of	  the	  piperidine	  ring	  however	  does	  not	  favour	  this	  binding	  position.	  The	  electron	  density	  suggests	  that	  the	  piperidine	  ring	  is	  oriented	  such	  that	  the	  amine	  is	  facing	  out	  of	  the	  TcTSSco	  active	  site	  (Figure	  6.5C).	  Furthermore,	  the	  position	  of	  Tyr119	  is	  also	  seen	  in	  two	  conformations;	  one	  conformation	  seen	  in	  all	  previous	   fragment	   complexes	  and	   the	  other	   is	   flipped	   into	   the	  active	   site	  termed	   here	   as	   the	   closed	   conformation.	   In	   the	   closed	   conformation	   the	   side	  chain	   hydroxyl	   of	   Tyr119hydrogen	   bonds	   with	   the	   amine	   of	   (S)-­‐3-­‐piperidinic	  acid	  in	  one	  of	  its	  conformations	  (Figure	  6.5D).	  	  	  
	   193	  

















	   194	  
The	   greater	   the	   number	   of	   interactions	  made	   by	   a	   fragment	   in	   the	   active	   site	  suggests	   the	   higher	   its	   affinity.	   Both	   isomers	   make	   similar	   interactions	   with	  
TcTSSco	  and	  have	  similar	  inhibitory	  capabilities.	  The	  closed	  position	  of	  Tyr119	  is	  also	  seen	  in	  the	  binding	  of	  Neu5Ac2en	  and	  sialic	  acid.	  The	  movement	  of	  Tyr119	  into	  the	  active	  site	  cleft	  distorts	  the	  acceptor/donor	  sugar	  binding	  site	  (Amaya	  et	  al.,	  2003).	  This	  movement	  also	  perturbs	  the	  binding	  of	  transition	  state	  analogue	  Neu5Ac2en	   by	   clashing	   with	   the	   glycerol	   moiety	   and	   is	   proposed	   to	   be	   the	  primary	   cause	   for	   the	   poor	   inhibition	   of	   TcTS	   by	   Neu5Ac2en	   (Amaya	   et	   al.,	  2003).	   This	   is	   not	   the	   case	   for	   (S)-­‐3-­‐piperidinic	   acid	  which	  does	   not	   possess	   a	  glycerol	  moiety.	  	  	  
6.3.3	  Inhibition	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  piperazine	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7- 7-8- 8-9- 9-
:-:-
A.	   B.	  
	   195	  
the	  ring:	  piperizine	  carboxylic	  acids	  (Figure	  6.6).	  In	  principle,	  these	  compounds	  should	  bind	  similarly	  to	  the	  piperidinic	  acids,	  however	  with	  the	  additional	  amine	  being	  capable	  of	  hydrogen	  bonding	  with	  both	  Tyr119	  and	  Asp59.	  	  The	   (R)-­‐2-­‐piperazine	   carboxylic	   acid	   is	   a	   better	   fragment	   inhibitor	   than	   the	  nipecotic	  acid	  enantiomers	  and	  the	  (S)-­‐2-­‐piperazine	  carboxylic	  acid.	  The	  IC50	  for	  (R)-­‐2-­‐piperazine	  carboxylic	  acid	   is	  12.6	  ±	  0.9	  mM,	  more	  than	  5-­‐fold	   lower	  than	  either	  R	  or	  S	  piperidinic	  acid	  (Figure	  6.7).	  The	  IC50	  of	  (S)-­‐2-­‐piperazine	  carboxylic	  acid	  is	  36.5	  ±	  6.2	  mM,	  more	  than	  2-­‐fold	  higher	  than	  (R)-­‐2-­‐piperazine	  carboxylic	  acid,	   however	   the	   standard	   error	   of	   this	   IC50	   is	   greater	   than	   10%	   and	   is	  inherently	  unreliable	  (Figure	  6.7).	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The	  addition	  of	  100	  mM	  (R)-­‐2-­‐piperazine	  carboxylic	  acid	  resulted	  in	  	  90.6	  ±	  0.6%	  inhibition	   whereas	   the	   same	   concentration	   of	   (S)-­‐2-­‐piperazine	   carboxylic	   acid	  resulted	  in	  69.4	  ±	  0.4	  %	  inhibition.	  	  Clearly	  (R)-­‐2-­‐piperazine	  carboxylic	  acid	  is	  a	  better	   inhibitor	   than	   (S)-­‐2-­‐piperazine	   carboxylic	   acid.	   The	   inhibition	  of	  TcTSSco	  from	   addition	   of	   100	  mM	   (S)-­‐2-­‐piperazine	   carboxylic	   is	   similar	   to	   the	   level	   of	  inhibition	  seen	  by	   the	  nipecotic	  acid	  enantiomers.	  From	  the	  structure	  of	   (R)-­‐2-­‐piperazine	  carboxylic	  acid	   in	  complex	  with	  TcTSSco	   it	   is	  clear	   that,	   compared	   to	  the	   (S)	   enantiomer,	   (R)-­‐2-­‐piperazine	   carboxylic	   acid	   makes	   more	   interactions	  with	  the	  protein	  (Figure	  8A).	  The	  carboxylic	  acid	  of	  (R)-­‐2-­‐piperazine	  carboxylic	  acid	   binds	   to	   the	   arginine	   triad	   and	   the	   N4	   hydrogen	   bonds	   to	   Asp59	   as	  predicted	  by	  the	  binding	  of	  (R)-­‐3-­‐piperidinic	  acid.	  N4	  also	  hydrogen	  bonds	  to	  a	  water	  molecule	  mediating	  interactions	  with	  Arg53	  and	  Asp96.	  We	  hypothesized	  that	  N1	  would	  induce	  the	  movement	  of	  Tyr119	  into	  the	  active	  site	  to	  hydrogen	  bond	  with	  the	  fragmentFrom	  the	  structure	  of	  (R)-­‐2-­‐piperazine	  carboxylic	  acid	  in	  complex	   with	   TcTSSco	   it	   is	   clear	   that,	   compared	   to	   the	   (S)	   enantiomer,	   (R)-­‐2-­‐piperazine	  carboxylic	  acid	  makes	  more	  interactions	  with	  the	  protein	  (Figure	  8A).	  The	   carboxylic	   acid	   of	   (R)-­‐2-­‐piperazine	   carboxylic	   acid	   binds	   to	   the	   arginine	  triad	  and	  the	  N4	  hydrogen	  bonds	  to	  Asp59	  as	  predicted	  by	  the	  binding	  of	  (R)-­‐3-­‐piperidinic	   acid.	   N4	   also	   hydrogen	   bonds	   to	   a	   water	   molecule	   mediating	  interactions	  with	  Arg53	  and	  Asp96.	  We	  hypothesized	  that	  N1	  would	  induce	  the	  movement	  of	  Tyr119	  into	  the	  active	  site	  to	  hydrogen	  bond	  with	  the	  fragment.	  	  	  This	  however	  was	  not	  the	  case	  and	  there	  is	  no	  evidence	  of	  movement	  of	  Tyr119.	  Instead,	  N1	  hydrogen	  bonds	  with	  the	  nucleophilic	  tyrosine,	  Tyr342,	  which	  may,	  in	  the	  case	  of	  this	  fragment,	  mimic	  the	  oxocarbenium	  ion-­‐like	  transition	  state.	  N1	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also	  interacts	  with	  Trp312	  and	  Arg245	  via	  a	  water	  molecule.	  The	  piperizine	  ring	  is	   bound	   in	   a	   chair	   conformation	   and	   although	   it	   does	   not	   mimic	   the	   boat	  conformation	  of	  the	  substrate	   it	  has	  a	  closer	  resemblance	  to	  the	  substrate	  than	  (S)-­‐2-­‐piperazine	  carboxylic	  acid	  (Figure	  6.9).	  
Figure	   6.8.	   (A)	  Stereo	   image	  of	   the	  binding	  of	   (R)-­‐2-­‐piperazine	  carboxylic	  acid	   (yellow)	   in	   the	  active	  site	  of	  TcTSSco	  (green)	  highlighting	  the	  polar	   interactions	  (black	  dashed	  lines).	  (B)	  Stereo	  image	   of	   the	   binding	   of	   (S)-­‐2-­‐piperazine	   carboxylic	   acid	   (yellow)	   in	   the	   active	   site	   of	   TcTSSco	  (green)	   highlighting	   the	   polar	   interactions.	   Both	   2-­‐piperazine	   carboxylic	   acids	   bind	   to	   the	  arginine	   triad	   and	   the	   catalytic	   aspartic	   acid.	   	   (R)-­‐2-­‐piperazine	   carboxylic	   acid	  however	  makes	  additional	   interactions	   with	   Arg53,	   Asp96	   and	   Trp312	   which	   are	   all	   mediated	   by	   water	  molecules.	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  In	   contrast,	   (S)-­‐2-­‐piperazine	   carboxylic	   acid	   in	   the	   complex	   with	   TcTSSco	   only	  interacts	  with	  the	  arginine	  triad	  and	  the	  catalytic	  aspartic	  acid,	  Asp59	  (Figure	  8).	  N1	  of	  (S)-­‐2-­‐piperazine	  carboxylic	  acid	  also	  hydrogen	  bonds	  to	  a	  water	  molecule	  which	  mediates	  interactions	  with	  one	  other	  residue,	  Arg35.	  N4	  does	  not	  interact	  with	   Tyr119	   or	   make	   any	   additional	   interactions	   with	   the	   protein.	   The	   ring	  conformation	  of	  (S)-­‐2-­‐piperazine	  carboxylic	  acid	  is	  a	  boat	  conformation	  and	  has	  almost	  no	  resemblance	  to	  the	  substrate	  (Figure	  6.9).	  	  	  
	  
Figure	   6.9.	   (A)	   The	   binding	   of	   (R)-­‐2-­‐piperazine	   carboxylic	   acid	   (yellow)	   in	   the	   active	   site	   of	  
TcTSSco	  (not	  shown)	  overlaid	  with	  the	  sialyllactose	  (green)	  and	  on	  its	  own	  (C).	  (B)	  The	  binding	  of	  (S)-­‐2-­‐piperazine	  carboxylic	  acid	  (yellow)	   in	  the	  active	  site	  of	  TcTSSco	  (not	  shown)	  overlaid	  with	  the	  sialyllactose	  (B,	  green)	  and	  on	  its	  own	  (D).	  (R)-­‐2-­‐piperazine	  carboxylic	  acid	  overlays	  with	  the	  conformation	  of	  the	  substrate	  sialyllactose	  better	  than	  the	  S	  isomer.	  	  
!"# $"#
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6.3.3	  Siastatin	  B	  
Figure	  6.10.	  The	  structures	  of	  siastatin	  B	  (A)	  and	  Neu5Ac2en	  (B).	  	  	  	  Siastatin	  B	  (Figure	  6.10)	  is	  one	  of	  a	  number	  of	  naturally	  occurring	  iminosugars.	  Siastatin	   B	   and	   the	   related	   compound	   siastatin	   A	   were	   isolated	   from	  Streptomyces	   (Umezawa	   et	   al.,	   1974).	   Siastatin	   B	   is	   a	   potent	   inhibitor	   of	   a	  number	   of	   bacterial	   sialidases	   including	   sialidases	   from	   C.	   perfringens	   and	  Streptomyces.	  It	  has	  also	  demonstrated	  similar	  inhibitory	  capabilities	  against	  β-­‐glucuronidase	  (bovine)	  and	  N-­‐acetyl-­‐β-­‐D-­‐glucosaminidase	  (equine)	  (Umezawa	  et	  al.,	   1974).	   Siastatin	   B	   is	   built	   upon	   a	   (R)-­‐3-­‐piperidinic	   acid	   frame	   and	   its	  similarity	  to	  the	  fragments	  identified	  here	  indicated	  that	  it	  may	  inhibit	  TcTS	  also.	  Here	  we	  present	  the	  first	  structure	  of	  siastatin	  B	  in	  complex	  with	  a	  glycosidase,	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that,	  like	  the	  fragments	  presented	  in	  this	  chapter,	  this	  is	  not	  the	  case.	  The	  amine	  of	  Siatatin	  B	  does	  make	   favorable	   interactions	  with	  TcTSSco	  but	  does	  not	  mimic	  the	   transition	   state	   of	   the	   substrate.	   Siastatin	   B	   is	   built	   around	   a	   (R)-­‐3-­‐piperidinic	  acid	  frame.	  Interestingly,	  unlike	  the	  previously	  discussed	  TcTSSco-­‐(R)-­‐3-­‐piperidinic	  acid	  structure,	  the	  amine	  of	  the	  ring	  of	  Siastatin	  B	  is	  oriented	  out	  of	  the	   active	   site.	   As	   seen	   in	   the	  TcTSSco-­‐(S)-­‐3-­‐piperidinic	   acid	   complex	   structure,	  the	   amine	   of	   the	   piperidine	   ring	   of	   siastatin	   B	   hydrogen	   bonds	   with	   Tyr119	  (Figure	   6.11).	   There	   is	   only	   one	   conformation	   seen	   for	   Tyr119	   in	   the	  TcTSSco-­‐siastatin	  B	  complex;	  Tyr119	  is	  present	  in	  the	  closed	  conformation	  (Figure	  6.12).	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Neu5Ac	  also	  maintaining	  a	   chair	   conformation	   it,	   like	  Neu5Ac2en,	   is	   subject	   to	  repulsive	  forces	  caused	  by	  the	  movement	  of	  Tyr119	  into	  the	  active	  site.	  The	  clash	  of	  the	  glycerol	  moiety	  of	  Neu5Ac	  and	  Neu5Ac2en	  with	  Tyr119	  forces	  a	  strained	  tilt	  on	  the	  pyranose	  ring	  (Amaya	  et	  al.	  2003).	  Since	  siastatin	  B	  does	  not	  possess	  a	  similar	   glycerol	  moiety	   it	   is	   not	   subject	   to	   the	   same	   repulsive	   forces	   hence	   its	  piperidine	   ring	  overlays	  well	  with	   sialyllactose	   structure	   in	  which	  Tyr119	   is	   in	  the	  open	  position	  and	  does	  not	  preclude	  the	  binding	  of	  the	  siallylactose	  glycerol	  moiety	  (Figure	  6.13).	  	  Like	   Neu5Ac2en	   and	   (R)-­‐3-­‐piperidinic	   acid,	   the	   carboxylic	   acid	   of	   siastatin	   B	  binds	   to	   the	   arginine	   triad.	   In	   the	   TcTSFr-­‐Neu5Ac2en	   complex	   structure,	   the	  catalytic	   tyrosine	   Tyr342	   is	   seen	   in	   two	   conformations	   and	   in	   one	   such	  conformation	  clashes	  with	  Neu5Ac2en	  and	  upon	  binding	  is	  forced	  to	  move	  into	  the	   other	   conformation.	   This	   is	   not	   the	   case	   for	   siastatin	   B	   were	   the	   catalytic	  tyrosine	  is	  only	  seen	  in	  the	  conformation	  as	  seen	  in	  the	  apo	  structure.	  The	  amine	  of	   the	  piperidine	  ring	   is	  2.6	  Å	   from	  Tyr119	  which	   is	  only	  present	   in	   the	  closed	  position.	   The	   amine	   also	   hydrogen	   bonds	   to	   a	   water	   molecule	   which	   further	  interacts	   with	   Asp96,	   Gln195	   and	   Glu230.	   This	   water	   molecule	   indicates	   that	  addition	  of	  polar	  substituents	  to	  the	  amine	  may	  increase	  entropy	  by	  expulsion	  of	  a	  water	  molecule	  from	  the	  active	  site	  and	  exploit	  a	  number	  of	  polar	  interactions	  (Michel	  et	  al	  2009).	  The	  addition	  of	  substituents	  at	  this	  position	  must	  have	  strict	  stereochemistry	  to	  ensure	  it	  doesn’t	  clash	  with	  Tyr119.	  As	  with	  Neu5Ac2en,	  the	  N-­‐acetyl	  group	  of	  siastatin	  B	  is	  3	  Å	  from	  the	  carboxylic	  acid	  of	  Asp96.	  The	  ketone	  of	   the	   N-­‐acetyl	   group	   of	   siastatin	   B	   hydrogen	   bonds	   with	   a	   water	   molecule	  mediating	  an	  interaction	  with	  Asn60	  (Figure	  6.11).	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Figure	  6.12.	  (A)	  The	  binding	  of	  (R)-­‐3-­‐piperidinic	   acid	   (yellow)	   in	   the	  active	  site	  of	  TcTSSco	  (grey	  cartoon)	  with	   the	   position	   of	   Tyr119	  represented	   as	   sticks	   (green).	   In	  this	   structure	   Tyr119	   does	   not	  make	   any	   interactions	   with	   the	  fragment	   and	   is	   in	   the	   open	  position.	   (B)	   The	   binding	   of	   (S)-­‐3-­‐piperidinic	   acid	   (yellow)	   in	   the	  active	   site	   of	   TcTSSco	   (grey)	   in	   the	  conformation	   where	   it	   faces	  Tyr119.	   In	   this	   structure	   Tyr119	  (green)	   hydrogen	   bonds	   (black	  dashed	   line)	  with	   the	  amine	  of	   (S)-­‐3-­‐piperidinic	  acid	  and	  is	  seen	  in	  two	  conformations.	   (C)	   The	   binding	   of	  siastatin	   B	   in	   the	   active	   site	   of	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The	  C3	  hydroxyl	  of	  siastatin	  B	  is	  3.3	  Å	  from	  Asp59	  and	  2.7	  Å	  from	  Arg35	  which	  is	  similar	   to	   the	   interactions	   made	   by	   the	   C4	   hydroxyl	   of	   Neu5Ac2en.	   The	   C3	  hydroxyl	   also	   hydrogen	   bonds	   with	   two	   water	   molecules	   which	   mediate	  interactions	   with	   Asp51	   and	   may	   indicate	   another	   avenue	   for	   the	   addition	   of	  substituents	   to	   this	   inhibitor.	   Unlike	   Neu5Ac2en,	   siastatin	   B	   has	   an	   additional	  hydroxyl	  on	  its	  C4	  which	  makes	  an	  interaction	  with	  TcTSSco	  by	  hydrogen	  bonding	  to	   the	   catalytic	   aspartic	   acid.	   This	   hydroxyl	  may	   act	   to	   displace	   the	   conserved	  water	  molecule	   responsible	   for	   the	   retention	   of	   the	   anomeric	   configuration	   of	  the	  product.	  The	  C4	  hydroxyl	  is	  2.5	  Å	  from	  Asp59	  and	  in	  this	  structure	  hydrogen	  bonds	  to	  a	  glycerol	  molecule.	  A	  similar	   interaction	   is	  made	  by	  the	  amine	  of	   the	  piperidine	   ring	   of	   (R)-­‐3-­‐piperidinic	   acid.	   Replacing	   the	   C4	   hydroxyl	   with	   an	  amine	  may	   significantly	   improve	  binding	  by	  providing	  a	  more	  attractive	   target	  for	  the	  nucleophilic	  tyrosine.	  	   	  	  The	   glycerol	   moiety	   of	   Neu5Ac2en	   clashes	   with	   the	   side	   chain	   hydroxyl	   of	  Tyr119	   resulting	   in	   poor	   inhibition.	   The	   glycerol	   moiety	   does	   however	   make	  several	   polar	   interactions	   with	   TcTS	   which	   aid	   binding.	   Siastatin	   B	   does	   not	  possess	   a	   glycerol	   moiety	   and	   is	   thus	   lacking	   these	   interactions.	   Siastatin	   B	  possesses	  a	  C3	  hydroxyl	  which	  increases	  interactions	  with	  TcTSSco	  and	  improves	  binding.	   Despite	   these	   differences	   the	   inhibition	   by	   these	   compounds	   is	  remarkably	   similar.	   The	   addition	   of	   10	   mM	   of	   siastatin	   B	   and	   Neu5Ac2en	  resulted	   in	   a	   67.8	   ±	   2.0	  %	   and	   59.2	   ±	   0.6	  %	   decrease	   in	   activity,	   respectively.	  	  Although	   it	   was	   not	   possible	   to	   experimentally	   derive	   accurate	   IC50s	   due	   to	  limitations	   in	   compound	   availability,	   this	   is	   consistent	   with	   the	   previously	  published	   IC50	   for	   Neu5Ac2en	   inhibiting	   TcTS	   of	   6	   mM	   (Amaya	   et	   al.,	   2003).	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These	  data	  indicate	  that	  siastatin	  B	  may	  be	  a	  better	  inhibitor	  for	  TcTSSco	  even	  if	  only	   marginally.	   This	   difference	   however	   is	   much	   greater	   when	   the	   potency	  efficiency	   index	   (PEI)	   is	   considered.	   The	   PEI	   is	   calculated	   by	   comparison	   of	  percentage	  inhibition	  at	  a	  fixed	  concentration	  divided	  by	  the	  molecular	  weight	  of	  the	   inhibitor	   (Abad-­‐Zapatero	   and	   	   Metz,	   2005.).	   The	   PEI	   of	   siastatin	   B	   is	   0.31	  compared	  with	  0.20	  for	  Neu5Ac2en.	  	  
Figure	   6.13.	   (A)	   The	   binding	   of	   siastatin	   B	   (yellow,	   sticks)	   in	   the	   active	   site	   of	  TcTSSco	   (grey,	  cartoon)	  overlaid	  with	  the	  substrate	  sialyllactose	  (green).	  (B)	  The	  binding	  of	  the	  transition	  state	  analogue	   and	   inhibitor	  Neu5Ac2en	   (yellow,	   sticks)	   in	   the	   active	   site	   of	  TcTSSco	   (grey)	   overlaid	  with	   the	   substrate	   sialyllactose	   (green).	   	   Siastatin	   B	   overlays	   better	   with	   the	   substrate	  sialyllactose	   than	   Neu5Ac2en.	   Neu5Ac2en	   is	   a	   poor	   inhibitor	   of	   TcTS	   due	   to	   repulsive	   forces	  between	  Tyr119	  and	  the	  glycerol	  side	  chain	  of	  Neu5Ac2en	  which	  siastatin	  B	  does	  not	  suffer	  from.	  	  
!"#
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6.4	  Future	  of	  inhibitor	  studies	  	  	  The	   IC50s	   of	   (R)-­‐2-­‐piperazine	   and	   siatatin	   B	   are	   still	   very	   high.	   The	   accepted	  method	   for	   assaying	   sialidase	   activity	   relies	   on	   the	   use	   of	   200	   μM	   substrate	  concentration.	   The	   IC50s	   do	   not	   take	   into	   account	   the	   high	   concentration	   of	  substrate	   used	   here	   and	   thus	   falsely	   make	   the	   IC50s	   appear	   worse.	   This	   is	  reflected	   in	   the	   literature	  where	   there	   are	   few	   compounds	  with	   low	   μM	   IC50s.	  Furthermore,	   there	   are	   only	   three	   TcTS-­‐inhibitor	   complexes	   validated	   by	  crystallography	   and	   published	   in	   the	   PDB.	   Current	   published	   inhibitors	   have	  IC50s	  in	  the	  high	  μM	  range	  and	  are	  only	  validated	  by	  virtual	  docking	  (Neres	  et	  al.,	  2007;	  Neres	  et	  al.,	  2009)	  with	   few	  exceptions.	  Here	  we	  have	  demonstrated	   the	  importance	  of	  validating	  inhibitors	  by	  a	  number	  of	  methods.	  	  Future	   studies	  would	   include	  utilizing	  more	  appropriate	  kinetic	  measurements	  for	  the	  compounds	  presented	  here.	  The	  inhibitory	  effect	  of	  siastatin	  B	  and	  (R)-­‐2-­‐piperazine	   carboxylic	   acid	   may	   be	   improved	   by	   rational	   design	   based	   on	   the	  reactive	  sites	  in	  the	  TcTS	  active	  site	  (Chapter	  4).	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7.	  Conclusions	  and	  future	  directions	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7.1	  The	  sialidase	  AfS	  from	  aspergillus	  fumigatus	  	  	  Trp202	  was	   identified	  as	  a	  possible	  contributing	   factor	   to	   the	  selectivity	  of	  AfS	  for	   sialic	   acid	   KDN	   rather	   than	   Neu5Ac.	   Future	   studies	   should	   include	  investigation	   of	   the	   ability	   of	   AfSR171L,W202V	   to	   utilize	   Neu5Ac	   conjugates	   as	  substrates.	   Attempts	   should	   be	   made	   to	   obtain	   a	   structure	   of	   AfSR171L,W202V	   in	  complex	  with	  Neu5Ac.	  To	  definitively	  prove	  that	  enlarging	  the	  active	  site	  cavity	  to	   accommodate	   the	  N-­‐acetyl	   of	  Neu5Ac	  by	  mutation	   from	  Trp202V	   to	  Val202	  decreases	   selectivity	   for	   KDN,	   the	   activity	   of	   AfSR171L,W202V	   toward	   Neu5Ac-­‐Mu	  should	   be	  measured	   and	   compared	   to	  AfSR171L	   and	  wild	   type	  AfS.	   Furthermore	  
AfS	   is	   uninhibited	   by	   Neu5Ac	   specific	   sialidase	   inhibitor	   Neu5Ac2en	   however	  potential	  studies	  could	  involve	  the	  ability	  of	  Neu5Ac2en	  to	  inhibit	  AfSR171L,W202V.	  If	   Neu5Ac2en	   was	   able	   to	   inhibit	   the	   cleavage	   of	   Neu5Ac-­‐Mu	   or	   KDN-­‐Mu	   by	  
AfSR171L,W202V	   it	   can	   be	   concluded	   that	   enlarging	   the	   active	   site	   cavity	   by	   the	  W202V	  mutation	  improves	  the	  affinity	  of	  AfS	  to	  sialic	  acids	  with	  larger	  groups	  at	  the	  C5	  position.	  	  	  Neu5Ac	   and	   KDN	   are	   only	   two	   members	   of	   a	   family	   of	   over	   fifty	   sialic	   acids	  which	   possess	   a	   range	   of	   substituents	   at	   the	   C5	   position	   as	   well	   as	   other	  positions	  (Angata	  and	  Varki,	  2002).	  To	  validate	  KDN	  as	  the	  true	  substrate	  of	  AfS	  it	   is	  necessary	   to	   compare	   the	  Kcat	   of	  AfS	   to	  various	  members	  of	   the	   sialic	   acid	  family	  of	  sugars.	  	  	  
AfS	   is	   the	   first	   structure	  of	  a	  KDN	  specific	   sialidase	   to	  be	  solved.	  Here	  we	  have	  compared	   AfS	   to	   structures	   of	   all	   sialidases	   were	   the	   structure	   is	   publically	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available	  to	  date.	  As	  structures	  of	  other	  KDN	  specific	  sialidases	  are	  elucidated	  it	  follows	   that	   comparison	   with	   AfS	   could	   lead	   to	   the	   discovery	   of	   a	   conserved	  motif	   responsible	   for	   the	  selectivity	  of	   these	  KDN	  specific	   sialidases.	  Sialic	  acid	  research	  has	  focused	  primarily	  on	  Neu5Ac	  due	  to	  its	  involvement	  in	  a	  number	  of	  high	  profile	  diseases	  (Taylor,	  1996).	  KDN	  and	  the	  rest	  of	  the	  sialic	  acid	  family	  are	  less	  well	   studied	   and	   as	   such	   their	   relative	   abundances	   in	   nature	   are	   not	  well	  documented	   currently.	   Expansion	   of	   sialic	   acid	   research	   may	   provide	   further	  answers	  to	  the	  purpose	  of	  KDN	  specific	  sialidases.	  	  	  The	  secondary	  binding	  site	  of	  AfS	  is	  unusual	   in	   its	  close	  proximity	  to	  the	  active	  site.	   Two	   further	   binding	   sites	   for	   the	   substrate	   analogue	   KDF	   were	   also	  identified	   in	   the	   structure	   of	   AfS	   in	   complex	   with	   KDF.	   With	   a	   potential	   four	  binding	   sites	   on	   a	   relatively	   small	   protein	   of	   only	   44	   kDa	   it	  was	   hypothesized	  that	   AfS	   may	   be	   specialized	   to	   cleave	   poly-­‐KDN.	   In	   order	   to	   validate	   this	  hypothesis	  it	  would	  be	  necessary	  to	  solve	  the	  structure	  of	  an	  inactive	  mutant	  of	  
AfS	  such	  as	  AfSD84A	  in	  complex	  with	  poly-­‐KDN.	  Unlike	  the	  endosialidase	  from	  the	  K1F	  E.	  coli	  bacteriophage	  AfS	  is	  capable	  of	  cleaving	  terminal	  sialic	  acids	  and	  not	  just	  from	  within	  a	  chain	  (Morley	  et	  al.,	  2009).	  Assuming	  that	  AfS	  has	  evolved	  to	  cleave	   poly-­‐KDN	   specifically	   the	  Kd	   of	  AfS	   for	   poly-­‐KDN	  would	   be	   significantly	  lower	   than	   for	   KDN	   monomers.	   	   To	   demonstrate	   this	   the	   Michalis-­‐Menten	  kinetics	   for	  AfS	  with	   varying	   length	   of	   poly-­‐KDN	  must	   be	   determined	   possibly	  using	  isothermal	  calorimetry.	  KDN	  polymers	  are	  not	  currently	  available	  in	  large	  enough	  quantities	  to	  allow	  this.	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7.2	  The	  Future	  directions	  of	  drug	  discovery	  for	  TcTs,	  the	  trans-­‐
sialidase	  from	  Trypanosoma	  cruzi	  
	  This	  study	  identified	  fragments	  proline,	  valine,	  serine,	  1,3-­‐thiazolane-­‐2-­‐caboxylic	  acid,	   (R)-­‐3-­‐piperidinic	   acid,	   (S)-­‐3-­‐piperidinic	   acid,	   (R)-­‐2-­‐piperazine	   carboxylic	  acids,	   (S)-­‐2-­‐piperazine	   carboxylic	   acid	   as	  well	   as	   lead	   compound	   siastatin	  B	   as	  inhibitors	  of	  TcTs.	  Summary	  of	   the	   interactions	  of	  each	  fragment	  with	  the	  TcTs	  identified	  reoccurring	  and	  important	  interactions	  (Table	  7.1).	  Future	  compounds	  should	   retain	   the	   carboxylic	   acid	  moiety	   as	   this	   interaction	   is	   conserved	   in	   all	  compounds	   validated	   by	   x-­‐ray	   crystallography	   in	   this	   thesis	   inferring	   the	  importance	   of	   this	   interaction	   in	   the	   binding	   of	   these	   inhibitors	   (Table	   7.1).	  Furthermore	   the	   arginine	   triad	   to	   which	   the	   carboxylic	   moiety	   binds	   is	   well	  conserved	  amongst	  sialidases	  due	  to	  its	  importance	  in	  substrate	  binding	  thus	  it	  is	   less	   likely	   to	  mutate	  and	  cause	  resistant	  strains	  of	  T.	  cruzi	   than	  residues	  not	  involved	  in	  substrate	  binding.	  	  Current	  sialidase	  inhibitors	  on	  the	  market	  for	  the	  treatment	  of	  influenza	  zanamivir	  and	  oseltamivir	  also	  contain	  a	  carboxylic	  acid.	  The	   carboxylic	   acid	   of	   these	   drugs	   interacts	   with	   the	   arginine	   triad	   of	   the	  influenza	  neuraminindase	  (von	  Itzstein,	  2007).	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Table	   1.	   Polar	   interactions	   of	   TcTsSco	   with	   inhibitors	   L-­‐proline,	   (R)-­‐3-­‐piperidinic	   acid,	   (S)-­‐3-­‐piperidinic	  acid,	   (R)-­‐2-­‐piperazine	  carboxylic	  acid,	   (S)-­‐2-­‐piperazine	  carboxylic	  acid	  and	  siastatin	  B.	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Small	  molecule	  inhibitors	  proline,	  valine,	  serine,	  1,3-­‐thiazolane-­‐2-­‐carboxylic	  acid,	  (R)-­‐3-­‐piperidinic	   acid	   and	   R	   and	   S	   2-­‐piperazine	   all	   possess	   an	   amine	   which	  hydrogen	  bonds	  with	  Asp59.	   The	   reoccurrence	   of	   this	   interaction	   amongst	   the	  small	  molecule	  inhibitors	  suggests	  that	  this	  interaction	  is	  important	  to	  inhibitor	  binding.	   Asp59	   is	   the	   acid/base	   catalyst	   and	   is	   essential	   to	   catalysis	   thus	   it	   is	  unlikely	   that	  TcTs	   could	   produce	   a	   functional	  mutant	   of	   Asp59	   that	   would	   be	  resistant	   to	   these	   inhibitors.	   Siastatin	   B	   possesses	   an	   amine	   in	   its	   piperadinic	  acid	   substructure	  however	   this	   amine	   is	   too	  distal	   to	   interact	  with	  Asp59.	  The	  amine	   of	   siatatin	   B	   hydrogen	   bonds	  with	   Tyr119	   as	   is	   also	   the	   case	   for	   (S)-­‐3-­‐piperidinic	  acid.	  This	  interaction	  causes	  the	  side	  chain	  of	  Tyr119	  to	  pivot	  into	  the	  active	   site	   (Amaya	   et	   al.,	   2003).	   The	   inhibitor	   and	   transition	   state	   analogue,	  Neu5Ac2en,	  also	  causes	   the	  movement	  of	   the	  Tyr119	  side	  chain	   into	   the	  active	  site.	  Neu5Ac2en	   is	   a	   poor	   inhibitor	   of	  TcTs	  due	   to	   a	   steric	   clash	  with	   catalytic	  tyrosine	   Tyr342.	   Neither	   the	   structure	   of	   siastatin	   B	   or	   (S)-­‐piperidinic	   acid	   in	  complex	   with	   TcTsSco	   display	   a	   similar	   clash	   with	   Tyr342	   as	   is	   seen	   in	   the	  Neu5Ac2en-­‐TcTs	   complex	   structure	   and	   thus	   may	   prove	   excellent	   lead	  compounds	  in	  the	  search	  for	  TcTs	  inhibitors.	  	  	  Taking	  piperazine	  carboxylic	  acid	  fragment	  as	  the	  minimum	  binding	  fragment	  of	  siastatin	  B	   then	   all	   of	   the	   additional	   groups	   that	   form	   siastatin	  B	   interact	  with	  
TcTsSco.	   	  The	  C4	  hydroxyl	  of	  siastatin	  B	   is	  within	  hydrogen	  bonding	  distance	  of	  both	  Arg53	  and	  Asp59.	  The	  C3	  hydroxyl	  hydrogen	  bonds	  with	  Asp96	  similar	  to	  the	  C4	  hydroxyl	  of	   the	   transition	  state	  analogue	  Neu5Ac2en,	  substantiating	   the	  importance	   of	   this	   interaction	   in	   binding	   and	   decreasing	   the	   likelihood	   of	  resistant	   strains	   of	   T.	   cruzi	   arising	   from	   mutations	   around	   this	   substituent	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(Buschiazzo	  et	  al.,	  2002).	  Another	  interaction	  shared	  by	  both	  siastatin	  B	  and	  the	  transition	   state	   analogue	   Neu5Ac2en	   is	   the	   amine	   of	   the	   N-­‐acetyl	   group	   with	  Asp96.	   Given	   that	   the	   C2	   N-­‐acetyl	   group	   and	   the	   C3and	   C4	   hydroxyls	   interact	  with	  TcTsSco	  and	  there	   is	   insufficient	  room	  around	  each	  group	  to	  accommodate	  larger	  substituents,	  future	  improvements	  to	  the	  binding	  of	  siastatin	  B	  to	  TcTsSco	  should	  be	  made	  at	  different	  points	  of	  the	  piperazine	  ring	  of	  siastatin	  B.	  	  	  	  	  	  Three	   druggable	   sites	   were	   identified	   in	   the	   active	   site	   of	   TcTs.	   All	   for	   the	  fragments	  that	  were	  identified	  in	  this	  study	  bind	  in	  site	  two	  and	  interact	  with	  the	  catalytic	  aspartic	  acid	  and	  arginine	  triad	  (figure	  7.1).	  To	  improve	  the	  inhibitory	  capacity	   of	   the	   lead	   compounds	   identified	   in	   this	   thesis	   additions	   to	   inhibitors	  should	   attempt	   to	   exploit	   these	   druggable	   sites.	   It	   should	   be	   noted	   that	  piperidinic	   acid	   and	   siastatin	   B	   cause	   the	  movement	   of	   Tyr119	   into	   the	   active	  site	   distorting	   the	   second	   and	   third	   druggable	   sites	   (figure	   7.1)	   and	   require	  different	  optimizations.	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Druggable	   site	   one	   (figure	   7.1)	   has	   been	   identified	   by	   the	   binding	   of	   Tris,	  sulphate	   or	   phosphate	   and	   DMSO	   in	   the	   complex	   structures	   of	   TcTsSco	   with	  valine,	   proline	   or	   1,3-­‐thiazolane-­‐2-­‐carboxylic	   acid,	   respectively.	   Given	   that	   the	  interactions	   of	   Tris,	   a	   tetrahedral	   ion	   and	   DMSO	   with	   TcTsSco	   are	   all	   polar,	  additions	  to	  lead	  compounds	  to	  improve	  binding	  in	  site	  one	  should	  also	  be	  polar.	  	  The	  glycerol	  group	  of	  the	  transition	  state	  analogue	  Neu5Ac2en	  binds	  in	  this	  site	  and	   thus	  a	  glycerol	   substituent	  on	   the	  amine	  of	   (R)-­‐3-­‐piperidinic	  acid	  or	  N4	  of	  (R)-­‐2-­‐piperazine	   carboxylic	   acid	   or	   the	   C6	   of	   (S)-­‐2-­‐piperazine	   carboxylic	   acid	  may	  improve	  binding	  of	  these	  fragments.	  A	  similar	  addition	  to	  (S)-­‐3-­‐piperidinic	  acid	  or	  siastatin	  B	  is	  likely	  to	  clash	  with	  Tyr119	  which	  is	  in	  the	  closed	  position	  in	  these	  structures.	  	  Druggable	  site	  one	  is	  between	  3-­‐4	  Å	  from	  druggable	  site	  2	  and	  thus	  small	  polar	  substitutions	  to	  (S)-­‐3-­‐piperidinic	  acid	  or	  siastatin	  B	  may	  or	  may	  not	   clash	   with	   Tyr119	   and	   would	   likely	   be	   too	   short	   to	   interact	   with	   polar	  residues	   in	   site	   one.	   We	   hypothesize	   that	   (R)-­‐3-­‐piperidinic	   acid	   with	   similar	  substituents	   to	   Neu5Ac2en,	   but	   in	   alternative	   positions,	   may	   prove	   a	   potent	  inhibitor;	  the	  addition	  of	  a	  glycerol	  moiety	  to	  the	  C6	  and	  an	  N-­‐acetyl	  group	  on	  the	  C5	   position	   (figure	   7.2).	   In	   theory	   this	   compound	  would	   be	   capable	   of	  making	  similar	  interactions	  with	  TcTs	  as	  the	  transition	  state	  analogue	  with	  the	  addition	  of	  hydrogen	  bond	  interactions	  with	  the	  catalytic	  aspartic	  acid	  without	  suffering	  from	  a	  clash	  with	  Tyr119.	  We	  also	  hypothesize	  that	  this	  approach	  may	  be	  even	  more	  effective	  with	  Neu5Ac2en-­‐like	  substituents	  to	  (R)-­‐2-­‐piperidinic	  acid	  as	  the	  addition	  of	  a	  hydroxyl	  to	  mimic	  that	  of	  the	  C4	  hydroxyl	  of	  Neu5Ac2en	  to	  the	  C7	  rather	  could	  be	  made	  (figure	  7.2).	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Figure	  7.2.	   	  The	  product	  of	  TcTs,	  Neu5Ac	  (A)	  and	  designed	  compounds	  with	  similar	  substituents	  to	   Neu5Ac	   (B	   &	   C).	   Compounds	   B	   and	   C	   are	   based	   on	   a	   (R)-­‐3-­‐piperidine	   ring	   (B)	   and	   (R)-­‐2-­‐piperidine	  ring	  rather	  than	  the	  pyranose	  ring	  of	  Neu5Ac.	  	  	  Druggable	  site	  three	  is	  hydrophobic	  as	  identified	  by	  the	  binding	  of	  DMSO	  in	  the	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exploitation	   of	   this	   site	   could	   confer	   inhibitor	   selectivity	   and	   possibly	   reduce	  toxicity.	  Site	  three	  is	  between	  2.8-­‐3	  Å	  from	  site	  two	  and	  as	  such	  any	  hydrophobic	  additions	   should	   extend	   two	   carbon	   bond	   lengths	   or	  more.	   The	   side	   chains	   of	  Tyr119	  and	  Trp312	  are	  parallel	  and	  the	  distance	  between	  the	  pair	  is	  roughly	  7.5	  Å.	  The	  addition	  of	  a	  phenyl	  ring	  to	  a	  lead	  compound	  to	  extent	  into	  site	  three,	  for	  example	   the	   C2	   of	   proline	   or	   (R)-­‐3-­‐piperidinic	   acid,	   may	   form	   π	   stacking	  interactions	   with	   Tyr119	   and	   Trp213	   (figure	   7.3).	   Furthermore	   hydrophobic	  substituents	  to	  inhibitors	  often	  improve	  bioavailability.	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Appendix	  
Primers	  	  
AfSR171L	  Forward	   ctg	  gga	  agg	  ccg	  cct	  gca	  cct	  gta	  cct	  cac	  Reverse	   gtg	  agg	  tac	  agg	  tgc	  agg	  cgg	  cct	  tcc	  cag	  
AfSD64A	  Forward	   cga	  cac	  acc	  aac	  caa	  gcc	  ttt	  ggc	  gac	  atc	  aac	  Reverse	   gtt	  gat	  gtc	  gcc	  aaa	  ggc	  ttg	  gtt	  ggt	  gtg	  tcg	  
AfSY358H	  Forward	   cgg	  gtc	  atg	  aag	  ggg	  gtc	  att	  cga	  gta	  tga	  cca	  ag	  Reverse	   ctt	  ggt	  cat	  act	  cga	  atg	  acc	  ccc	  ttc	  atg	  acc	  cg	  
AfSR171L,W202V	  Forward	   gac	  ggc	  tgg	  gcc	  gtg	  gac	  gcg	  gtc	  g	  	  Reverse	   ccg	  acc	  gcg	  tcc	  acg	  gcc	  cag	  ccg	  tc	  
TcTsSco	  Forward	   cgc	  tcg	  cta	  cga	  aac	  atc	  caa	  Reverse	   gcg	  agc	  gat	  gct	  ttg	  tag	  gtt	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Inhibition	  assay	  results	  for	  TcTSSco	  	  	  
Molecular	  
weight	   Compound	  
%	  
inhibition	  
at	  2	  mM	   Structure	  
97.12	   1-­‐methyl-­‐1H-­‐pyrazol-­‐5-­‐ylamine	   15.2	  ±	  2.5	  
	  
98.10	   5-­‐methylisoxazol-­‐3-­‐amine	   9.2	  ±	  16.6	  
	  
100.12	   tetrahydro-­‐4H-­‐pyran-­‐4-­‐one	   13.3	  ±	  47.8	  
	  
112.13	   6-­‐methyl-­‐2,3,4,5-­‐tetrahydropyridazin-­‐3-­‐one	   6.7	  ±	  0.6	  
	  
112.13	   (5-­‐methyl-­‐3-­‐isoxazolyl)methylamine	   12.9	  ±	  23.1	  
	  
114.19	   2,5-­‐dimethylpiperazine	   29.4	  ±	  22.1	  
	  
116.16	   tetrahydro-­‐2H-­‐pyran-­‐4-­‐ylmethanol	   39.3	  ±	  52.0	  
	  
118.59	   3-­‐chlorothiophene	   16.9	  ±	  15.5	  
	  
123.11	   isonicotinic	  acid	   12.8	  ±	  7.2	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127.21	   (3-­‐methyl-­‐2-­‐thienyl)methylamine	   12.1	  ±	  28.5	  
	  
128.15	   thiophene-­‐2-­‐carboxylic	  acid	   2.6	  ±	  0.5	  
	  
131.18	   2,6-­‐dimethylbenzonitrile	   30.5	  ±	  22.1	  
	  
132.16	   1-­‐eth-­‐1-­‐ynyl-­‐4-­‐methoxybenzene	   14.8	  ±	  16.8	  
	  
134.14	   6-­‐methoxynicotinonitrile	   31.9	  ±	  31.7	  
	  
136.08	   3-­‐(trifluoromethyl)-­‐1H-­‐pyrazole	   5.8	  ±	  6.6	  
	  
136.13	   2-­‐amino-­‐6-­‐fluorobenzonitrile	   23.5	  ±	  46.3	  
	  
142.18	   methyl	  thiophene-­‐2-­‐carboxylate	   37.5	  ±	  45.4	  
	  
143.14	   N1-­‐methyl-­‐2,4-­‐difluoroaniline	   39.4	  ±	  52.8	  
	  
147.18	   2-­‐(4-­‐methoxyphenyl)acetonitrile	   38.2	  ±	  10.7	  
	  
147.18	   1-­‐benzofuran-­‐5-­‐ylmethylamine	   30.6	  ±	  26.6	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147.22	   8-­‐methyl-­‐1,2,3,4-­‐tetrahydroquinoline	   32.9	  ±	  14.6	   	  
149.19	   2,3-­‐dimethylbenzamide	   23.6	  ±	  35.0	  
	  
149.24	   4-­‐(tert-­‐butyl)aniline	   19.3	  ±	  9.2	  
	  
150.18	   methyl	  3-­‐methylbenzoate	   42.3	  ±45.5	  
	  
150.18	   2,3-­‐dihydro-­‐1-­‐benzofuran-­‐2-­‐ylmethanol	   32.6	  ±	  35.6	  
 
 	  
150.18	   N1-­‐(3-­‐pyridylmethyl)acetamide	   32.3	  ±	  38.5	  
	  
151.19	   5-­‐acetylthiophene-­‐2-­‐carbonitrile	   14.9	  ±	  10.8	  
	  
152.15	   2-­‐(2-­‐hydroxyphenyl)acetic	  acid	   51.1	  ±	  34.7	  
	  
152.19	   2-­‐methylbicyclo[2.2.1]hept-­‐5-­‐ene-­‐2-­‐carboxylic	  acid	   5.3	  ±	  5.5	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166.18	   2,3-­‐dihydro-­‐1,4-­‐benzodioxin-­‐5-­‐ylmethanol	   11.6	  ±	  10.3	  
	  
168.16	   4-­‐(trifluoromethyl)cyclohexan-­‐1-­‐ol	   1.8	  ±	  14.3	  
	  
168.17	   N-­‐(4-­‐fluorobenzyl)urea	   7.5	  ±	  28.6	  
	  
184.65	   4-­‐chloro-­‐5-­‐methylthieno[2,3-­‐d]pyrimidine	   29.9	  ±	  17.4	  
	  
185.22	   2,2-­‐dimethyl-­‐2H-­‐chromene-­‐6-­‐carbonitrile	   19.0	  ±	  13.2	  
	  
185.22	   (4-­‐pyrid-­‐3-­‐ylphenyl)methanol	   21.8	  ±	  2.3	  
	  
185.22	   (4-­‐pyrid-­‐2-­‐ylphenyl)methanol	   28.6	  ±	  7.0	  
	  
186.14	   2-­‐(trifluoromethyl)-­‐1H-­‐benzo[d]imidazole	   12.9	  ±	  7.8	  
	  
186.14	   4-­‐amino-­‐2-­‐(trifluoromethyl)benzonitrile	   14.3	  ±	  2.1	  
	  
186.21	   (3-­‐pyrimidin-­‐5-­‐ylphenyl)methanol	   27.7	  ±	  2.2	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188.23	   (5-­‐methyl-­‐1-­‐phenyl-­‐1H-­‐pyrazol-­‐4-­‐yl)methanol	   17.7	  ±	  5.0	  
	  
188.23	   (1-­‐methyl-­‐3-­‐phenyl-­‐1H-­‐pyrazol-­‐5-­‐yl)methanol	   12.7	  ±	  4.9	  
	  
188.23	   (1-­‐methyl-­‐5-­‐phenyl-­‐1H-­‐pyrazol-­‐3-­‐yl)methanol	   19.6	  ±	  1.5	  
	  
188.23	   (1-­‐benzyl-­‐1H-­‐imidazol-­‐2-­‐yl)methanol	   22.5	  ±	  5.1	  
	  
188.23	   [4-­‐(1H-­‐imidazol-­‐1-­‐ylmethyl)phenyl]methanol	   18.4	  ±	  2.2	  
	  
189.21	   3-­‐(1H-­‐indol-­‐3-­‐yl)propanoic	  acid	   11.7	  ±	  5.4	  
	  
189.21	   (5-­‐methyl-­‐3-­‐phenyl-­‐4-­‐isoxazolyl)methanol	   14.1	  ±	  2.7	  
	  
189.21	   N1-­‐(1-­‐oxo-­‐2,3-­‐dihydro-­‐1H-­‐inden-­‐5-­‐yl)acetamide	   18.2	  ±	  9.6	  
	  
189.21	   2,3-­‐dimethyl-­‐1H-­‐indole-­‐5-­‐carboxylic	  acid	   78.0	  ±	  2.1	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190.65	   methyl	  3-­‐chloro-­‐4-­‐methylthiophene-­‐2-­‐carboxylate	   26.5	  ±	  4.0	  
	  
192.14	   [4-­‐(trifluoromethoxy)phenyl]methanol	   21.0	  ±	  2.6	  
	  
192.21	   2,2-­‐dimethyl-­‐2,3-­‐dihydro-­‐1-­‐benzofuran-­‐7-­‐carboxylic	  acid	   32.7	  ±	  2.4	  
	  
192.31	   3-­‐(phenylthio)thiophene	   31.2	  ±	  7.9	  
	  
	  









	   226	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   227	  
Bibliography	  	  
 Abad-­‐Zapatero,	  C.	  &	  Metz,	  J.	  T.	  (2005).	  Ligand	  efficiency	  indices	  as	  guideposts	  for	  drug	  discovery.	  Drug	  Discovery	  Today,	  10	  (7),	  464-­‐469	  	  Adams,	   P.	   D.,	   Grosse-­‐Kunstleve,	   R.	  W.,	   Hung,	   L.	  W.,	   Ioerger,	   T.	   R.,	   McCoy,	   A.	   J.,	  Moriarty,	  N.	  W.,	  Read,	  R.	  J.,	  Sacchettini,	  J.	  C.,	  Sauter,	  N.	  K.	  &	  Terwilliger,	  T.	  C.	   2002.	   PHENIX:	   building	   new	   software	   for	   automated	   crystallographic	  structure	   determination.	   Acta	   Crystallographica	   Section	   D-­‐Biological	  
Crystallography,	  58,	  1948-­‐1954.	  	  Agusti,	   R.,	   Paris,	   G.,	   Ratier,	   L.,	   Frasch,	   A.	   C.	   C.	   &	   Lederkremer	   (2004).	   Lactose	  derivatives	   are	   inhibitors	   of	   Trypanosoma	   cruzi	   trans-­‐sialidase	   activity	  toward	   convetional	   substrates	   in	   vitro	  and	   in	   vivo.	   Glycobiology,	   14	   (7),	  659-­‐670.	  	  	  Aisner,	   J.,	   Schimpff,	   S.	   C.	   &	   Wiernik,	   P.	   H.	   1977.	   Treatment	   of	   Invasive	  Aspergillosis	   -­‐	   Relation	   of	   Early	   Diagnosis	   and	   Treatment	   to	   Response.	  
Annals	  of	  Internal	  Medicine,	  86,	  539-­‐543.	  	  Amaya,	   M.	   F.,	   Buschiazzo,	   A.,	   Nguyen,	   T.	   &	   Alzari,	   P.	   M.	   (2003).	   The	   high	  resolution	   structures	   of	   free	   and	   inhibitor-­‐bound	   Trypanosoma	   rangeli	  sialidase	   and	   its	   comparison	   with	   T.	   cruzi	   trans-­‐sialidase.	   Journal	  
Molecular	  Biology,	  325,	  773-­‐784.	  	  Amaya,	  M.	  F.,	  Watts,	  A.	  G.,	  Damager,	   I.,	  Wehenkel,	  A.,	  Nguyen,	  T.,	  Buschiazzo,	  A.,	  Paris,	   G.,	   Frasch,	   A.	   C.,	   Withers,	   S.	   G.	   &	   Alzari,	   P.	   M.	   (2004).	   Structural	  insights	   into	   the	   catalytic	   mechanism	   of	   Trypanosoma	   cruzi	   trans-­‐sialidase.	  Structure,	  12,	  775-­‐784.	  	  Angata,	  T.	  &	  Varki,	  A.	   (2002).	  Chemical	  diversity	   in	   the	   sialic	   acids	   and	   related	  alpha-­‐keto	  acids:	  an	  evolutionary	  perspective.	  Chemical	  Review,	  102,	  439-­‐69.	  	  Arioka,	   S.,	   Sakagami,	  M.,	  Uematsu,	  R.,	  Yamaguchi,	  H.,	  Togame,	  H.,	  Takemoto,	  H.,	  Hinou,	   H.	   &	   Nishimura,	   S.	   (2010).	   Potent	   inhibitor	   scaffold	   against	  
Trypanosoma	  cruzi	   trans-­‐sialidase.	  Bioorganic	  &	  Medicinal	  Chemistry,	  18,	  1633-­‐1640.	  	  Bahadur,	   R.	   P.,	   Chakrabarti,	   P.,	   Rodier,	   F.	   &	   Janin,	   J.	   (2004).	   A	   dissection	   of	  specific	   and	   non-­‐specific	   protein-­‐protein	   interfaces.	   Journal	   Molecular	  
Biology.,	  336	  (4),	  943-­‐955.	  	  Bailey,	   S.	   1994.	   The	   Ccp4	   Suite	   -­‐	   Programs	   for	   Protein	   Crystallography.	   Acta	  
Crystallographica	  Section	  D-­‐Biological	  Crystallography,	  50,	  760-­‐763.	  	  
	   228	  
Barry,	  G.	  T.	  (1958).	  Colominic	  acid,	  a	  polymer	  of	  N-­‐acetylneuraminic	  acid.	  Journal	  
of	  Experimental	  Medicine.,	  107	  (4),	  507-­‐521	  	  Bhattacharjee,	  A.	  K.,	   Jennings,	  H.	  J.,	  Kenny,	  C.	  P.,	  Martin,	  A.	  &	  Smith,	  I.	  C.	  (1975).	  Structural	   determination	   of	   the	   sialic	   acid	   polysaccharide	   antigens	   of	  Neisseria	   meningitidis	   serogroups	   B	   and	   C	   with	   carbon	   13	   nuclear	  magnetic	  resonance.	  Journal	  of	  Biological	  Chemistry,	  250,	  1926-­‐1932.	  	  Blix,	  G.,	  Lindberg,	  E.,	  Odin,	  L.	  &	  Werner,	  I.	  (1955).	  Sialic	  Acids.	  Nature,	  175,	  340-­‐341	  	  Bonten,	  E.	  J.,	  Arts,	  W.	  F.,	  Beck,	  M.,	  Covanis,	  A.,	  Donati,	  M.	  A.,	  Parini,	  R.,	  Zammarchi,	  E.	   &	   D'Azzo,	   A.	   (2000).	   Novel	   mutations	   in	   lysosomal	   neuraminidase	  identify	   functional	   domains	   and	  determine	   clinical	   severity	   in	   sialidosis.	  
Humuman	  Molecular	  Genetics,	  9,	  2715-­‐25.	  	  Boraston,	  A.	  B.,	   Ficko-­‐Blean,	  E.	  &	  Healeyt,	  M.	   (2007).	   Carbohydrate	   recognition	  by	  a	  large	  sialidase	  toxin	  from	  Clostridium	  perfringenis.	  Biochemistry,	  46,	  11352-­‐11360.	  	  Bortolussi,	   R.,	   Ferrieri	   P.,	   Bjorksten,	   B.	   &	   Quie,	   P.	   G.	   (1979).	   Capsular	   K1	  polysaccharide	   of	  Escherichia	   coli:	   relationship	   to	   virulence	   in	   newborn	  rats	  and	  resistance	  to	  phagocytosis.	  Infection	  and	  Immunity,	  25,	  293-­‐298.	  	  Brear,	   P.,	   Telford,	   T.,	   Taylor,	   G.	   L.	   &	   Westwood,	   N.	   J.	   (2012).	   Synthesis	   and	  structural	   charachterisation	   of	   selective	   Non-­‐carbohydrate-­‐based	  inhibitors	  of	  bacterial	  sialidases.	  ChemBioChem,	  13,	  2374-­‐2382.	  	  Brumshtein,	  B.,	  Aguilar-­‐Moncayo,	  Garcia-­‐Moreno,	  M.	  I.,	  Mellet,	  C.	  O.,	  Fernandez,	  J.	  M.	  G.,	  Silman,	  I.,	  Shaaltiel,	  Y.,	  Aviezer,	  D.,	  Sussman,	  J.	  L.	  &	  Futerman,	  A.	  H.	  (2009).	   6-­‐amino-­‐6-­‐deoxy-­‐5,6-­‐di-­‐N-­‐(N'-­‐octyliminomethylidene)	  nojirimycin:	   Synthesis,	   biological	   evaluatio,	   and	   crystal	   structure	   in	  complex	  with	  acid	  β-­‐glucosidase.	  ChemBioChem,	  10	  (9),	  1480-­‐1485.	  	  Buchini,	  S.,	  Buschiazzo,	  A.	  &	  Withers,	  S.	  G.	   (2008).	  A	  new	  generation	  of	  specific	  
Trypanosoma	   cruzi	   trans-­‐sialidase	   inhibitors.	   Angewandte	   Chemie,	   120	  (14),	  2740-­‐2743.	  	  Burmeister,	  W.	   P.,	   Henrissat,	   B.,	   Bosso,	   C.,	   Cusack,	   S.	   &	   Ruigrok,	   R.	  W.	   (1993).	  Influenza	   B	   virus	   neuraminidase	   can	   synthesize	   its	   own	   inhibitor.	  
Structure,	  1,	  19-­‐26.	  	  Buschiazzo,	   A.	   &	   Alzari,	   P.	   M.	   (2008).	   Structural	   insights	   into	   sialic	   acid	  enzymology.	  Current	  Opinion	  in	  Chemical	  Biology,	  12,	  565-­‐572.	  	  Buschiazzo,	  A.,	  Tavares,	  G.	  A.,	  Campetella,	  O.,	  Spinelli,	  S.,	  Cremona,	  M.	  L.,	  Paris,	  G.,	  Amaya,	  M.	   F.,	   Frasch,	   A.	   C.	   C.	   &	   Alzari,	   P.	   M.	   (2002).	   Structural	   basis	   of	  sialyltransferase	  activity	  in	  trypanosomal	  sialidases.	  Embo	  J.,	  19,	  16-­‐24.	  	  
	   229	  
Carvalho,	  S.	  T.,	  Sola-­‐Penna,	  M.,	  Oliveira,	  I.	  A.,	  Pita,	  S.,	  Goncalves,	  A.	  S.,	  Neves,	  B.	  C.,	  Sousa,	   F.	   R.,	   Freire-­‐de-­‐Lima,	   L.,	   Kurogochi,	   M.,	   Hinou,	   H.,	   Nishimura,	   S.,	  Mendonca-­‐Previato,	   L.,	   Previato,	   J.	   O.	   &	   Todeschini,	   A.	   R.	   (2010).	   A	   new	  class	   of	   mechanism-­‐based	   inhibitors	   for	   Trypanosoma	   cruzi	   trans-­‐sialidase	   and	   their	   influence	   on	   parasite	   virulence.	  Glycobiology,	   20	   (8),	  1034-­‐1045.	  	  Castro,	  A.	  J.,	  de	  Mecca,	  M.	  M.	  &	  Bartel,	  L.	  C.	  (2006).	  Toxic	  side	  effects	  of	  drugs	  used	  to	   treat	   Chagas	   disease	   (American	   Trypanosomiasis).	   Human	  
Experimental	  Toxicology,	  26	  (8),	  471-­‐479	  	  Carbohydrate	  Active	  EnZYmes	   (2013).	  Glycoside	  Hydrolase	  Family	  33	   [Online].	  Available	  at	  http://www.cazy.org/fam/GH33.html	  	  Carbohydrate	  Active	  EnZYmes	   (2013).	  Glycoside	  Hydrolase	  Family	  34	   [Online].	  Available	  at	  http://www.cazy.org/fam/GH34.html	  	  Carbohydrate	  Active	  EnZYmes	   (2013).	  Glycoside	  Hydrolase	  Family	  83	   [Online].	  Available	  at	  http://www.cazy.org/fam/GH83.html	  	  Centers	   for	   Disease	   control	   and	   and	   prevention	   (2013)	   Parasites	   -­‐	   American	  Trypanosomiasis	   [Online].	   Available	   at	  http://www.cdc.gov/parasites/chagas/treatment.html	  	  Chang,	  D.,	  Smalley,	  D.	  J.,	  Tucker,	  D.	  L.,	  Leatham,	  M.	  P.,	  Norris	  W.	  E.,	  Stevenson,	  S.	  J.,	  Anderson,	  A.	  B.,	  Grissom,	  J.	  E.,	  Laux,	  D.	  C.,	  Cohen,	  P.	  S.	  &	  Conway,	  T.	  (2004).	  Carbon	  nutrition	  of	  Escherichia	  coli	  in	  the	  mouse	  intestine.	  Proceedings	  of	  
the	  National	  Academy	  of	  life	  Sciences,	  101,	  7427-­‐7432.	  	  Chavas,	  L.	  M.,	  Tringali,	  C.,	  Fusi,	  P.,	  Venerando,	  B.,	  Tettamanti,	  G.,	  Kato,	  R.,	  Monti,	  E.	  &	  Wakatsuki,	  S.	  (2005).	  Crystal	  structure	  of	  the	  human	  cytosolic	  sialidase	  Neu2.	  Evidence	  for	  the	  dynamic	  nature	  of	  substrate	  recognition.	  Journal	  of	  
Biological	  Chemistry,	  280,	  469-­‐75.	  	  Chien,	   C.	   H.,	   Shann,	   Y.	   J.	   &	   Sheu,	   S.	   Y.	   (1996).	   Site-­‐directed	   mutations	   of	   the	  catalytic	  and	  conserved	  amino	  acids	  of	  the	  neuraminidase	  gene,	  nanH,	  of	  Clostridium	   perfringens	   ATCC	   10543.	   Enzyme	  Microbial	   Technology,	   19,	  267-­‐76.	  	  Chou,	  H.	  H.,	  Takematsu,	  H.,	  Diaz,	  S.,	  Iber,	  J.,	  Nickerson,	  E.,	  Wright,	  K.	  L.,	  Muchmore,	  E.	  A.,	  Nelson,	  D.	  L.,	  Warren,	  S.	  T.	  &	  Varki,	  A.	  (1998).	  A	  mutation	  in	  human	  CMP-­‐sialic	   acid	   hydroxylase	   occurred	   after	   the	   Homo-­‐Pan	   divergence.	  
Proceedings	  of	  the	  National	  Academy	  of	  life	  Sciences,	  95,	  11751-­‐11756.	  	  Chong,	  A.	  K.,	  Pegg,	  M.	  S.,	  Taylor,	  N.	  R.	  &	  Von	   Itzstein,	  M.	   (1992).	  Evidence	   for	  a	  sialosyl	   cation	   transition-­‐state	   complex	   in	   the	   reaction	  of	   sialidase	   from	  influenza	  virus.	  European	  Journal	  of	  Biochemistry,	  207,	  335-­‐43.	  	  
	   230	  
Chuenkova,	   M.	   &	   Pereira,	   M.	   E.	   A.	   (1995).	   Trypanosoma	   cruzi	   trans-­‐sialidase:	  enhances	   of	   virulence	   in	   a	   murine	  model	   of	   Chagas'	   disease.	   Journal	   of	  
Experimental	  Medicine,	  181,	  1693-­‐1703.	  	  Colman,	  P.	  M.,	  Varghese,	  J.	  N.	  &	  Laver,	  W.	  G.	  (1983).	  Structure	  of	  the	  catalytic	  and	  antigenic	  sites	  in	  influenza	  virus	  neuraminidase.	  Nature,	  303,	  41-­‐44.	  	  Connaris,	  H.,	  Crocker,	  P.	  R.	  &	  Taylor,	  G.	  L.	  (2009).	  Enhancing	  the	  receptor	  affinity	  of	   the	   sialic	   acid-­‐binding	   domain	   of	   Vibrio	   cholerae	   sialidase	   through	  multivalency.	  Journal	  Biological	  Chemistry,	  284,	  7339-­‐7351.	  	  Copley,	   R.	   R.,	   Russel,	   R.	   B.	   &	   Ponting,	   C.	   P.	   (2001).	   Sialidase-­‐like	   Asp-­‐boxes:	  sequence-­‐similar	  structures	  within	  different	  protein	  folds.	  Protein	  Science,	  10,	  285-­‐92.	  	  Crennell,	  S.	  J.,	  Garman,	  E.	  F.,	  Laver,	  W.	  G.,	  Vimr,	  E.	  R.	  &	  Taylor,	  G.	  L.	  (1994).	  Crystal	  structure	   of	   Vibrio	   cholerae	   neuraminidase	   reveals	   dual	   lectin-­‐like	  domains	  in	  addition	  to	  the	  catalytic	  domain.	  Stucture,	  2,	  535-­‐544.	  	  Crennell,	  S.	  J.,	  Garman,	  E.	  F.,	  Laver,	  W.	  G.,	  Vimr,	  E.	  R.	  &	  Taylor,	  G.	  L.	  (1993).	  Crystal	  structure	   of	   a	   bacterial	   sialidase	   (from	   Salmonella	   typhimurium	   LT2)	  shows	  the	  same	  fold	  as	  an	  influenza	  virus	  neuraminidase.	  Proceedings	  of	  
the	  National	  Academy	  of	  life	  Sciences,	  90,	  9852-­‐6.	  	  Dalvit,	   C.,	   Fogliatto,	   G.,	   Stewart,	   A.,	   Veronesi,	   M.	   &	   Stockman,	   B.	   (2001).	  WaterLOGSY	   as	   a	  method	   for	   primary	  NMR	   screening:	   Practical	   aspects	  and	  range	  of	  applicability.	  Journal	  Biomolecular	  NMR.,	  21,	  349-­‐359.	  	  Davies,	   G.	   &	   Henrissat,	   B.	   (1995).	   Structures	   and	   mechanisms	   of	   glycosyl	  hydrolases.	  Structure,	  3,	  853-­‐859.	  	  Denning,	  D.	  W.	  (1998).	  Invasive	  aspergillosis.	  Clinical	  Infectious	  Diseases,	  26,	  781-­‐803.	  	  Denning,	   D.	   W.,	   Marinus,	   A.,	   Cohen,	   J.,	   Spence,	   D.,	   Herbrecht,	   R.,	   Pagano,	   L.,	  Kibbler,	   C.,	   Kcrmery,	   V.,	   Offner,	   F.,	   Cordonnier,	   C.,	   Jehn,	   U.,	   Ellis,	   M.,	  Collette,	  L.,	  Sylvester,	  R.	  &	  GR,	  E.	   I.	  F.	   I.	  C.	  (1998).	  An	  EORTC	  multicentre	  prospective	   survey	   of	   invasive	   aspergillosis	   in	   haematological	   patients:	  Diagnosis	  and	  therapeutic	  outcome.	  Journal	  of	  Infection,	  37,	  173-­‐180.	  	  Edwards,	  M.	   S.,	   Kasper,	  D.	   L.,	   Jennings,	  H.	   J.,	   Baker,	   C.	   J.	  &	  Nicholson-­‐Weller,	   A.	  (1982).	   Capsular	   sialic	   acid	   prevents	   activation	   of	   the	   alternative	  complement	   pathway	   by	   type	   III,	   group	   B	   streptococci.	   Journal	   of	  
Immunology,	  128,	  1278-­‐1283.	  	  Egan,	   W.,	   Liu,	   T.	   Y.,	   Dorow,	   D.,	   Cohen,	   J.	   S.,	   Robbins,	   J.	   D.,	   Gotschlich,	   E.	   C.	   &	  Robbins,	   J.	  B.	  (1977).	  Structural	  studies	  on	  the	  sialic	  acid	  polysaccharide	  antigen	  of	  Escherichia	  coli	  strain	  Bos-­‐12.	  Biochemistry	  16,	  3687-­‐3692.	  	  
	   231	  
Emanuelsson,	   O.,	   Brunak,	   S.,	   von	   Heijne,	   G.,	   &	   Nielsen,	   H.	   (2007).	   Locating	  proteins	   in	   the	   cell	   using	   TargetP,	   SignalP	   and	   related	   tools.	   Nature	  
Protocols,	  2,	  953-­‐971.	  	  Emsley,	   P.	   &	   Cowtan,	   K.	   (2004).	   Coot:	   model-­‐building	   tools	   for	   molecular	  graphics.	  Acta	  Crystallographica	  Section	  D-­‐Biological	  Crystallography,	   60,	  2126-­‐2132.	  	  Etzioni,	   A.,	   Frydman,	   M.,	   Pollack,	   S.,	   Avidor,	   I.,	   Phillips,	   M.	   L.,	   Paulson,	   J.	   C.	   &	  Gershoni-­‐Baruch,	  R.	  (1992).	  Recurrent	  sever	  infections	  caused	  by	  a	  novel	  leukocyte	   adhesion	   deficiency.	   New	   England	   Journal	   of	   Medicine,	   327,	  1789-­‐1792.	  	  	  Farrari,	  J.,	  Harris,	  R.	  &	  Warner,	  T.	  G.	  (1994).	  Cloning	  and	  expression	  of	  a	  soluble	  sialidase	   from	   Chinese	   hamster	   ovary	   cells:	   sequence	   alignment	  similarities	  to	  bacterial	  sialidases.	  Glycobiology,	  4,	  367-­‐73.	  	  Frasch,	   A.	   C.	   C.	   (2000).	   Functional	   diversity	   in	   the	   trans-­‐sialidase	   and	  muchin	  families	  in	  Trypanosoma	  cruzi.	  Parisitology	  Today,	  16	  (7),	  282-­‐286.	  	  	  Gallien,	  S.,	  Fournier,	  S.,	  Porcher,	  R.,	  Bottero,	  J.,	  Ribaud,	  P.,	  Sulahian,	  A.,	  Socie,	  G.	  &	  Molina,	   J.	   M.	   (2008).	   Therapeutic	   outcome	   and	   prognostic	   factors	   of	  invasive	  aspergillosis	  in	  an	  infectious	  disease	  department:	  a	  review	  of	  34	  cases.	  Infection,	  36,	  533-­‐8.	  	  Gaskell,	   A.,	   Crennell,	   S.	   &	   Taylor,	   G.	   (1995).	   The	   three	   domains	   of	   a	   bacterial	  sialidase:	   a	   beta-­‐propeller,	   an	   immunoglobulin	  module	   and	   a	   galactose-­‐binding	  jelly-­‐roll.	  Structure,	  3,	  1197-­‐205.	  	  Gloster,	  T.	  M.,	  Williams,	  S.	   J.,	  Roberts,	  S.,	  Tarling,	  C.	  A.,	  Wicki,	   J.,	  Withers,	  S.	  G.	  &	  Davies,	  G.	  J.	  (2004).	  Atomic	  resolution	  analysis	  of	  the	  binding	  of	  xylobiose-­‐derived	  deoxynojirimycin	  and	  isofagomine	  to	  xylanase	  Xyn10A.	  Chemistry	  
Communications,	  1794-­‐1795.	  	  Gottschalk,	  A.	  &	  Lind,	  P.	  E.	  (1949).	  Product	  of	  interaction	  between	  influenza	  virus	  enzyme	  and	  ovomucin.	  Nature,	  164,	  232-­‐233.	  	  Gut,	   H.,	   King,	   S.	   J.	   &	  Walsh,	   M.	   A.	   (2008).	   Structural	   and	   functional	   studies	   of	  Streptococcus	   pneumoniae	   neuraminidase	   B:	   An	   intramolecular	   trans-­‐sialidase.	  FEBS	  Letters,	  582,	  3348-­‐52.	  	  Hancock,	   S.	   M.	   &	   Withers,	   S.	   G.	   (2007).	   Glycosidases:	   Functions,	   families	   and	  folds.	  Encyclopiedia	  of	  Life	  Sciences.	  	  	  Hartnell,	  A.,	  Steel,	   J.,	  Turley,	  H.,	   Jones,	  M.,	   Jackson,	  D.	  G.	  &	  Crocker,	  P.	  R.	  (2001).	  Characterization	   of	   human	   sialoadhesin,	   a	   sialic	   acid	   binding	   receptor	  expressed	  by	  resident	  and	  inflammatory	  macrophage	  populations.	  Blood,	  97,	  288-­‐296.	  	  
	   232	  
Haselhorst,	  T.,	  Stummeyer,	  K.,	  Muhlenhoff,	  M.,	  Scharper,	  W.,	  Gerardy-­‐Schahn,	  R.	  &	  Von	  Itzstein,	  M.	  (2006).	  Endosialidase	  NF	  appears	  to	  bind	  polySia	  DP5	  in	  a	  helical	  conformation.	  Chembiochem,	  7,	  1875-­‐7.	  	  Henikoff,	   S.	   &	   Henikoff,	   J.	   G.	   (1992).	   Amino-­‐Acid	   Substitution	   Matrices	   from	  Protein	   Blocks.	   Proceedings	   of	   the	   National	   Academy	   of	   Sciences	   of	   the	  
United	  States	  of	  America,	  89,	  10915-­‐10919.	  	  Hirst,	   G.	   K.	   (1941).	   The	   agglutination	   of	   red	   cells	   by	   allantoic	   fluid	   of	   chick	  embryos	  infected	  with	  influenza	  virus.	  Science,	  94,	  22-­‐23.	  	  Howard,	   S.	   J.,	   Pasqualotto,	   A.	   C.	   &	   Denning,	   D.	   W.	   (2010).	   Azole	   resistance	   in	  allergic	   bronchopulmonary	   aspergillosis	   and	   Aspergillus	   bronchitis.	  
Clinical	  Microbiology	  and	  Infection,	  16,	  683-­‐688.	  	  Howe,	  C.,	  Rose,	  H.	  M.	  &	  Schneider,	  L.	  (1957).	  Enzymic	  action	  of	  influenza	  virus	  on	  human	  erythrocyte	  stroma	  components.	  Experimental	  Biological	  Medicine,	  96,	  88-­‐94.	  	  Inoue,	   S.,	   Kitajima,	   K.	   &	   Inoue,	   Y.	   (1996).	   Identification	   of	   2-­‐Keto-­‐3-­‐deoxy0D-­‐glycero-­‐D-­‐galactonononic	   acid	   (KDN,	  Deaminoneuraminic	   acid)	   residues	  in	   mammalian	   tissues	   and	   humans	   lung	   carcinoma	   cell.	   Journal	   of	  
Biological	  Chemistry,	  271,	  24341-­‐24344.	  	  Inoue,	  S.,	  Lin,	  S.,	  Chang,	  T.,	  Wu,	  S.,	  Yao,	  C.,	  Chu,	  T.,	  Troy	  II,	  F.	  A.	  &	  Inoue,	  Y.	  (1998).	  Identification	   of	   deaminated	   sialic	   acid	   (2-­‐Keto-­‐3-­‐deoxy0D-­‐glycero-­‐D-­‐galactonononic	  acid)	  in	  human	  red	  blood	  cells	  and	  its	  elevated	  expression	  in	  fetal	  chord	  red	  blood	  cells	  and	  ovarian	  cancer	  cells.	  Journal	  of	  Biological	  
Chemistry,	  273,	  27199-­‐27204.	  	  Itzstein,	   	   M.	   (2007).	   The	  war	   against	   influenza:	   discovery	   and	   development	   of	  sialidase	  inhibitors.	  Natures	  Reviews	  Drug	  Discovery,	  6,	  967-­‐974.	  	  	  Jackson,	  Y.,	  Alirol,	  E.,	  Getaz,	  L.,	  Wolff,	  H.,	  Combescure,	  C.	  &	  Chappuis,	  F.	   (2010).	  Tolerance	   and	   safety	   of	   nifurtimox	   in	   patients	   with	   chronic	   chagas	  disease.	  Clinical	  Infectious	  diseases,	  51	  (10),	  69-­‐75.	  	  Jin,	   L.,	   McLean,	   P.	   A.,	   Neel,	   B.,	   G.	   &	   Wortis	   H.	   H.	   (2002).	   Sialic	   acid	   binding	  domains	   of	   CD22	   are	   required	   of	   B	   cell	   receptor	   signaling.	   Journal	   of	  
Experimental	  medicine,	  195,	  1199-­‐1205.	  	  Jones	  G.,	  Willett	  P.,	  Glen	  R.	  C.,	  Leach	  A.	  R.	  &	  Taylor	  R.	  (1997).	  Development	  and	  validation	  of	  a	  genetic	  algorithm	  for	  flexible	  docking.	  Journal	  of	  Molecular	  
Biology,	  267	  (3),	  727-­‐748.	  	  Kahler,	  C.	  M.,	  Martin,	  L.	  E.,	  Shih,	  G.	  C.,	  Rahman,	  M.	  M.,	  Carlson,	  R.	  W.	  &	  Stephens	  D.	  S.	   (1998).	   The	   (α2è8)-­‐Linked	   polysialic	   acid	   capsule	   and	  lipooligosaccharide	  structure	  both	  contribute	  to	  the	  ability	  of	  serogroup	  B	  
	   233	  
Neisseria	  meningitidis	   to	  resist	   the	  bactericidal	  activity	  of	  normal	  human	  serum.	  Infection	  and	  Immunity,	  66,	  5939-­‐5947.	  	  Kiefel,	  M.	  J.	  &	  Von	  Itzstein,	  M.	  (2002).	  Recent	  advances	  in	  the	  synthesis	  of	  sialic	  acid	   derivatives	   and	   sialylmimetics	   as	   biological	   probes.	   Chemical	  
Reviews,	  102,	  471-­‐90.	  	  Kim,	  J.	  H.,	  Ryu,	  H.	  W.,	  Shim,	  J.	  H.,	  Park,	  K.	  H.	  &	  Withers,	  S.	  G.	  (2009).	  development	  of	   new	   and	   selective	   Trypanosoma	   cruzi	   trans-­‐sialidase	   inhibitors	   from	  sulfonamide	   chalcones	   and	   their	   derivatives.	   ChemBioChem,	   10	   (15),	  2471-­‐2479.	  	  Klein,	  N.,	  Hurwitz,	  I.	  &	  Durvasula,	  R.	  (2013).	  Chagas	  disease:	  Global	  epidemiology	  and	  evolving	  methods	   for	   control.	  Dynamic	  models	  of	  Infectious	  Diseases,	  139-­‐167.	  	  Krissinel,	  E.	  &	  Henrick,	  K.	  (2007).	   Interface	  of	  macromolecular	  assemblies	  from	  crystalline	  state.	  Journal	  of	  Molecular	  Biology,	  372,	  774-­‐797.	  	  Lammerts	  van	  Bueren,	  A.,	  Popat,	  S.	  D.,	  Lin,	  C.	  &	  Davies,	  G.	  J.	  (2010).	  Structural	  and	  theromdynamic	  analyses	  of	  α-­‐L-­‐Fucosidase	   inhibitors.	  ChemBioChem,	   11	  (14),	  1971-­‐1974.	  	  Landmesser,	  L.,	  Dahm,	  L.,	  Tang,	   J.	  &	  Rutishauser,	  U.	   (1990).	  Polysialic	   acid	  as	  a	  regulator	   of	   intramuscular	   nerve	   branching	   during	   embryonic	  development.	  Neuron,	  4,	  655-­‐667.	  	  Leslie,	   A.	   G.	   (2006).	   The	   integration	   of	   macromolecular	   diffraction	   data.	   Acta	  
Crystallographica	  Section	  D-­‐Biological	  Crystallography,	  62,	  48-­‐57.	  	  Lopez,	   O.,	   Qing,	   F.,	   Pedersen,	   C.	   M.	   &	   Bols,	   M.	   (2013).	   Enzyme	   inhibition	   by	  iminosugars:	   Analysis	   and	   insite	   into	   the	   glycosidase-­‐iminosugar	  dependency	  of	  pH.	  Bioorganic	  Medicinal	  Chemistry	  In	  press	  	  Lovell,	  S.	  C.,	  Davis,	  I.	  W.,	  Adrendall,	  W.	  B.,	  DE	  Bakker,	  P.	  I.	  W.,	  Word,	  J.	  M.,	  Prisant,	  M.	  G.,	  Richardson,	  J.	  S.	  &	  Richardson,	  D.	  C.	  (2003).	  Structure	  validation	  by	  C	   alpha	   geometry:	   phi,psi	   and	   C	   beta	   deviation.	   Proteins-­‐Structure	  
Function	  and	  Genetics,	  50,	  437-­‐450.	  	  Luo,	  Y.,	  Li,	  S.	  C.,	  Chou,	  M.	  Y.,	  Li,	  Y.	  T.	  &	  Luo,	  M.	  (1998).	  The	  crystal	  structure	  of	  an	  intramolecular	   trans-­‐sialidase	   with	   a	   NeuAc	   alpha2-­‐-­‐>3Gal	   specificity.	  
Structure,	  6,	  521-­‐30.	  	  Luo,	   Y.,	   Li,	   S.	   C.,	   Li,	   Y.	   T.	   &	   Luo,	   M.	   (1999).	   The	   1.8	   A	   structures	   of	   leech	  intramolecular	   trans-­‐sialidase	   complexes:	   evidence	   of	   its	   enzymatic	  mechanism.	  Journal	  of	  Molecular	  Biology,	  285,	  323-­‐32.	  	  Manzi,	  A.	  E.,	  Higa,	  H.	  H.,	  Diaz,	  S.	  &	  Varki,	  A.	  (1994).	  Intramolecular	  self-­‐cleavage	  of	  polysialic	  acid.	  Journal	  of	  Biological	  Chemistry,	  269,	  23617-­‐24.	  
	   234	  
	  Marr,	  K.	  A.,	  Boeckh,	  M.,	  Carter,	  R.	  A.,	  Kim,	  H.	  W.	  &	  Corey,	  L.	  (2004).	  Combination	  antifungal	   therapy	   for	   invasive	   aspergillosis.	   Clinical	   Infectious	  Diseases,	  39,	  797-­‐802.	  	  Marr,	  K.	  A.,	  Carter,	  R.	  A.,	  Crippa,	  F.,	  Wald,	  A.	  &	  Corey,	  L.	  (2002).	  Epidemiology	  and	  outcome	   of	   mould	   infections	   in	   hematopoietic	   stem	   cell	   transplant	  recipients.	  Clinical	  Infectious	  Diseases,	  34,	  909-­‐917.	  	  McGowen,	   M.	   M.,	   Vionnet,	   J.	   &	   Vann,	   W.	   F.	   (2001).	   Wlongation	   of	   alternating	  α2,8/2,9	  polysialic	  acid	  by	  the	  Escherichia	  coli	  K92	  polysialyltransferase.	  
Glycobiology,	  11	  (8),	  613-­‐620.	  	  Michel,	   J.,	   Tirado-­‐Rives,	   J.	   &	   Jorgensen,	   W.	   L.	   (2009).	   Energetics	   of	   displacing	  water	   molecules	   from	   protein	   binding	   sites:	   consequences	   for	   ligand	  optimization.	   Journal	  of	  the	  American	  Chemical	  Society,	   131	   (42),	  15403-­‐15411.	  	  Miller,	   C.	   A.,	   Wang,	   P.	   &	   Flashner,	   M.	   (1978).	   Mechanism	   of	   Arthrobacter	  sialophilus	  neuraminidase:	  the	  binding	  of	  substrates	  and	  transition-­‐state	  analogs.	  Biochemical	  Biophysical	  Reseach	  Communications,	  83,	  1479-­‐87.	  	  Morley,	  T.	  J.,	  Willis,	  L.	  M.,	  Whitfield,	  C.,	  Wakarchuk,	  W.	  W.	  &	  Withers,	  S.	  G.	  (2009).	  A	   new	   sialidase	   mechanism:	   bacteriophage	   K1F	   endo-­‐sialidase	   is	   an	  inverting	  glycosidase.	  Journal	  of	  Biological	  Chemistry,	  284,	  17404-­‐10.	  	  Moustafa,	   I.,	   Connaris,	  H.,	   Taylor,	  M.,	   Zaitsev,	   V.,	   Kiefel,	  M.	   J.,	  Wilson,	   J.	   C.,	   Von-­‐Itzstein,	   M.	   &	   Taylor	   (2004).	   Sialic	   acid	   recognition	   by	   Vibrio	   cholerae	  neuraminidase.	  Journal	  of	  Biological	  Chemistry,	  279,	  40819.	  	  	  Mullins,	   J.,	   Harvey,	   R.	   &	   Seaton,	   A.	   (1976).	   Sources	   and	   incidence	   of	   airborne	  
Aspergillus	  fumigatus	  (Fres).	  Clinical	  and	  Experimental	  Allergy,	  6	  (3),	  209-­‐217.	  	  Murray,	  C.	  W.	  &	  Rees,	  D.	  C.	   (2009).	  The	   rise	  of	   fragment-­‐based	  drug	  discovery.	  
Nature	  Chemistry,	  1,	  187-­‐192.	  	  Murshudov,	   G.	   N.,	   Vagin,	   A.	   A.	   &	   Dodson,	   E.	   J.	   1997.	   Refinement	   of	  macromolecular	   structures	   by	   the	   maximum-­‐likelihood	   method.	   Acta	  
Crystallographica	  Section	  D-­‐Biological	  Crystallography,	  53,	  240-­‐255.	  	  Neres,	   J.,	   Bonnet,	   P.,	   Edwards,	   P.	   N.,	   Kotian,	   P.	   L.,	   Buschiazzo,	   A.,	   Alzari,	   P.	   M.,	  Bryce,	  R.	  A.	  &	  Douglas,	  K.	  T.	  (2007).	  Benzoic	  acid	  and	  pyridine	  derivatives	  as	  inhibitors	  of	  Trypanosoma	  cruzi	  trans-­‐sialidase.	  Bioorganic	  &	  Medicinal	  
Chemistry,	  15	  (5),	  2106-­‐2119.	  	  Neres,	   J.,	   Brewer,	   M.	   L.	   Ratier,	   L.,	   Botti,	   H.,	   Buschiazzo,	   A.,	   Edwards,	   P.	   N.,	  Mortenson,	  P.	  N.,	  Charlton,	  M.	  H.,	  Alzari,	  P.	  M.,	  Frasch,	  A.	  C.,	  Bryce,	  R.	  A.	  &	  Douglas,	  K.	  T.	  (2009).	  Discovery	  of	  novel	  inhibitors	  of	  Trypanosoma	  cruzi	  
	   235	  
trans-­‐sialidase	  from	  in	  silico	  screening.	  Bioorganic	  &	  Medicinal	  Chemistry	  
Letters,	  19	  (3),	  589-­‐596.	  	  	  Newstead,	  S.	  L.,	  Potter,	  J.	  A.,	  Wilson,	  J.	  C.,	  Xu,	  G.,	  Chien,	  C.	  H.,	  Watts,	  A.	  G.,	  Withers,	  S.	  G.	  &	  Taylor,	  G.	  L.	  (2008).	  The	  structure	  of	  Clostridium	  perfringens	  NanI	  sialidase	   and	   its	   catalytic	   intermediates.	   Journal	   of	   Biological	   Chemistry,	  283,	  9080-­‐8.	  	  Newstead,	   S.	   L.,	   Watson,	   J.	   N.,	   Bennet,	   A.	   J.	   &	   Taylor,	   G.	   (2005).	   Galactose	  recognition	  by	   the	  carbohydrate-­‐binding	  module	  of	  a	  bacterial	   sialidase.	  
Acta	   Crystallographica	   Section	   D-­‐Biological	   Crystallography,	   61,	   1483-­‐1491.	  	  Nishimura	   Y.,	   Shitara	   E.,	   Adachi	   H.,	   Toyoshima	   M.,	   Nakajima	   M.,	   Okami	   Y.	   &	  Takeuch	   T.	   (2000).	   Flexible	   synthesis	   and	   biological	   activity	   of	   Uronic	  acid-­‐type	   gem-­‐diamene	   1N-­‐iminosugars:	   a	   new	   family	   of	   glycosidase	  inhibitors.	  Journal	  of	  Organic	  Chemistry,	  65,	  2-­‐11.	  	  Nishimura,	  Y.	  (2009).	  Gem-­‐diamine	  -­‐1-­‐N-­‐iminosugars	  as	  versatile	  glycomimetics:	  synthesis,	   biological	   activity	   and	   therapeutic	   potential.	   Journal	   of	  
Antibiotics,	  62,	  407-­‐423.	  	  Nishino,	  S.,	  Kuroyanagi,	  H.,	  Terada,	  T.,	  Inoue,	  S.,	  Inoue,	  Y.,	  Troy,	  F.	  A.	  &	  Kitajima,	  K.	  (1996).	   Induction,	   localization,	   and	   purification	   of	   a	   novel	   sialidase,	  deaminoneuraminidase	   (KDNase),	   from	   Sphingobacterium	   multivorum.	  
Journal	  of	  Biological	  Chemistry,	  271,	  2909-­‐13.	  	  Oppezzo,	   P.,	   Obal,	   G.,	   Baraibar,	  M.	   A.,	   Pritsch,	   O.,	   Alzari,	   P.	  M.	   &	   Buschiazzo,	   A.	  (2011).	  Crystal	  structure	  of	  an	  enzymatically	  inactive	  trans-­‐sialidase-­‐like	  lectin	   from	   Trypanosoma	   cruzi:	   The	   carbohydrate	   binding	   mechanism	  involves	   residual	   sialidase	   activity.	   Biochimica	   et	   Biophysica	   Acta,	   1814	  (9),	  1154-­‐1161.	  	  Otwinowski,	  Z.	  &	  Minor,	  W.	  (1997).	  Processing	  of	  X-­‐ray	  diffraction	  data	  collected	  in	  oscillation	  mode.	  Methods	  in	  EnzymologyI,	  276	  (A),	  307-­‐326.	  	  Paris,	  G.,	  Ratier,	  L.,	  Amaya,	  M.	  F.,	  Nguyen,	  T.,	  Alzari,	  P.	  M.	  &	  Frasch,	  A.	  C.	  (2005).	  A	  sialidase	   mutant	   displaying	   trans-­‐sialidase	   activity.	   Journal	   of	  Molecular	  
Biology,	  345,	  923-­‐934.	  	  Pavlova,	  N.	  V.,	  Yuziuk,	   J.	  A.,	  Nakagawa,	  H.,	  Kiso,	  M.,	  Li,	  S.	  C.	  &	  Li,	  Y.	  T.	  (1999).	  2-­‐Keto-­‐3-­‐deoxy-­‐D-­‐glycero-­‐D-­‐galacto-­‐nononic	   acid	   (KDN)-­‐	   and	   N-­‐acetylneuraminic	   acid-­‐cleaving	   sialidase	   (KDN-­‐sialidase)	   and	   KDN-­‐cleaving	   hydrolase	   (KDNase)	   from	   the	   hepatopancreas	   of	   oyster,	  Crassostrea	  virginica.	  Journal	  of	  Biological	  Chemistry,	  274,	  31974-­‐31980.	  	  Pereira,	  M.	  E.	  A.,	  Zhang,	  K.,	  Gong,	  Y.,	  Herrera,	  E.	  M.	  and	  Ming,	  M.	  (1996).	  invasive	  phenotype	   of	   Trypanosoma	   cruzi	   restricted	   to	   a	   population	   expressing	  
trans-­‐Sialidase.	  Infection	  and	  Immunity.,	  64	  (9),	  3884-­‐3892.	  
	   236	  
	  Perez-­‐Molina,	   J.	   A.,	   Perez-­‐Ayala,	   A.,	   Moreno,	   S.,	   Fernandez-­‐Gonzalez,	   M.	   C.,	  Zamora,	   J.	  &	  Lopez-­‐Velez,	  R.	   (2009).	  Use	  of	   benzidazole	   to	   treat	   chronic	  Chagas	   disease:	   a	   systemic	   review	   with	   meta-­‐analysis.	   Journal	   of	  
Antimicrobial	  Chemotherapy,	  64	  (6),	  1139-­‐1147	  	  Prata,	  A.	   (2001).	  Clinical	   and	  epidemiological	   aspects	  of	  Chagas	  disease.	  Lancet	  
Infectious	  Diseases,	  1,	  92-­‐100.	  	  Qu,	  B.,	  Ziak,	  M.,	  Zuber,	  C.	  &	  Rothe,	  J.	  (1996).	  Poly(alpha	  2,8,-­‐deaminoneuraminic	  acid)	   is	   expressed	   in	   lung	   on	   a	   single	   150-­‐kDa	   glycoprotein	   and	   is	   an	  oncodevelopmental	   antigen.	   Proceedings	   of	   the	   National	   Academy	   of	  
Sciences	  of	  the	  United	  States	  of	  America,	  93,	  8995-­‐8998.	  	  Quistgaard,	  E.	  M.	  &	  Thirup,	  S.	  S.	  (2009).	  Sequence	  and	  structural	  analysis	  of	  the	  Asp-­‐box	  motif	  and	  Asp-­‐box	  beta-­‐propellers;	  a	  widespread	  propeller-­‐type	  characteristic	  of	  the	  Vps10	  domain	  family	  and	  several	  glycoside	  hydrolase	  families.	  BioMed	  Central	  Structural	  Biology,	  9,	  46.	  	  Rassi,	  A.,	  Rassi,	  A.	  &	  Marin-­‐Neto,	  J.	  A.	  (2010).	  Chagas	  disease.	  Lancet,	  9723	  (375),	  1388-­‐1402.	  	  Rees,	  D.	  C.,	  Congreve,	  M.,	  Murray,	  C.	  W.	  &	  Carr,	  R.	   (2004).	  Fragment-­‐based	   lead	  discovery.	  Nature	  Reviews,	  3,	  660-­‐672.	  	  	  Ribaud,	  P.,	   Chastang,	  C.,	   Latge,	   J.	   P.,	  Baffroy-­‐Lafitte,	   L.,	   Parquet,	  N.,	  Devergie,	  A.,	  Esperou,	   H.,	   Selimi,	   F.,	   Rocha,	   V.,	   Derouin,	   F.,	   Socie,	   G.	   &	   Gluckman,	   E.	  (1999).	   Survival	   and	   prognostic	   factors	   of	   invasive	   aspergillosis	   after	  allogeneic	   bone	  marrow	   transplantation.	   Clinical	   Infectious	  Diseases,	   28,	  322-­‐330.	  	  Roggentin,	  P.,	  Rothe,	  B.,	  Kaper,	  J.	  B.,	  Galen,	  J.,	  Lawrisuk,	  L.,	  Vimr,	  E.	  R.	  &	  Schauer,	  R.	   (1989).	   Conserved	   sequences	   in	   bacterial	   and	   viral	   sialidases.	  
Glycoconjugate	  Journal,	  6,	  349-­‐53.	  	  Roggentin,	   P.,	   Schauer,	   R.,	   Hoyer,	   L.	   L.	   &	   Vimr,	   E.	   R.	   (1993).	   The	   sialidase	  superfamily	   and	   its	   spread	   by	   horizontal	   gene	   transfer.	   Molecular	  
Microbiology,	  9,	  915-­‐21.	  	  Rothe,	  B.,	  Roggentin,	  P.	  &	  Schauer,	  R.	  (1991).	  The	  sialidase	  gene	  from	  Clostridium	  septicum:	   cloning,	   sequencing,	   expression	   in	   Escherichia	   coli	   and	  identification	   of	   conserved	   sequences	   in	   sialidases	   and	   other	   proteins.	  
Molecular	  Geneticis	  and	  Genomics,	  226,	  190-­‐7.	  	  Russell,	  R.	  B.	  (1998).	  Detection	  of	  protein	  three-­‐dimensional	  side-­‐chain	  patterns:	  new	  examples	  of	  convergent	  evolution.	  Journal	  of	  Molecular	  Biology,	  279,	  1211-­‐27.	  	  
	   237	  
Rutishauser,	   U.	   &	   Landmesser,	   L.	   (1996).	   Polysialic	   acid	   in	   the	   vertebrate	  nervous	  system:a	  promoter	  of	  plasticity	  in	  cell-­‐cell	  interactions.	  Trends	  in	  
Neurosciences,	  19,	  422-­‐427.	  	  Sadler,	   J.	   E.,	   Rearick,	   J.	   I.	   &	   Hill,	   R.	   L.	   (1979).	   Purification	   to	   homogeneity	   and	  enzymatic	   characterization	   of	   an	   alpha-­‐N-­‐acetylgalactosaminide	   alpha	   2	  leads	   to	  6	   sialyltransferase	   from	  porcine	   submaxillary	   glands.	   Journal	  of	  
Biological	  Chemistry,	  254,	  5934-­‐5941	  	  Saha,	  R.	  P.,	  Bahadur,	  R.	  P.,	  Pal,	  A.,	  Mandal,	  S.	  &	  Chakrabarti,	  P.	  (2006).	  ProFace:	  a	  server	   for	   the	   analysis	   of	   physiochemical	   features	   of	   protein-­‐proetin	  interfaces.	  BioMed	  Central	  Structural	  Biology,	  6	  (11).	  	  Sato,	  C.,	  Kitijima,	  K.,	  Tazawa,	  I.,	  Inoue,	  Y.,	  Inoue,	  S.	  &	  Troy,	  F.	  A.	  (1993).	  Structural	  diversity	  in	  the	  α	  2-­‐-­‐>8-­‐linked	  polysialic	  acid	  chains	  in	  salmonid	  fish	  egg	  glycoproteins.	  Occurrence	  of	  poly(Neu5Ac),	   poly(Neu5Gc),	   poly(Neu5Ac,	  Neu5Gc),	  poly(KD)	  and	  their	  partially	  acelated	  forms.	  Journal	  of	  Biological	  
Chemistry,	  268,	  23657-­‐23684.	  	  	  Schenkman,	   S.,	   Jiang,	  M.	   S.,	   Hart,	   G.	  W.	   &	   Nussenzweig,	   V.	   (1991).	   A	   novel	   cell	  surface	   trans-­‐sialidase	   of	   Trypanosoma	   cruzi	   generates	   a	   stage-­‐specific	  epitope	  required	  for	  invasion	  of	  mammalian	  cells.	  Cell,	  65,	  1117-­‐25.	  	  Schenkman,	  S.	  &	  Eichinger,	  D.	  (1993).	  Trypanosoma	  cruzi	  trans-­‐sialidase	  and	  cell	  invasion.	  Parasitology	  Today,	  9	  (6),	  218-­‐222.	  	  Schmunis,	   G.	   A.	   (2007).	   Epidemiology	   of	   Chagas	   disease	   in	   non-­‐endemic	  countries:	   the	   role	   of	   international	   migration.	   Memorias	   do	   Instituto	  
Oswaldo	  Cruz,	  102,	  75-­‐85.	  	  Schuttelkopf,	   A.	   W.	   &	   van	   Aalten,	   D.	   M.	   F.	   (2004).	   PRODRG	   -­‐	   atool	   for	   high-­‐throughput	   crystallography	   of	   protein-­‐ligand	   complexes.	   Acta	  
Crystallographica	  Section	  D-­‐Biological	  Crystallography,	  60,	  1355-­‐1363.	  	  Sheldrick,	   G.	   M.	   (2010).	   Experimental	   phasing	   with	   SHELXC/D/E:	   combining	  chain	  tracing	  with	  density	  modification.	  Acta	  Crystallographica	  Section	  D-­‐
Biological	  Crystallography,	  66,	  476-­‐485.	  	  Shinya,	  K.,	  Ebina,	  M.,	  Yamada,	  S.,	  Ono,	  M.,	  Kasai,	  N.	  &	  Kawaoka,	  Y.	  (2006).	  Avian	  flu:	  Influenza	  virus	  receptors	  in	  the	  human	  airwar.	  Nature,	  440,	  435-­‐436.	  	  Shitara,	  E.,	  Nishimura,	  Y.,	  Nerome,	  K.,	  Hiramoto,	  Y.	  &	  Takeuchi	  (2000).	  Synthesis	  of	   6-­‐acetamido-­‐5-­‐amino-­‐	   and	   -­‐5-­‐guanidino-­‐3,4dehydro-­‐N-­‐(2-­‐ethylbutyryl)-­‐3-­‐piperidinecarboxylic	   acids	   related	   to	   zanamivir	   and	  oseltamivir,	  inhibitors	  of	  influenza	  virus	  neraminidase.	  Organic	  Letters,	  2	  (24),	  3837-­‐3840.	  	  Spiro,	   R.	   G.	   (1964).	   Periodate	   oxidation	   of	   the	   glycoprotein	   fetuin.	   Journal	  
Biological	  Chemistry,	  239,	  567-­‐573.	  
	   238	  
	  Stummeyer,	   K.,	   Dickmanns,	   A.,	  Muhlenhoff,	  M.,	   Gerardy-­‐Schahn,	   R.	   &	   Ficner,	   R.	  (2005).	  Crystal	  structure	  of	  the	  polysialic	  acid-­‐degrading	  endosialidase	  of	  bacteriophage	  K1F.	  Nature	  Structural	  Molecular	  Biology,	  12,	  90-­‐6.	  	  Takasaki,	  S.,	  Yamashita,	  K.,	  Suzuki,	  K.,	  Iwanaga,	  S.	  &	  Kobata,	  A.	  (1979).	  The	  sugar	  chains	  of	  cold	  insoluble	  globulin.	  A	  protein	  related	  to	  fibronectin.	  Journal	  
of	  Biological	  Chemistry,	  254,	  8548-­‐8553.	  	  Tanaka,	   H.,	   Ito,	   F.	   &	   Iwasaki,	   T.	   (1994).	   Two	   sialidases	   which	   preferentially	  hydrolyze	   sialyl	   alpha	   2-­‐8	   linkage	   from	   Bacteroides	   fragilis	   SBT3182.	  
Journal	  of	  Biochemistry,	  115,	  318-­‐21.	  	  Taylor,	   G.	   (1996).	   Sialidases:	   structures,	   biological	   significance	   and	   therapeutic	  potential.	  Current	  Opinions	  in	  Structural	  Biology,	  6,	  830-­‐7.	  	  Terada,	   T.,	   Kitajima,	   K.,	   Inoue,	   S.,	   Wilson,	   J.	   C.,	   Norton,	   A.	   K.,	   Kong,	   D.	   C.	   M.,	  Thomson,	   R.	   J.,	   Von	   Itzstein,	   M.	   &	   Inoue,	   Y.	   (1997).	   Catalysis	   by	   a	   new	  sialidase,	   deaminoneuraminic	   acid	   residue-­‐cleaving	   enzyme	   (KDNase	  Sm),	   initially	   forms	   a	   less	   stable	   alpha-­‐anomer	   of	   3-­‐deoxy-­‐D-­‐glycero-­‐D-­‐galacto-­‐nonulosonic	  acid	  and	  is	  strongly	  inhibited	  by	  the	  transition	  state	  analogue,	   2-­‐deoxy-­‐2,3-­‐didehydro-­‐D-­‐glycero-­‐D-­‐galacto-­‐2-­‐nonulopyranosonic	   acid,	   but	   not	   by	   2-­‐deoxy-­‐2,3-­‐didehydro-­‐N-­‐acetylneuraminic	  acid.	  Journal	  of	  Biological	  Chemistry,	  272,	  5452-­‐5456.	  	  Tiralongo,	   J.,	  Wohlschlarger,	  T.,	  Tiralongo,	  E.	  &	  Kiefel,	  M.	   J.	   (2009).	   Inhibition	  of	  Aspergillus	  fumigatus	  conidia	  binding	  to	  extracellular	  matrix	  proteins	  by	  sialic	  acids:	  a	  pH	  effect?	  Microbiology-­‐Sgm,	  155,	  3100-­‐3109.	  	  Tringali,	  C.,	  Lupo,	  B.,	  Anastasia,	  L.,	  Papini,	  N.,	  Monyi,	  E.,	  Bresciani,	  R.,	  Tettamanti,	  G.	  &	  Venerando,	  B.	  (2007).	  Expression	  of	  sialidase	  Neu2	  in	  leukemic	  K562	  cells	   induces	   apoptosis	   by	   impairing	   Bcr-­‐Abl/Src	   kinases	   signaling.	  
Journal	  of	  Biological	  Chemistry,	  282,	  14364-­‐72.	  	  Tomlinson,	   S.,	   Pontes	  de	  Carvalho,	   L.	   C.,	  Vandekerckhove,	   F.	  &	  Nussenzweig,	  V.	  (1994).	   Role	   of	   sialic	   acid	   in	   the	   resistance	   of	   Trypanosoma	   cruzi	  trypomastigotes	   to	   complement.	   Journal	   of	   Immunology,	   153	   (7),	   3141-­‐3147.	  	  Umezawa,	  H.,	  Aoyagi,	  T.,	  Komiyama,	  T.,	  Morishima,	  H.,	  Hamada,	  M.	  &	  Takeuchi,	  T.	  (1974).	  Purification	  and	  charachterization	  of	  a	  sialidase	  inhibitor,	  siatatin,	  produced	  by	  Streptomyces.	  Journal	  of	  Antibiotics,	  27	  (12),	  963-­‐969.	  	  Varghese,	   J.	   N.	   &	   Colman,	   P.	   M.	   (1991).	   Three-­‐dimensional	   structure	   of	   the	  neuraminidase	   of	   influenza	   virus	   A/Tokyo/3/67	   at	   2.2	   Å	   resolution.	  
Journal	  of	  Molecular	  Biology,	  221,	  473-­‐486.	  	  
	   239	  
Varghese,	  J.	  N.,	  Laver,	  W.	  G.,	  Colman,	  P.	  M.	  (1983).	  Structure	  of	  the	  influenza	  virus	  glycoprotein	  antigen	  neuraminidase	  at	  2.9	  Å	  resolution.	  Nature,	  303,	  35-­‐40.	  	  Varki,	  N.	  M.	  &	  Varki,	  A.	  (2007).	  Diversity	  in	  cell	  surface	  sialic	  acid	  presentations:	  implications	  for	  biology	  and	  disease.	  Laboratory	  Investigation,	  87,	  851-­‐7.	  	  Verdonk,	  M.	  L.,	  Cole,	   J.	  C.,	  Hartshorn,	  M.	   J.,	  Murray,	  C.	  W.	  &	  Taylor,	  R.	  D.	  (2003).	  Improved	   protein-­‐ligand-­‐docking	   using	   GOLD.	   Proteins:	   Structure,	  
Function	  and	  Bioinformatics,	  52	  (4),	  609-­‐623.	  	  	  Vimr,	  E.	  R.	  &	  Troy,	  F.	  A.	  (1985).	  Identification	  of	  an	  inducible	  catabolic	  system	  for	  sialic	  acids	  (nan)	  in	  Escherichia	  coli.	  Journal	  of	  Bacteriology,	  164,	  845-­‐853.	  	  Vimr,	  E.	  R.,	  Kalidova,	  K.	  A.,	  Deszo,	  E.	  L.	  &	  Steenbergen,	  S.	  M.	  (2004).	  Diversity	  of	  microbial	   sialic	   acid	   metabolism.	   Microbiology	   and	   Molecular	   Biology	  
Reviews,	  68,	  132-­‐53.	  	  Vocaldo,	   D.	   J.	   &	   Davies,	   G.	   J.	   (2008).	   Mechanistic	   insights	   into	   glycosidase	  chemistry.	  Current	  Opinion	  in	  Chemical	  Biology,	  12,	  539-­‐55.	  	  Wang,	   Q.,	   Graham,	   R.	  W.,	   Trimbur,	   D.,	  Warren,	   R.	   A.	   J.	   &	  Withers,	   S.	   G.	   (1994).	  Changing	  enzymatic	  reaction	  mechanisms	  by	  mutagenisis:	  Coversion	  of	  a	  retaining	   glucosidase	   to	   an	   inverting	   enzyme.	   Journal	   of	   the	   Americal	  
Chemical	  Society,	  116,	  11594-­‐11595.	  	  Warwas,	  M.	  L.,	  Yeung,	  J.	  H.	  F,	  Indurugalla,	  D.,	  Mooers,	  A.	  O.,	  Bennet,	  A.	  J.	  &	  Moore,	  M.	   M.	   (2010).	   Cloning	   and	   charicterization	   of	   a	   sialidase	   from	   the	  filamentous	  fungus,	  Aspergillus	  fumugatus.	  Glycoconjugate,	  27,	  533-­‐548	  	  Warwas,	  M.	  L.,	  Watson,	   J.	  N.,	  Bennet,	  A.	   J.	  &	  Moore,	  M.	  M.	  (2007).	  Structure	  and	  role	  of	  sialic	  acids	  on	  the	  surface	  of	  Aspergillus	  fumigatus	  conidiospores.	  
Glycobiology,	  17,	  401-­‐410.	  	  Wasylnka,	   J.	   A.	   &	   Moore,	   M.	   M.	   (2000).	   Adhesion	   of	   Aspergillus	   species	   to	  extracellular	   matrix	   proteins:	   Evidence	   for	   involvement	   of	   negatively	  charged	  carbohydrates	  on	  the	  conidial	  surface.	  Infection	  and	  Immunity,	  68	  (6),	  3377-­‐3384.	  	  Wasylnka,	   J.	   A.,	   Simmer,	  M.	   I.	   &	  Moore,	  M.	  M.	   (2001).	  Differences	   in	   sialic	   acid	  density	   in	   pathogenic	   and	   non-­‐pathogenic	   Aspergillus	   species.	  
Microbiology-­‐Uk,	  147,	  869-­‐877.	  	  Watson,	   J.	  N.,	  Dookhun,	  V.,	  Borgford,	  T.	   J.	  &	  Bennet,	  A.	   J.	   (2003).	  Mutagenesis	  of	  the	   conserved	   active-­‐site	   tyrosine	   changes	   a	   retaining	   sialidase	   into	   an	  inverting	  sialidase.	  Biochemistry,	  42,	  12682-­‐90.	  	  Watts,	  A.	  G.,	  Damager,	   I.,	  Amaya,	  M.	  L.,	  Buschiazzo,	  A.,	  Alzari,	  P.,	  Frasch,	  A.	  C.	  &	  Withers,	  S.	  G.	  (2003).	  Trypanosoma	  cruzi	  trans-­‐sialidase	  operates	  through	  
	   240	  
a	   covalent	   sialyl-­‐enzyme	   intermediate:	   tyrosine	   is	   the	   catalytic	  nucleophile.	  Journal	  of	  the	  American	  Chemical	  Society,	  125,	  7532-­‐3.	  	  Watts,	   A.	   G.,	   Oppezzo,	   P.,	   Withers,	   S.	   G.,	   Alzari,	   P.	   M.	   &	   Buschiazzo,	   A.	   (2006).	  Structural	   and	   kinetic	   analysis	   of	   two	   covalent	   sialosyl-­‐enzyme	  intermediates	   on	   Trypanosoma	   rangeli	   sialidase.	   Journal	   Biological	  
Chemistry,	  281,	  4149-­‐55.	  	  WHO,	   2013.	   Chagas	   disease	   fact	   sheert	   [Online].	   Available	   at:	  http://www.who.int/mediacentre/factsheets/fs340/en/index.html	  	  Xu,	  G.	  (2009).	  Structural	  studies	  on	  the	  sialidase	  from	  Streptococcus	  pneumoniae	  and	  Pseudomonas	  aeruginosa.	  Thesis	  from	  the	  University	  of	  St	  andrews.	  	  Xu,	   G.,	   Li,	   X.,	   Andrew,	   P.	   W.	   &	   Taylor,	   G.	   L.	   (2008a).	   Structure	   of	   the	   catalytic	  domain	   of	   Streptococcus	   pneumoniae	   sialidase	   NanA.	   Acta	  
Crystallographica	  Section	  F,	  64,	  772-­‐775.	  	  Xu,	   G.,	   Potter,	   J.	   A.,	   Russell,	   R.	   J.,	   Oggioni,	   M.	   R.,	   Andrew,	   P.	  W.	   &	   Taylor,	   G.	   L.	  (2008b)	   Crystal	   structure	   of	   the	   NanB	   sialidase	   from	   Streptococcus	  pneumoniae.	  Journal	  of	  Molecular	  Biology,	  384,	  436-­‐49.	  	  Xu,	  G.,	  Ryan,	  C.,	  Kiefel,	  M.	  J.,	  Wilson,	  J.	  C.	  &	  Taylor,	  G.	  L.	  (2009).	  Structural	  studies	  on	   the	   Pseudomonas	   aeruginosa	   sialidase-­‐like	   enzyme	   PA2794	   suggest	  substrate	   and	  mechanistic	   variations.	   Journal	   of	  Molecular	   Biology,	   386,	  828-­‐40.	  	  Yabu,	  M.,	  Korekane,	  H.,	  Hatano,	  K.,	  Kaneda,	  Y.,	  Nonomura,	  N.,	  Sato,	  C.,	  Kitajima,	  K.	  &	  Miyamoto,	  Y.	  (2013).	  Occurance	  of	  free	  deaminoneuraminic	  acid	  (KDN)-­‐containing	   compex-­‐type	   N-­‐glycans	   in	   human	   prostate	   cancers.	  
Glycobiology,	  23,	  634-­‐642.	  	  Yogalingam,	  G.,	  Bonten,	  E.	  J.,	  Van	  De	  Vlekkert,	  D.,	  Hu,	  H.,	  Moshiach,	  S.,	  Connell,	  S.	  A.	   &	   D'Azzo,	   A.	   (2008).	   Neuraminidase	   1	   is	   a	   negative	   regulator	   of	  lysosomal	  exocytosis.	  Developmental	  Cell,	  15,	  74-­‐86.	  	  Zechel,	  D.	  L.	  &	  Withers,	  S.	  G.	  (2000).	  Glycosidase	  Mechanisms:	  Anatomyof	  a	  finely	  tuned	  catalyst.	  Accademy	  of	  Chemical	  Reseach,	  33,	  11-­‐18.	  	  	  	  	  	  	  
	   241	  
Publications	  and	  PDB	  codes	  
	  
Publications	  	  	  Telford,	   J.	   C.,	   Yeung,	   J.	  H.	   F.,	   Xu,	   G.,	   Kiefel,	  M.	   J.,	  Watts,	   A.	   G.,	  Hader,	   S.,	   Chan,	   J.,	  Bennet,	   A.	   J.,	   Moore,	   M.	   M	   &	   Taylor,	   G.	   L.	   (2011).	   The	   Aspergillus	   fumigatus	  sialidase	   is	   a	   3-­‐deoxy-­‐D-­‐glycero-­‐D-­‐galacto-­‐2-­‐nonulosonic	   acid	   hydrolase	  (KDNase).	  Journal	  of	  Biological	  Chemistry,	  286	  (12),	  10783-­‐10792.	  	  	  Brear,	   P.,	   Telford,	   J.	   C.,	   Taylor,	   G.	   L.	   &	   Westwood,	   N.	   J.	   (2012).	   Synthesis	   and	  structural	   characterisation	   of	   selective	     non -­‐carbohydrate-­‐based	   inhibitors	   of	  bacterial	  sialidases.	  ChemBioChem,	  13,	  2374-­‐2382.	  	  	  Yeung,	  J.	  H.	  F.,	  Telford	  J.	  C.,	  Shidoosavee	  F.	  S.,	  Bennet	  A.	  J.,	  Taylor	  G.	  L.	  &	  Moore	  M.,	  M.	  (2013).	  Kinetic	  and	  structural	  evaluation	  of	  selected	  active	  site	  mutants	  of	  the	  
Aspergillus	  fumigatus	  KDNase	  (Sialidase).	  Biochemistry,	  52	  (51),	  9177-­‐9186.	  
	  	  
PDB	  codes	  	  
	  
AfS	  –	  2XCY	  	  
AfS-­‐KDN	  –	  2XZI	  	  
AfS-­‐KDN2en	  –	  2XZJ	  	  
AfS-­‐KDF	  –	  2XZK	  	  
	  	  	  	  	  	  	  
	  
